



(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
**04.11.2015 Bulletin 2015/45**

(51) Int Cl.:  
**C12N 15/63 (2006.01)**

(21) Application number: **15154565.4**

(22) Date of filing: **12.12.2013**

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**

- **Massachusetts Institute of Technology**  
**Cambridge, MA 02142-1324 (US)**
- **President and Fellows of Harvard College**  
**Cambridge, MA 02138-3876 (US)**

(30) Priority: **12.12.2012 US 201261736527 P**  
**02.01.2013 US 201361748427 P**  
**30.01.2013 US 201361758468 P**  
**25.02.2013 US 201361769046 P**  
**15.03.2013 US 201361791409 P**  
**15.03.2013 US 201361802174 P**  
**28.03.2013 US 201361806375 P**  
**20.04.2013 US 201361814263 P**  
**06.05.2013 US 201361819803 P**  
**28.05.2013 US 201361828130 P**  
**17.06.2013 US 201361835931 P**  
**17.06.2013 US 201361836127 P**

(72) Inventors:

- **Zhang, Feng**  
**Cambridge, MA 02139 (US)**
- **Cong, Le**  
**Cambridge, MA 02142 (US)**
- **Hsu, Patrick**  
**Cambridge, MA 02138 (US)**
- **Ran, Fei**  
**Boston, MA 02116 (US)**

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:  
**13818570.7 / 2 771 468**

(74) Representative: **Williams, Gareth Owen**  
**Marks & Clerk LLP**  
**62-68 Hills Road**  
**Cambridge**  
**CB2 1LA (GB)**

(71) Applicants:

- **The Broad Institute, Inc.**  
**Cambridge, MA 02142 (US)**

Remarks:

- This application was filed on 10-02-2015 as a divisional application to the application mentioned under INID code 62.
- Claims filed after the date of filing of the application (Rule 68(4) EPC).

(54) **Engineering of systems, methods and optimized guide compositions for sequence manipulation**

(57) The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR-Cas system.




FIG. 1

**Description**

## RELATED APPLICATIONS AND INCORPORATION BY REFERENCE

**[0001]** This application claims priority to US provisional patent application 61/836,127 entitled ENGINEERING OF SYSTEMS, METHODS AND OPTIMIZED COMPOSITIONS FOR SEQUENCE MANIPULATION filed on June 17, 2013. This application also claims priority to US provisional patent applications 61/758,468; 61/769,046; 61/802,174; 61/806,375; 61/814,263; 61/819,803 and 61/828,130 each entitled ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION, filed on January 30, 2013; February 25, 2013; March 15, 2013; March 28, 2013; April 20, 2013; May 6, 2013 and May 28, 2013 respectively. Priority is also claimed to US provisional patent applications 61/736,527 and 61/748,427, both entitled SYSTEMS METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION filed on December 12, 2012 and January 2, 2013, respectively. Priority is also claimed to US provisional patent applications 61/791,409 and 61/835,931 both entitled BI-2011/008/44790.02.2003 and BI-2011/008/44790.03.2003 filed on March 15, 2013 and June 17, 2013 respectively.

**[0002]** Reference is also made to US provisional patent applications 61/835,936, 61/836,101, 61/836,080, 61/836,123 and 61/835,973 each filed June 17, 2013.

**[0003]** The foregoing applications, and all documents cited therein or during their prosecution ("appln cited documents") and all documents cited or referenced in the appln cited documents, and all documents cited or referenced herein ("herein cited documents"), and all documents cited or referenced in herein cited documents, together with any manufacturer's instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the invention. More specifically, all referenced documents are incorporated by reference to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference.

## FIELD OF THE INVENTION

**[0004]** The present invention generally relates to systems, methods and compositions used for the control of gene expression involving sequence targeting, such as genome perturbation or gene-editing, that may use vector systems related to Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and components thereof.

## STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

**[0005]** This invention was made with government support awarded by the National Institutes of Health, NIH Pioneer Award DP1MH100706. The government has certain rights in the invention.

## BACKGROUND OF THE INVENTION

**[0006]** Recent advances in genome sequencing techniques and analysis methods have significantly accelerated the ability to catalog and map genetic factors associated with a diverse range of biological functions and diseases. Precise genome targeting technologies are needed to enable systematic reverse engineering of causal genetic variations by allowing selective perturbation of individual genetic elements, as well as to advance synthetic biology, biotechnological, and medical applications. Although genome-editing techniques such as designer zinc fingers, transcription activator-like effectors (TALEs), or homing meganucleases are available for producing targeted genome perturbations, there remains a need for new genome engineering technologies that are affordable, easy to set up, scalable, and amenable to targeting multiple positions within the eukaryotic genome.

## SUMMARY OF THE INVENTION

**[0007]** There exists a pressing need for alternative and robust systems and techniques for sequence targeting with a wide array of applications. This invention addresses this need and provides related advantages. The CRISPR/Cas or the CRISPR-Cas system (both terms are used interchangeably throughout this application) does not require the generation of customized proteins to target specific sequences but rather a single Cas enzyme can be programmed by a short RNA molecule to recognize a specific DNA target, in other words the Cas enzyme can be recruited to a specific DNA target using said short RNA molecule. Adding the CRISPR-Cas system to the repertoire of genome sequencing techniques and analysis methods may significantly simplify the methodology and accelerate the ability to catalog and map genetic factors associated with a diverse range of biological functions and diseases. To utilize the CRISPR-Cas system effectively for genome editing without deleterious effects, it is critical to understand aspects of engineering and optimization of these genome engineering tools, which are aspects of the claimed invention.

**[0008]** In one aspect, the invention provides a vector system comprising one or more vectors. In some embodiments, the system comprises: (a) a first regulatory element operably linked to a tracr mate sequence and one or more insertion sites for inserting one or more guide sequences upstream of the tracr mate sequence, wherein when expressed, the guide sequence directs sequence-specific binding of a CRISPR complex to a target sequence in a cell, e.g., eukaryotic cell, wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence; and (b) a second regulatory element operably linked to an enzyme-coding sequence encoding said CRISPR enzyme comprising a nuclear localization sequence; wherein components (a) and (b) are located on the same or different vectors of the system. In some embodiments, component (a) further comprises the tracr sequence downstream of the tracr mate sequence under the control of the first regulatory element. In some embodiments, component (a) further comprises two or more guide sequences operably linked to the first regulatory element, wherein when expressed, each of the two or more guide sequences direct sequence specific binding of a CRISPR complex to a different target sequence in a eukaryotic cell. In some embodiments, the system comprises the tracr sequence under the control of a third regulatory element, such as a polymerase III promoter. In some embodiments, the tracr sequence exhibits at least 50%, 60%, 70%, 80%, 90%, 95%, or 99% of sequence complementarity along the length of the tracr mate sequence when optimally aligned. In some embodiments, the CRISPR complex comprises one or more nuclear localization sequences of sufficient strength to drive accumulation of said CRISPR complex in a detectable amount in the nucleus of a eukaryotic cell. Without wishing to be bound by theory, it is believed that a nuclear localization sequence is not necessary for CRISPR complex activity in eukaryotes, but that including such sequences enhances activity of the system, especially as to targeting nucleic acid molecules in the nucleus. In some embodiments, the CRISPR enzyme is a type II CRISPR system enzyme. In some embodiments, the CRISPR enzyme is a Cas9 enzyme. In some embodiments, the Cas9 enzyme is *S. pneumonia*, *S. pyogenes*, or *S. thermophilus* Cas9, and may include mutated Cas9 derived from these organisms. The enzyme may be a Cas9 homolog or ortholog. In some embodiments, the CRISPR enzyme is codon-optimized for expression in a eukaryotic cell. In some embodiments, the CRISPR enzyme directs cleavage of one or two strands at the location of the target sequence. In some embodiments, the CRISPR enzyme lacks DNA strand cleavage activity. In some embodiments, the first regulatory element is a polymerase III promoter. In some embodiments, the second regulatory element is a polymerase II promoter. In some embodiments, the guide sequence is at least 15, 16, 17, 18, 19, 20, 25 nucleotides, or between 10-30, or between 15-25, or between 15-20 nucleotides in length. In general, and throughout this specification, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. Vectors include, but are not limited to, nucleic acid molecules that are single-stranded, double-stranded, or partially double-stranded; nucleic acid molecules that comprise one or more free ends, no free ends (e.g. circular); nucleic acid molecules that comprise DNA, RNA, or both; and other varieties of polynucleotides known in the art. One type of vector is a "plasmid," which refers to a circular double stranded DNA loop into which additional DNA segments can be inserted, such as by standard molecular cloning techniques. Another type of vector is a viral vector, wherein virally-derived DNA or RNA sequences are present in the vector for packaging into a virus (e.g. retroviruses, replication defective retroviruses, adenoviruses, replication defective adenoviruses, and adeno-associated viruses). Viral vectors also include polynucleotides carried by a virus for transfection into a host cell. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g. bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as "expression vectors." Common expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.

**[0009]** Recombinant expression vectors can comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory elements, which may be selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory element(s) in a manner that allows for expression of the nucleotide sequence (e.g. in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).

**[0010]** The term "regulatory element" is intended to include promoters, enhancers, internal ribosomal entry sites (IRES), and other expression control elements (e.g. transcription termination signals, such as polyadenylation signals and poly-U sequences). Such regulatory elements are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory elements include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). A tissue-specific promoter may direct expression primarily in a desired tissue of interest, such as muscle, neuron, bone, skin, blood, specific organs (e.g. liver, pancreas), or particular cell types (e.g. lymphocytes). Regulatory elements may also direct expression in a

temporal-dependent manner, such as in a cell-cycle dependent or developmental stage-dependent manner, which may or may not also be tissue or cell-type specific. In some embodiments, a vector comprises one or more pol III promoter (e.g. 1, 2, 3, 4, 5, or more pol III promoters), one or more pol II promoters (e.g. 1, 2, 3, 4, 5, or more pol II promoters), one or more pol I promoters (e.g. 1, 2, 3, 4, 5, or more pol I promoters), or combinations thereof. Examples of pol III promoters include, but are not limited to, U6 and H1 promoters. Examples of pol II promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer) [see, e.g., Boshart et al, Cell, 41:521-530 (1985)], the SV40 promoter, the dihydrofolate reductase promoter, the  $\beta$ -actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EF1 $\alpha$  promoter. Also encompassed by the term "regulatory element" are enhancer elements, such as WPRE; CMV enhancers; the R-U5' segment in LTR of HTLV-I (Mol. Cell. Biol., Vol. 8(1), p. 466-472, 1988); SV40 enhancer; and the intron sequence between exons 2 and 3 of rabbit  $\beta$ -globin (Proc. Natl. Acad. Sci. USA., Vol. 78(3), p. 1527-31, 1981). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression desired, etc. A vector can be introduced into host cells to thereby produce transcripts, proteins, or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., clustered regularly interspersed short palindromic repeats (CRISPR) transcripts, proteins, enzymes, mutant forms thereof, fusion proteins thereof, etc.).

**[0011]** Advantageous vectors include lentiviruses and adeno-associated viruses, and types of such vectors can also be selected for targeting particular types of cells.

**[0012]** In one aspect, the invention provides a vector comprising a regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme comprising one or more nuclear localization sequences. In some embodiments, said regulatory element drives transcription of the CRISPR enzyme in a eukaryotic cell such that said CRISPR enzyme accumulates in a detectable amount in the nucleus of the eukaryotic cell. In some embodiments, the regulatory element is a polymerase II promoter. In some embodiments, the CRISPR enzyme is a type II CRISPR system enzyme. In some embodiments, the CRISPR enzyme is a Cas9 enzyme. In some embodiments, the Cas9 enzyme is *S. pneumonia*, *S. pyogenes* or *S. thermophilus* Cas9, and may include mutated Cas9 derived from these organisms. In some embodiments, the CRISPR enzyme is codon-optimized for expression in a eukaryotic cell. In some embodiments, the CRISPR enzyme directs cleavage of one or two strands at the location of the target sequence. In some embodiments, the CRISPR enzyme lacks DNA strand cleavage activity.

**[0013]** In one aspect, the invention provides a CRISPR enzyme comprising one or more nuclear localization sequences of sufficient strength to drive accumulation of said CRISPR enzyme in a detectable amount in the nucleus of a eukaryotic cell. In some embodiments, the CRISPR enzyme is a type II CRISPR system enzyme. In some embodiments, the CRISPR enzyme is a Cas9 enzyme. In some embodiments, the Cas9 enzyme is *S. pneumonia*, *S. pyogenes* or *S. thermophilus* Cas9, and may include mutated Cas9 derived from these organisms. The enzyme may be a Cas9 homolog or ortholog. In some embodiments, the CRISPR enzyme lacks the ability to cleave one or more strands of a target sequence to which it binds.

**[0014]** In one aspect, the invention provides a eukaryotic host cell comprising (a) a first regulatory element operably linked to a tracr mate sequence and one or more insertion sites for inserting one or more guide sequences upstream of the tracr mate sequence, wherein when expressed, the guide sequence directs sequence-specific binding of a CRISPR complex to a target sequence in a eukaryotic cell, wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence; and/or (b) a second regulatory element operably linked to an enzyme-coding sequence encoding said CRISPR enzyme comprising a nuclear localization sequence. In some embodiments, the host cell comprises components (a) and (b). In some embodiments, component (a), component (b), or components (a) and (b) are stably integrated into a genome of the host eukaryotic cell. In some embodiments, component (a) further comprises the tracr sequence downstream of the tracr mate sequence under the control of the first regulatory element. In some embodiments, component (a) further comprises two or more guide sequences operably linked to the first regulatory element, wherein when expressed, each of the two or more guide sequences direct sequence specific binding of a CRISPR complex to a different target sequence in a eukaryotic cell. In some embodiments, the eukaryotic host cell further comprises a third regulatory element, such as a polymerase III promoter, operably linked to said tracr sequence. In some embodiments, the tracr sequence exhibits at least 50%, 60%, 70%, 80%, 90%, 95%, or 99% of sequence complementarity along the length of the tracr mate sequence when optimally aligned. In some embodiments, the CRISPR enzyme comprises one or more nuclear localization sequences of sufficient strength to drive accumulation of said CRISPR enzyme in a detectable amount in the nucleus of a eukaryotic cell. In some embodiments, the CRISPR enzyme is a type II CRISPR system enzyme. In some embodiments, the CRISPR enzyme is a Cas9 enzyme. In some embodiments, the Cas9 enzyme is *S. pneumonia*, *S. pyogenes* or *S. thermophilus* Cas9, and may include mutated Cas9 derived from these organisms. The enzyme may be a Cas9 homolog or ortholog. In some embodiments, the CRISPR enzyme is codon-optimized for expression in a eukaryotic cell. In some embodiments, the CRISPR enzyme directs cleavage of one or two strands at the location of the target sequence. In some embodiments, the CRISPR enzyme lacks DNA strand cleavage activity. In



some embodiments, the first regulatory element is a polymerase III promoter. In some embodiments, the second regulatory element is a polymerase II promoter. In some embodiments, the guide sequence is at least 15, 16, 17, 18, 19, 20, 25 nucleotides, or between 10-30, or between 15-25, or between 15-20 nucleotides in length. In an aspect, the invention provides a non-human eukaryotic organism; preferably a multicellular eukaryotic organism, comprising a eukaryotic host cell according to any of the described embodiments. In other aspects, the invention provides a eukaryotic organism; preferably a multicellular eukaryotic organism, comprising a eukaryotic host cell according to any of the described embodiments. The organism in some embodiments of these aspects may be an animal; for example a mammal. Also, the organism may be an arthropod such as an insect. The organism also may be a plant. Further, the organism may be a fungus.

**[0015]** In one aspect, the invention provides a kit comprising one or more of the components described herein. In some embodiments, the kit comprises a vector system and instructions for using the kit. In some embodiments, the vector system comprises (a) a first regulatory element operably linked to a *tracr* mate sequence and one or more insertion sites for inserting one or more guide sequences upstream of the *tracr* mate sequence, wherein when expressed, the guide sequence directs sequence-specific binding of a CRISPR complex to a target sequence in a eukaryotic cell, wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the *tracr* mate sequence that is hybridized to the *tracr* sequence; and/or (b) a second regulatory element operably linked to an enzyme-coding sequence encoding said CRISPR enzyme comprising a nuclear localization sequence. In some embodiments, the kit comprises components (a) and (b) located on the same or different vectors of the system. In some embodiments, component (a) further comprises the *tracr* sequence downstream of the *tracr* mate sequence under the control of the first regulatory element. In some embodiments, component (a) further comprises two or more guide sequences operably linked to the first regulatory element, wherein when expressed, each of the two or more guide sequences direct sequence specific binding of a CRISPR complex to a different target sequence in a eukaryotic cell. In some embodiments, the system further comprises a third regulatory element, such as a polymerase III promoter, operably linked to said *tracr* sequence. In some embodiments, the *tracr* sequence exhibits at least 50%, 60%, 70%, 80%, 90%, 95%, or 99% of sequence complementarity along the length of the *tracr* mate sequence when optimally aligned. In some embodiments, the CRISPR enzyme comprises one or more nuclear localization sequences of sufficient strength to drive accumulation of said CRISPR enzyme in a detectable amount in the nucleus of a eukaryotic cell. In some embodiments, the CRISPR enzyme is a type II CRISPR system enzyme. In some embodiments, the CRISPR enzyme is a Cas9 enzyme. In some embodiments, the Cas9 enzyme is *S. pneumonia*, *S. pyogenes* or *S. thermophilus* Cas9, and may include mutated Cas9 derived from these organisms. The enzyme may be a Cas9 homolog or ortholog. In some embodiments, the CRISPR enzyme is codon-optimized for expression in a eukaryotic cell. In some embodiments, the CRISPR enzyme directs cleavage of one or two strands at the location of the target sequence. In some embodiments, the CRISPR enzyme lacks DNA strand cleavage activity. In some embodiments, the first regulatory element is a polymerase III promoter. In some embodiments, the second regulatory element is a polymerase II promoter. In some embodiments, the guide sequence is at least 15, 16, 17, 18, 19, 20, 25 nucleotides, or between 10-30, or between 15-25, or between 15-20 nucleotides in length.

**[0016]** In one aspect, the invention provides a method of modifying a target polynucleotide in a eukaryotic cell. In some embodiments, the method comprises allowing a CRISPR complex to bind to the target polynucleotide to effect cleavage of said target polynucleotide thereby modifying the target polynucleotide, wherein the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said target polynucleotide, wherein said guide sequence is linked to a *tracr* mate sequence which in turn hybridizes to a *tracr* sequence. In some embodiments, said cleavage comprises cleaving one or two strands at the location of the target sequence by said CRISPR enzyme. In some embodiments, said cleavage results in decreased transcription of a target gene. In some embodiments, the method further comprises repairing said cleaved target polynucleotide by homologous recombination with an exogenous template polynucleotide, wherein said repair results in a mutation comprising an insertion, deletion, or substitution of one or more nucleotides of said target polynucleotide. In some embodiments, said mutation results in one or more amino acid changes in a protein expressed from a gene comprising the target sequence. In some embodiments, the method further comprises delivering one or more vectors to said eukaryotic cell, wherein the one or more vectors drive expression of one or more of: the CRISPR enzyme, the guide sequence linked to the *tracr* mate sequence, and the *tracr* sequence. In some embodiments, said vectors are delivered to the eukaryotic cell in a subject. In some embodiments, said modifying takes place in said eukaryotic cell in a cell culture. In some embodiments, the method further comprises isolating said eukaryotic cell from a subject prior to said modifying. In some embodiments, the method further comprises returning said eukaryotic cell and/or cells derived therefrom to said subject.

**[0017]** In one aspect, the invention provides a method of modifying expression of a polynucleotide in a eukaryotic cell. In some embodiments, the method comprises allowing a CRISPR complex to bind to the polynucleotide such that said binding results in increased or decreased expression of said polynucleotide; wherein the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said polynucleotide, wherein said guide sequence is linked to a *tracr* mate sequence which in turn hybridizes to a *tracr* sequence. In some embodiments,

the method further comprises delivering one or more vectors to said eukaryotic cells, wherein the one or more vectors drive expression of one or more of: the CRISPR enzyme, the guide sequence linked to the tracr mate sequence, and the tracr sequence.

**[0018]** In one aspect, the invention provides a method of generating a model eukaryotic cell comprising a mutated disease gene. In some embodiments, a disease gene is any gene associated with an increase in the risk of having or developing a disease. In some embodiments, the method comprises (a) introducing one or more vectors into a eukaryotic cell, wherein the one or more vectors drive expression of one or more of: a CRISPR enzyme, a guide sequence linked to a tracr mate sequence, and a tracr sequence; and (b) allowing a CRISPR complex to bind to a target polynucleotide to effect cleavage of the target polynucleotide within said disease gene, wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence within the target polynucleotide, and (2) the tracr mate sequence that is hybridized to the tracr sequence, thereby generating a model eukaryotic cell comprising a mutated disease gene. In some embodiments, said cleavage comprises cleaving one or two strands at the location of the target sequence by said CRISPR enzyme. In some embodiments, said cleavage results in decreased transcription of a target gene. In some embodiments, the method further comprises repairing said cleaved target polynucleotide by homologous recombination with an exogenous template polynucleotide, wherein said repair results in a mutation comprising an insertion, deletion, or substitution of one or more nucleotides of said target polynucleotide. In some embodiments, said mutation results in one or more amino acid changes in a protein expression from a gene comprising the target sequence.

**[0019]** In one aspect, the invention provides a method for developing a biologically active agent that modulates a cell signaling event associated with a disease gene. In some embodiments, a disease gene is any gene associated with an increase in the risk of having or developing a disease. In some embodiments, the method comprises (a) contacting a test compound with a model cell of any one of the described embodiments; and (b) detecting a change in a readout that is indicative of a reduction or an augmentation of a cell signaling event associated with said mutation in said disease gene, thereby developing said biologically active agent that modulates said cell signaling event associated with said disease gene.

**[0020]** In one aspect, the invention provides a recombinant polynucleotide comprising a guide sequence upstream of a tracr mate sequence, wherein the guide sequence when expressed directs sequence-specific binding of a CRISPR complex to a corresponding target sequence present in a eukaryotic cell. In some embodiments, the target sequence is a viral sequence present in a eukaryotic cell. In some embodiments, the target sequence is a proto-oncogene or an oncogene.

**[0021]** In one aspect the invention provides for a method of selecting one or more prokaryotic cell(s) by introducing one or more mutations in a gene in the one or more prokaryotic cell (s), the method comprising: introducing one or more vectors into the prokaryotic cell (s), wherein the one or more vectors drive expression of one or more of: a CRISPR enzyme, a guide sequence linked to a tracr mate sequence, a tracr sequence, and a editing template; wherein the editing template comprises the one or more mutations that abolish CRISPR enzyme cleavage; allowing homologous recombination of the editing template with the target polynucleotide in the cell(s) to be selected; allowing a CRISPR complex to bind to a target polynucleotide to effect cleavage of the target polynucleotide within said gene, wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence within the target polynucleotide, and (2) the tracr mate sequence that is hybridized to the tracr sequence, wherein binding of the CRISPR complex to the target polynucleotide induces cell death, thereby allowing one or more prokaryotic cell(s) in which one or more mutations have been introduced to be selected. In a preferred embodiment, the CRISPR enzyme is Cas9. In another aspect of the invention the cell to be selected may be a eukaryotic cell. Aspects of the invention allow for selection of specific cells without requiring a selection marker or a two-step process that may include a counter-selection system.

**[0022]** In some aspects the invention provides a non-naturally occurring or engineered composition comprising a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, (b) a tracr mate sequence, and (c) a tracr sequence wherein (a), (b) and (c) are arranged in a 5' to 3' orientation, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence,

or

a CRISPR enzyme system, wherein the system is encoded by a vector system comprising one or more vectors comprising I. a first regulatory element operably linked to a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises (a) one or more guide sequences capable of hybridizing to one or more target sequences in a eukaryotic cell, (b) a tracr mate sequence, and (c) one or more tracr sequences, and II. a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme comprising at least

one or more nuclear localization sequences, wherein (a), (b) and (c) are arranged in a 5' to 3' orientation, wherein components I and II are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, or a multiplexed CRISPR enzyme system, wherein the system is encoded by a vector system comprising one or more vectors comprising I. a first regulatory element operably linked to (a) one or more guide sequences capable of hybridizing to a target sequence in a cell, and (b) at least one or more tracr mate sequences, II. a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme, and III. a third regulatory element operably linked to a tracr sequence, wherein components I, II and III are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, and wherein in the multiplexed system multiple guide sequences and a single tracr sequence is used; and wherein one or more of the guide, tracr and tracr mate sequences are modified to improve stability.

**[0023]** In aspects of the invention, the modification comprises an engineered secondary structure. For example, the modification can comprise a reduction in a region of hybridization between the tracr mate sequence and the tracr sequence. For example, the modification also may comprise fusing the tracr mate sequence and the tracr sequence through an artificial loop. The modification may comprise the tracr sequence having a length between 40 and 120bp. In embodiments of the invention, the tracr sequence is between 40 bp and full length of the tracr. In certain embodiments, the length of tracrRNA includes at least nucleotides 1-67 and in some embodiments at least nucleotides 1-85 of the wild type tracrRNA. In some embodiments, at least nucleotides corresponding to nucleotides 1-67 or 1-85 of wild type *S. pyogenes* Cas9 tracrRNA may be used. Where the CRISPR system uses enzymes other than Cas9, or other than SpCas9, then corresponding nucleotides in the relevant wild type tracrRNA may be present. In some embodiments, the length of tracrRNA includes no more than nucleotides 1-67 or 1-85 of the wild type tracrRNA. The modification may comprise sequence optimization. In certain aspects, sequence optimization may comprise reducing the incidence of polyT sequences in the tracr and/or tracr mate sequence. Sequence optimization may be combined with reduction in the region of hybridization between the tracr mate sequence and the tracr sequence; for example, a reduced length tracr sequence.

**[0024]** In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises reduction in polyT sequences in the tracr and/or tracr mate sequence. In some aspects of the invention, one or more Ts present in a poly-T sequence of the relevant wild type sequence (that is, a stretch of more than 3, 4, 5, 6, or more contiguous T bases; in some embodiments, a stretch of no more than 10, 9, 8, 7, 6 contiguous T bases) may be substituted with a non-T nucleotide, e.g., an A, so that the string is broken down into smaller stretches of Ts with each stretch having 4, or fewer than 4 (for example, 3 or 2) contiguous Ts. Bases other than A may be used for substitution, for example C or G, or non-naturally occurring nucleotides or modified nucleotides. If the string of Ts is involved in the formation of a hairpin (or stem loop), then it is advantageous that the complementary base for the non-T base be changed to complement the non-T nucleotide. For example, if the non-T base is an A, then its complement may be changed to a T, e.g., to preserve or assist in the preservation of secondary structure. For instance, 5'-TTTTT can be altered to become 5'-TTTAT and the complementary 5'-AAAAA can be changed into 5'-ATAAA.

**[0025]** In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises adding a polyT terminator sequence. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises adding a polyT terminator sequence in tracr and/or tracr mate sequences. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises adding a polyT terminator sequence in the guide sequence. The polyT terminator sequence may comprise 5 contiguous T bases, or more than 5.

**[0026]** In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises altering loops and/or hairpins. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises providing a minimum of two hairpins in the guide sequence. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises providing a hairpin formed by complementation between the tracr and tracr mate (direct repeat) sequence. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises providing one or more further hairpin(s) at or towards the 3' end of the tracrRNA sequence. For example, a hairpin may be formed by providing self complementary sequences within the tracrRNA sequence joined by a loop such that a hairpin is formed on self folding. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises providing additional hairpins added to the 3' of the guide sequence. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises extending the 5' end of the guide sequence. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein

the modification comprises providing one or more hairpins in the 5' end of the guide sequence. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises appending the sequence (5'-AGGACGAAGTCCTAA) to the 5' end of the guide sequence. Other sequences suitable for forming hairpins will be known to the skilled person, and may be used in certain aspects of the invention. In some aspects of the invention, at least 2, 3, 4, 5, or more additional hairpins are provided. In some aspects of the invention, no more than 10, 9, 8, 7, 6 additional hairpins are provided. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises two hairpins. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises three hairpins. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises at most five hairpins.

**[0027]** In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises providing cross linking, or providing one or more modified nucleotides in the polynucleotide sequence. Modified nucleotides and/or cross linking may be provided in any or all of the tracr, tracr mate, and/or guide sequences, and/or in the enzyme coding sequence, and/or in vector sequences. Modifications may include inclusion of at least one non naturally occurring nucleotide, or a modified nucleotide, or analogs thereof. Modified nucleotides may be modified at the ribose, phosphate, and/or base moiety. Modified nucleotides may include 2'-O-methyl analogs, 2'-deoxy analogs, or 2'-fluoro analogs. The nucleic acid backbone may be modified, for example, a phosphorothioate backbone may be used. The use of locked nucleic acids (LNA) or bridged nucleic acids (BNA) may also be possible. Further examples of modified bases include, but are not limited to, 2-aminopurine, 5-bromo-uridine, pseudouridine, inosine, 7-methylguanosine.

**[0028]** It will be understood that any or all of the above modifications may be provided in isolation or in combination in a given CRISPR-Cas system or CRISPR enzyme system. Such a system may include one, two, three, four, five, or more of said modifications.

**[0029]** In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the CRISPR enzyme is a type II CRISPR system enzyme, e.g., a Cas9 enzyme. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the CRISPR enzyme is comprised of less than one thousand amino acids, or less than four thousand amino acids. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the Cas9 enzyme is StCas9 or SlCas9, or the Cas9 enzyme is a Cas9 enzyme from an organism selected from the group consisting of genus *Streptococcus*, *Campylobacter*, *Nitratifactor*, *Staphylococcus*, *Parvibaculum*, *Roseburia*, *Neisseria*, *Gluconacetobacter*, *Azospirillum*, *Sphaerochaeta*, *Lactobacillus*, *Eubacterium* or *Corynebacter*. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the CRISPR enzyme is a nuclease directing cleavage of both strands at the location of the target sequence.

**[0030]** In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the first regulatory element is a polymerase III promoter. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the second regulatory element is a polymerase II promoter.

**[0031]** In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the guide sequence comprises at least fifteen nucleotides.

**[0032]** In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises optimized tracr sequence and/or optimized guide sequence RNA and/or co-fold structure of tracr sequence and/or tracr mate sequence(s) and/or stabilizing secondary structures of tracr sequence and/or tracr sequence with a reduced region of base-pairing and/or tracr sequence fused RNA elements; and/or, in the multiplexed system there are two RNAs comprising a tracer and comprising a plurality of guides or one RNA comprising a plurality of chimerics.

**[0033]** In aspects of the invention the chimeric RNA architecture is further optimized according to the results of mutagenesis studies. In chimeric RNA with two or more hairpins, mutations in the proximal direct repeat to stabilize the hairpin may result in ablation of CRISPR complex activity. Mutations in the distal direct repeat to shorten or stabilize the hairpin may have no effect on CRISPR complex activity. Sequence randomization in the bulge region between the proximal and distal repeats may significantly reduce CRISPR complex activity. Single base pair changes or sequence randomization in the linker region between hairpins may result in complete loss of CRISPR complex activity. Hairpin stabilization of the distal hairpins that follow the first hairpin after the guide sequence may result in maintenance or improvement of CRISPR complex activity. Accordingly, in preferred embodiments of the invention, the chimeric RNA architecture may be further optimized by generating a smaller chimeric RNA which may be beneficial for therapeutic delivery options and other uses and this may be achieved by altering the distal direct repeat so as to shorten or stabilize the hairpin. In further preferred embodiments of the invention, the chimeric RNA architecture may be further optimized by stabilizing one or more of the distal hairpins. Stabilization of hairpins may include modifying sequences suitable for forming hairpins. In some aspects of the invention, at least 2, 3, 4, 5, or more additional hairpins are provided. In some aspects of the invention, no more than 10, 9, 8, 7, 6 additional hairpins are provided. In some aspects of the invention stabilization may be cross linking and other modifications. Modifications may include inclusion of at least one non naturally occurring nucleotide, or a modified nucleotide, or analogs thereof. Modified nucleotides may be modified at the ribose, phosphate, and/or base moiety. Modified nucleotides may include 2'-O-methyl analogs, 2'-deoxy analogs, or 2'-fluoro

analogues. The nucleic acid backbone may be modified, for example, a phosphorothioate backbone may be used. The use of locked nucleic acids (LNA) or bridged nucleic acids (BNA) may also be possible. Further examples of modified bases include, but are not limited to, 2-aminopurine, 5-bromo-uridine, pseudouridine, inosine, 7-methylguanosine.

**[0034]** In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the CRISPR enzyme is codon-optimized for expression in a eukaryotic cell.

**[0035]** Accordingly, in some aspects of the invention, the length of tracrRNA required in a construct of the invention, e.g., a chimeric construct, need not necessarily be fixed, and in some aspects of the invention it can be between 40 and 120bp, and in some aspects of the invention up to the full length of the tracr, e.g., in some aspects of the invention, until the 3' end of tracr as punctuated by the transcription termination signal in the bacterial genome. In certain embodiments, the length of tracrRNA includes at least nucleotides 1-67 and in some embodiments at least nucleotides 1-85 of the wild type tracrRNA. In some embodiments, at least nucleotides corresponding to nucleotides 1-67 or 1-85 of wild type *S. pyogenes* Cas9 tracrRNA may be used. Where the CRISPR system uses enzymes other than Cas9, or other than SpCas9, then corresponding nucleotides in the relevant wild type tracrRNA may be present. In some embodiments, the length of tracrRNA includes no more than nucleotides 1-67 or 1-85 of the wild type tracrRNA. With respect to sequence optimization (e.g., reduction in polyT sequences), e.g., as to strings of Ts internal to the tracr mate (direct repeat) or tracrRNA, in some aspects of the invention, one or more Ts present in a poly-T sequence of the relevant wild type sequence (that is, a stretch of more than 3, 4, 5, 6, or more contiguous T bases; in some embodiments, a stretch of no more than 10, 9, 8, 7, 6 contiguous T bases) may be substituted with a non-T nucleotide, e.g., an A, so that the string is broken down into smaller stretches of Ts with each stretch having 4, or fewer than 4 (for example, 3 or 2) contiguous Ts. If the string of Ts is involved in the formation of a hairpin (or stem loop), then it is advantageous that the complementary base for the non-T base be changed to complement the non-T nucleotide. For example, if the non-T base is an A, then its complement may be changed to a T, e.g., to preserve or assist in the preservation of secondary structure. For instance, 5'-TTTTT can be altered to become 5'-TTTAT and the complementary 5'-AAAAA can be changed into 5'-ATAAA. As to the presence of polyT terminator sequences in tracr + tracr mate transcript, e.g., a polyT terminator (TTTTT or more), in some aspects of the invention it is advantageous that such be added to end of the transcript, whether it is in two RNA (tracr and tracr mate) or single guide RNA form. Concerning loops and hairpins in tracr and tracr mate transcripts, in some aspects of the invention it is advantageous that a minimum of two hairpins be present in the chimeric guide RNA. A first hairpin can be the hairpin formed by complementation between the tracr and tracr mate (direct repeat) sequence. A second hairpin can be at the 3' end of the tracrRNA sequence, and this can provide secondary structure for interaction with Cas9. Additional hairpins may be added to the 3' of the guide RNA, e.g., in some aspects of the invention to increase the stability of the guide RNA. Additionally, the 5' end of the guide RNA, in some aspects of the invention, may be extended. In some aspects of the invention, one may consider 20bp in the 5' end as a guide sequence. The 5' portion may be extended. One or more hairpins can be provided in the 5' portion, e.g., in some aspects of the invention, this may also improve the stability of the guide RNA. In some aspects of the invention, the specific hairpin can be provided by appending the sequence (5'-AGGACGAAGTCCTAA) to the 5' end of the guide sequence, and, in some aspects of the invention, this may help improve stability. Other sequences suitable for forming hairpins will be known to the skilled person, and may be used in certain aspects of the invention. In some aspects of the invention, at least 2, 3, 4, 5, or more additional hairpins are provided. In some aspects of the invention, no more than 10, 9, 8, 7, 6 additional hairpins are provided. The foregoing also provides aspects of the invention involving secondary structure in guide sequences. In some aspects of the invention there may be cross linking and other modifications, e.g., to improve stability. Modifications may include inclusion of at least one non naturally occurring nucleotide, or a modified nucleotide, or analogs thereof. Modified nucleotides may be modified at the ribose, phosphate, and/or base moiety. Modified nucleotides may include 2'-O-methyl analogs, 2'-deoxy analogs, or 2'-fluoro analogs. The nucleic acid backbone may be modified, for example, a phosphorothioate backbone may be used. The use of locked nucleic acids (LNA) or bridged nucleic acids (BNA) may also be possible. Further examples of modified bases include, but are not limited to, 2-aminopurine, 5-bromo-uridine, pseudouridine, inosine, 7-methylguanosine. Such modifications or cross linking may be present in the guide sequence or other sequences adjacent the guide sequence.

**[0036]** Accordingly, it is an object of the invention not to encompass within the invention any previously known product, process of making the product, or method of using the product such that Applicants reserve the right and hereby disclose a disclaimer of any previously known product, process, or method. It is further noted that the invention does not intend to encompass within the scope of the invention any product, process, or making of the product or method of using the product, which does not meet the written description and enablement requirements of the USPTO (35 U.S.C. § 112, first paragraph) or the EPO (Article 83 of the EPC), such that Applicants reserve the right and hereby disclose a disclaimer of any previously described product, process of making the product, or method of using the product.

**[0037]** It is noted that in this disclosure and particularly in the claims and/or paragraphs, terms such as "comprises", "comprising", "comprising" and the like can have the meaning attributed to it in U.S. Patent law; e.g., they can mean "includes", "included", "including", and the like; and that terms such as "consisting essentially of" and "consists essentially of" have the meaning ascribed to them in U.S. Patent law, e.g., they allow for elements not explicitly recited, but exclude

elements that are found in the prior art or that affect a basic or novel characteristic of the invention. These and other embodiments are disclosed or are obvious from and encompassed by, the following Detailed Description.

## BRIEF DESCRIPTION OF THE DRAWINGS

**[0038]** The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:

**Figure 1** shows a schematic model of the CRISPR system. The Cas9 nuclease from *Streptococcus pyogenes* (yellow) is targeted to genomic DNA by a synthetic guide RNA (sgRNA) consisting of a 20-nt guide sequence (blue) and a scaffold (red). The guide sequence base-pairs with the DNA target (blue), directly upstream of a requisite 5'-NGG protospacer adjacent motif (PAM; magenta), and Cas9 mediates a double-stranded break (DSB) ~3 bp upstream of the PAM (red triangle).

**Figure 2A-F** illustrates an exemplary CRISPR system, a possible mechanism of action, an example adaptation for expression in eukaryotic cells, and results of tests assessing nuclear localization and CRISPR activity.

**Figure 3A-C** illustrates an exemplary expression cassette for expression of CRISPR system elements in eukaryotic cells, predicted structures of example guide sequences, and CRISPR system activity as measured in eukaryotic and prokaryotic cells.

**Figure 4A-D** illustrates results of an evaluation of SpCas9 specificity for an example target.

**Figure 5A-G** illustrates an exemplary vector system and results for its use in directing homologous recombination in eukaryotic cells.

**Figure 6A-C** illustrates a comparison of different tracrRNA transcripts for Cas9-mediated gene targeting.

**Figure 7A-D** illustrates an exemplary CRISPR system, an example adaptation for expression in eukaryotic cells, and results of tests assessing CRISPR activity.

**Figure 8A-C** illustrates exemplary manipulations of a CRISPR system for targeting of genomic loci in mammalian cells.

**Figure 9A-B** illustrates the results of a Northern blot analysis of crRNA processing in mammalian cells.

**Figure 10A-C** illustrates a schematic representation of chimeric RNAs and results of SURVEYOR assays for CRISPR system activity in eukaryotic cells.

**Figure 11A-B** illustrates a graphical representation of the results of SURVEYOR assays for CRISPR system activity in eukaryotic cells.

**Figure 12** illustrates predicted secondary structures for exemplary chimeric RNAs comprising a guide sequence, tracr mate sequence, and tracr sequence.

**Figure 13** is a phylogenetic tree of Cas genes

**Figure 14A-F** shows the phylogenetic analysis revealing five families of Cas9s, including three groups of large Cas9s (~1400 amino acids) and two of small Cas9s (~1100 amino acids).

**Figure 15** shows a graph depicting the function of different optimized guide RNAs.

**Figure 16** shows the sequence and structure of different guide chimeric RNAs.

**Figure 17** shows the co-fold structure of the tracrRNA and direct repeat.

**Figure 18 A and B** shows data from the StlCas9 chimeric guide RNA optimization *in vitro*.

**Figure 19A-B** shows cleavage of either unmethylated or methylated targets by SpCas9 cell lysate.

**Figure 20A-G** shows the optimization of guide RNA architecture for SpCas9-mediated mammalian genome editing.

(a) Schematic of bicistronic expression vector (PX330) for U6 promoter-driven single guide RNA (sgRNA) and CBh promoter-driven human codon-optimized *Streptococcus pyogenes* Cas9 (*hSpCas9*) used for all subsequent experiments. The sgRNA consists of a 20-nt guide sequence (blue) and scaffold (red), truncated at various positions as indicated. (b) SURVEYOR assay for SpCas9-mediated indels at the human *EMX1* and *PVALB* loci. Arrows indicate the expected SURVEYOR fragments ( $n = 3$ ). (c) Northern blot analysis for the four sgRNA truncation architectures, with U1 as loading control. (d) Both wildtype (wt) or nickase mutant (D10A) of SpCas9 promoted insertion of a *HindIII* site into the human *EMX1* gene. Single stranded oligonucleotides (ssODNs), oriented in either the sense or antisense direction relative to genome sequence, were used as homologous recombination templates. (e) Schematic of the human *SERPINB5* locus. sgRNAs and PAMs are indicated by colored bars above sequence; methylcytosine (Me) are highlighted (pink) and numbered relative to the transcriptional start site (TSS, +1). (f) Methylation status of *SERPINB5* assayed by bisulfite sequencing of 16 clones. Filled circles, methylated CpG; open circles, unmethylated CpG. (g) Modification efficiency by three sgRNAs targeting the methylated region of *SERPINB5*, assayed by deep sequencing ( $n = 2$ ). Error bars indicate Wilson intervals (Online Methods).

**Figure 21A-B** shows the further optimization of CRISPR-Cas sgRNA architecture. (a) Schematic of four additional

sgRNA architectures, I-IV. Each consists of a 20-nt guide sequence (blue) joined to the direct repeat (DR, grey), which hybridizes to the tracrRNA (red). The DR-tracrRNA hybrid is truncated at +12 or +22, as indicated, with an artificial GAAA stem loop. tracrRNA truncation positions are numbered according to the previously reported transcription start site for tracrRNA. sgRNA architectures II and IV carry mutations within their poly-U tracts, which could serve as premature transcriptional terminators. (b) SURVEYOR assay for SpCas9-mediated indels at the human *EMX1* locus for target sites 1-3. Arrows indicate the expected SURVEYOR fragments ( $n = 3$ ).

**Figure 22** illustrates visualization of some target sites in the human genome.

**Figure 23A-B** shows (A) a schematic of the sgRNA and (B) the SURVEYOR analysis of five sgRNA variants for SaCas9 for an optimal truncated architecture with highest cleavage efficiency

**[0039]** The figures herein are for illustrative purposes only and are not necessarily drawn to scale.

## DETAILED DESCRIPTION OF THE INVENTION

**[0040]** The terms "polynucleotide", "nucleotide", "nucleotide sequence", "nucleic acid" and "oligonucleotide" are used interchangeably. They refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides may have any three dimensional structure, and may perform any function, known or unknown. The following are non limiting examples of polynucleotides: coding or non-coding regions of a gene or gene fragment, loci (locus) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, short interfering RNA (siRNA), short-hairpin RNA (shRNA), micro-RNA (miRNA), ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A polynucleotide may comprise one or more modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The sequence of nucleotides may be interrupted by non nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component.

**[0041]** In aspects of the invention the terms "chimeric RNA", "chimeric guide RNA", "guide RNA", "single guide RNA" and "synthetic guide RNA" are used interchangeably and refer to the polynucleotide sequence comprising the guide sequence, the tracr sequence and the tracr mate sequence. The term "guide sequence" refers to the about 20bp sequence within the guide RNA that specifies the target site and may be used interchangeably with the terms "guide" or "spacer". The term "tracr mate sequence" may also be used interchangeably with the term "direct repeat(s)".

**[0042]** As used herein the term "wild type" is a term of the art understood by skilled persons and means the typical form of an organism, strain, gene or characteristic as it occurs in nature as distinguished from mutant or variant forms.

**[0043]** As used herein the term "variant" should be taken to mean the exhibition of qualities that have a pattern that deviates from what occurs in nature.

**[0044]** The terms "non-naturally occurring" or "engineered" are used interchangeably and indicate the involvement of the hand of man. The terms, when referring to nucleic acid molecules or polypeptides mean that the nucleic acid molecule or the polypeptide is at least substantially free from at least one other component with which they are naturally associated in nature and as found in nature.

**[0045]** "Complementarity" refers to the ability of a nucleic acid to form hydrogen bond(s) with another nucleic acid sequence by either traditional Watson-Crick base-pairing or other non-traditional types. A percent complementarity indicates the percentage of residues in a nucleic acid molecule which can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, 10 out of 10 being 50%, 60%, 70%, 80%, 90%, and 100% complementary). "Perfectly complementary" means that all the contiguous residues of a nucleic acid sequence will hydrogen bond with the same number of contiguous residues in a second nucleic acid sequence. "Substantially complementary" as used herein refers to a degree of complementarity that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% over a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, or more nucleotides, or refers to two nucleic acids that hybridize under stringent conditions.

**[0046]** As used herein, "stringent conditions" for hybridization refer to conditions under which a nucleic acid having complementarity to a target sequence predominantly hybridizes with the target sequence, and substantially does not hybridize to non-target sequences. Stringent conditions are generally sequence-dependent, and vary depending on a number of factors. In general, the longer the sequence, the higher the temperature at which the sequence specifically hybridizes to its target sequence. Non-limiting examples of stringent conditions are described in detail in Tijssen (1993), Laboratory Techniques In Biochemistry And Molecular Biology-Hybridization With Nucleic Acid Probes Part I, Second Chapter "Overview of principles of hybridization and the strategy of nucleic acid probe assay", Elsevier, N.Y.

**[0047]** "Hybridization" refers to a reaction in which one or more polynucleotides react to form a complex that is stabilized via hydrogen bonding between the bases of the nucleotide residues. The hydrogen bonding may occur by Watson Crick base pairing, Hoogsteen binding, or in any other sequence specific manner. The complex may comprise two strands

forming a duplex structure, three or more strands forming a multi stranded complex, a single self hybridizing strand, or any combination of these. A hybridization reaction may constitute a step in a more extensive process, such as the initiation of PCR, or the cleavage of a polynucleotide by an enzyme. A sequence capable of hybridizing with a given sequence is referred to as the "complement" of the given sequence.

**[0048]** As used herein, "stabilization" or "increasing stability" with respect to components of the CRISPR system relate to securing or steadying the structure of the molecule. This may be accomplished by introduction of one or mutations, including single or multiple base pair changes, increasing the number of hair pins, cross linking, breaking up particular stretches of nucleotides and other modifications. Modifications may include inclusion of at least one non naturally occurring nucleotide, or a modified nucleotide, or analogs thereof. Modified nucleotides may be modified at the ribose, phosphate, and/or base moiety. Modified nucleotides may include 2'-O-methyl analogs, 2'-deoxy analogs, or 2'-fluoro analogs. The nucleic acid backbone may be modified, for example, a phosphorothioate backbone may be used. The use of locked nucleic acids (LNA) or bridged nucleic acids (BNA) may also be possible. Further examples of modified bases include, but are not limited to, 2-aminopurine, 5-bromo-uridine, pseudouridine, inosine, 7-methylguanosine. These modifications may apply to any component of the CRISPR system. In a preferred embodiment these modifications are made to the RNA components, e.g. the guide RNA or chimeric polynucleotide sequence.

**[0049]** As used herein, "expression" refers to the process by which a polynucleotide is transcribed from a DNA template (such as into and mRNA or other RNA transcript) and/or the process by which a transcribed mRNA is subsequently translated into peptides, polypeptides, or proteins. Transcripts and encoded polypeptides may be collectively referred to as "gene product." If the polynucleotide is derived from genomic DNA, expression may include splicing of the mRNA in a eukaryotic cell.

**[0050]** The terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non amino acids. The terms also encompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component. As used herein the term "amino acid" includes natural and/or unnatural or synthetic amino acids, including glycine and both the D or L optical isomers, and amino acid analogs and peptidomimetics.

**[0051]** The terms "subject," "individual," and "patient" are used interchangeably herein to refer to a vertebrate, preferably a mammal, more preferably a human. Mammals include, but are not limited to, murines, simians, humans, farm animals, sport animals, and pets. Tissues, cells and their progeny of a biological entity obtained in vivo or cultured in vitro are also encompassed. In some embodiments, a subject may be an invertebrate animal, for example, an insect or a nematode; while in others, a subject may be a plant or a fungus.

**[0052]** The terms "therapeutic agent", "therapeutic capable agent" or "treatment agent" are used interchangeably and refer to a molecule or compound that confers some beneficial effect upon administration to a subject. The beneficial effect includes enablement of diagnostic determinations; amelioration of a disease, symptom, disorder, or pathological condition; reducing or preventing the onset of a disease, symptom, disorder or condition; and generally counteracting a disease, symptom, disorder or pathological condition.

**[0053]** As used herein, "treatment" or "treating," or "palliating" or "ameliorating" are used interchangeably. These terms refer to an approach for obtaining beneficial or desired results including but not limited to a therapeutic benefit and/or a prophylactic benefit. By therapeutic benefit is meant any therapeutically relevant improvement in or effect on one or more diseases, conditions, or symptoms under treatment. For prophylactic benefit, the compositions may be administered to a subject at risk of developing a particular disease, condition, or symptom, or to a subject reporting one or more of the physiological symptoms of a disease, even though the disease, condition, or symptom may not have yet been manifested.

**[0054]** The term "effective amount" or "therapeutically effective amount" refers to the amount of an agent that is sufficient to effect beneficial or desired results. The therapeutically effective amount may vary depending upon one or more of: the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art. The term also applies to a dose that will provide an image for detection by any one of the imaging methods described herein. The specific dose may vary depending on one or more of: the particular agent chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to be imaged, and the physical delivery system in which it is carried.

**[0055]** The practice of the present invention employs, unless otherwise indicated, conventional techniques of immunology, biochemistry, chemistry, molecular biology, microbiology, cell biology, genomics and recombinant DNA, which are within the skill of the art. See Sambrook, Fritsch and Maniatis, MOLECULAR CLONING: A LABORATORY MANUAL, 2nd edition (1989); CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (F. M. Ausubel, et al. eds., (1987)); the series METHODS IN ENZYMOLOGY (Academic Press, Inc.): PCR 2: A PRACTICAL APPROACH (M.J. MacPherson, B.D. Hames and G.R. Taylor eds. (1995)), Harlow and Lane, eds. (1988) ANTIBODIES, A LABORATORY MANUAL, and ANIMAL CELL CULTURE (R.I. Freshney, ed. (1987)).



**[0056]** Several aspects of the invention relate to vector systems comprising one or more vectors, or vectors as such. Vectors can be designed for expression of CRISPR transcripts (e.g. nucleic acid transcripts, proteins, or enzymes) in prokaryotic or eukaryotic cells. For example, CRISPR transcripts can be expressed in bacterial cells such as *Escherichia coli*, insect cells (using baculovirus expression vectors), yeast cells, or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.

**[0057]** Vectors may be introduced and propagated in a prokaryote. In some embodiments, a prokaryote is used to amplify copies of a vector to be introduced into a eukaryotic cell or as an intermediate vector in the production of a vector to be introduced into a eukaryotic cell (e.g. amplifying a plasmid as part of a viral vector packaging system). In some embodiments, a prokaryote is used to amplify copies of a vector and express one or more nucleic acids, such as to provide a source of one or more proteins for delivery to a host cell or host organism. Expression of proteins in prokaryotes is most often carried out in *Escherichia coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, such as to the amino terminus of the recombinant protein. Such fusion vectors may serve one or more purposes, such as: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Example fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988. Gene 67: 31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) that fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

**[0058]** Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amrann et al., (1988) Gene 69:301-315) and pET 11d (Studier et al., GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).

**[0059]** In some embodiments, a vector is a yeast expression vector. Examples of vectors for expression in yeast *Saccharomyces cerevisiae* include pYepSec1 (Baldari, et al., 1987. EMBO J. 6: 229-234), pMFa (Kuijan and Herskowitz, 1982. Cell 30: 933-943), pJRY88 (Schultz et al., 1987. Gene 54: 113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (Invitrogen Corp, San Diego, Calif.).

**[0060]** In some embodiments, a vector drives protein expression in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., SF9 cells) include the pAc series (Smith, et al., 1983. Mol. Cell. Biol. 3: 2156-2165) and the pVL series (Lucklow and Summers, 1989. Virology 170: 31-39).

**[0061]** In some embodiments, a vector is capable of driving expression of one or more sequences in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, 1987. Nature 329: 840) and pMT2PC (Kaufman, et al., 1987. EMBO J. 6: 187-195). When used in mammalian cells, the expression vector's control functions are typically provided by one or more regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, simian virus 40, and others disclosed herein and known in the art. For other suitable expression systems for both prokaryotic and eukaryotic cells see, e.g., Chapters 16 and 17 of Sambrook, et al., MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

**[0062]** In some embodiments, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, et al., 1987. Genes Dev. 1: 268-277), lymphoid-specific promoters (Calame and Eaton, 1988. Adv. Immunol. 43: 235-275), in particular promoters of T cell receptors (Winoto and Baltimore, 1989. EMBO J. 8: 729-733) and immunoglobulins (Baneiji, et al., 1983. Cell 33: 729-740; Queen and Baltimore, 1983. Cell 33: 741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle, 1989. Proc. Natl. Acad. Sci. USA 86: 5473-5477), pancreas-specific promoters (Edlund, et al., 1985. Science 230: 912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, e.g., the murine hox promoters (Kessel and Gruss, 1990. Science 249: 374-379) and the  $\alpha$ -fetoprotein promoter (Campes and Tilghman, 1989. Genes Dev. 3: 537-546).

**[0063]** In some embodiments, a regulatory element is operably linked to one or more elements of a CRISPR system so as to drive expression of the one or more elements of the CRISPR system. In general, CRISPRs (Clustered Regularly Interspaced Short Palindromic Repeats), also known as SPIDRs (SPacer Interspersed Direct Repeats), constitute a family of DNA loci that are usually specific to a particular bacterial species. The CRISPR locus comprises a distinct class of interspersed short sequence repeats (SSRs) that were recognized in *E. coli* (Ishino et al., J. Bacteriol., 169:5429-5433

[1987]; and Nakata et al., J. Bacteriol., 171:3553-3556 [1989]), and associated genes. Similar interspersed SSRs have been identified in *Haloferax mediterranei*, *Streptococcus pyogenes*, *Anabaena*, and *Mycobacterium tuberculosis* (See, Groenen et al., Mol. Microbiol., 10:1057-1065 [1993]; Hoe et al., Emerg. Infect. Dis., 5:254-263 [1999]; Masepohl et al., Biochim. Biophys. Acta 1307:26-30 [1996]; and Mojica et al., Mol. Microbiol., 17:85-93 [1995]). The CRISPR loci typically differ from other SSRs by the structure of the repeats, which have been termed short regularly spaced repeats (SRSRs) (Janssen et al., OMICS J. Integ. Biol., 6:23-33 [2002]; and Mojica et al., Mol. Microbiol., 36:244-246 [2000]). In general, the repeats are short elements that occur in clusters that are regularly spaced by unique intervening sequences with a substantially constant length (Mojica et al., [2000], supra). Although the repeat sequences are highly conserved between strains, the number of interspersed repeats and the sequences of the spacer regions typically differ from strain to strain (van Embden et al., J. Bacteriol., 182:2393-2401 [2000]). CRISPR loci have been identified in more than 40 prokaryotes (See e.g., Jansen et al., Mol. Microbiol., 43:1565-1575 [2002]; and Mojica et al., [2005]) including, but not limited to *Aeropyrum*, *Pyrobaculum*, *Sulfolobus*, *Archaeoglobus*, *Halocarcula*, *Methartohacterium*, *Methanococcus*, *Methanosarcina*, *Methartopyrus*, *Pyrococcus*, *Picrophilus*, *Thermoplasma*, *Corynebacterium*, *Mycobacterium*, *Streptomyces*, *Aquifex*, *Porphyromonas*, *Chlorobium*, *Thermus*, *Bacillus*, *Listeria*, *Staphylococcus*, *Clostridium*, *Thermoanaerobacter*, *Mycoplasma*, *Fusobacterium*, *Azarcus*, *Chromobacterium*, *Neisseria*, *Nitrosomonas*, *Desulfovibrio*, *Geobacter*, *Myxococcus*, *Campylobacter*, *Wolinella*, *Acinetobacter*, *Erwinia*, *Escherichia*, *Legionella*, *Methylococcus*, *Pasteurella*, *Photobacterium*, *Salmonella*, *Xanthomonas*, *Yersinia*, *Treponema*, and *Thermotoga*.

**[0064]** In general, "CRISPR system" refers collectively to transcripts and other elements involved in the expression of or directing the activity of CRISPR-associated ("Cas") genes, including sequences encoding a Cas gene, a tracr (trans-activating CRISPR) sequence (e.g. tracrRNA or an active partial tracrRNA), a tracr-mate sequence (encompassing a "direct repeat" and a tracrRNA-processed partial direct repeat in the context of an endogenous CRISPR system), a guide sequence (also referred to as a "spacer" in the context of an endogenous CRISPR system), or other sequences and transcripts from a CRISPR locus. In some embodiments, one or more elements of a CRISPR system is derived from a type I, type II, or type III CRISPR system. In some embodiments, one or more elements of a CRISPR system is derived from a particular organism comprising an endogenous CRISPR system, such as *Streptococcus pyogenes*. In general, a CRISPR system is characterized by elements that promote the formation of a CRISPR complex at the site of a target sequence (also referred to as a protospacer in the context of an endogenous CRISPR system). In the context of formation of a CRISPR complex, "target sequence" refers to a sequence to which a guide sequence is designed to have complementarity, where hybridization between a target sequence and a guide sequence promotes the formation of a CRISPR complex. Full complementarity is not necessarily required, provided there is sufficient complementarity to cause hybridisation and promote formation of a CRISPR complex. A target sequence may comprise any polynucleotide, such as DNA or RNA polynucleotides. In some embodiments, a target sequence is located in the nucleus or cytoplasm of a cell. In some embodiments, the target sequence may be within an organelle of a eukaryotic cell, for example, mitochondrion or chloroplast. A sequence or template that may be used for recombination into the targeted locus comprising the target sequences is referred to as an "editing template" or "editing polynucleotide" or "editing sequence". In aspects of the invention, an exogenous template polynucleotide may be referred to as an editing template. In an aspect of the invention the recombination is homologous recombination.

**[0065]** Typically, in the context of an endogenous CRISPR system, formation of a CRISPR complex (comprising a guide sequence hybridized to a target sequence and complexed with one or more Cas proteins) results in cleavage of one or both strands in or near (e.g. within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or more base pairs from) the target sequence. Without wishing to be bound by theory, the tracr sequence, which may comprise or consist of all or a portion of a wild-type tracr sequence (e.g. about or more than about 20, 26, 32, 45, 48, 54, 63, 67, 85, or more nucleotides of a wild-type tracr sequence), may also form part of a CRISPR complex, such as by hybridization along at least a portion of the tracr sequence to all or a portion of a tracr mate sequence that is operably linked to the guide sequence. In some embodiments, the tracr sequence has sufficient complementarity to a tracr mate sequence to hybridise and participate in formation of a CRISPR complex. As with the target sequence, it is believed that complete complementarity is not needed, provided there is sufficient to be functional. In some embodiments, the tracr sequence has at least 50%, 60%, 70%, 80%, 90%, 95% or 99% of sequence complementarity along the length of the tracr mate sequence when optimally aligned. In some embodiments, one or more vectors driving expression of one or more elements of a CRISPR system are introduced into a host cell such that expression of the elements of the CRISPR system direct formation of a CRISPR complex at one or more target sites. For example, a Cas enzyme, a guide sequence linked to a tracr-mate sequence, and a tracr sequence could each be operably linked to separate regulatory elements on separate vectors. Alternatively, two or more of the elements expressed from the same or different regulatory elements, may be combined in a single vector, with one or more additional vectors providing any components of the CRISPR system not included in the first vector. CRISPR system elements that are combined in a single vector may be arranged in any suitable orientation, such as one element located 5' with respect to ("upstream" of) or 3' with respect to ("downstream" of) a second element. The coding sequence of one element may be located on the same or opposite strand of the coding sequence of a second element, and oriented in the same or opposite direction. In some embodiments, a single promoter drives expression of a transcript encoding

a CRISPR enzyme and one or more of the guide sequence, tracr mate sequence (optionally operably linked to the guide sequence), and a tracr sequence embedded within one or more intron sequences (e.g. each in a different intron, two or more in at least one intron, or all in a single intron). In some embodiments, the CRISPR enzyme, guide sequence, tracr mate sequence, and tracr sequence are operably linked to and expressed from the same promoter.

**[0066]** In some embodiments, a vector comprises one or more insertion sites, such as a restriction endonuclease recognition sequence (also referred to as a "cloning site"). In some embodiments, one or more insertion sites (e.g. about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more insertion sites) are located upstream and/or downstream of one or more sequence elements of one or more vectors. In some embodiments, a vector comprises an insertion site upstream of a tracr mate sequence, and optionally downstream of a regulatory element operably linked to the tracr mate sequence, such that following insertion of a guide sequence into the insertion site and upon expression the guide sequence directs sequence-specific binding of a CRISPR complex to a target sequence in a eukaryotic cell. In some embodiments, a vector comprises two or more insertion sites, each insertion site being located between two tracr mate sequences so as to allow insertion of a guide sequence at each site. In such an arrangement, the two or more guide sequences may comprise two or more copies of a single guide sequence, two or more different guide sequences, or combinations of these. When multiple different guide sequences are used, a single expression construct may be used to target CRISPR activity to multiple different, corresponding target sequences within a cell. For example, a single vector may comprise about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or more guide sequences. In some embodiments, about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more such guide-sequence-containing vectors may be provided, and optionally delivered to a cell.

**[0067]** In some embodiments, a vector comprises a regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme, such as a Cas protein. Non-limiting examples of Cas proteins include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas10, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, homologs thereof, or modified versions thereof. These enzymes are known; for example, the amino acid sequence of *S. pyogenes* Cas9 protein may be found in the SwissProt database under accession number Q99ZW2. In some embodiments, the unmodified CRISPR enzyme has DNA cleavage activity, such as Cas9. In some embodiments the CRISPR enzyme is Cas9, and may be Cas9 from *S. pyogenes* or *S. pneumoniae*. In some embodiments, the CRISPR enzyme directs cleavage of one or both strands at the location of a target sequence, such as within the target sequence and/or within the complement of the target sequence. In some embodiments, the CRISPR enzyme directs cleavage of one or both strands within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500, or more base pairs from the first or last nucleotide of a target sequence. In some embodiments, a vector encodes a CRISPR enzyme that is mutated to with respect to a corresponding wild-type enzyme such that the mutated CRISPR enzyme lacks the ability to cleave one or both strands of a target polynucleotide containing a target sequence. For example, an aspartate-to-alanine substitution (D10A) in the RuvC I catalytic domain of Cas9 from *S. pyogenes* converts Cas9 from a nuclease that cleaves both strands to a nickase (cleaves a single strand). Other examples of mutations that render Cas9 a nickase include, without limitation, H840A, N854A, and N863A. In some embodiments, a Cas9 nickase may be used in combination with guide sequenc(es), e.g., two guide sequences, which target respectively sense and antisense strands of the DNA target. This combination allows both strands to be nicked and used to induce NHEJ. Applicants have demonstrated (data not shown) the efficacy of two nickase targets (i.e., sgRNAs targeted at the same location but to different strands of DNA) in inducing mutagenic NHEJ. A single nickase (Cas9-D10A with a single sgRNA) is unable to induce NHEJ and create indels but Applicants have shown that double nickase (Cas9-D10A and two sgRNAs targeted to different strands at the same location) can do so in human embryonic stem cells (hESCs). The efficiency is about 50% of nuclease (i.e., regular Cas9 without D10 mutation) in hESCs.

**[0068]** As a further example, two or more catalytic domains of Cas9 (RuvC I, RuvC II, and RuvC III) may be mutated to produce a mutated Cas9 substantially lacking all DNA cleavage activity. In some embodiments, a D10A mutation is combined with one or more of H840A, N854A, or N863A mutations to produce a Cas9 enzyme substantially lacking all DNA cleavage activity. In some embodiments, a CRISPR enzyme is considered to substantially lack all DNA cleavage activity when the DNA cleavage activity of the mutated enzyme is less than about 25%, 10%, 5%, 1%, 0.1%, 0.01%, or lower with respect to its non-mutated form. Other mutations may be useful; where the Cas9 or other CRISPR enzyme is from a species other than *S. pyogenes*, mutations in corresponding amino acids may be made to achieve similar effects.

**[0069]** In some embodiments, an enzyme coding sequence encoding a CRISPR enzyme is codon optimized for expression in particular cells, such as eukaryotic cells. The eukaryotic cells may be those of or derived from a particular organism, such as a mammal, including but not limited to human, mouse, rat, rabbit, dog, or non-human primate. In general, codon optimization refers to a process of modifying a nucleic acid sequence for enhanced expression in the host cells of interest by replacing at least one codon (e.g. about or more than about 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more codons) of the native sequence with codons that are more frequently or most frequently used in the genes of that host cell while maintaining the native amino acid sequence. Various species exhibit particular bias for certain codons of a particular amino acid. Codon bias (differences in codon usage between organisms) often correlates with the efficiency

of translation of messenger RNA (mRNA), which is in turn believed to be dependent on, among other things, the properties of the codons being translated and the availability of particular transfer RNA (tRNA) molecules. The predominance of selected tRNAs in a cell is generally a reflection of the codons used most frequently in peptide synthesis. Accordingly, genes can be tailored for optimal gene expression in a given organism based on codon optimization. Codon usage tables are readily available, for example, at the "Codon Usage Database", and these tables can be adapted in a number of ways. See Nakamura, Y., et al. "Codon usage tabulated from the international DNA sequence databases: status for the year 2000" Nucl. Acids Res. 28:292 (2000). Computer algorithms for codon optimizing a particular sequence for expression in a particular host cell are also available, such as Gene Forge (Aptagen; Jacobus, PA), are also available. In some embodiments, one or more codons (e.g. 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more, or all codons) in a sequence encoding a CRISPR enzyme correspond to the most frequently used codon for a particular amino acid.

**[0070]** In some embodiments, a vector encodes a CRISPR enzyme comprising one or more nuclear localization sequences (NLSs), such as about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs. In some embodiments, the CRISPR enzyme comprises about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs at or near the amino-terminus, about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs at or near the carboxy-terminus, or a combination of these (e.g. one or more NLS at the amino-terminus and one or more NLS at the carboxy terminus). When more than one NLS is present, each may be selected independently of the others, such that a single NLS may be present in more than one copy and/or in combination with one or more other NLSs present in one or more copies. In a preferred embodiment of the invention, the CRISPR enzyme comprises at most 6 NLSs. In some embodiments, an NLS is considered near the N- or C-terminus when the nearest amino acid of the NLS is within about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50, or more amino acids along the polypeptide chain from the N- or C-terminus. Typically, an NLS consists of one or more short sequences of positively charged lysines or arginines exposed on the protein surface, but other types of NLS are known. Non-limiting examples of NLSs include an NLS sequence derived from: the NLS of the SV40 virus large T-antigen, having the amino acid sequence PKKKRKV; the NLS from nucleoplasmin (e.g. the nucleoplasmin bipartite NLS with the sequence KRPAATKAGQAKKKK); the c-myc NLS having the amino acid sequence PAAKRVKLD or RQRRNELKRSP; the hRNPA1 M9 NLS having the sequence NQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRN-QGGY; the sequence RMRIZFKNKGKDTAELRRRRVEVSVELRKAKKDEQILKRRNV of the IBB domain from importin-alpha; the sequences VSRKRPRP and PPKKARED of the myoma T protein; the sequence POPKKKPL of human p53; the sequence SALIKKKKKMAP of mouse c-abl IV; the sequences DRLRR and PKQKKRK of the influenza virus NS1; the sequence RKLKKKIKKL of the Hepatitis virus delta antigen; the sequence REKKKFLKRR of the mouse Mx1 protein; the sequence KRKGDEVDGVDEVAKKKSKK of the human poly(ADP-ribose) polymerase; and the sequence RKCLQAG-MNLEARKTKK of the steroid hormone receptors (human) glucocorticoid.

**[0071]** In general, the one or more NLSs are of sufficient strength to drive accumulation of the CRISPR enzyme in a detectable amount in the nucleus of a eukaryotic cell. In general, strength of nuclear localization activity may derive from the number of NLSs in the CRISPR enzyme, the particular NLS(s) used, or a combination of these factors. Detection of accumulation in the nucleus may be performed by any suitable technique. For example, a detectable marker may be fused to the CRISPR enzyme, such that location within a cell may be visualized, such as in combination with a means for detecting the location of the nucleus (e.g. a stain specific for the nucleus such as DAPI). Examples of detectable markers include fluorescent proteins (such as Green fluorescent proteins, or GFP; RFP; CFP), and epitope tags (HA tag, flag tag, SNAP tag). Cell nuclei may also be isolated from cells, the contents of which may then be analyzed by any suitable process for detecting protein, such as immunohistochemistry, Western blot, or enzyme activity assay. Accumulation in the nucleus may also be determined indirectly, such as by an assay for the effect of CRISPR complex formation (e.g. assay for DNA cleavage or mutation at the target sequence, or assay for altered gene expression activity affected by CRISPR complex formation and/or CRISPR enzyme activity), as compared to a control not exposed to the CRISPR enzyme or complex, or exposed to a CRISPR enzyme lacking the one or more NLSs.

**[0072]** In general, a guide sequence is any polynucleotide sequence having sufficient complementarity with a target polynucleotide sequence to hybridize with the target sequence and direct sequence-specific binding of a CRISPR complex to the target sequence. In some embodiments, the degree of complementarity between a guide sequence and its corresponding target sequence, when optimally aligned using a suitable alignment algorithm, is about or more than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or more. Optimal alignment may be determined with the use of any suitable algorithm for aligning sequences, non-limiting example of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler Transform (e.g. the Burrows Wheeler Aligner), ClustalW, Clustal X, BLAT, Novoalign (Novocraft Technologies, ELAND (Illumina, San Diego, CA), SOAP (available at soap.genomics.org.cn), and Maq (available at maq.sourceforge.net). In some embodiments, a guide sequence is about or more than about 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75, or more nucleotides in length. In some embodiments, a guide sequence is less than about 75, 50, 45, 40, 35, 30, 25, 20, 15, 12, or fewer nucleotides in length. The ability of a guide sequence to direct sequence-specific binding of a CRISPR complex to a target sequence may be assessed by any suitable assay. For example, the components of a CRISPR system sufficient to form a CRISPR complex, including the guide sequence to be tested, may be provided

to a host cell having the corresponding target sequence, such as by transfection with vectors encoding the components of the CRISPR sequence, followed by an assessment of preferential cleavage within the target sequence, such as by Surveyor assay as described herein. Similarly, cleavage of a target polynucleotide sequence may be evaluated in a test tube by providing the target sequence, components of a CRISPR complex, including the guide sequence to be tested and a control guide sequence different from the test guide sequence, and comparing binding or rate of cleavage at the target sequence between the test and control guide sequence reactions. Other assays are possible, and will occur to those skilled in the art.

**[0073]** A guide sequence may be selected to target any target sequence. In some embodiments, the target sequence is a sequence within a genome of a cell. Exemplary target sequences include those that are unique in the target genome. For example, for the *S. pyogenes* Cas9, a unique target sequence in a genome may include a Cas9 target site of the form MMMMMMMNNNNNNNNNNNNXGG where NNNNNNNNNNNNNXGG (N is A, G, T, or C; and X can be anything) has a single occurrence in the genome. A unique target sequence in a genome may include an *S. pyogenes* Cas9 target site of the form MMMMMMMNNNNNNNNNNNNXGG where NNNNNNNNNNNNNXGG (N is A, G, T, or C; and X can be anything) has a single occurrence in the genome. For the *S. thermophilus* CRISPR1 Cas9, a unique target sequence in a genome may include a Cas9 target site of the form MMMMMMMNNNNNNNNNNNNXXAGAAW where NNNNNNNNNNNNNXXAGAAW (N is A, G, T, or C; X can be anything; and W is A or T) has a single occurrence in the genome. A unique target sequence in a genome may include an *S. thermophilus* CRISPR1 Cas9 target site of the form MMMMMMMNNNNNNNNNNNNXXAGAAW where NNNNNNNNNNNNNXXAGAAW (N is A, G, T, or C; X can be anything; and W is A or T) has a single occurrence in the genome. For the *S. pyogenes* Cas9, a unique target sequence in a genome may include a Cas9 target site of the form MMMMMMMNNNNNNNNNNNNXGGXG where NNNNNNNNNNNNNXGGXG (N is A, G, T, or C; and X can be anything) has a single occurrence in the genome. A unique target sequence in a genome may include an *S. pyogenes* Cas9 target site of the form MMMMMMMNNNNNNNNNNNNXGGXG where NNNNNNNNNNNNNXGGXG (N is A, G, T, or C; and X can be anything) has a single occurrence in the genome. In each of these sequences "M" may be A, G, T, or C, and need not be considered in identifying a sequence as unique.

**[0074]** In some embodiments, a guide sequence is selected to reduce the degree of secondary structure within the guide sequence. Secondary structure may be determined by any suitable polynucleotide folding algorithm. Some programs are based on calculating the minimal Gibbs free energy. An example of one such algorithm is mFold, as described by Zuker and Stiegler (Nucleic Acids Res. 9 (1981), 133-148). Another example folding algorithm is the online webserver RNAfold, developed at Institute for Theoretical Chemistry at the University of Vienna, using the centroid structure prediction algorithm (see e.g. A.R. Gruber et al., 2008, Cell 106(1): 23-24; and PA Carr and GM Church, 2009, Nature Biotechnology 27(12): 1151-62). Further algorithms may be found in U.S. application Serial No. TBA (Broad Reference BI-2012/084 44790.11.2022); incorporated herein by reference.

**[0075]** In general, a tracr mate sequence includes any sequence that has sufficient complementarity with a tracr sequence to promote one or more of: (1) excision of a guide sequence flanked by tracr mate sequences in a cell containing the corresponding tracr sequence; and (2) formation of a CRISPR complex at a target sequence, wherein the CRISPR complex comprises the tracr mate sequence hybridized to the tracr sequence. In general, degree of complementarity is with reference to the optimal alignment of the tracr mate sequence and tracr sequence, along the length of the shorter of the two sequences. Optimal alignment may be determined by any suitable alignment algorithm, and may further account for secondary structures, such as self-complementarity within either the tracr sequence or tracr mate sequence. In some embodiments, the degree of complementarity between the tracr sequence and tracr mate sequence along the length of the shorter of the two when optimally aligned is about or more than about 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97.5%, 99%, or higher. Example illustrations of optimal alignment between a tracr sequence and a tracr mate sequence are provided in Figures 12B and 13B. In some embodiments, the tracr sequence is about or more than about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50, or more nucleotides in length. In some embodiments, the tracr sequence and tracr mate sequence are contained within a single transcript, such that hybridization between the two produces a transcript having a secondary structure, such as a hairpin. Preferred loop forming sequences for use in hairpin structures are four nucleotides in length, and most preferably have the sequence GAAA. However, longer or shorter loop sequences may be used, as may alternative sequences. The sequences preferably include a nucleotide triplet (for example, AAA), and an additional nucleotide (for example C or G). Examples of loop forming sequences include CAAA and AAAG. In an embodiment of the invention, the transcript or transcribed polynucleotide sequence has at least two or more hairpins. In preferred embodiments, the transcript has two, three, four or five hairpins. In a further embodiment of the invention, the transcript has at most five hairpins. In some embodiments, the single transcript further includes a transcription termination sequence; preferably this is a polyT sequence, for example six T nucleotides. An example illustration of such a hairpin structure is provided in the lower portion of Figure 13B, where the portion of the sequence 5' of the final "N" and upstream of the loop corresponds to the tracr mate sequence, and the portion of the sequence 3' of the loop corresponds to the tracr sequence. Further non-limiting examples of single polynucleotides comprising a guide sequence, a tracr mate sequence, and a tracr sequence are as follows (listed 5' to 3'),

where "N" represents a base of a guide sequence, the first block of lower case letters represent the tracr mate sequence, and the second block of lower case letters represent the tracr sequence, and the final poly-T sequence represents the transcription terminator: (1) NNNNNNNNNNNNNNNNNNNNNggtttgtactctcaagatttaGAAAtaatcttcgagaagctacaagataa-ggctt catgccgaaatcaacacctgtcattttatggcagggtgttttcgtatttaaTTTTTT; (2) NNNNNNNNNNNNNNNNNNNNNggtttgtactct-caGAAAtgcagaagctacaagataaggcttcatgccgaaatca acacctgtcattttatggcagggtgttttcgtatttaaTTTTTT; (3) NNNNNN-NNNNNNNNNNNNNNNNNNNNggtttgtactctcaGAAAtgcagaagctacaagataaggcttcatgccgaaatca acacctgtcattttatggcagggt-gtTTTTTT; (4) NNNNNNNNNNNNNNNNNNNNNgtttagagctaGAAAtagcaagtaaaataaggctagtcggttatcaacttgaaaa agt-ggcaccgagtcggtgcTTTTTT; (5) NNNNNNNNNNNNNNNNNNNNNgtttagagctaGAAATAGcaagtaaaataaggctagtc-cggttatcaacttgaa aaagtgtTTTTTT; and (6) NNNNNNNNNNNNNNNNNNNNNgtttagagctagAAATAGcaagtaaaataag-gctagtcggttatcaTTTTTT TTT. In some embodiments, sequences (1) to (3) are used in combination with Cas9 from *S. thermophilus* CRISPR1. In some embodiments, sequences (4) to (6) are used in combination with Cas9 from *S. pyogenes*. In some embodiments, the tracr sequence is a separate transcript from a transcript comprising the tracr mate sequence (such as illustrated in the top portion of Figure 13B).

**[0076]** In some embodiments, a recombination template is also provided. A recombination template may be a component of another vector as described herein, contained in a separate vector, or provided as a separate polynucleotide. In some embodiments, a recombination template is designed to serve as a template in homologous recombination, such as within or near a target sequence nicked or cleaved by a CRISPR enzyme as a part of a CRISPR complex. A template polynucleotide may be of any suitable length, such as about or more than about 10, 15, 20, 25, 50, 75, 100, 150, 200, 500, 1000, or more nucleotides in length. In some embodiments, the template polynucleotide is complementary to a portion of a polynucleotide comprising the target sequence. When optimally aligned, a template polynucleotide might overlap with one or more nucleotides of a target sequences (e.g. about or more than about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100 or more nucleotides). In some embodiments, when a template sequence and a polynucleotide comprising a target sequence are optimally aligned, the nearest nucleotide of the template polynucleotide is within about 1, 5, 10, 15, 20, 25, 50, 75, 100, 200, 300, 400, 500, 1000, 5000, 10000, or more nucleotides from the target sequence.

**[0077]** In some embodiments, the CRISPR enzyme is part of a fusion protein comprising one or more heterologous protein domains (e.g. about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more domains in addition to the CRISPR enzyme). A CRISPR enzyme fusion protein may comprise any additional protein sequence, and optionally a linker sequence between any two domains. Examples of protein domains that may be fused to a CRISPR enzyme include, without limitation, epitope tags, reporter gene sequences, and protein domains having one or more of the following activities: methylase activity, demethylase activity, transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, RNA cleavage activity and nucleic acid binding activity. Non-limiting examples of epitope tags include histidine (His) tags, V5 tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags. Examples of reporter genes include, but are not limited to, glutathione-S-transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT) beta-galactosidase, beta-glucuronidase, luciferase, green fluorescent protein (GFP), HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), and autofluorescent proteins including blue fluorescent protein (BFP). A CRISPR enzyme may be fused to a gene sequence encoding a protein or a fragment of a protein that bind DNA molecules or bind other cellular molecules, including but not limited to maltose binding protein (MBP), S-tag, Lex A DNA binding domain (DBD) fusions, GAL4 DNA binding domain fusions, and herpes simplex virus (HSV) BP16 protein fusions. Additional domains that may form part of a fusion protein comprising a CRISPR enzyme are described in US20110059502, incorporated herein by reference. In some embodiments, a tagged CRISPR enzyme is used to identify the location of a target sequence.

**[0078]** In some aspects, the invention provides methods comprising delivering one or more polynucleotides, such as or one or more vectors as described herein, one or more transcripts thereof, and/or one or more proteins transcribed therefrom, to a host cell. In some aspects, the invention further provides cells produced by such methods, and organisms (such as animals, plants, or fungi) comprising or produced from such cells. In some embodiments, a CRISPR enzyme in combination with (and optionally complexed with) a guide sequence is delivered to a cell. Conventional viral and non-viral based gene transfer methods can be used to introduce nucleic acids in mammalian cells or target tissues. Such methods can be used to administer nucleic acids encoding components of a CRISPR system to cells in culture, or in a host organism. Non-viral vector delivery systems include DNA plasmids, RNA (e.g. a transcript of a vector described herein), naked nucleic acid, and nucleic acid complexed with a delivery vehicle, such as a liposome. Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell. For a review of gene therapy procedures, see Anderson, Science 256:808-813 (1992); Nabel & Felgner, TIBTECH 11:211-217 (1993); Mitani & Caskey, TIBTECH 11:162-166 (1993); Dillon, TIBTECH 11:167-175 (1993); Miller, Nature 357:455-460 (1992); Van Brunt, Biotechnology 6(10):1149-1154 (1988); Vigne, Restorative Neurology and Neuroscience 8:35-36 (1995); Kremer & Perricaudet, British Medical Bulletin 51(1):31-44 (1995); Haddada et al., in Current Topics in Microbiology and Immunology Doerfler and Böhm (eds) (1995); and Yu et al., Gene Therapy 1:13-26 (1994).

**[0079]** Methods of non-viral delivery of nucleic acids include lipofection, nucleofection, microinjection, biolistics, viro-somes, liposomes, immunoliposomes, polycation or lipid:nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA. Lipofection is described in e.g., U.S. Pat. Nos. 5,049,386, 4,946,787; and 4,897,355) and lipofection reagents are sold commercially (e.g., Transfectam™ and Lipofectin™). Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides include those of Felgner, WO 91/17424; WO 91/16024. Delivery can be to cells (e.g. in vitro or ex vivo administration) or target tissues (e.g. in vivo administration).

**[0080]** The preparation of lipid:nucleic acid complexes, including targeted liposomes such as immunolipid complexes, is well known to one of skill in the art (see, e.g., Crystal, Science 270:404-410 (1995); Blaese et al., Cancer Gene Ther. 2:291-297 (1995); Behr et al., Bioconjugate Chem. 5:382-389 (1994); Remy et al., Bioconjugate Chem. 5:647-654 (1994); Gao et al., Gene Therapy 2:710-722 (1995); Ahmad et al., Cancer Res. 52:4817-4820 (1992); U.S. Pat. Nos. 4,186,183, 4,217,344, 4,235,871, 4,261,975, 4,485,054, 4,501,728, 4,774,085, 4,837,028, and 4,946,787).

**[0081]** The use of RNA or DNA viral based systems for the delivery of nucleic acids takes advantage of highly evolved processes for targeting a virus to specific cells in the body and trafficking the viral payload to the nucleus. Viral vectors can be administered directly to patients (in vivo) or they can be used to treat cells in vitro, and the modified cells may optionally be administered to patients (ex vivo). Conventional viral based systems could include retroviral, lentivirus, adenoviral, adeno-associated and herpes simplex virus vectors for gene transfer. Integration in the host genome is possible with the retrovirus, lentivirus, and adeno-associated virus gene transfer methods, often resulting in long term expression of the inserted transgene. Additionally, high transduction efficiencies have been observed in many different cell types and target tissues.

**[0082]** The tropism of a retrovirus can be altered by incorporating foreign envelope proteins, expanding the potential target population of target cells. Lentiviral vectors are retroviral vectors that are able to transduce or infect non-dividing cells and typically produce high viral titers. Selection of a retroviral gene transfer system would therefore depend on the target tissue. Retroviral vectors are comprised of cis-acting long terminal repeats with packaging capacity for up to 6-10 kb of foreign sequence. The minimum cis-acting LTRs are sufficient for replication and packaging of the vectors, which are then used to integrate the therapeutic gene into the target cell to provide permanent transgene expression. Widely used retroviral vectors include those based upon murine leukemia virus (MuLV), gibbon ape leukemia virus (GaLV), Simian Immuno deficiency virus (SIV), human immuno deficiency virus (HIV), and combinations thereof (see, e.g., Buchscher et al., J. Virol. 66:2731-2739 (1992); Johann et al., J. Virol. 66:1635-1640 (1992); Sommerfelt et al., Virol. 176:58-59 (1990); Wilson et al., J. Virol. 63:2374-2378 (1989); Miller et al., J. Virol. 65:2220-2224 (1991); PCT/US94/05700).

**[0083]** In applications where transient expression is preferred, adenoviral based systems may be used. Adenoviral based vectors are capable of very high transduction efficiency in many cell types and do not require cell division. With such vectors, high titer and levels of expression have been obtained. This vector can be produced in large quantities in a relatively simple system. Adeno-associated virus ("AAV") vectors may also be used to transduce cells with target nucleic acids, e.g., in the in vitro production of nucleic acids and peptides, and for in vivo and ex vivo gene therapy procedures (see, e.g., West et al., Virology 160:38-47 (1987); U.S. Pat. No. 4,797,368; WO 93/24641; Kotin, Human Gene Therapy 5:793-801 (1994); Muzyczka, J. Clin. Invest. 94:1351 (1994). Construction of recombinant AAV vectors are described in a number of publications, including U.S. Pat. No. 5,173,414; Tratschin et al., Mol. Cell. Biol. 5:3251-3260 (1985); Tratschin, et al., Mol. Cell. Biol. 4:2072-2081 (1984); Hermonat & Muzyczka, PNAS 81:6466-6470 (1984); and Samulski et al., J. Virol. 63:03822-3828 (1989).

**[0084]** Packaging cells are typically used to form virus particles that are capable of infecting a host cell. Such cells include 293 cells, which package adenovirus, and  $\psi$ 2 cells or PA317 cells, which package retrovirus. Viral vectors used in gene therapy are usually generated by producing a cell line that packages a nucleic acid vector into a viral particle. The vectors typically contain the minimal viral sequences required for packaging and subsequent integration into a host, other viral sequences being replaced by an expression cassette for the polynucleotide(s) to be expressed. The missing viral functions are typically supplied in trans by the packaging cell line. For example, AAV vectors used in gene therapy typically only possess ITR sequences from the AAV genome which are required for packaging and integration into the host genome. Viral DNA is packaged in a cell line, which contains a helper plasmid encoding the other AAV genes, namely rep and cap, but lacking ITR sequences. The cell line may also be infected with adenovirus as a helper. The helper virus promotes replication of the AAV vector and expression of AAV genes from the helper plasmid. The helper plasmid is not packaged in significant amounts due to a lack of ITR sequences. Contamination with adenovirus can be reduced by, e.g., heat treatment to which adenovirus is more sensitive than AAV. Additional methods for the delivery of nucleic acids to cells are known to those skilled in the art. See, for example, US20030087817, incorporated herein by reference.

**[0085]** In some embodiments, a host cell is transiently or non-transiently transfected with one or more vectors described herein. In some embodiments, a cell is transfected as it naturally occurs in a subject. In some embodiments, a cell that is transfected is taken from a subject. In some embodiments, the cell is derived from cells taken from a subject, such as a cell line. A wide variety of cell lines for tissue culture are known in the art. Examples of cell lines include, but are

not limited to, C8161, CCRF-CEM, MOLT, mIMCD-3, NHDF, HeLa-S3, Huh1, Huh4, Huh7, HUVEC, HASMC, HEKn, HEKa, MiaPaCell, Panc1, PC-3, TF1, CTLL-2, C1R, Rat6, CV1, RPTE, A10, T24, J82, A375, ARH-77, Calu1, SW480, SW620, SKOV3, SK-UT, CaCo2, P388D1, SEM-K2, WEHI-231, HB56, TIB55, Jurkat, J45.01, LRMB, Bcl-1, BC-3, IC21, DLD2, Raw264.7, NRK, NRK-52E, MRC5, MEF, Hep G2, HeLa B, HeLa T4, COS, COS-1, COS-6, COS-M6A, BS-C-1 monkey kidney epithelial, BALB/ 3T3 mouse embryo fibroblast, 3T3 Swiss, 3T3-L1, 132-d5 human fetal fibroblasts; 10.1 mouse fibroblasts, 293-T, 3T3, 721, 9L, A2780, A2780ADR, A2780cis, A172, A20, A253, A431, A-549, ALC, B16, B35, BCP-1 cells, BEAS-2B, bEnd.3, BHK-21, BR 293, BxPC3, C3H-10T1/2, C6/36, Cal-27, CHO, CHO-7, CHO-IR, CHO-K1, CHO-K2, CHO-T, CHO Dhfr -/-, COR-L23, COR-L23/CPR, COR-L23/5010, COR-L23/R23, COS-7, COV-434, CML T1, CMT, CT26, D17, DH82, DU145, DuCaP, EL4, EM2, EM3, EMT6/AR1, EMT6/AR10.0, FM3, H1299, H69, HB54, HB55, HCA2, HEK-293, HeLa, Hepalcl7, HL-60, HMEC, HT-29, Jurkat, JY cells, K562 cells, Ku812, KCL22, KG1, KYO1, LNCap, Ma-Mel 1-48, MC-38, MCF-7, MCF-10A, MDA-MB-231, MDA-MB-468, MDA-MB-435, MDCK II, MDCK II, MOR/0.2R, MONO-MAC 6, MTD-1A, MyEnd, NCI-H69/CPR, NCI-H69/LX10, NCI-H69/LX20, NCI-H69/LX4, NIH-3T3, NALM-1, NW-145, OPCN / OPCT cell lines, Peer, PNT-1A / PNT 2, RenCa, RIN-5F, RMA/RMAS, Saos-2 cells, Sf-9, SkBr3, T2, T-47D, T84, THP1 cell line, U373, U87, U937, VCaP, Vero cells, WM39, WT-49, X63, YAC-1, YAR, and transgenic varieties thereof. Cell lines are available from a variety of sources known to those with skill in the art (see, e.g., the American Type Culture Collection (ATCC) (Manassus, Va.)). In some embodiments, a cell transfected with one or more vectors described herein is used to establish a new cell line comprising one or more vector-derived sequences. In some embodiments, a cell transiently transfected with the components of a CRISPR system as described herein (such as by transient transfection of one or more vectors, or transfection with RNA), and modified through the activity of a CRISPR complex, is used to establish a new cell line comprising cells containing the modification but lacking any other exogenous sequence. In some embodiments, cells transiently or non-transiently transfected with one or more vectors described herein, or cell lines derived from such cells are used in assessing one or more test compounds.

**[0086]** In some embodiments, one or more vectors described herein are used to produce a non-human transgenic animal or transgenic plant. In some embodiments, the transgenic animal is a mammal, such as a mouse, rat, or rabbit. In certain embodiments, the organism or subject is a plant. In certain embodiments, the organism or subject or plant is algae. Methods for producing transgenic plants and animals are known in the art, and generally begin with a method of cell transfection, such as described herein. Transgenic animals are also provided, as are transgenic plants, especially crops and algae. The transgenic animal or plant may be useful in applications outside of providing a disease model. These may include food or feed production through expression of, for instance, higher protein, carbohydrate, nutrient or vitamins levels than would normally be seen in the wildtype. In this regard, transgenic plants, especially pulses and tubers, and animals, especially mammals such as livestock (cows, sheep, goats and pigs), but also poultry and edible insects, are preferred.

**[0087]** Transgenic algae or other plants such as rape may be particularly useful in the production of vegetable oils or biofuels such as alcohols (especially methanol and ethanol), for instance. These may be engineered to express or overexpress high levels of oil or alcohols for use in the oil or biofuel industries.

**[0088]** In one aspect, the invention provides for methods of modifying a target polynucleotide in a eukaryotic cell. In some embodiments, the method comprises allowing a CRISPR complex to bind to the target polynucleotide to effect cleavage of said target polynucleotide thereby modifying the target polynucleotide, wherein the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said target polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence.

**[0089]** In one aspect, the invention provides a method of modifying expression of a polynucleotide in a eukaryotic cell. In some embodiments, the method comprises allowing a CRISPR complex to bind to the polynucleotide such that said binding results in increased or decreased expression of said polynucleotide; wherein the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence.

**[0090]** With recent advances in crop genomics, the ability to use CRISPR-Cas systems to perform efficient and cost effective gene editing and manipulation will allow the rapid selection and comparison of single and multiplexed genetic manipulations to transform such genomes for improved production and enhanced traits. In this regard reference is made to US patents and publications: US Patent No. 6,603,061 - Agrobacterium-Mediated Plant Transformation Method; US Patent No. 7,868,149 - Plant Genome Sequences and Uses Thereof and US 2009/0100536 - Transgenic Plants with Enhanced Agronomic Traits, all the contents and disclosure of each of which are herein incorporated by reference in their entirety. In the practice of the invention, the contents and disclosure of Morrell et al "Crop genomics: advances and applications" Nat Rev Genet. 2011 Dec 29;13(2):85-96 are also herein incorporated by reference in their entirety. In an advantageous embodiment of the invention, the CRISPR/Cas9 system is used to engineer microalgae (Example 14). Accordingly, reference herein to animal cells may also apply, mutatis mutandis, to plant cells unless otherwise apparent.

**[0091]** In one aspect, the invention provides for methods of modifying a target polynucleotide in a eukaryotic cell, which may be in vivo, ex vivo or in vitro. In some embodiments, the method comprises sampling a cell or population of



cells from a human or non-human animal or plant (including micro-algae), and modifying the cell or cells. Culturing may occur at any stage ex vivo. The cell or cells may even be re-introduced into the non-human animal or plant (including micro-algae).

**[0092]** In one aspect, the invention provides kits containing any one or more of the elements disclosed in the above methods and compositions. In some embodiments, the kit comprises a vector system and instructions for using the kit. In some embodiments, the vector system comprises (a) a first regulatory element operably linked to a tracr mate sequence and one or more insertion sites for inserting a guide sequence upstream of the tracr mate sequence, wherein when expressed, the guide sequence directs sequence-specific binding of a CRISPR complex to a target sequence in a eukaryotic cell, wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence; and/or (b) a second regulatory element operably linked to an enzyme-coding sequence encoding said CRISPR enzyme comprising a nuclear localization sequence. Elements may provide individually or in combinations, and may be provided in any suitable container, such as a vial, a bottle, or a tube. In some embodiments, the kit includes instructions in one or more languages, for example in more than one language.

**[0093]** In some embodiments, a kit comprises one or more reagents for use in a process utilizing one or more of the elements described herein. Reagents may be provided in any suitable container. For example, a kit may provide one or more reaction or storage buffers. Reagents may be provided in a form that is usable in a particular assay, or in a form that requires addition of one or more other components before use (e.g. in concentrate or lyophilized form). A buffer can be any buffer, including but not limited to a sodium carbonate buffer, a sodium bicarbonate buffer, a borate buffer, a Tris buffer, a MOPS buffer, a HEPES buffer, and combinations thereof. In some embodiments, the buffer is alkaline. In some embodiments, the buffer has a pH from about 7 to about 10. In some embodiments, the kit comprises one or more oligonucleotides corresponding to a guide sequence for insertion into a vector so as to operably link the guide sequence and a regulatory element. In some embodiments, the kit comprises a homologous recombination template polynucleotide.

**[0094]** In one aspect, the invention provides methods for using one or more elements of a CRISPR system. The CRISPR complex of the invention provides an effective means for modifying a target polynucleotide. The CRISPR complex of the invention has a wide variety of utility including modifying (e.g., deleting, inserting, translocating, inactivating, activating) a target polynucleotide in a multiplicity of cell types. As such the CRISPR complex of the invention has a broad spectrum of applications in, e.g., gene therapy, drug screening, disease diagnosis, and prognosis. An exemplary CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within the target polynucleotide. The guide sequence is linked to a tracr mate sequence, which in turn hybridizes to a tracr sequence.

**[0095]** The target polynucleotide of a CRISPR complex can be any polynucleotide endogenous or exogenous to the eukaryotic cell. For example, the target polynucleotide can be a polynucleotide residing in the nucleus of the eukaryotic cell. The target polynucleotide can be a sequence coding a gene product (e.g., a protein) or a non-coding sequence (e.g., a regulatory polynucleotide or a junk DNA). Without wishing to be bound by theory, it is believed that the target sequence should be associated with a PAM (protospacer adjacent motif); that is, a short sequence recognised by the CRISPR complex. The precise sequence and length requirements for the PAM differ depending on the CRISPR enzyme used, but PAMs are typically 2-5 base pair sequences adjacent the protospacer (that is, the target sequence). Examples of PAM sequences are given in the examples section below, and the skilled person will be able to identify further PAM sequences for use with a given CRISPR enzyme.

**[0096]** The target polynucleotide of a CRISPR complex may include a number of disease-associated genes and polynucleotides as well as signaling biochemical pathway-associated genes and polynucleotides as listed in US provisional patent applications 61/736,527 and 61/748,427 having Broad reference BI-2011/008/WSGR Docket No. 44063-701.101 and BI-2011/008/WSGR Docket No. 44063-701.102 respectively, both entitled SYSTEMS METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION filed on December 12, 2012 and January 2, 2013, respectively, the contents of all of which are herein incorporated by reference in their entirety.

**[0097]** Examples of target polynucleotides include a sequence associated with a signaling biochemical pathway, e.g., a signaling biochemical pathway-associated gene or polynucleotide. Examples of target polynucleotides include a disease associated gene or polynucleotide. A "disease-associated" gene or polynucleotide refers to any gene or polynucleotide which is yielding transcription or translation products at an abnormal level or in an abnormal form in cells derived from a disease-affected tissues compared with tissues or cells of a non disease control. It may be a gene that becomes expressed at an abnormally high level; it may be a gene that becomes expressed at an abnormally low level, where the altered expression correlates with the occurrence and/or progression of the disease. A disease-associated gene also refers to a gene possessing mutation(s) or genetic variation that is directly responsible or is in linkage disequilibrium with a gene(s) that is responsible for the etiology of a disease. The transcribed or translated products may be known or unknown, and may be at a normal or abnormal level.

**[0098]** Examples of disease-associated genes and polynucleotides are available from McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, Md.) and National Center for Biotechnology Information, National

## EP 2 940 140 A1

Library of Medicine (Bethesda, Md.), available on the World Wide Web.

**[0099]** Examples of disease-associated genes and polynucleotides are listed in Tables A and B. Disease specific information is available from McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, Md.) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, Md.), available on the World

**[0100]** Mutations in these genes and pathways can result in production of improper proteins or proteins in improper amounts which affect function. Further examples of genes, diseases and proteins are hereby incorporated by reference from US Provisional applications 61/736,527 and 61/748,427. Such genes, proteins and pathways may be the target polynucleotide of a CRISPR complex.

**Table A**

DISEASE/DISORDERS	GENE(S)
Neoplasia	PTEN; ATM; ATR; EGFR; ERBB2; ERBB3; ERBB4;
	Notch1; Notch2; Notch3; Notch4; AKT; AKT2; AKT3; HIF;
	HIF1a; HIF3a; Met; HRG; Bcl2; PPAR alpha; PPAR
	gamma; WT1 (Wilms Tumor); FGF Receptor Family
	members (5 members: 1, 2, 3, 4, 5); CDKN2a; APC; RB
	(retinoblastoma); MEN1; VHL; BRCA1; BRCA2; AR
	(Androgen Receptor); TSG101; IGF; IGF Receptor; Igf1 (4
	variants); Igf2 (3 variants); Igf 1 Receptor; Igf 2 Receptor;
	Bax; Bcl2; caspases family (9 members:
	1, 2, 3, 4, 6, 7, 8, 9, 12); Kras; Apc
Age-related Macular	Abcr; Ccl2; Cc2; cp (ceruloplasmin); Timp3; cathepsinD;
Degeneration	Vldlr; Ccr2
Schizophrenia	Neuregulin1 (Nrg1); Erb4 (receptor for Neuregulin);
	Complexin1 (Cplx1); Tph1 Tryptophan hydroxylase; Tph2
	Tryptophan hydroxylase 2; Neurexin 1; GSK3; GSK3a;
	GSK3b
Disorders	5-HTT (Slc6a4); COMT; DRD (Drd1a); SLC6A3; DAOA;
	DTNBP1; Dao (Dao1)
Trinucleotide Repeat	HTT (Huntington's Dx); SBMA/SMAX1/AR (Kennedy's
Disorders	Dx); FXN/X25 (Friedrich's Ataxia); ATX3 (Machado-
	Joseph's Dx); ATXN1 and ATXN2 (spinocerebellar
	ataxias); DMPK (myotonic dystrophy); Atrophin-1 and Atn1
	(DRPLA Dx); CBP (Creb-BP - global instability); VLDLR
	(Alzheimer's); Atxn7; Atxn10
Fragile X Syndrome	FMR2; FXR1; FXR2; mGLUR5
Secretase Related	APH-1 (alpha and beta); Presenilin (Psen1); nicastrin
Disorders	(Ncstn); PEN-2
Others	Nos1; Parp1; Nat1; Nat2
Prion - related disorders	Prp
ALS	SOD1; ALS2; STEX; FUS; TARDBP; VEGF (VEGF-a;

(continued)

DISEASE/DISORDERS	GENE(S)
	VEGF-b; VEGF-c)
Drug addiction	Prkce (alcohol); Drd2; Drd4; ABAT (alcohol); GRIA2;
	Grm5; Grin1; Htrlb; Grin2a; Drd3; Pdyn; Gria1 (alcohol)
Autism	Mecp2; BZRAP1; MDGA2; Sema5A; Neurexin 1; Fragile X
	(FMR2 (AFF2); FXR1; FXR2; Mglur5)
Alzheimer's Disease	E1; CHIP; UCH; UBB; Tau; LRP; PICALM; Clusterin; PS1;
	SORL1; CR1; Vldlr; Uba1; Uba3; CHIP28 (Aqp1,
	Aquaporin 1); Uchl1; Uchl3; APP
Inflammation	IL-10; IL-1 (IL-1a; IL-1b); IL-13; IL-17 (IL-17a (CTLA8); IL-
	17b; IL-17c; IL-17d; IL-17f); IL-23; Cx3cr1; ptpn22; TNFa;
	NOD2/CARD15 for IBD; IL-6; IL-12 (IL-12a; IL-12b);
	CTLA4; Cx3c11
Parkinson's Disease	x-Synuclein; DJ-1; LRRK2; Parkin; PINK1

**Table B:**

Blood and coagulation diseases and disorders	Anemia (CDAN1, CDA1, RPS19, DBA, PKLR, PK1, NT5C3, UMPH1, PSN1, RHAG, RH50A, NRAMP2, SPTB, ALAS2, ANH1, ASB, ABCB7, ABC7, ASAT); Bare lymphocyte syndrome (TAPBP, TPSN, TAP2, ABCB3, PSF2, RING11, MHC2TA, C2TA, RFX5, RFXAP, RFX5), Bleeding disorders (TBXA2R, P2RX1, P2X1); Factor H and factor H-like 1 (HF1, CFH, HUS); Factor V and factor VIII (MCFD2); Factor VII deficiency (F7); Factor X deficiency (F10); Factor XI deficiency (F11); Factor XII deficiency (F12, HAF); Factor XIIIa deficiency (F13A1, F13A); Factor XIIIB deficiency (F13B); Fanconi anemia (FANCA, FACA, FA1, FA, FAA, FAAP95, FAAP90, FLJ34064, FANCB, FANCC, FACC, BRCA2, FANCD1, FANCD2, FANCD, FACD, FAD, FANCE, FACE, FANCF, XRCC9, FANCG, BRIP1, BACH1, FANCI, PHF9, FANCL, FANCM, KIAA1596); Hemophagocytic lymphohistiocytosis disorders (PRF1, HPLH2, UNC13D, MUNC13-4, HPLH3, HLH3, FHL3); Hemophilia A (F8, F8C, HEMA); Hemophilia B (F9, HEMB), Hemorrhagic disorders (PI, ATT, F5); Leukocyte deficiencies and disorders (ITGB2, CD18, LCAMB, LAD, EIF2B1, EIF2BA, EIF2B2, EIF2B3, EIF2B5, LVWM, CACH, CLE, EIF2B4); Sickle cell anemia (HBB); Thalassemia (HBA2, HBB, HBD, LCRB, HBA1).
Cell dysregulation and oncology diseases and disorders	B-cell non-Hodgkin lymphoma (BCL7A, BCL7); Leukemia (TAL1, TCL5, SCL, TAL2, FLT3, NBS1, NBS, ZNFN1A1, IK1, LYF1, HOXD4, HOX4B, BCR, CML, PHL, ALL, ARNT, KRAS2, RASK2, GMPS, AF10, ARHGEF12, LARG, KIAA0382, CALM, CLTH, CEBPA, CEBP, CHIC2, BTL, FLT3, KIT, PBT, LPP, NPM1, NUP214, D9S46E, CAN, CAIN, RUNX1, CBFA2, AML1, WHSC1L1, NSD3, FLT3, AF1Q, NPM1, NUMA1, ZNF145, PLZF, PML, MYL, STAT5B, AF10, CALM, CLTH, ARL11, ARLTS1, P2RX7, P2X7, BCR, CML, PHL, ALL, GRAF, NF1, VRNF, WSS, NFNS, PTPN11, PTP2C, SHP2, NS1, BCL2, CCND1, PRAD1, BCL1, TCRA, GATA1, GF1, ERYF1, NFE1, ABL1, NQO1, DIA4, NMOR1, NUP214, D9S46E, CAN, CAIN).

(continued)

5	Inflammation and immune related diseases and disorders	AIDS (KIR3DL1, NKAT3, NKB1, AMB11, KIR3DS1, IFNG, CXCL12, SDF1); Autoimmune lymphoproliferative syndrome (TNFRSF6, APT1, FAS, CD95, ALPS1A); Combined immunodeficiency, (IL2RG, SCIDX1, SCIDX, IMD4); HIV-1 (CCL5, SCYA5, D17S136E, TCP228), HIV susceptibility or infection (IL10, CSIF, CMKBR2, CCR2, CMKBR5, CCCKR5 (CCR5)); Immunodeficiencies (CD3E, CD3G, AICDA, AID, HIGM2, TNFRSF5, CD40, UNG, DGU, HIGM4, TNFSF5, CD40LG, HIGM1, IGM, FOXP3, IPEX, AIID, XPID, PIDX, TNFRSF14B, TACI); Inflammation (IL-10, IL-1 (IL-1a, IL-1b), IL-13, IL-17 (IL-17a (CTLA8), IL-17b, IL-17c, IL-17d, IL-17f), IL-23, Cx3cr1, ptpn22, TNFa, NOD2/CARD15 for IBD, IL-6, IL-12 (IL-12a, IL-12b), CTLA4, Cx3cl1); Severe combined immunodeficiencies (SCIDs)(JAK3, JAKL, DCLRE1C, ARTEMIS, SCIDA, RAG1, RAG2, ADA, PTPRC, CD45, LCA, IL7R, CD3D, T3D, IL2RG, SCIDX1, SCIDX, IMD4).
10		
15		
20	Metabolic, liver, kidney and protein diseases and disorders	Amyloid neuropathy (TTR, PALB); Amyloidosis (APOA1, APP, AAA, CVAP, AD1, GSN, FGA, LYZ, TTR, PALB); Cirrhosis (KRT18, KRT8, CIRH1A, NAIC, TEX292, KIAA1988); Cystic fibrosis (CFTR, ABCC7, CF, MRP7); Glycogen storage diseases (SLC2A2, GLUT2, G6PC, G6PT, G6PT1, GAA, LAMP2, LAMPB, AGL, GDE, GBE1, GYS2, PYGL, PFKM); Hepatic adenoma, 142330 (TCF1, HNF1A, MODY3), Hepatic failure, early onset, and neurologic disorder (SCOD1, SCO1), Hepatic lipase deficiency (LIPC), Hepatoblastoma, cancer and carcinomas (CTNNB1, PDGFRL, PDGRL, PRLTS, AXIN1, AXIN, CTNNB1, TP53, P53, LFS1, IGF2R, MPRI, MET, CASP8, MCH5; Medullary cystic kidney disease (UMOD, HNFJ, FJHN, MCKD2, ADMCKD2); Phenylketonuria (PAH, PKU1, QDPR, DHPR, PTS); Polycystic kidney and hepatic disease (FCYT, PKHD1, ARPKD, PKD1, PKD2, PKD4, PKDTS, PRKCSH, G19P1, PCLD, SEC63).
25		
30	Muscular / Skeletal diseases and disorders	Becker muscular dystrophy (DMD, BMD, MYF6), Duchenne Muscular Dystrophy (DMD, BMD); Emery-Dreifuss muscular dystrophy (LMNA, LMN1, EMD2, FPLD, CMD1A, HGPS, LGMD1B, LMNA, LMN1, EMD2, FPLD, CMD1A); Facioscapulohumeral muscular dystrophy (FSHMD1A, FSHD1A); Muscular dystrophy (FKRP, MDC1C, LGMD2I, LAMA2, LAMM, LARGE, KIAA0609, MDC1D, FCMD, TTID, MYOT, CAPN3, CANP3, DYSF, LGMD2B, SGCG, LGMD2C, DMDA1, SCG3, SGCA, ADL, DAG2, LGMD2D, DMDA2, SGCB, LGMD2E, SGCD, SGD, LGMD2F, CMD1L, TCAP, LGMD2G, CMD1N, TRIM32, HT2A, LGMD2H, FKRP, MDC1C, LGMD2I, TTN, CMD1G, TMD, LGMD2J, POMT1, CAV3, LGMD1C, SEPN1, SELN, RSMD1, PLEC1, PLTN, EBS1); Osteopetrosis (LRP5, BMND1, LRP7, LR3, OPPG, VBCH2, CLCN7, CLC7, OPTA2, OSTM1, GL, TCIRG1, TIRC7, OC116, OPTB1); Muscular atrophy (VAPB, VAPC, ALS8, SMN1, SMA1, SMA2, SMA3, SMA4, BSCL2, SPG17, GARS, SMAD1, CMT2D, HEXB, IGHMBP2, SMUBP2, CATF1, SMARD1).
35		
40		

(continued)

5	Neurological and neuronal diseases and disorders	ALS (SOD1, ALS2, STEX, FUS, TARDBP, VEGF (VEGF-a, VEGF-b, VEGF-c); Alzheimer disease (APP, AAA, CVAP, AD1, APOE, AD2, PSEN2, AD4, STM2, APBB2, FE65L1, NOS3, PLAUI, URK, ACE, DCP1, ACE1, MPO, PACIP1, PAXIP1L, PTIP, A2M, BLMH, BMH, PSEN1, AD3); Autism (Mecp2, BZRAP1, MDGA2, Sema5A, Neurexin 1, GLO1, MECP2, RTT, PPMX, MRX16, MRX79, NLGN3, NLGN4, KIAA1260, AUTSX2); Fragile X Syndrome (FMR2, FXR1, FXR2, mGLUR5); Huntington's disease and disease like disorders (HD, IT15, PRNP, PRIP, JPH3, JP3, HDL2, TBP, SCA17); Parkinson disease (NR4A2, NURR1, NOT, TINUR, SNCAIP, TBP, SCA17, SNCA, NACP, PARK1, PARK4, DJ1, PARK7, LRRK2, PARK8, PINK1, PARK6, UCHL1, PARK5, SNCA, NACP, PARK1, PARK4, PRKN, PARK2, PDJ, DBH, NDUFV2); Rett syndrome (MECP2, RTT, PPMX, MRX16, MRX79, CDKL5, STK9, MECP2, RTT, PPMX, MRX16, MRX79, x-Synuclein, DJ-1); Schizophrenia (Neuregulin1 (Nrg1), Erb4 (receptor for Neuregulin), Complexin1 (Cplx1), Tph1 Tryptophan hydroxylase, Tph2, Tryptophan hydroxylase 2, Neurexin 1, GSK3, GSK3a, GSK3b, 5-HTT (Slc6a4), COMT, DRD (Drd1a), SLC6A3, DAOA, DTNBP1, Dao (Dao1)); Secretase Related Disorders (APH-1 (alpha and beta), Presenilin (Psen1), nicastrin, (Ncstn), PEN-2, Nos1, Parp1, Nat1, Nat2); Trinucleotide Repeat Disorders (HTT (Huntington's Dx), SBMA/SMAX1/AR (Kennedy's Dx), FXN/X25 (Friedrich's Ataxia), ATX3 (Machado-Joseph's Dx), ATXN1 and ATXN2 (spinocerebellar ataxias), DMPK (myotonic dystrophy), Atrophin-1 and Atn1 (DRPLA Dx), CBP (Creb-BP - global instability), VLDLR (Alzheimer's), Atxn7, Atxn10).
10		
15		
20		
25	Occular diseases and disorders	Age-related macular degeneration (Abcr, Ccl2, Cc2, cp (ceruloplasmin), Timp3, cathepsinD, Vldlr, Ccr2); Cataract (CRYAA, CRYA1, CRYBB2, CRYB2, PITX3, BFSP2, CP49, CP47, CRYAA, CRYA1, PAX6, AN2, MGDA, CRYBA1, CRYB1, CRYGC, CRYG3, CCL, LIM2, MP19, CRYGD, CRYG4, BFSP2, CP49, CP47, HSF4, CTM, HSF4, CTM, MIP, AQP0, CRYAB, CRYA2, CTPP2, CRYBB1, CRYGD, CRYG4, CRYBB2, CRYB2, CRYGC, CRYG3, CCL, CRYAA, CRYA1, GJA8, CX50, CAE1, GJA3, CX46, CZP3, CAE3, CCM1, CAM, KRIT1); Corneal clouding and dystrophy (APOA1, TGFB1, CSD2, CDGG1, CSD, BIGH3, CDG2, TACSTD2, TROP2, M1S1, VSX1, RINX, PPCD, PPD, KTCN, COL8A2, FECD, PPCD2, PIP5K3, CFD); Cornea plana congenital (KERA, CNA2); Glaucoma (MYOC, TIGR, GLC1A, JOAG, GPOA, OPTN, GLC1E, FIP2, HYPL, NRP, CYP1B1, GLC3A, OPA1, NTG, NPG, CYP1B1, GLC3A); Leber congenital amaurosis (CRB1, RP12, CRX, CORD2, CRD, RPGRIP1, LCA6, CORD9, RPE65, RP20, AIPL1, LCA4, GUCY2D, GUC2D, LCA1, CORD6, RDH12, LCA3); Macular dystrophy (ELOVL4, ADMD, STGD2, STGD3, RDS, RP7, PRPH2, PRPH, AVMD, AOFMD, VMD2).
30		
35		

Table C:

40	CELLULAR FUNCTION	GENES
	PI3K/AKT Signaling	PRKCE; ITGAM; ITGA5; IRAK1; PRKAA2; EIF2AK2;
45		PTEN; EIF4E; PRKCZ; GRK6; MAPK1; TSC1; PLK1;
		AKT2; IKBKB; PIK3CA; CDK8; CDKN1B; NFKB2; BCL2;
		PIK3CB; PPP2R1A; MAPK8; BCL2L1; MAPK3; TSC2;
50		ITGA1; KRAS; EIF4EBP1; RELA; PRKCD; NOS3;
		PRKAA1; MAPK9; CDK2; PPP2CA; PIM1; ITGB7;
		YWHAZ; ILK; TP53; RAF1; IKBKG; RELB; DYRK1A;
		CDKN1A; ITGB1; MAP2K2; JAK1; AKT1; JAK2; PIK3R1;
55		CHUK; PDPK1; PPP2R5C; CTNNB 1; MAP2K1; NFKB 1;
		PAK3; ITGB3; CCND1; GSK3A; FRAP1; SFN; ITGA2;
		TTK; CSNK1A1; BRAF; GSK3B; AKT3; FOXO1; SGK;

# EP 2 940 140 A1

(continued)

5  
  
10  
  
15  
  
20  
  
25  
  
30  
  
35  
  
40  
  
45  
  
50  
  
55

CELLULAR FUNCTION	GENES
	HSP90AA1; RPS6KB1
ERK/MAPK Signaling	PRKCE; ITGAM; ITGA5; HSPB1; IRAK1; PRKAA2;
	EIF2AK2; RAC1; RAP1A; TLN1; EIF4E; ELK1; GRK6;
	MAPK1; RAC2; PLK1; AKT2; PIK3CA; CDK8; CREB1;
	PRKCI; PTK2; FOS; RPS6KA4; PIK3CB; PPP2R1A;
	PIK3C3; MAPK8; MAPK3; ITGA1; ETS1; KRAS; MYCN;
	EIF4EBP1; PPARG; PRKCD; PRKAA1; MAPK9; SRC;
	CDK2; PPP2CA; PIM1; PIK3C2A; ITGB7; YWHAZ;
	PPP1CC; KSR1; PXN; RAF1; FYN; DYRK1A; ITGB1;
	MAP2K2; PAK4; PIK3R1; STAT3; PPP2R5C; MAP2K1;
	PAK3; ITGB3; ESR1; ITGA2; MYC; TTK; CSNK1A1;
	CRKL; BRAF; ATF4; PRKCA; SRF; STAT1; SGK
Glucocorticoid Receptor	RAC1; TAF4B; EP300; SMAD2; TRAF6; PCAF; ELK1;
Signaling	MAPK1; SMAD3; AKT2; IKBKB; NCOR2; UBE2I;
	PIK3CA; CREB1; FOS; HSPA5; NFKB2; BCL2;
	MAP3K14; STAT5B; PIK3CB; PIK3C3; MAPK8; BCL2L1;
	MAPK3; TSC22D3; MAPK10; NRIP1; KRAS; MAPK13;
	RELA; STAT5A; MAPK9; NOS2A; PBX1; NR3C1;
	PIK3C2A; CDKN1C; TRAF2; SERPINE1; NCOA3;
	MAPK14; TNF; RAF1; IKBKG; MAP3K7; CREBBP;
	CDKN1A; MAP2K2; JAK1; IL8; NCOA2; AKT1; JAK2;
	PIK3R1; CHUK; STAT3; MAP2K1; NFKB1; TGFB1;
	ESR1; SMAD4; CEBPB; JUN; AR; AKT3; CCL2; MMP1;
	STAT1; IL6; HSP90AA1
Axonal Guidance Signaling	PRKCE; ITGAM; ROCK1; ITGA5; CXCR4; ADAM 12;
	IGF1; RAC1; RAP1A; EIF4E; PRKCZ; NRP1; NTRK2;
	ARHGEF7; SMO; ROCK2; MAPK1; PGF; RAC2;
	PTPN11; GNAS; AKT2; PIK3CA; ERBB2; PRKCI; PTK2;
	CFL1; GNAQ; PIK3CB; CXCL12; PIK3C3; WNT11;
	PRKD1; GNB2L1; ABL1; MAPK3; ITGA1; KRAS; RHOA;
	PRKCD; PIK3C2A; ITGB7; GLI2; PXN; VASP; RAF1;
	FYN; ITGB1; MAP2K2; PAK4; ADAM 17; AKT1; PIK3R1;
	GLI1; WNT5A; ADAM10; MAP2K1; PAK3; ITGB3;
	CDC42; VEGFA; ITGA2; EPHA8; CRKL; RND1; GSK3B;
	AKT3; PRKCA
Ephrin Receptor Signaling	PRKCE; ITGAM; ROCK1; ITGA5; CXCR4; IRAK1;
	PRKAA2; EIF2AK2; RAC1; RAP1A; GRK6; ROCK2;
	MAPK1; PGF; RAC2; PTPN11; GNAS; PLK1; AKT2;

# EP 2 940 140 A1

(continued)

5  
  
  
  
  
10  
  
  
  
  
15  
  
  
  
  
20  
  
  
  
  
25  
  
  
  
  
30  
  
  
  
  
35  
  
  
  
  
40  
  
  
  
  
45  
  
  
  
  
50  
  
  
  
  
55

CELLULAR FUNCTION	GENES
	DOK1; CDK8; CREB1; PTK2; CFL1; GNAQ; MAP3K14;
	CXCL12; MAPK8; GNB2L1; ABL1; MAPK3; ITGA1;
	KRAS; RHOA; PRKCD; PRKAA1; MAPK9; SRC; CDK2;
	PIM1; ITGB7; PXN; RAF1; FYN; DYRK1A; ITGB1;
	MAP2K2; PAK4; AKT1; JAK2; STAT3; ADAM10;
	MAP2K1; PAK3; ITGB3; CDC42; VEGFA; ITGA2;
	EPHA8; TTK; CSNK1A1; CRKL; BRAF; PTPN13; ATF4;
	AKT3; SGK
Actin Cytoskeleton	ACTN4; PRKCE; ITGAM; ROCK1; ITGA5; IRAK1;
Signaling	PRKAA2; EIF2AK2; RAC1; INS; ARHGEF7; GRK6;
	ROCK2; MAPK1; RAC2; PLK1; AKT2; PIK3CA; CDK8;
	PTK2; CFL1; PIK3CB; MYH9; DIAPH1; PIK3C3; MAPK8;
	F2R; MAPK3; SLC9A1; ITGA1; KRAS; RHOA; PRKCD;
	PRKAA1; MAPK9; CDK2; PIM1; PIK3C2A; ITGB7;
	PPP1CC; PXN; VIL2; RAF1; GSN; DYRK1A; ITGB1;
	MAP2K2; PAK4; PIP5K1A; PIK3R1; MAP2K1; PAK3;
	ITGB3; CDC42; APC; ITGA2; TTK; CSNK1A1; CRKL;
	BRAF; VAV3; SGK
Huntington's Disease	PRKCE; IGF1; EP300; RCOR1; PRKCD; HDAC4; TGM2;
Signaling	MAPK1; CAPNS1; AKT2; EGFR; NCOR2; SP1; CAPN2;
	PIK3CA; HDAC5; CREB1; PRKCI; HSPA5; REST;
	GNAQ; PIK3CB; PIK3C3; MAPK8; IGF1R; PRKD1;
	GNB2L1; BCL2L1; CAPN1; MAPK3; CASP8; HDAC2;
	HDAC7A; PRKCD; HDAC11; MAPK9; HDAC9; PIK3C2A;
	HDAC3; TP53; CASP9; CREBBP; AKT1; PIK3R1;
	PDPK1; CASP1; APAF1; FRAP1; CASP2; JUN; BAX;
	ATF4; AKT3; PRKCA; CLTC; SGK; HDAC6; CASP3
Apoptosis Signaling	PRKCE; ROCK1; BID; IRAK1; PRKAA2; EIF2AK2; BAK1;
	BIRC4; GRK6; MAPK1; CAPNS1; PLK1; AKT2; IKBKB;
	CAPN2; CDK8; FAS; NFKB2; BCL2; MAP3K14; MAPK8;
	BCL2L1; CAPN1; MAPK3; CASP8; KRAS; RELA;
	PRKCD; PRKAA1; MAPK9; CDK2; PIM1; TP53; TNF;
	RAF1; IKBKG; RELB; CASP9; DYRK1A; MAP2K2;
	CHUK; APAF1; MAP2K1; NFKB1; PAK3; LMNA; CASP2;
	BIRC2; TTK; CSNK1A1; BRAF; BAX; PRKCA; SGK;
	CASP3; BIRC3; PARP1
B Cell Receptor Signaling	RAC1; PTEN; LYN; ELK1; MAPK1; RAC2; PTPN11;
	AKT2; IKBKB; PIK3CA; CREB1; SYK; NFKB2; CAMK2A;

# EP 2 940 140 A1

(continued)

5

10

15

20

25

30

35

40

45

50

55

CELLULAR FUNCTION	GENES
	MAP3K14; PIK3CB; PIK3C3; MAPK8; BCL2L1; ABL1;
	MAPK3; ETS1; KRAS; MAPK13; RELA; PTPN6; MAPK9;
	EGR1; PIK3C2A; BTK; MAPK14; RAF1; IKBKG; RELB;
	MAP3K7; MAP2K2; AKT1; PIK3R1; CHUK; MAP2K1;
	NFKB1; CDC42; GSK3A; FRAP1; BCL6; BCL10; JUN;
	GSK3B; ATF4; AKT3; VAV3; RPS6KB1
Leukocyte Extravasation	ACTN4; CD44; PRKCE; ITGAM; ROCK1; CXCR4; CYBA;
Signaling	RAC1; RAP1A; PRKCZ; ROCK2; RAC2; PTPN11;
	MMP14; PIK3CA; PRKCI; PTK2; PIK3CB; CXCL12;
	PIK3C3; MAPK8; PRKD1; ABL1; MAPK10; CYBB;
	MAPK13; RHOA; PRKCD; MAPK9; SRC; PIK3C2A; BTK;
	MAPK14; NOX1; PXN; VIL2; VASP; ITGB1; MAP2K2;
	CTNND1; PIK3R1; CTNNB1; CLDN1; CDC42; F11R; ITK;
	CRKL; VAV3; CTTN; PRKCA; MMP1; MMP9
Integrin Signaling	ACTN4; ITGAM; ROCK1; ITGA5; RAC1; PTEN; RAP1A;
	TLN1; ARHGEF7; MAPK1; RAC2; CAPNS1; AKT2;
	CAPN2; PIK3CA; PTK2; PIK3CB; PIK3C3; MAPK8;
	CAV1; CAPN1; ABL1; MAPK3; ITGA1; KRAS; RHOA;
	SRC; PIK3C2A; ITGB7; PPP1CC; ILK; PXN; VASP;
	RAF1; FYN; ITGB1; MAP2K2; PAK4; AKT1; PIK3R1;
	TNK2; MAP2K1; PAK3; ITGB3; CDC42; RND3; ITGA2;
	CRKL; BRAF; GSK3B; AKT3
Acute Phase Response	IRAK1; SOD2; MYD88; TRAF6; ELK1; MAPK1; PTPN11;
Signaling	AKT2; IKBKB; PIK3CA; FOS; NFKB2; MAP3K14;
	PIK3CB; MAPK8; RIPK1; MAPK3; IL6ST; KRAS;
	MAPK13; IL6R; RELA; SOCS1; MAPK9; FTL; NR3C1;
	TRAF2; SERPINE1; MAPK14; TNF; RAF1; PDK1;
	IKBKG; RELB; MAP3K7; MAP2K2; AKT1; JAK2; PIK3R1;
	CHUK; STAT3; MAP2K1; NFKB1; FRAP1; CEBPB; JUN;
	AKT3; IL1R1; IL6
PTEN Signaling	ITGAM; ITGA5; RAC1; PTEN; PRKCZ; BCL2L11;
	MAPK1; RAC2; AKT2; EGFR; IKBKB; CBL; PIK3CA;
	CDKN1B; PTK2; NFKB2; BCL2; PIK3CB; BCL2L1;
	MAPK3; ITGA1; KRAS; ITGB7; ILK; PDGFRB; INSR;
	RAF1; IKBKG; CASP9; CDKN1A; ITGB1; MAP2K2;
	AKT1; PIK3R1; CHUK; PDGFRA; PDPK1; MAP2K1;
	NFKB1; ITGB3; CDC42; CCND1; GSK3A; ITGA2;
	GSK3B; AKT3; FOXO1; CASP3; RPS6KB1



# EP 2 940 140 A1

(continued)

5

10

15

20

25

30

35

40

45

50

55

CELLULAR FUNCTION	GENES
p53 Signaling	PTEN; EP300; BBC3; PCAF; FASN; BRCA1; GADD45A;
	BIRC5; AKT2; PIK3CA; CHEK1; TP53INP1; BCL2;
	PIK3CB; PIK3C3; MAPK8; THBS1; ATR; BCL2L1; E2F1;
	PMAIP1; CHEK2; TNFRSF10B; TP73; RB1; HDAC9;
	CDK2; PIK3C2A; MAPK14; TP53; LRDD; CDKN1A;
	HIPK2; AKT1; PIK3R1; RRM2B; APAF1; CTNNB1;
	SIRT1; CCND1; PRKDC; ATM; SFN; CDKN2A; JUN;
	SNAI2; GSK3B; BAX; AKT3
Aryl Hydrocarbon Receptor	HSPB1; EP300; FASN; TGM2; RXRA; MAPK1; NQO1;
Signaling	NCOR2; SP1; ARNT; CDKN1B; FOS; CHEK1;
	SMARCA4; NFKB2; MAPK8; ALDH1A1; ATR; E2F1;
	MAPK3; NRIP1; CHEK2; RELA; TP73; GSTP1; RB1;
	SRC; CDK2; AHR; NFE2L2; NCOA3; TP53; TNF;
	CDKN1A; NCOA2; APAF1; NFKB1; CCND1; ATM; ESR1;
	CDKN2A; MYC; JUN; ESR2; BAX; IL6; CYP1B1;
	HSP90AA1
Xenobiotic Metabolism	PRKCE; EP300; PRKCZ; RXRA; MAPK1; NQO1;
Signaling	NCOR2; PIK3CA; ARNT; PRKCI; NFKB2; CAMK2A;
	PIK3CB; PPP2R1A; PIK3C3; MAPK8; PRKD1;
	ALDH1A1; MAPK3; NRIP1; KRAS; MAPK13; PRKCD;
	GSTP1; MAPK9; NOS2A; ABCB1; AHR; PPP2CA; FTL;
	NFE2L2; PIK3C2A; PPARGC1A; MAPK14; TNF; RAF1;
	CREBBP; MAP2K2; PIK3R1; PPP2R5C; MAP2K1;
	NFKB1; KEAP1; PRKCA; EIF2AK3; IL6; CYP1B1;
	HSP90AA1
SAPK/JNK Signaling	PRKCE; IRAK1; PRKAA2; EIF2AK2; RAC1; ELK1;
	GRK6; MAPK1; GADD45A; RAC2; PLK1; AKT2; PIK3CA;
	FADD; CDK8; PIK3CB; PIK3C3; MAPK8; RIPK1;
	GNB2L1; IRS1; MAPK3; MAPK10; DAXX; KRAS;
	PRKCD; PRKAA1; MAPK9; CDK2; PIM1; PIK3C2A;
	TRAF2; TP53; LCK; MAP3K7; DYRK1A; MAP2K2;
	PIK3R1; MAP2K1; PAK3; CDC42; JUN; TTK; CSNK1A1;
	CRKL; BRAF; SGK
PPAr/RXR Signaling	PRKAA2; EP300; INS; SMAD2; TRAF6; PPARA; FASN;
	RXRA; MAPK1; SMAD3; GNAS; IKBKB; NCOR2;
	ABCA1; GNAQ; NFKB2; MAP3K14; STAT5B; MAPK8;
	IRS1; MAPK3; KRAS; RELA; PRKAA1; PPARGC1A;
	NCOA3; MAPK14; INSR; RAF1; IKBKG; RELB; MAP3K7;

# EP 2 940 140 A1

(continued)

5

10

15

20

25

30

35

40

45

50

55

CELLULAR FUNCTION	GENES
	CREBBP; MAP2K2; JAK2; CHUK; MAP2K1; NFKB1;
	TGFBR1; SMAD4; JUN; IL1R1; PRKCA; IL6; HSP90AA1;
	ADIPOQ
NF-KB Signaling	IRAK1; EIF2AK2; EP300; INS; MYD88; PRKCZ; TRAF6;
	TBK1; AKT2; EGFR; IKBKB; PIK3CA; BTRC; NFKB2;
	MAP3K14; PIK3CB; PIK3C3; MAPK8; RIPK1; HDAC2;
	KRAS; RELA; PIK3C2A; TRAF2; TLR4; PDGFRB; TNF;
	INSR; LCK; IKBKG; RELB; MAP3K7; CREBBP; AKT1;
	PIK3R1; CHUK; PDGFRA; NFKB1; TLR2; BCL10;
	GSK3B; AKT3; TNFAIP3; IL1R1
Neuregulin Signaling	ERBB4; PRKCE; ITGAM; ITGA5; PTEN; PRKCZ; ELK1;
	MAPK1; PTPN11; AKT2; EGFR; ERBB2; PRKCI;
	CDKN1B; STAT5B; PRKD1; MAPK3; ITGA1; KRAS;
	PRKCD; STAT5A; SRC; ITGB7; RAF1; ITGB1; MAP2K2;
	ADAM17; AKT1; PIK3R1; PDPK1; MAP2K1; ITGB3;
	EREG; FRAP1; PSEN1; ITGA2; MYC; NRG1; CRKL;
	AKT3; PRKCA; HSP90AA1; RPS6KB1
Wnt & Beta catenin	CD44; EP300; LRP6; DVL3; CSNK1E; GJA1; SMO;
Signaling	AKT2; PIN1; CDH1; BTRC; GNAQ; MARK2; PPP2R1A;
	WNT11; SRC; DKK1; PPP2CA; SOX6; SFRP2; ILK;
	LEF1; SOX9; TP53; MAP3K7; CREBBP; TCF7L2; AKT1;
	PPP2R5C; WNT5A; LRP5; CTNNB1; TGFBR1; CCND1;
	GSK3A; DVL1; APC; CDKN2A; MYC; CSNK1A1; GSK3B;
	AKT3; SOX2
Insulin Receptor Signaling	PTEN; INS; EIF4E; PTPN1; PRKCZ; MAPK1; TSC1;
	PTPN11; AKT2; CBL; PIK3CA; PRKCI; PIK3CB; PIK3C3;
	MAPK8; IRS1; MAPK3; TSC2; KRAS; EIF4EBP1;
	SLC2A4; PIK3C2A; PPP1CC; INSR; RAF1; FYN;
	MAP2K2; JAK1; AKT1; JAK2; PIK3R1; PDPK1; MAP2K1;
	GSK3A; FRAP1; CRKL; GSK3B; AKT3; FOXO1; SGK;
	RPS6KB1
IL-6 Signaling	HSPB1; TRAF6; MAPKAPK2; ELK1; MAPK1; PTPN11;
	IKBKB; FOS; NFKB2; MAP3K14; MAPK8; MAPK3;
	MAPK10; IL6ST; KRAS; MAPK13; IL6R; RELA; SOCS1;
	MAPK9; ABCB1; TRAF2; MAPK14; TNF; RAF1; IKBKG;
	RELB; MAP3K7; MAP2K2; IL8; JAK2; CHUK; STAT3;
	MAP2K1; NFKB1; CEBPB; JUN; IL1R1; SRF; IL6
Hepatic Cholestasis	PRKCE; IRAK1; INS; MYD88; PRKCZ; TRAF6; PPARA;

# EP 2 940 140 A1

(continued)

5  
  
  
  
  
10  
  
  
15  
  
  
  
20  
  
  
25  
  
  
  
30  
  
  
35  
  
  
40  
  
  
45  
  
  
50  
  
  
55

CELLULAR FUNCTION	GENES
	RXRA; IKBKB; PRKCI; NFKB2; MAP3K14; MAPK8;
	PRKD1; MAPK10; RELA; PRKCD; MAPK9; ABCB1;
	TRAF2; TLR4; TNF; INSR; IKBKG; RELB; MAP3K7; IL8;
	CHUK; NR1H2; TJP2; NFKB1; ESR1; SREBF1; FGFR4;
	JUN; IL1R1; PRKCA; IL6
IGF-1 Signaling	IGF1; PRKCZ; ELK1; MAPK1; PTPN11; NEDD4; AKT2;
	PIK3CA; PRKCI; PTK2; FOS; PIK3CB; PIK3C3; MAPK8;
	IGF1R; IRS1; MAPK3; IGFBP7; KRAS; PIK3C2A;
	YWHAZ; PXN; RAF1; CASP9; MAP2K2; AKT1; PIK3R1;
	PDPK1; MAP2K1; IGFBP2; SFN; JUN; CYR61; AKT3;
	FOXO1; SRF; CTGF; RPS6KB1
NRF2-mediated Oxidative	PRKCE; EP300; SOD2; PRKCZ; MAPK1; SQSTM1;
Stress Response	NQO1; PIK3CA; PRKCI; FOS; PIK3CB; PIK3C3; MAPK8;
	PRKD1; MAPK3; KRAS; PRKCD; GSTP1; MAPK9; FTL;
	NFE2L2; PIK3C2A; MAPK14; RAF1; MAP3K7; CREBBP;
	MAP2K2; AKT1; PIK3R1; MAP2K1; PPIB; JUN; KEAP1;
	GSK3B; ATF4; PRKCA; EIF2AK3; HSP90AA1
Hepatic Fibrosis/Hepatic	EDN1; IGF1; KDR; FLT1; SMAD2; FGFR1; MET; PGF;
Stellate Cell Activation	SMAD3; EGFR; FAS; CSF1; NFKB2; BCL2; MYH9;
	IGF1R; IL6R; RELA; TLR4; PDGFRB; TNF; RELB; IL8;
	PDGFRA; NFKB1; TGFB1; SMAD4; VEGFA; BAX;
	IL1R1; CCL2; HGF; MMP1; STAT1; IL6; CTGF; MMP9
PPAR Signaling	EP300; INS; TRAF6; PPARA; RXRA; MAPK1; IKBKB;
	NCOR2; FOS; NFKB2; MAP3K14; STAT5B; MAPK3;
	NRIP1; KRAS; PPARG; RELA; STAT5A; TRAF2;
	PPARGC1A; PDGFRB; TNF; INSR; RAF1; IKBKG;
	RELB; MAP3K7; CREBBP; MAP2K2; CHUK; PDGFRA;
	MAP2K1; NFKB1; JUN; IL1R1; HSP90AA1
Fc Epsilon RI Signaling	PRKCE; RAC1; PRKCZ; LYN; MAPK1; RAC2; PTPN11;
	AKT2; PIK3CA; SYK; PRKCI; PIK3CB; PIK3C3; MAPK8;
	PRKD1; MAPK3; MAPK10; KRAS; MAPK13; PRKCD;
	MAPK9; PIK3C2A; BTK; MAPK14; TNF; RAF1; FYN;
	MAP2K2; AKT1; PIK3R1; PDPK1; MAP2K1; AKT3;
	VAV3; PRKCA
G-Protein Coupled	PRKCE; RAP1A; RGS16; MAPK1; GNAS; AKT2; IKBKB;
Receptor Signaling	PIK3CA; CREB1; GNAQ; NFKB2; CAMK2A; PIK3CB;
	PIK3C3; MAPK3; KRAS; RELA; SRC; PIK3C2A; RAF1;
	IKBKG; RELB; FYN; MAP2K2; AKT1; PIK3R1; CHUK;

# EP 2 940 140 A1

(continued)

5

10

15

20

25

30

35

40

45

50

55

CELLULAR FUNCTION	GENES
	PDPK1; STAT3; MAP2K1; NFKB1; BRAF; ATF4; AKT3;
	PRKCA
Inositol Phosphate	PRKCE; IRAK1; PRKAA2; EIF2AK2; PTEN; GRK6;
Metabolism	MAPK1; PLK1; AKT2; PIK3CA; CDK8; PIK3CB; PIK3C3;
	MAPK8; MAPK3; PRKCD; PRKAA1; MAPK9; CDK2;
	PIM1; PIK3C2A; DYRK1A; MAP2K2; PIP5K1A; PIK3R1;
	MAP2K1; PAK3; ATM; TTK; CSNK1A1; BRAF; SGK
PDGF Signaling	EIF2AK2; ELK1; ABL2; MAPK1; PIK3CA; FOS; PIK3CB;
	PIK3C3; MAPK8; CAV1; ABL1; MAPK3; KRAS; SRC;
	PIK3C2A; PDGFRB; RAF1; MAP2K2; JAK1; JAK2;
	PIK3R1; PDGFRA; STAT3; SPHK1; MAP2K1; MYC;
	JUN; CRKL; PRKCA; SRF; STAT1; SPHK2
VEGF Signaling	ACTN4; ROCK1; KDR; FLT1; ROCK2; MAPK1; PGF;
	AKT2; PIK3CA; ARNT; PTK2; BCL2; PIK3CB; PIK3C3;
	BCL2L1; MAPK3; KRAS; HIF1A; NOS3; PIK3C2A; PXN;
	RAF1; MAP2K2; ELAVL1; AKT1; PIK3R1; MAP2K1; SFN;
	VEGFA; AKT3; FOXO1; PRKCA
Natural Killer Cell Signaling	PRKCE; RAC1; PRKCZ; MAPK1; RAC2; PTPN11;
	KIR2DL3; AKT2; PIK3CA; SYK; PRKCI; PIK3CB;
	PIK3C3; PRKD1; MAPK3; KRAS; PRKCD; PTPN6;
	PIK3C2A; LCK; RAF1; FYN; MAP2K2; PAK4; AKT1;
	PIK3R1; MAP2K1; PAK3; AKT3; VAV3; PRKCA
Cell Cycle: G1/S	HDAC4; SMAD3; SUV39H1; HDAC5; CDKN1B; BTRC;
Checkpoint Regulation	ATR; ABL1; E2F1; HDAC2; HDAC7A; RB1; HDAC11;
	HDAC9; CDK2; E2F2; HDAC3; TP53; CDKN1A; CCND1;
	E2F4; ATM; RBL2; SMAD4; CDKN2A; MYC; NRG1;
	GSK3B; RBL1; HDAC6
T Cell Receptor Signaling	RAC1; ELK1; MAPK1; IKBKB; CBL; PIK3CA; FOS;
	NFKB2; PIK3CB; PIK3C3; MAPK8; MAPK3; KRAS;
	RELA; PIK3C2A; BTK; LCK; RAF1; IKBKG; RELB; FYN;
	MAP2K2; PIK3R1; CHUK; MAP2K1; NFKB1; ITK; BCL10;
	JUN; VAV3
Death Receptor Signaling	CRADD; HSPB1; BID; BIRC4; TBK1; IKBKB; FADD;
	FAS; NFKB2; BCL2; MAP3K14; MAPK8; RIPK1; CASP8;
	DAXX; TNFRSF10B; RELA; TRAF2; TNF; IKBKG; RELB;
	CASP9; CHUK; APAF1; NFKB1; CASP2; BIRC2; CASP3;
	BIRC3
FGF Signaling	RAC1; FGFR1; MET; MAPKAPK2; MAPK1; PTPN11;

# EP 2 940 140 A1

(continued)

5

10

15

20

25

30

35

40

45

50

55

CELLULAR FUNCTION	GENES
	AKT2; PIK3CA; CREB1; PIK3CB; PIK3C3; MAPK8;
	MAPK3; MAPK13; PTPN6; PIK3C2A; MAPK14; RAF1;
	AKT1; PIK3R1; STAT3; MAP2K1; FGFR4; CRKL; ATF4;
	AKT3; PRKCA; HGF
GM-CSF Signaling	LYN; ELK1; MAPK1; PTPN11; AKT2; PIK3CA; CAMK2A;
	STAT5B; PIK3CB; PIK3C3; GNB2L1; BCL2L1; MAPK3;
	ETS1; KRAS; RUNX1; PIM1; PIK3C2A; RAF1; MAP2K2;
	AKT1; JAK2; PIK3R1; STAT3; MAP2K1; CCND1; AKT3;
	STAT1
Amyotrophic Lateral	BID; IGF1; RAC1; BIRC4; PGF; CAPNS1; CAPN2;
Sclerosis Signaling	PIK3CA; BCL2; PIK3CB; PIK3C3; BCL2L1; CAPN1;
	PIK3C2A; TP53; CASP9; PIK3R1; RAB5A; CASP1;
	APAF1; VEGFA; BIRC2; BAX; AKT3; CASP3; BIRC3
JAK/Stat Signaling	PTPN1; MAPK1; PTPN11; AKT2; PIK3CA; STAT5B;
	PIK3CB; PIK3C3; MAPK3; KRAS; SOCS1; STAT5A;
	PTPN6; PIK3C2A; RAF1; CDKN1A; MAP2K2; JAK1;
	AKT1; JAK2; PIK3R1; STAT3; MAP2K1; FRAP1; AKT3;
	STAT1
Nicotinate and	PRKCE; IRAK1; PRKAA2; EIF2AK2; GRK6; MAPK1;
Nicotinamide	
Metabolism	PLK1; AKT2; CDK8; MAPK8; MAPK3; PRKCD; PRKAA1;
	PBEF1; MAPK9; CDK2; PIM1; DYRK1A; MAP2K2;
	MAP2K1; PAK3; NT5E; TTK; CSNK1A1; BRAF; SGK
Chemokine Signaling	CXCR4; ROCK2; MAPK1; PTK2; FOS; CFL1; GNAQ;
	CAMK2A; CXCL12; MAPK8; MAPK3; KRAS; MAPK13;
	RHOA; CCR3; SRC; PPP1CC; MAPK14; NOX1; RAF1;
	MAP2K2; MAP2K1; JUN; CCL2; PRKCA
IL-2 Signaling	ELK1; MAPK1; PTPN11; AKT2; PIK3CA; SYK; FOS;
	STAT5B; PIK3CB; PIK3C3; MAPK8; MAPK3; KRAS;
	SOCS1; STAT5A; PIK3C2A; LCK; RAF1; MAP2K2;
	JAK1; AKT1; PIK3R1; MAP2K1; JUN; AKT3
Synaptic Long Term	PRKCE; IGF1; PRKCZ; PRDX6; LYN; MAPK1; GNAS;
Depression	PRKCI; GNAQ; PPP2R1A; IGF1R; PRKD1; MAPK3;
	KRAS; GRN; PRKCD; NOS3; NOS2A; PPP2CA;
	YWHAZ; RAF1; MAP2K2; PPP2R5C; MAP2K1; PRKCA
Estrogen Receptor	TAF4B; EP300; CARM1; PCAF; MAPK1; NCOR2;
Signaling	SMARCA4; MAPK3; NRIP1; KRAS; SRC; NR3C1;
	HDAC3; PPARGC1A; RBM9; NCOA3; RAF1; CREBBP;

# EP 2 940 140 A1

(continued)

5

10

15

20

25

30

35

40

45

50

55

CELLULAR FUNCTION	GENES
	MAP2K2; NCOA2; MAP2K1; PRKDC; ESR1; ESR2
Protein Ubiquitination	TRAF6; SMURF1; BIRC4; BRCA1; UCHL1; NEDD4;
Pathway	CBL; UBE2I; BTRC; HSPA5; USP7; USP10; FBXW7;
	USP9X; STUB1; USP22; B2M; BIRC2; PARK2; USP8;
	USP1; VHL; HSP90AA1; BIRC3
IL-10 Signaling	TRAF6; CCR1; ELK1; IKBKB; SP1; FOS; NFkB2;
	MAP3K14; MAPK8; MAPK13; RELA; MAPK14; TNF;
	IKBKG; RELB; MAP3K7; JAK1; CHUK; STAT3; NFkB1;
	JUN; IL1R1; IL6
VDR/RXR Activation	PRKCE; EP300; PRKCZ; RXRA; GADD45A; HES1;
	NCOR2; SP1; PRKCI; CDKN1B; PRKD1; PRKCD;
	RUNX2; KLF4; YY1; NCOA3; CDKN1A; NCOA2; SPP1;
	LRP5; CEBPB; FOXO1; PRKCA
TGF-beta Signaling	EP300; SMAD2; SMURF1; MAPK1; SMAD3; SMAD1;
	FOS; MAPK8; MAPK3; KRAS; MAPK9; RUNX2;
	SERPINE1; RAF1; MAP3K7; CREBBP; MAP2K2;
	MAP2K1; TGFB1; SMAD4; JUN; SMAD5
Toll-like Receptor Signaling	IRAK1; EIF2AK2; MYD88; TRAF6; PPARA; ELK1;
	IKBKB; FOS; NFkB2; MAP3K14; MAPK8; MAPK13;
	RELA; TLR4; MAPK14; IKBKG; RELB; MAP3K7; CHUK;
	NFkB1; TLR2; JUN
p38 MAPK Signaling	HSPB1; IRAK1; TRAF6; MAPKAPK2; ELK1; FADD; FAS;
	CREB1; DDIT3; RPS6KA4; DAXX; MAPK13; TRAF2;
	MAPK14; TNF; MAP3K7; TGFB1; MYC; ATF4; IL1R1;
	SRF; STAT1
Neurotrophin/TRK Signaling	NTRK2; MAPK1; PTPN11; PIK3CA; CREB1; FOS;
	PIK3CB; PIK3C3; MAPK8; MAPK3; KRAS; PIK3C2A;
	RAF1; MAP2K2; AKT1; PIK3R1; PDPK1; MAP2K1;
	CDC42; JUN; ATF4
FXR/RXR Activation	INS; PPARA; FASN; RXRA; AKT2; SDC1; MAPK8;
	APOB; MAPK10; PPARG; MTP; MAPK9; PPARGC1A;
	TNF; CREBBP; AKT1; SREBF1; FGFR4; AKT3; FOXO1
Synaptic Long Term	PRKCE; RAP1A; EP300; PRKCZ; MAPK1; CREB1;
Potentiation	PRKCI; GNAQ; CAMK2A; PRKD1; MAPK3; KRAS;
	PRKCD; PPP1CC; RAF1; CREBBP; MAP2K2; MAP2K1;
	ATF4; PRKCA
Calcium Signaling	RAP1A; EP300; HDAC4; MAPK1; HDAC5; CREB1;
	CAMK2A; MYH9; MAPK3; HDAC2; HDAC7A; HDAC11;

# EP 2 940 140 A1

(continued)

5  
  
  
  
  
10  
  
  
  
  
  
15  
  
  
  
  
  
  
20  
  
  
  
  
  
  
25  
  
  
  
  
  
  
30  
  
  
  
  
  
  
35  
  
  
  
  
  
  
40  
  
  
  
  
  
  
45  
  
  
  
  
  
  
50  
  
  
  
  
  
  
55

CELLULAR FUNCTION	GENES
	HDAC9; HDAC3; CREBBP; CALR; CAMKK2; ATF4;
	HDAC6
EGF Signaling	ELK1; MAPK1; EGFR; PIK3CA; FOS; PIK3CB; PIK3C3;
	MAPK8; MAPK3; PIK3C2A; RAF1; JAK1; PIK3R1;
	STAT3; MAP2K1; JUN; PRKCA; SRF; STAT1
Hypoxia Signaling in the	EDN1; PTEN; EP300; NQO1; UBE2I; CREB 1; ARNT;
Cardiovascular System	HIF1A; SLC2A4; NOS3; TP53; LDHA; AKT1; ATM;
	VEGFA; JUN; ATF4; VHL; HSP90AA1
LPS/IL-1 Mediated Inhibition	IRAK1; MYD88; TRAF6; PPARA; RXRA; ABCA1;
of RXR Function	MAPK8; ALDH1A1; GSTP1; MAPK9; ABCB1; TRAF2;
	TLR4; TNF; MAP3K7; NR1H2; SREBF1; JUN; IL1R1
LXR/RXR Activation	FASN; RXRA; NCOR2; ABCA1; NFKB2; IRF3; RELA;
	NOS2A; TLR4; TNF; RELB; LDLR; NR1H2; NFKB1;
	SREBF1; IL1R1; CCL2; IL6; MMP9
Amyloid Processing	PRKCE; CSNK1E; MAPK1; CAPNS1; AKT2; CAPN2;
	CAPN1; MAPK3; MAPK13; MAPT; MAPK14; AKT1;
	PSEN1; CSNK1A1; GSK3B; AKT3; APP
IL-4 Signaling	AKT2; PIK3CA; PIK3CB; PIK3C3; IRS1; KRAS; SOCS1;
	PTPN6; NR3C1; PIK3C2A; JAK1; AKT1; JAK2; PIK3R1;
	FRAP1; AKT3; RPS6KB1
Cell Cycle: G2/M DNA	EP300; PCAF; BRCA1; GADD45A; PLK1; BTRC;
Damage Checkpoint	CHEK1; ATR; CHEK2; YWHAZ; TP53; CDKN1A;
Regulation	PRKDC; ATM; SFN; CDKN2A
Nitric Oxide Signaling in the	KDR; FLT1; PGF; AKT2; PIK3CA; PIK3CB; PIK3C3;
Cardiovascular System	CAV1; PRKCD; NOS3; PIK3C2A; AKT1; PIK3R1;
	VEGFA; AKT3; HSP90AA1
Purine Metabolism	NME2; SMARCA4; MYH9; RRM2; ADAR; EIF2AK4;
	PKM2; ENTPD1; RAD51; RRM2B; TJP2; RAD51C;
	NT5E; POLD1; NME1
cAMP-mediated Signaling	RAP1A; MAPK1; GNAS; CREB1; CAMK2A; MAPK3;
	SRC; RAF1; MAP2K2; STAT3; MAP2K1; BRAF; ATF4
Mitochondrial Dysfunction	SOD2; MAPK8; CASP8; MAPK10; MAPK9; CASP9;
	PARK7; PSEN1; PARK2; APP; CASP3
Notch Signaling	HES1; JAG1; NUMB; NOTCH4; ADAM 17; NOTCH2;
	PSEN1; NOTCH3; NOTCH 1; DLL4
Endoplasmic Reticulum	HSPA5; MAPK8; XBP1; TRAF2; ATF6; CASP9; ATF4;
Stress Pathway	EIF2AK3; CASP3
Pyrimidine Metabolism	NME2; AICDA; RRM2; EIF2AK4; ENTPD1; RRM2B;

# EP 2 940 140 A1

(continued)

5  
  
10  
  
15  
  
20  
  
25  
  
30  
  
35  
  
40  
  
45  
  
50  
  
55

CELLULAR FUNCTION	GENES
	NT5E; POLD1; NME1
Parkinson's Signaling	UCHL1; MAPK8; MAPK13; MAPK14; CASP9; PARK7;
	PARK2; CASP3
Cardiac & Beta Adrenergic	GNAS; GNAQ; PPP2R1A; GNB2L1; PPP2CA; PPP1CC;
Signaling	PPP2R5C
Glycolysis/Gluconeogenesis	HK2; GCK; GPI; ALDH1A1; PKM2; LDHA; HK1
Interferon Signaling	IRF1; SOCS1; JAK1; JAK2; IFITM1; STAT1; IFIT3
Sonic Hedgehog Signaling	ARRB2; SMO; GLI2; DYRK1A; GLI1; GSK3B; DYRK1B
Glycerophospholipid	PLD1; GRN; GPAM; YWHAZ; SPHK1; SPHK2
Metabolism	
Phospholipid Degradation	PRDX6; PLD1; GRN; YWHAZ; SPHK1; SPHK2
Tryptophan Metabolism	SIAH2; PRMT5; NEDD4; ALDH1A1; CYP1B1; SIAH1
Lysine Degradation	SUV39H1; EHMT2; NSD1; SETD7; PPP2R5C
Nucleotide Excision Repair	ERCC5; ERCC4; XPA; XPC; ERCC1
Pathway	
Starch and Sucrose	UCHL1; HK2; GCK; GPI; HK1
Metabolism	
Aminosugars Metabolism	NQO1; HK2; GCK; HK1
Arachidonic Acid	PRDX6; GRN; YWHAZ; CYP1B1
Metabolism	
Circadian Rhythm Signaling	CSNK1E; CREB1; ATF4; NR1D1
Coagulation System	BDKRB1; F2R; SERPINE1; F3
Dopamine Receptor	PPP2R1A; PPP2CA; PPP1CC; PPP2R5C
Signaling	
Glutathione Metabolism	IDH2; GSTP1; ANPEP; IDH1
Glycerolipid Metabolism	ALDH1A1; GPAM; SPHK1; SPHK2
Linoleic Acid Metabolism	PRDX6; GRN; YWHAZ; CYP1B1
Methionine Metabolism	DNMT1; DNMT3B; AHCY; DNMT3A
Pyruvate Metabolism	GLO1; ALDH1A1; PKM2; LDHA
Arginine and Proline	ALDH1A1; NOS3; NOS2A
Metabolism	
Eicosanoid Signaling	PRDX6; GRN; YWHAZ
Fructose and Mannose	HK2; GCK; HK1
Metabolism	
Galactose Metabolism	HK2; GCK; HK1
Stilbene, Coumarine and	PRDX6; PRDX1; TYR
Lignin Biosynthesis	
Antigen Presentation	CALR; B2M



(continued)

	CELLULAR FUNCTION	GENES
5	Pathway	
	Biosynthesis of Steroids	NQO1; DHCR7
	Butanoate Metabolism	ALDH1A1; NLGN1
	Citrate Cycle	IDH2; IDH1
10	Fatty Acid Metabolism	ALDH1A1; CYP1B1
	Glycerophospholipid	PRDX6; CHKA
	Metabolism	
15	Histidine Metabolism	PRMT5; ALDH1A1
	Inositol Metabolism	ERO1L; APEX1
	Metabolism of Xenobiotics	GSTP1; CYP1B1
	by Cytochrome p450	
20	Methane Metabolism	PRDX6; PRDX1
	Phenylalanine Metabolism	PRDX6; PRDX1
	Propanoate Metabolism	ALDH1A1; LDHA
25	Selenoamino Acid	PRMT5; AHCY
	Metabolism	
	Sphingolipid Metabolism	SPHK1; SPHK2
	Aminophosphonate	PRMT5
30	Metabolism	
	Androgen and Estrogen	PRMT5
	Metabolism	
35	Ascorbate and Aldarate	ALDH1A1
	Metabolism	
	Bile Acid Biosynthesis	ALDH1A1
	Cysteine Metabolism	LDHA
40	Fatty Acid Biosynthesis	FASN
	Glutamate Receptor	GNB2L1
	Signaling	
45	NRF2-mediated Oxidative	PRDX1
	Stress Response	
	Pentose Phosphate	GPI
	Pathway	
50	Pentose and Glucuronate	UCHL1
	Interconversions	
	Retinol Metabolism	ALDH1A1
55	Riboflavin Metabolism	TYR
	Tyrosine Metabolism	PRMT5, TYR
	Ubiquinone Biosynthesis	PRMT5

(continued)

CELLULAR FUNCTION	GENES
Valine, Leucine and Isoleucine Degradation	ALDH1A1
Glycine, Serine and Threonine Metabolism	CHKA
Lysine Degradation	ALDH1A1
Pain/Taste	TRPM5; TRPA1
Pain	TRPM7; TRPC5; TRPC6; TRPC1; Cnr1; cnr2; Grk2; Trpa1; Pomc; Cgrp; Crf; Pka; Era; Nr2b; TRPM5; Prkaca; Prkacb; Prkar1a; Prkar2a
Mitochondrial Function	AIF; CytC; SMAC (Diablo); Aifm-1; Aifm-2
Developmental Neurology	BMP-4; Chordin (Chrd); Noggin (Nog); WNT (Wnt2; Wnt2b; Wnt3a; Wnt4; Wnt5a; Wnt6; Wnt7b; Wnt8b; Wnt9a; Wnt9b; Wnt10a; Wnt10b; Wnt16); beta-catenin; Dkk-1; Frizzled related proteins; Otx-2; Gbx2; FGF-8; Reelin; Dab1; unc-86 (Pou4f1 or Brn3a); Numb; Reln

**[0101]** Embodiments of the invention also relate to methods and compositions related to knocking out genes, amplifying genes and repairing particular mutations associated with DNA repeat instability and neurological disorders (Robert D. Wells, Tetsuo Ashizawa, Genetic Instabilities and Neurological Diseases, Second Edition, Academic Press, Oct 13, 2011 - Medical). Specific aspects of tandem repeat sequences have been found to be responsible for more than twenty human diseases (New insights into repeat instability: role of RNA-DNA hybrids. Mclvor EI, Polak U, Napierala M. RNA Biol. 2010 Sep-Oct;7(5):551-8). The CRISPR-Cas system may be harnessed to correct these defects of genomic instability.

**[0102]** A further aspect of the invention relates to utilizing the CRISPR-Cas system for correcting defects in the EMP2A and EMP2B genes that have been identified to be associated with Lafora disease. Lafora disease is an autosomal recessive condition which is characterized by progressive myoclonus epilepsy which may start as epileptic seizures in adolescence. A few cases of the disease may be caused by mutations in genes yet to be identified. The disease causes seizures, muscle spasms, difficulty walking, dementia, and eventually death. There is currently no therapy that has proven effective against disease progression. Other genetic abnormalities associated with epilepsy may also be targeted by the CRISPR-Cas system and the underlying genetics is further described in Genetics of Epilepsy and Genetic Epilepsies, edited by Giuliano Avanzini, Jeffrey L. Noebels, Mariani Foundation Paediatric Neurology; 2009).

**[0103]** In yet another aspect of the invention, the CRISPR-Cas system may be used to correct ocular defects that arise from several genetic mutations further described in Genetic Diseases of the Eye, Second Edition, edited by Elias I. Traboulsi, Oxford University Press, 2012.

**[0104]** Several further aspects of the invention relate to correcting defects associated with a wide range of genetic diseases which are further described on the website of the National Institutes of Health under the topic subsection Genetic Disorders. The genetic brain diseases may include but are not limited to Adrenoleukodystrophy, Agenesis of the Corpus Callosum, Aicardi Syndrome, Alpers' Disease, Alzheimer's Disease, Barth Syndrome, Batten Disease, CADASIL, Cerebellar Degeneration, Fabry's Disease, Gerstmann-Straussler-Scheinker Disease, Huntington's Disease and other Triplet Repeat Disorders, Leigh's Disease, Lesch-Nyhan Syndrome, Menkes Disease, Mitochondrial Myopathies and NINDS Colpocephaly. These diseases are further described on the website of the National Institutes of Health under the subsection Genetic Brain Disorders.

**[0105]** In some embodiments, the condition may be neoplasia. In some embodiments, where the condition is neoplasia, the genes to be targeted are any of those listed in Table A (in this case PTEN as well as so forth). In some embodiments, the condition may be Age-related Macular Degeneration. In some embodiments, the condition may be a Schizophrenic Disorder. In some embodiments, the condition may be a Trinucleotide Repeat Disorder. In some embodiments, the condition may be Fragile X Syndrome. In some embodiments, the condition may be a Secretase Related Disorder. In some embodiments, the condition may be a Prion - related disorder. In some embodiments, the condition may be ALS.

In some embodiments, the condition may be a drug addiction. In some embodiments, the condition may be Autism. In some embodiments, the condition may be Alzheimer's Disease. In some embodiments, the condition may be inflammation. In some embodiments, the condition may be Parkinson's Disease.

**[0106]** Examples of proteins associated with Parkinson's disease include but are not limited to  $\alpha$ -synuclein, DJ-1, LRRK2, PINK1, Parkin, UCHL1, Synphilin-1, and NURR1.

**[0107]** Examples of addiction-related proteins may include ABAT for example.

**[0108]** Examples of inflammation-related proteins may include the monocyte chemoattractant protein-1 (MCP1) encoded by the Ccr2 gene, the C-C chemokine receptor type 5 (CCR5) encoded by the Ccr5 gene, the IgG receptor IIB (FCGR2b, also termed CD32) encoded by the Fcgr2b gene, or the Fc epsilon R1g (FCER1g) protein encoded by the Fcer1g gene, for example.

**[0109]** Examples of cardiovascular diseases associated proteins may include IL1B (interleukin 1, beta), XDH (xanthine dehydrogenase), TP53 (tumor protein p53), PTGIS (prostaglandin I2 (prostacyclin) synthase), MB (myoglobin), IL4 (interleukin 4), ANGPT1 (angiopoietin 1), ABCG8 (ATP-binding cassette, sub-family G (WHITE), member 8), or CTSK (cathepsin K), for example.

**[0110]** Examples of Alzheimer's disease associated proteins may include the very low density lipoprotein receptor protein (VLDLR) encoded by the VLDLR gene, the ubiquitin-like modifier activating enzyme 1 (UBA1) encoded by the UBA1 gene, or the NEDD8-activating enzyme E1 catalytic subunit protein (UBE1C) encoded by the UBA3 gene, for example.

**[0111]** Examples of proteins associated with Autism Spectrum Disorder may include the benzodiazepine receptor (peripheral) associated protein 1 (BZRAP1) encoded by the BZRAP1 gene, the AF4/FMR2 family member 2 protein (AFF2) encoded by the AFF2 gene (also termed MFR2), the fragile X mental retardation autosomal homolog 1 protein (FXR1) encoded by the FXR1 gene, or the fragile X mental retardation autosomal homolog 2 protein (FXR2) encoded by the FXR2 gene, for example.

**[0112]** Examples of proteins associated with Macular Degeneration may include the ATP-binding cassette, sub-family A (ABC1) member 4 protein (ABCA4) encoded by the ABCR gene, the apolipoprotein E protein (APOE) encoded by the APOE gene, or the chemokine (C-C motif) Ligand 2 protein (CCL2) encoded by the CCL2 gene, for example.

**[0113]** Examples of proteins associated with Schizophrenia may include NRG1, ErbB4, CPLX1, TPH1, TPH2, NRXN1, GSK3A, BDNF, DISC1, GSK3B, and combinations thereof.

**[0114]** Examples of proteins involved in tumor suppression may include ATM (ataxia telangiectasia mutated), ATR (ataxia telangiectasia and Rad3 related), EGFR (epidermal growth factor receptor), ERBB2 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2), ERBB3 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 3), ERBB4 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 4), Notch 1, Notch2, Notch 3, or Notch 4, for example.

**[0115]** Examples of proteins associated with a secretase disorder may include PSENEN (presenilin enhancer 2 homolog (C. elegans)), CTSB (cathepsin B), PSEN1 (presenilin 1), APP (amyloid beta (A4) precursor protein), APH1B (anterior pharynx defective 1 homolog B (C. elegans)), PSEN2 (presenilin 2 (Alzheimer disease 4)), or BACE1 (beta-site APP-cleaving enzyme 1), for example.

**[0116]** Examples of proteins associated with Amyotrophic Lateral Sclerosis may include SOD1 (superoxide dismutase 1), ALS2 (amyotrophic lateral sclerosis 2), FUS (fused in sarcoma), TARDBP (TAR DNA binding protein), VAGFA (vascular endothelial growth factor A), VAGFB (vascular endothelial growth factor B), and VAGFC (vascular endothelial growth factor C), and any combination thereof.

**[0117]** Examples of proteins associated with prion diseases may include SOD1 (superoxide dismutase 1), ALS2 (amyotrophic lateral sclerosis 2), FUS (fused in sarcoma), TARDBP (TAR DNA binding protein), VAGFA (vascular endothelial growth factor A), VAGFB (vascular endothelial growth factor B), and VAGFC (vascular endothelial growth factor C), and any combination thereof.

**[0118]** Examples of proteins related to neurodegenerative conditions in prion disorders may include A2M (Alpha-2-Macroglobulin), AATF (Apoptosis antagonizing transcription factor), ACPP (Acid phosphatase prostate), ACTA2 (Actin alpha 2 smooth muscle aorta), ADAM22 (ADAM metalloproteinase domain), ADORA3 (Adenosine A3 receptor), or ADRA1D (Alpha-1D adrenergic receptor for Alpha-1D adrenoreceptor), for example.

**[0119]** Examples of proteins associated with Immunodeficiency may include A2M [alpha-2-macroglobulin]; AANAT [arylalkylamine N-acetyltransferase]; ABCA1 [ATP-binding cassette, sub-family A (ABC1), member 1]; ABCA2 [ATP-binding cassette, sub-family A (ABC1), member 2]; or ABCA3 [ATP-binding cassette, sub-family A (ABC1), member 3]; for example.

**[0120]** Examples of proteins associated with Trinucleotide Repeat Disorders include AR (androgen receptor), FMR1 (fragile X mental retardation 1), HTT (huntingtin), or DMPK (dystrophia myotonica-protein kinase), FXN (frataxin), ATXN2 (ataxin 2), for example.

**[0121]** Examples of proteins associated with Neurotransmission Disorders include SST (somatostatin), NOS1 (nitric oxide synthase 1 (neuronal)), ADRA2A (adrenergic, alpha-2A-, receptor), ADRA2C (adrenergic, alpha-2C-, receptor), TACR1 (tachykinin receptor 1), or HTR2c (5-hydroxytryptamine (serotonin) receptor 2C), for example.

**[0122]** Examples of neurodevelopmental-associated sequences include A2BP1 [ataxin 2-binding protein 1], AADAT [amino adipate aminotransferase], AANAT [arylalkylamine N-acetyltransferase], ABAT [4-aminobutyrate aminotransferase], ABCA1 [ATP-binding cassette, sub-family A (ABC1), member 1], or ABCA13 [ATP-binding cassette, sub-family A (ABC1), member 13], for example.

**[0123]** Further examples of preferred conditions treatable with the present system include may be selected from: Aicardi-Goutières Syndrome; Alexander Disease; Allan-Herndon-Dudley Syndrome; POLG-Related Disorders; Alpha-Mannosidosis (Type II and III); Alström Syndrome; Angelman Syndrome; Ataxia-Telangiectasia; Neuronal Ceroid-Lipofuscinoses; Beta-Thalassemia; Bilateral Optic Atrophy and (Infantile) Optic Atrophy Type 1; Retinoblastoma (bilateral); Canavan Disease; Cerebrooculofacioskeletal Syndrome 1 [COFS1]; Cerebrotendinous Xanthomatosis; Cornelia de Lange Syndrome; MAPT-Related Disorders; Genetic Prion Diseases; Dravet Syndrome; Early-Onset Familial Alzheimer Disease; Friedreich Ataxia [FRDA]; Fryns Syndrome; Fucosidosis; Fukuyama Congenital Muscular Dystrophy; Galactosialidosis; Gaucher Disease; Organic Acidemias; Hemophagocytic Lymphohistiocytosis; Hutchinson-Gilford Progeria Syndrome; Mucopolidosis II; Infantile Free Sialic Acid Storage Disease; PLA2G6-Associated Neurodegeneration; Jervell and Lange-Nielsen Syndrome; Junctional Epidermolysis Bullosa; Huntington Disease; Krabbe Disease (Infantile); Mitochondrial DNA-Associated Leigh Syndrome and NARP; Lesch-Nyhan Syndrome; LIS1-Associated Lissencephaly; Lowe Syndrome; Maple Syrup Urine Disease; MECP2 Duplication Syndrome; ATP7A-Related Copper Transport Disorders; LAMA2-Related Muscular Dystrophy; Arylsulfatase A Deficiency; Mucopolysaccharidosis Types I, II or III; Peroxisome Biogenesis Disorders, Zellweger Syndrome Spectrum; Neurodegeneration with Brain Iron Accumulation Disorders; Acid Sphingomyelinase Deficiency; Niemann-Pick Disease Type C; Glycine Encephalopathy; ARX-Related Disorders; Urea Cycle Disorders; COL1A1/2-Related Osteogenesis Imperfecta; Mitochondrial DNA Deletion Syndromes; PLP1-Related Disorders; Perry Syndrome; Phelan-McDermid Syndrome; Glycogen Storage Disease Type II (Pompe Disease) (Infantile); MAPT-Related Disorders; MECP2-Related Disorders; Rhizomelic Chondrodysplasia Punctata Type 1; Roberts Syndrome; Sandhoff Disease; Schindler Disease - Type 1; Adenosine Deaminase Deficiency; Smith-Lemli-Opitz Syndrome; Spinal Muscular Atrophy; Infantile-Onset Spinocerebellar Ataxia; Hexosaminidase A Deficiency; Thanatophoric Dysplasia Type 1; Collagen Type VI-Related Disorders; Usher Syndrome Type I; Congenital Muscular Dystrophy; Wolf-Hirschhorn Syndrome; Lysosomal Acid Lipase Deficiency; and Xeroderma Pigmentosum.

**[0124]** Chronic administration of protein therapeutics may elicit unacceptable immune responses to the specific protein. The immunogenicity of protein drugs can be ascribed to a few immunodominant helper T lymphocyte (HTL) epitopes. Reducing the MHC binding affinity of these HTL epitopes contained within these proteins can generate drugs with lower immunogenicity (Tangri S, et al. ("Rationally engineered therapeutic proteins with reduced immunogenicity" J Immunol. 2005 Mar 15;174(6):3187-96.) In the present invention, the immunogenicity of the CRISPR enzyme in particular may be reduced following the approach first set out in Tangri et al with respect to erythropoietin and subsequently developed. Accordingly, directed evolution or rational design may be used to reduce the immunogenicity of the CRISPR enzyme (for instance a Cas9) in the host species (human or other species).

**[0125]** In plants, pathogens are often host-specific. For example, *Fusarium oxysporum* f. sp. *lycopersici* causes tomato wilt but attacks only tomato, and *F. oxysporum* f. *dianthii* *Puccinia graminis* f. sp. *tritici* attacks only wheat. Plants have existing and induced defenses to resist most pathogens. Mutations and recombination events across plant generations lead to genetic variability that gives rise to susceptibility, especially as pathogens reproduce with more frequency than plants. In plants there can be non-host resistance, e.g., the host and pathogen are incompatible. There can also be Horizontal Resistance, e.g., partial resistance against all races of a pathogen, typically controlled by many genes and Vertical Resistance, e.g., complete resistance to some races of a pathogen but not to other races, typically controlled by a few genes. In a Gene-for-Gene level, plants and pathogens evolve together, and the genetic changes in one balance changes in other. Accordingly, using Natural Variability, breeders combine most useful genes for Yield, Quality, Uniformity, Hardiness, Resistance. The sources of resistance genes include native or foreign Varieties, Heirloom Varieties, Wild Plant Relatives, and Induced Mutations, e.g., treating plant material with mutagenic agents. Using the present invention, plant breeders are provided with a new tool to induce mutations. Accordingly, one skilled in the art can analyze the genome of sources of resistance genes, and in Varieties having desired characteristics or traits employ the present invention to induce the rise of resistance genes, with more precision than previous mutagenic agents and hence accelerate and improve plant breeding programs.

**[0126]** As will be apparent, it is envisaged that the present system can be used to target any polynucleotide sequence of interest. Some examples of conditions or diseases that might be usefully treated using the present system are included in the Tables above and examples of genes currently associated with those conditions are also provided there. However, the genes exemplified are not exhaustive.

## EXAMPLES

**[0127]** The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion. The present examples, along with the methods described herein

are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses which are encompassed within the spirit of the invention as defined by the scope of the claims will occur to those skilled in the art.

#### 5 Example 1: CRISPR Complex Activity in the Nucleus of a Eukaryotic Cell

**[0128]** An example type II CRISPR system is the type II CRISPR locus from *Streptococcus pyogenes* SF370, which contains a cluster of four genes Cas9, Cas1, Cas2, and Csn1, as well as two non-coding RNA elements, tracrRNA and a characteristic array of repetitive sequences (direct repeats) interspaced by short stretches of non-repetitive sequences (spacers, about 30bp each). In this system, targeted DNA double-strand break (DSB) is generated in four sequential steps (Figure 2A). First, two non-coding RNAs, the pre-crRNA array and tracrRNA, are transcribed from the CRISPR locus. Second, tracrRNA hybridizes to the direct repeats of pre-crRNA, which is then processed into mature crRNAs containing individual spacer sequences. Third, the mature crRNA:tracrRNA complex directs Cas9 to the DNA target consisting of the protospacer and the corresponding PAM via heteroduplex formation between the spacer region of the crRNA and the protospacer DNA. Finally, Cas9 mediates cleavage of target DNA upstream of PAM to create a DSB within the protospacer (Figure 2A). This example describes an example process for adapting this RNA-programmable nuclease system to direct CRISPR complex activity in the nuclei of eukaryotic cells.

**[0129]** To improve expression of CRISPR components in mammalian cells, two genes from the SF370 locus 1 of *Streptococcus pyogenes* (*S. pyogenes*) were codon-optimized, Cas9 (*SpCas9*) and RNase III (*SpRNase III*). To facilitate nuclear localization, a nuclear localization signal (NLS) was included at the amino (N)- or carboxyl (C)-termini of both SpCas9 and SpRNase III (Figure 2B). To facilitate visualization of protein expression, a fluorescent protein marker was also included at the N- or C-termini of both proteins (Figure 2B). A version of SpCas9 with an NLS attached to both N- and C-termini (2xNLS-SpCas9) was also generated. Constructs containing NLS-fused SpCas9 and SpRNase III were transfected into 293FT human embryonic kidney (HEK) cells, and the relative positioning of the NLS to SpCas9 and SpRNase III was found to affect their nuclear localization efficiency. Whereas the C-terminal NLS was sufficient to target SpRNase III to the nucleus, attachment of a single copy of these particular NLS's to either the N- or C-terminus of SpCas9 was unable to achieve adequate nuclear localization in this system. In this example, the C-terminal NLS was that of nucleoplasmin (KRPAATKKAGQAKKKK), and the C-terminal NLS was that of the SV40 large T-antigen (PKKKRKV). Of the versions of SpCas9 tested, only 2xNLS-SpCas9 exhibited nuclear localization (Figure 2B).

**[0130]** The tracrRNA from the CRISPR locus of *S. pyogenes* SF370 has two transcriptional start sites, giving rise to two transcripts of 89-nucleotides (nt) and 171nt that are subsequently processed into identical 75nt mature tracrRNAs. The shorter 89nt tracrRNA was selected for expression in mammalian cells (expression constructs illustrated in Figure 6, with functionality as determined by results of Surveyor assay shown in Figure 6B). Transcription start sites are marked as +1, and transcription terminator and the sequence probed by northern blot are also indicated. Expression of processed tracrRNA was also confirmed by Northern blot. Figure 7C shows results of a Northern blot analysis of total RNA extracted from 293FT cells transfected with U6 expression constructs carrying long or short tracrRNA, as well as SpCas9 and DR-EMX1(1)-DR. Left and right panels are from 293FT cells transfected without or with SpRNase III, respectively. U6 indicate loading control blotted with a probe targeting human U6 snRNA. Transfection of the short tracrRNA expression construct led to abundant levels of the processed form of tracrRNA (~75bp). Very low amounts of long tracrRNA are detected on the Northern blot.

**[0131]** To promote precise transcriptional initiation, the RNA polymerase III-based U6 promoter was selected to drive the expression of tracrRNA (Figure 2C). Similarly, a U6 promoter-based construct was developed to express a pre-crRNA array consisting of a single spacer flanked by two direct repeats (DRs, also encompassed by the term "tracr-mate sequences"; Figure 2C). The initial spacer was designed to target a 33-base-pair (bp) target site (30-bp protospacer plus a 3-bp CRISPR motif (PAM) sequence satisfying the NGG recognition motif of Cas9) in the human *EMX1* locus (Figure 2C), a key gene in the development of the cerebral cortex.

**[0132]** To test whether heterologous expression of the CRISPR system (SpCas9, SpRNase III, tracrRNA, and pre-crRNA) in mammalian cells can achieve targeted cleavage of mammalian chromosomes, HEK 293FT cells were transfected with combinations of CRISPR components. Since DSBs in mammalian nuclei are partially repaired by the non-homologous end joining (NHEJ) pathway, which leads to the formation of indels, the Surveyor assay was used to detect potential cleavage activity at the target *EMX1* locus (see e.g. Guschin et al., 2010, Methods Mol Biol 649: 247). Co-transfection of all four CRISPR components was able to induce up to 5.0% cleavage in the protospacer (see Figure 2D). Co-transfection of all CRISPR components minus SpRNase III also induced up to 4.7% indel in the protospacer, suggesting that there may be endogenous mammalian RNases that are capable of assisting with crRNA maturation, such as for example the related Dicer and Drosha enzymes. Removing any of the remaining three components abolished the genome cleavage activity of the CRISPR system (Figure 2D). Sanger sequencing of amplicons containing the target locus verified the cleavage activity: in 43 sequenced clones, 5 mutated alleles (11.6%) were found. Similar experiments using a variety of guide sequences produced indel percentages as high as 29% (see Figures 4-8, 10 and 11). These

results define a three-component system for efficient CRISPR-mediated genome modification in mammalian cells.

**[0133]** To optimize the cleavage efficiency, Applicants also tested whether different isoforms of tracrRNA affected the cleavage efficiency and found that, in this example system, only the short (89-bp) transcript form was able to mediate cleavage of the human *EMX1* genomic locus. Figure 9 provides an additional Northern blot analysis of crRNA processing in mammalian cells. Figure 9A illustrates a schematic showing the expression vector for a single spacer flanked by two direct repeats (DR-*EMX1*(1)-DR). The 30bp spacer targeting the human

**[0134]** *EMX1* locus protospacer 1 and the direct repeat sequences are shown in the sequence beneath Figure 9A. The line indicates the region whose reverse-complement sequence was used to generate Northern blot probes for *EMX1*(1) crRNA detection. Figure 9B shows a Northern blot analysis of total RNA extracted from 293FT cells transfected with U6 expression constructs carrying DR-*EMX1*(1)-DR. Left and right panels are from 293FT cells transfected without or with SpRNase III respectively. DR-*EMX1*(1)-DR was processed into mature crRNAs only in the presence of SpCas9 and short tracrRNA and was not dependent on the presence of SpRNase III. The mature crRNA detected from transfected 293FT total RNA is ~33bp and is shorter than the 39-42bp mature crRNA from *S. pyogenes*. These results demonstrate that a CRISPR system can be transplanted into eukaryotic cells and reprogrammed to facilitate cleavage of endogenous mammalian target polynucleotides.

**[0135]** Figure 2 illustrates the bacterial CRISPR system described in this example. Figure 2A illustrates a schematic showing the CRISPR locus 1 from *Streptococcus pyogenes* SF370 and a proposed mechanism of CRISPR-mediated DNA cleavage by this system. Mature crRNA processed from the direct repeat-spacer array directs Cas9 to genomic targets consisting of complementary protospacers and a protospacer-adjacent motif (PAM). Upon target-spacer base pairing, Cas9 mediates a double-strand break in the target DNA. Figure 2B illustrates engineering of *S. pyogenes* Cas9 (SpCas9) and RNase III (SpRNase III) with nuclear localization signals (NLSs) to enable import into the mammalian nucleus. Figure 2C illustrates mammalian expression of SpCas9 and SpRNase III driven by the constitutive EF1a promoter and tracrRNA and pre-crRNA array (DR-Spacer-DR) driven by the RNA Pol3 promoter U6 to promote precise transcription initiation and termination. A protospacer from the human *EMX1* locus with a satisfactory PAM sequence is used as the spacer in the pre-crRNA array. Figure 2D illustrates surveyor nuclease assay for SpCas9-mediated minor insertions and deletions. SpCas9 was expressed with and without SpRNase III, tracrRNA, and a pre-crRNA array carrying the *EMX1*-target spacer. Figure 2E illustrates a schematic representation of base pairing between target locus and *EMX1*-targeting crRNA, as well as an example chromatogram showing a micro deletion adjacent to the SpCas9 cleavage site. Figure 2F illustrates mutated alleles identified from sequencing analysis of 43 clonal amplicons showing a variety of micro insertions and deletions. Dashes indicate deleted bases, and non-aligned or mismatched bases indicate insertions or mutations. Scale bar = 10µm.

**[0136]** To further simplify the three-component system, a chimeric crRNA-tracrRNA hybrid design was adapted, where a mature crRNA (comprising a guide sequence) is fused to a partial tracrRNA via a stem-loop to mimic the natural crRNA:tracrRNA duplex (Figure 3A).

**[0137]** Guide sequences can be inserted between BbsI sites using annealed oligonucleotides. Protospacers on the sense and anti-sense strands are indicated above and below the DNA sequences, respectively. A modification rate of 6.3% and 0.75% was achieved for the human *PVALB* and mouse *Th* loci respectively, demonstrating the broad applicability of the CRISPR system in modifying different loci across multiple organisms. While cleavage was only detected with one out of three spacers for each locus using the chimeric constructs, all target sequences were cleaved with efficiency of indel production reaching 27% when using the co-expressed pre-crRNA arrangement (Figures 4 and 5).

**[0138]** Figure 5 provides a further illustration that SpCas9 can be reprogrammed to target multiple genomic loci in mammalian cells. Figure 5A provides a schematic of the human *EMX1* locus showing the location of five protospacers, indicated by the underlined sequences. Figure 5B provides a schematic of the pre-crRNA/tracrRNA complex showing hybridization between the direct repeat region of the pre-crRNA and tracrRNA (top), and a schematic of a chimeric RNA design comprising a 20bp guide sequence, and tracr mate and tracr sequences consisting of partial direct repeat and tracrRNA sequences hybridized in a hairpin structure (bottom). Results of a Surveyor assay comparing the efficacy of Cas9-mediated cleavage at five protospacers in the human *EMX1* locus is illustrated in Figure 5C. Each protospacer is targeted using either processed pre-crRNA/tracrRNA complex (crRNA) or chimeric RNA (chiRNA).

**[0139]** Since the secondary structure of RNA can be crucial for intermolecular interactions, a structure prediction algorithm based on minimum free energy and Boltzmann-weighted structure ensemble was used to compare the putative secondary structure of all guide sequences used in our genome targeting experiment (Figure 3B) (see e.g. Gruber *et al.*, 2008, Nucleic Acids Research, 36: W70). Analysis revealed that in most cases, the effective guide sequences in the chimeric crRNA context were substantially free of secondary structure motifs, whereas the ineffective guide sequences were more likely to form internal secondary structures that could prevent base pairing with the target protospacer DNA. It is thus possible that variability in the spacer secondary structure might impact the efficiency of CRISPR-mediated interference when using a chimeric crRNA.

**[0140]** Figure 3 illustrates example expression vectors. Figure 3A provides a schematic of a bi-cistronic vector for driving the expression of a synthetic crRNA-tracrRNA chimera (chimeric RNA) as well as SpCas9. The chimeric guide

RNA contains a 20-bp guide sequence corresponding to the protospacer in the genomic target site. Figure 3B provides a schematic showing guide sequences targeting the human *EMX1*, *PVALB*, and mouse *Th* loci, as well as their predicted secondary structures. The modification efficiency at each target site is indicated below the RNA secondary structure drawing (*EMX1*,  $n = 216$  amplicon sequencing reads; *PVALB*,  $n = 224$  reads; *Th*,  $n = 265$  reads). The folding algorithm produced an output with each base colored according to its probability of assuming the predicted secondary structure, as indicated by a rainbow scale that is reproduced in Figure 3B in gray scale. Further vector designs for SpCas9 are shown in Figure 3A, including single expression vectors incorporating a U6 promoter linked to an insertion site for a guide oligo, and a Cbh promoter linked to SpCas9 coding sequence.

**[0141]** To test whether spacers containing secondary structures are able to function in prokaryotic cells where CRISPRs naturally operate, transformation interference of protospacer-bearing plasmids were tested in an *E. coli* strain heterologously expressing the *S. pyogenes* SF370 CRISPR locus 1 (Figure 3C). The CRISPR locus was cloned into a low-copy *E. coli* expression vector and the crRNA array was replaced with a single spacer flanked by a pair of DRs (pCRISPR). *E. coli* strains harboring different pCRISPR plasmids were transformed with challenge plasmids containing the corresponding protospacer and PAM sequences (Figure 3C). In the bacterial assay, all spacers facilitated efficient CRISPR interference (Figure 3C). These results suggest that there may be additional factors affecting the efficiency of CRISPR activity in mammalian cells.

**[0142]** To investigate the specificity of CRISPR-mediated cleavage, the effect of single-nucleotide mutations in the guide sequence on protospacer cleavage in the mammalian genome was analyzed using a series of *EMX1*-targeting chimeric crRNAs with single point mutations (Figure 4A). Figure 4B illustrates results of a Surveyor nuclease assay comparing the cleavage efficiency of Cas9 when paired with different mutant chimeric RNAs. Single-base mismatch up to 12-bp 5' of the PAM substantially abrogated genomic cleavage by SpCas9, whereas spacers with mutations at farther upstream positions retained activity against the original protospacer target (Figure 4B). In addition to the PAM, SpCas9 has single-base specificity within the last 12-bp of the spacer. Furthermore, CRISPR is able to mediate genomic cleavage as efficiently as a pair of TALE nucleases (TALEN) targeting the same *EMX1* protospacer. Figure 4C provides a schematic showing the design of TALENs targeting *EMX1*, and Figure 4D shows a Surveyor gel comparing the efficiency of TALEN and Cas9 ( $n=3$ ).

**[0143]** Having established a set of components for achieving CRISPR-mediated gene editing in mammalian cells through the error-prone NHEJ mechanism, the ability of CRISPR to stimulate homologous recombination (HR), a high fidelity gene repair pathway for making precise edits in the genome, was tested. The wild type SpCas9 is able to mediate site-specific DSBs, which can be repaired through both NHEJ and HR. In addition, an aspartate-to-alanine substitution (D10A) in the RuvC I catalytic domain of SpCas9 was engineered to convert the nuclease into a nickase (SpCas9n; illustrated in Figure 5A) (see e.g. Sapranasaks et al., 2011, Cucleic Acis Research, 39: 9275; Gasiunas et al., 2012, Proc. Natl. Acad. Sci. USA, 109:E2579), such that nicked genomic DNA undergoes the high-fidelity homology-directed repair (HDR). Surveyor assay confirmed that SpCas9n does not generate indels at the *EMX1* protospacer target. As illustrated in Figure 5B, co-expression of *EMX1*-targeting chimeric crRNA with SpCas9 produced indels in the target site, whereas co-expression with SpCas9n did not ( $n=3$ ). Moreover, sequencing of 327 amplicons did not detect any indels induced by SpCas9n. The same locus was selected to test CRISPR-mediated HR by co-transfecting HEK 293FT cells with the chimeric RNA targeting *EMX1*, hSpCas9 or hSpCas9n, as well as a HR template to introduce a pair of restriction sites (*HindIII* and *NheI*) near the protospacer. Figure 5C provides a schematic illustration of the HR strategy, with relative locations of recombination points and primer annealing sequences (arrows). SpCas9 and SpCas9n indeed catalyzed integration of the HR template into the *EMX1* locus. PCR amplification of the target region followed by restriction digest with *HindIII* revealed cleavage products corresponding to expected fragment sizes (arrows in restriction fragment length polymorphism gel analysis shown in Figure 5D), with SpCas9 and SpCas9n mediating similar levels of HR efficiencies. Applicants further verified HR using Sanger sequencing of genomic amplicons (Figure 5E). These results demonstrate the utility of CRISPR for facilitating targeted gene insertion in the mammalian genome. Given the 14-bp (12-bp from the spacer and 2-bp from the PAM) target specificity of the wild type SpCas9, the availability of a nickase can significantly reduce the likelihood of off-target modifications, since single strand breaks are not substrates for the error-prone NHEJ pathway.

**[0144]** Expression constructs mimicking the natural architecture of CRISPR loci with arrayed spacers (Figure 2A) were constructed to test the possibility of multiplexed sequence targeting. Using a single CRISPR array encoding a pair of *EMX1*- and *PVALB*-targeting spacers, efficient cleavage at both loci was detected (Figure 4F, showing both a schematic design of the crRNA array and a Surveyor blot showing efficient mediation of cleavage). Targeted deletion of larger genomic regions through concurrent DSBs using spacers against two targets within *EMX1* spaced by 119bp was also tested, and a 1.6% deletion efficacy (3 out of 182 amplicons; Figure 5G) was detected. This demonstrates that the CRISPR system can mediate multiplexed editing within a single genome.

*Example 2: CRISPR system Modifications and alternatives*

**[0145]** The ability to use RNA to program sequence-specific DNA cleavage defines a new class of genome engineering tools for a variety of research and industrial applications. Several aspects of the CRISPR system can be further improved to increase the efficiency and versatility of CRISPR targeting. Optimal Cas9 activity may depend on the availability of free  $Mg^{2+}$  at levels higher than that present in the mammalian nucleus (see e.g. Jinek et al., 2012, Science, 337:816), and the preference for an NGG motif immediately downstream of the protospacer restricts the ability to target on average every 12-bp in the human genome. Some of these constraints can be overcome by exploring the diversity of CRISPR loci across the microbial metagenome (see e.g. Makarova et al., 2011, Nat Rev Microbiol, 9:467). Other CRISPR loci may be transplanted into the mammalian cellular milieu by a process similar to that described in Example 1. The modification efficiency at each target site is indicated below the RNA secondary structures. The algorithm generating the structures colors each base according to its probability of assuming the predicted secondary structure. RNA guide spacers 1 and 2 induced 14% and 6.4%, respectively. Statistical analysis of cleavage activity across biological replica at these two protospacer sites is also provided in Figure 7.

*Example 3: Sample target sequence selection algorithm*

**[0146]** A software program is designed to identify candidate CRISPR target sequences on both strands of an input DNA sequence based on desired guide sequence length and a CRISPR motif sequence (PAM) for a specified CRISPR enzyme. For example, target sites for Cas9 from *S. pyogenes*, with PAM sequences NGG, may be identified by searching for 5'-N<sub>x</sub>NGG-3' both on the input sequence and on the reverse-complement of the input. Likewise, target sites for Cas9 of *S. thermophilus* CRISPR1, with PAM sequence NNAGAAW, may be identified by searching for 5'-N<sub>x</sub>NNAGAAW-3' both on the input sequence and on the reverse-complement of the input. Likewise, target sites for Cas9 of *S. thermophilus* CRISPR3, with PAM sequence NGGNG, may be identified by searching for 5'-N<sub>x</sub>NGGNG-3' both on the input sequence and on the reverse-complement of the input. The value "x" in N<sub>x</sub> may be fixed by the program or specified by the user, such as 20.

**[0147]** Since multiple occurrences in the genome of the DNA target site may lead to nonspecific genome editing, after identifying all potential sites, the program filters out sequences based on the number of times they appear in the relevant reference genome. For those CRISPR enzymes for which sequence specificity is determined by a 'seed' sequence, such as the 11-12bp 5' from the PAM sequence, including the PAM sequence itself, the filtering step may be based on the seed sequence. Thus, to avoid editing at additional genomic loci, results are filtered based on the number of occurrences of the seed:PAM sequence in the relevant genome. The user may be allowed to choose the length of the seed sequence. The user may also be allowed to specify the number of occurrences of the seed:PAM sequence in a genome for purposes of passing the filter. The default is to screen for unique sequences. Filtration level is altered by changing both the length of the seed sequence and the number of occurrences of the sequence in the genome. The program may in addition or alternatively provide the sequence of a guide sequence complementary to the reported target sequence(s) by providing the reverse complement of the identified target sequence(s).

**[0148]** Further details of methods and algorithms to optimize sequence selection can be found found in U.S. application Serial No. TBA (Broad Reference BI-2012/084 44790.11.2022); incorporated herein by reference.

*Example 4: Evaluation of multiple chimeric crRNA-tracrRNA hybrids*

**[0149]** This example describes results obtained for chimeric RNAs (chiRNAs; comprising a guide sequence, a tracr mate sequence, and a tracr sequence in a single transcript) having tracr sequences that incorporate different lengths of wild-type tracrRNA sequence. Figure 18a illustrates a schematic of a bicistronic expression vector for chimeric RNA and Cas9. Cas9 is driven by the CBh promoter and the chimeric RNA is driven by a U6 promoter. The chimeric guide RNA consists of a 20bp guide sequence (Ns) joined to the tracr sequence (running from the first "U" of the lower strand to the end of the transcript), which is truncated at various positions as indicated. The guide and tracr sequences are separated by the tracr-mate sequence GUUUUAGAGCUA followed by the loop sequence GAAA. Results of SURVEYOR assays for Cas9-mediated indels at the human *EMX1* and *PVALB* loci are illustrated in Figure 18b and 18c, respectively. Arrows indicate the expected SURVEYOR fragments. ChiRNAs are indicated by their "+n" designation, and crRNA refers to a hybrid RNA where guide and tracr sequences are expressed as separate transcripts. Quantification of these results, performed in triplicate, are illustrated by histogram in Figures 11a and 11b, corresponding to Figures 10b and 10c, respectively ("N.D." indicates no indels detected). Protospacer IDs and their corresponding genomic target, protospacer sequence, PAM sequence, and strand location are provided in Table D. Guide sequences were designed to be complementary to the entire protospacer sequence in the case of separate transcripts in the hybrid system, or only to the underlined portion in the case of chimeric RNAs.



Table D:

protospacer ID	genomic target	protospacer sequence (5' to 3')	PAM	Stran d
1	<i>EMX1</i>	GGACATCGATGTCACCTCCAATGACTAG GG	TGG	+
2	<i>EMX1</i>	CATTGGAGGTGACATCGATGTCCTCCCC AT	TGG	-
3	<i>EMX1</i>	GGAAGGGCCTGAGTCCGAGCAGAAGAA GAA	GGG	+
4	<i>PVALB</i>	GGTGGCGAGAGGGGCGGAGATTGGGTGT TC	AGG	+
5	<i>PVALB</i>	ATGCAGGAGGGTGGCGAGAGGGGCCGA GAT	TGG	+

#### Cell culture and transfection

**[0150]** Human embryonic kidney (HEK) cell line 293FT (Life Technologies) was maintained in Dulbecco's modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (HyClone), 2mM GlutaMAX (Life Technologies), 100U/mL penicillin, and 100µg/mL streptomycin at 37°C with 5% CO<sub>2</sub> incubation. 293FT cells were seeded onto 24-well plates (Corning) 24 hours prior to transfection at a density of 150,000 cells per well. Cells were transfected using Lipofectamine 2000 (Life Technologies) following the manufacturer's recommended protocol. For each well of a 24-well plate, a total of 500ng plasmid was used.

#### SURVEYOR assay for genome modification

**[0151]** 293FT cells were transfected with plasmid DNA as described above. Cells were incubated at 37°C for 72 hours post-transfection prior to genomic DNA extraction. Genomic DNA was extracted using the QuickExtract DNA Extraction Solution (Epicentre) following the manufacturer's protocol. Briefly, pelleted cells were resuspended in QuickExtract solution and incubated at 65°C for 15 minutes and 98°C for 10 minutes. The genomic region flanking the CRISPR target site for each gene was PCR amplified (primers listed in Table E), and products were purified using QiaQuick Spin Column (Qiagen) following the manufacturer's protocol. 400ng total of the purified PCR products were mixed with 2µl 10X Taq DNA Polymerase PCR buffer (Enzymatics) and ultrapure water to a final volume of 20µl, and subjected to a re-annealing process to enable heteroduplex formation: 95°C for 10min, 95°C to 85°C ramping at - 2°C/s, 85°C to 25°C at - 0.25°C/s, and 25°C hold for 1 minute. After re-annealing, products were treated with SURVEYOR nuclease and SURVEYOR enhancer S (Transgenomics) following the manufacturer's recommended protocol, and analyzed on 4-20% Novex TBE poly-acrylamide gels (Life Technologies). Gels were stained with SYBR Gold DNA stain (Life Technologies) for 30 minutes and imaged with a Gel Doc gel imaging system (Bio-rad). Quantification was based on relative band intensities.

Table E:

primer name	genomic target	primer sequence (5' to 3')
Sp-EMX1-F	<i>EMX1</i>	AAAACCACCCTTCTCTCTGGC
Sp-EMX1-R	<i>EMX1</i>	GGAGATTGGAGACACGGAGA G
Sp-PVALB-F	<i>PVALB</i>	CTGGAAAGCCAATGCCTGAC
Sp-PVALB-R	<i>PVALB</i>	GGCAGCAAACCTCCTTGTCT

#### Computational identification of unique CRISPR target sites

**[0152]** To identify unique target sites for the *S. pyogenes* SF370 Cas9 (SpCas9) enzyme in the human, mouse, rat,

zebrafish, fruit fly, and *C. elegans* genome, we developed a software package to scan both strands of a DNA sequence and identify all possible SpCas9 target sites. For this example, each SpCas9 target site was operationally defined as a 20bp sequence followed by an NGG protospacer adjacent motif (PAM) sequence, and we identified all sequences satisfying this 5'-N<sub>20</sub>-NGG-3' definition on all chromosomes. To prevent non-specific genome editing, after identifying all potential sites, all target sites were filtered based on the number of times they appear in the relevant reference genome. To take advantage of sequence specificity of Cas9 activity conferred by a 'seed' sequence, which can be, for example, approximately 11-12bp sequence 5' from the PAM sequence, 5'-NNNNNNNNNN-NGG-3' sequences were selected to be unique in the relevant genome. All genomic sequences were downloaded from the UCSC Genome Browser (Human genome hg19, Mouse genome mm9, Rat genome rn5, Zebrafish genome danRer7, *D. melanogaster* genome dm4 and *C. elegans* genome ce10). The full search results are available to browse using UCSC Genome Browser information. An example visualization of some target sites in the human genome is provided in Figure 22.

**[0153]** Initially, three sites within the *EMX1* locus in human HEK 293FT cells were targeted. Genome modification efficiency of each chiRNA was assessed using the SURVEYOR nuclease assay, which detects mutations resulting from DNA double-strand breaks (DSBs) and their subsequent repair by the non-homologous end joining (NHEJ) DNA damage repair pathway. Constructs designated chiRNA(+n) indicate that up to the +n nucleotide of wild-type tracrRNA is included in the chimeric RNA construct, with values of 48, 54, 67, and 85 used for n. Chimeric RNAs containing longer fragments of wild-type tracrRNA (chiRNA(+67) and chiRNA(+85)) mediated DNA cleavage at all three *EMX1* target sites, with chiRNA(+85) in particular demonstrating significantly higher levels of DNA cleavage than the corresponding crRNA/tracrRNA hybrids that expressed guide and tracr sequences in separate transcripts (Figures 10b and 10a). Two sites in the *PVALB* locus that yielded no detectable cleavage using the hybrid system (guide sequence and tracr sequence expressed as separate transcripts) were also targeted using chiRNAs. chiRNA(+67) and chiRNA(+85) were able to mediate significant cleavage at the two *PVALB* protospacers (Figures 10c and 10b).

**[0154]** For all five targets in the *EMX1* and *PVALB* loci, a consistent increase in genome modification efficiency with increasing tracr sequence length was observed. Without wishing to be bound by any theory, the secondary structure formed by the 3' end of the tracrRNA may play a role in enhancing the rate of CRISPR complex formation. An illustration of predicted secondary structures for each of the chimeric RNAs used in this example is provided in Figure 21. The secondary structure was predicted using RNAfold (<http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi>) using minimum free energy and partition function algorithm. Pseudocolor for each based (reproduced in grayscale) indicates the probability of pairing. Because chiRNAs with longer tracr sequences were able to cleave targets that were not cleaved by native CRISPR crRNA/tracrRNA hybrids, it is possible that chimeric RNA may be loaded onto Cas9 more efficiently than its native hybrid counterpart. To facilitate the application of Cas9 for site-specific genome editing in eukaryotic cells and organisms, all predicted unique target sites for the *S. pyogenes* Cas9 were computationally identified in the human, mouse, rat, zebra fish, *C. elegans*, and *D. melanogaster* genomes. Chimeric RNAs can be designed for Cas9 enzymes from other microbes to expand the target space of CRISPR RNA-programmable nucleases.

**[0155]** Figures 11 and 21 illustrate exemplary bicistronic expression vectors for expression of chimeric RNA including up to the +85 nucleotide of wild-type tracr RNA sequence, and SpCas9 with nuclear localization sequences. SpCas9 is expressed from a CBh promoter and terminated with the bGH polyA signal (bGH pA). The expanded sequence illustrated immediately below the schematic corresponds to the region surrounding the guide sequence insertion site, and includes, from 5' to 3', 3'-portion of the U6 promoter (first shaded region), BbsI cleavage sites (arrows), partial direct repeat (tracr mate sequence GTTTTAGAGCTA, underlined), loop sequence GAAA, and +85 tracr sequence (underlined sequence following loop sequence). An exemplary guide sequence insert is illustrated below the guide sequence insertion site, with nucleotides of the guide sequence for a selected target represented by an "N".

**[0156]** Sequences described in the above examples are as follows (polynucleotide sequences are 5' to 3'):

**[0157]** U6-short tracrRNA (*Streptococcus pyogenes* SF370):

GAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAGA  
 GAGATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTG  
 ACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAATTTATGTTTTAAAT  
 GGACTATCATATGCTTACCGTAACTTGAAAGTATTTTCGATTTCTTGGCTTTATATATC  
 TTGTGGAAAGGACGAAACACCGGAACCATTCAAAACAGCATAGCAAGTTAAAT  
 AAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTTT

(bold = tracrRNA sequence; underline = terminator sequence)

**[0158]** U6-long tracrRNA (*Streptococcus pyogenes* SF370):

5 GAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAGA  
 GAGATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTG  
 10 ACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAAT  
 GGACTATCATATGCTTACCGTAACTTGAAAGTATTTTCGATTTCTTGGCTTTATATATC  
 TTGTGGAAAGGACGAAACACCGGTAGTATTAAGTATTGTTTTATGGCTGATAAATTT  
 15 CTTTGAATTTCTCCTTGATTATTTGTTATAAAAAGTTATAAAAATAATCTTGTTGGAACC  
 ATTCAAAACAGCATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAG  
 TGGCACCGAGTCGGTGCTTTTTTTT

20 **[0159]** U6-DR-BbsI backbone-DR (*Streptococcus pyogenes* SF370):

GAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAGA  
 25 GAGATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTG  
 ACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAAT  
 GGACTATCATATGCTTACCGTAACTTGAAAGTATTTTCGATTTCTTGGCTTTATATATC  
 30 TTGTGGAAAGGACGAAACACCGGGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAA  
 ACGGGTCTTCGAGAAGACGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAC

35 **[0160]** U6-chimeric RNA-BbsI backbone (*Streptococcus pyogenes* SF370)

GAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAGA  
 GAGATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTG  
 40 ACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAAT  
 GGACTATCATATGCTTACCGTAACTTGAAAGTATTTTCGATTTCTTGGCTTTATATATC  
 TTGTGGAAAGGACGAAACACCGGGTCTTCGAGAAGACCTGTTTTAGAGCTAGAAAT  
 45 AGCAAGTTAAAATAAGGCTAGTCCG

**[0161]** NLS-SpCas9-EGFP:

50

55

MDYKDHDGDYKDHDIDYKDDDDKMAPKKKRKVGIHGVPAADKKYSIGLDIGTNSVG  
 WAVITDEYKVPSSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRK  
 5 NRICYLQEIFSNEMAKVDDSFHRLSEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYH  
 LRKKLVDSTDKADLRILIYALAHMIKFRGHFLIEGDLNPDNSDVKLFIQLVQTYNQLFE  
 ENPINASGVDAKAILSARLSKSRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDL  
 10 AEDAKLQLSKDQTYDDDLNLLAQIGDQYADLFLAAKNLSDAILSDILRVNTEITKAPLS  
 ASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIK  
 PILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYFPLKDNR  
 15 EKIEKILTRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEVVDKGASAQSFIERMTN  
 FDKNLPNEKVLPHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTN  
 20 RKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILE  
 DIVLTLTLFEDREMIEERLKYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSG  
 KTILDFLKSDGFANRNFMLIHDDSLTFKEDIQKAQVSGQGDLSLHEHIANLAGSPAIKKG  
 25 ILQTVKVVDLVKVMGRHKPENIVIAMARENQTTQKGQKNSRERMKRIEELGKELGSQI  
 LKEHPVENTQLQNEKLYLYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSID  
 NKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSE  
 30 LDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSCLVSDFRKDF  
 QFYKVVREINNYHHAHDAYLNAVVGTAIIKKYPKLESEFVYGDYKVYDVRKMIKSEQE  
 IKGATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLS  
 35 MPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVV  
 AKVEKGKSKKLKSVKELLGITIMERSSSFENPIDFLEAKGYKEVKKDLIIKLPKYSLEFE  
 NGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKH  
 40 YLDEIIEQISEFSKRVLADANLDKVL SAYNKHARDKPIREQAENIIHLFTLTNLGAPAAFKY  
 FDTTIDRKRYTSTKEVLDTLIHQSI TGLYETRIDLSQLGGDAAAVSKGEELFTGVVPILV  
 45 ELDGDVNGHKFSVSGEGEGDATYGKLT LKFICTTGKLPVPWPTLVTTLTYGVCFSRYP  
 DHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKED  
 GNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGP  
 50 VLLPDNHYLSTQSALSKDPNEKRDHMLLEFVTAAGITLGMDELYK

**[0162]** SpCas9-EGFP-NLS:

55

MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA  
 EATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSSFFHRLEESFLVEEDKKHERHPIF  
 5 GNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRILIYLAHAHMIKFRGHFLIEGDLNPDNS  
 DVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRLENLIAQLPGEKKNGLFG  
 NLIASLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLNLLAQIGDQYADLFLAAKNLSD  
 10 AILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGY  
 AGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGEL  
 HAILRRQEDFYFPLKDNREKIEKILTRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEE  
 15 VVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPA  
 FLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLL  
 KIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTG  
 20 WGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQG  
 DSLHEHIANLAGSPAIIKKGILQTVKVVDDELVKVMGRHKPENIVIEMARENQTTQKGQKN  
 25 SRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSD  
 YDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLIT  
 QRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIRE  
 30 VKVITLKSCLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTAIIKKYPKLESEFVYG  
 DYKVYDVRKMIKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEI  
 VWDKGRDFATVRKVLSPQVNVIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPPK  
 35 YGGFDSPTVAYSVLVVAKEVGKSKKLKSVKELLGITIMERSSSFENPIDFLEAKGYKE  
 VKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGS  
 PEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVLADANLDKVL SAYNKH RDKPIREQAENI  
 40 IHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVL DATLIHQ SITGLYETRIDLSQLGGDAA  
 AVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLT LKFICTTGKLPVPWP  
 45 TLVTTLTLYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEG  
 DTLVNRIELKGIDFKEDGNILGHKLEYNYN SHNVYIMADKQKNGIKVNFKIRHNIEDGSV  
 QLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDH MVLLEFVTAAGITLGMD  
 50 ELYKKRPAATKKAGQAKKKK

**[0163]** NLS-SpCas9-EGFP-NLS:

55

MDYKDHDGDYKDHDIDYKDDDDKMAPKKKRKVGIHGVPAAADKKYSIGLDIGTNSVG  
 WAVITDEYKVPSSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRK  
 5 NRICYLQEIFSNEMAKVDDSFHRLSEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYH  
 LRKKLV DSTKADLR LIYLALAHMIKFRGHFLIEGDLNPDNSDVKLFIQLVQTYNQLFE  
 ENPINASGVDAKAILSARLSKSRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDL  
 10 AEDAKLQLSKD TYDDDLNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLS  
 ASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIK  
 PILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYFPFLKDNR  
 15 EKIEKILTRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTN  
 FDKNLPNEKVLPHKSHLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTN  
 RKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILE  
 20 DIVLTLTLFEDREMIEERLKYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSG  
 KTILDFLKSDGFANRNFMLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIIKKG  
 ILQTVKVVDDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQI  
 25 LKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSID  
 NKVLTRSDKNRGKSDNVPSEEVVKMKKNYWRQLLNAKLITQRKFDNLTKAERGGLSE  
 30 LDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSCLVSDFRKDF  
 QFYKVBREINNYHHAHDAYLNAVVG TALIKKYPKLESEFVYGDYKVYDVRKMIKSEQE  
 IGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLS  
 35 MPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVV  
 AKVEKGKSKKLKSVKELLGITIMERSSSFENPIDFLEAKGYKEVKKDLIIKLPKYSLFELE  
 40 NGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKH  
 YLDEIIEQISEFSKRVLADANLDKVLSAYNKH RDKPIREQAENIIHLFTLTNLGAPAAFKY  
 FDTTIDRKRYTSTKEVLDATLIHQ SITGLYETRIDLSQLGGDAAAVSKGEELFTGVVPILV  
 45 ELDGDVNGHKFSVSGEGEGDATY GKLTLKFICTTGKLPVPWPTLVTTLT YGVQCFSRYP  
 DHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRA EVKFEGDTLVNRIELKGIDFKED  
 GNILGHKLEYNYN SHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGP  
 50 VLLPDNH YLSTQSALSKDPNEKRDH MVLLFVTAAGITLGMDELYKKRPAATKKAGQA  
 KKKK

[0164] NLS-SpCas9-NLS:

MDYKDHDGDYKDHDIDYKDDDDKMAPKKKRKVGIHGVPAADKKYSIGLDIGTNSVG  
 WAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRK  
 5 NRICYLQEIFSNEMAKVDDSFHRLSEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYH  
 LRKKLVDSTDKADLRILIYLAHAHMIKFRGHFLIEGDLNPDNSDVKLFIQLVQTYNQLFE  
 ENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDL  
 10 AEDAKLQLSKDQYDDDLNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLS  
 ASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIK  
 PILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYFPLKDNR  
 15 EKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTN  
 FDKNLPNEKVLPHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTN  
 RKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIKDKDFLDNEENEDILE  
 20 DIVLTLTLFEDREMIEERLKYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSG  
 KTILDFLKSDGFANRNFMLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKG  
 ILQTVKVVDLVKVMGRHKPENIVIAMARENQTTQKGQKNSRERMKRIEEGIKELGSQI  
 25 LKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSID  
 NKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSE  
 30 LDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSCLVSDFRKDF  
 QFYKVINNYHHAHDAYLNAVVGTAIIKKYPKLESEFVYGDYKVYDVRKMIKSEQE  
 IGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLS  
 35 MPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVV  
 AKVEKGKSKKLKSVKELLGITIMERSSSFENPIDFLEAKGYKEVKKDLIIKLPKYSLFELE  
 NGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKH  
 40 YLDEIIIEQISEFSKRVLADANLDKVLSAYNKHHRDKPIREQAENIIHLFTLTNLGAPAAFYK  
 FDTTIDRKRYTSTKEVLDTLIHQSTGLYETRIDLSQLGGDKRPAATKKAGQAKKKK

45 **[0165]** NLS-mCherry-SpRNase3:

50

55

MFLFLSLTSFLSSSRTLVSKEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYE  
 GTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVM  
 5 NFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPDGPVMQKKTMGWEASSERMYPED  
 GALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVE  
 QYERAEGRHSTGGMDELYKGSKQLEELLSTSFDIQFNDLTLLTETAFTHTSYANEHRLLN  
 10 VSHNERLEFLGDAVLQLIISEYLFAYPKKTEGDMSKLRSMIVREESLAGFSRFCSDAYI  
 KLGKGEEKSGGRRRDTILGDLFEAFLGALLLDKGIDAVRRFLKQVMIPQVEKGNFERVK  
 DYKTCLQEFLQTKGDVAIDYQVISEKGPAHAKQFEVSIVVNGAVLSKGLGKSKKLAEQD  
 15 AAKNALAQLSEV

**[0166]** SpRNase3-mCherry-NLS:

20 MKQLEELLSTSFDIQFNDLTLLTETAFTHTSYANEHRLLN  
 VSHNERLEFLGDAVLQLIISEY  
 LFAKYPPKTEGDMSKLRSMIVREESLAGFSRFCSDAYIKLGKGEEKSGGRRRDTILGDL  
 FEAFLGALLLDKGIDAVRRFLKQVMIPQVEKGNFERVKDYKTCLQEFLQTKGDVAIDYQ  
 25 VISEKGPAHAKQFEVSIVVNGAVLSKGLGKSKKLAEQDAAKNALAQLSEVGSVSKGEE  
 DNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDIL  
 SPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFI  
 30 YKVKLRGTNFPDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAE  
 VKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKKRP  
 35 AATKKAGQAKKKK

**[0167]** NLS-SpCas9n-NLS (the D10A nickase mutation is lowercase):

40

45

50

55



MDYKDHDGDYKDHDIDYKDDDDKMAPKKKRKVGIHGVPAADKKYSIGLaIGTNSVGW  
 AVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKN  
 5 RICYLQEIFSNEMAKVDDSFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHL  
 RKKLVDSTDKADLRILIYLAHAHMIKFRGHFLIEGDLNPDNSDVKLFIQLVQTYNQLFEE  
 NPINASGVDAKAILSARLSKSRLENLIAQLPGEKKNGLFGNLIASLGLTPNFKSNFDLA  
 10 EDAKLQLSKDITYDDDLNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSA  
 SMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPI  
 LEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYFPLKDNREK  
 15 IEKILTRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFD  
 KNLPNEKVLPHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNR  
 KVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILE  
 20 DIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSG  
 KTILDFLKSDGFANRNFQMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKG  
 ILQTVKVVDLVKVMGRHHPENIVIAMARENQTTQKGQKNSRERMKRIEEGIKELGSQI  
 25 LKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSID  
 NKVLTRSDKNRGKSDNVPSEEVVKMKKNYWRQLLNAKLITQRKFDNLTKAERGGLSE  
 LDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSCLVSDFRKDF  
 30 QFYKVBREINNYHHAHDAYLNAVVGTAIIKKYPKLESEFVYGDYKVYDVRKMIKSEQE  
 IGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLS  
 MPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVV  
 35 AKVEKGKSKKLKSVKELLGITIMERSSSFENPIDFLEAKGYKEVKKDLIILPKYSLFELE  
 NGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKH  
 40 YLDEIIEQISEFSKRVLADANLDKVLSAYNKHDKPIREQAENIIHLFTLTNLGAPAAFKY  
 FDTTIDRKRYTSTKEVLDTLIHQSTGLYETRIDLSQLGGDKRPAATKKAGQAKKKK

[0168] hEMX1-HR Template-HindIII-NheI:

GAATGCTGCCCTCAGACCCGCTTCCTCCCTGTCCTTGTCTGTCCAAGGAGAATGAGG  
 TCTCACTGGTGGATTTCGGACTACCCTGAGGAGCTGGCACCTGAGGGACAAGGCCC  
 50 CCCACCTGCCCAGCTCCAGCCTCTGATGAGGGGTGGGAGAGAGCTACATGAGGTTG  
 CTAAGAAAGCCTCCCCTGAAGGAGACCACACAGTGTGTGAGGTTGGAGTCTCTAGC  
 AGCGGGTTCTGTGCCCCCAGGGATAGTCTGGCTGTCCAGGCACTGCTCTTGATATAA  
 55 ACACCACCTCCTAGTTATGAAACCATGCCCATCTGCCTCTCTGTATGGAAAAGAGC

ATGGGGCTGGCCCCGTGGGGTGGTGTCCACTTTAGGCCCTGTGGGAGATCATGGGAA  
 CCCACGCAGTGGGTCATAGGCTCTCTCATTTACTACTCACATCCACTCTGTGAAGAA  
 5 GCGATTATGATCTCTCCTCTAGAAACTCGTAGAGTCCCATGTCTGCCGGCTTCCAGA  
 GCCTGCACTCCTCCACCTTGGCTTGGCTTTGCTGGGGCTAGAGGAGCTAGGATGCAC  
 AGCAGCTCTGTGACCCTTTGTTTGAGAGGAACAGGAAAACCACCCTTCTCTCTGGCC  
 10 CACTGTGTCTCTTCCCTGCCCTGCCATCCCCTTCTGTGAATGTTAGACCCATGGGAGC  
 AGCTGGTCAGAGGGGACCCCGGCCTGGGGCCCCTAACCCCTATGTAGCCTCAGTCTTC  
 CCATCAGGCTCTCAGCTCAGCCTGAGTGTTGAGGCCCCAGTGGCTGCTCTGGGGGCC  
 15 TCCTGAGTTTCTCATCTGTGCCCCCTCCCTCCCTGGCCCAGGTGAAGGTGTGGTTCCAG  
 AACCGGAGGACAAAGTACAAACGGCAGAAGCTGGAGGAGGAAGGGCCTGAGTCCG  
 AGCAGAAGAAGAAGGGCTCCCATCACATCAACCGGTGGCGCATTGCCACGAAGCAG  
 20 GCCAATGGGGAGGACATCGATGTCACCTCCAATGACaagcttgctagcGGTGGGCAACCAC  
 AAACCCACGAGGGCAGAGTGCTGCTTGCTGCTGGCCAGGCCCTGCGTGGGCCCAA  
 GCTGGACTCTGGCCACTCCCTGGCCAGGCTTTGGGGAGGCCTGGAGTCATGGCCCCA  
 25 CAGGGCTTGAAGCCCGGGGCCGCCATTGACAGAGGGACAAGCAATGGGCTGGCTGA  
 GGCTGGGACCACTTGGCCTTCTCCTCGGAGAGCCTGCCTGCCTGGGCGGGCCCGCC  
 CGCCACCGCAGCCTCCCAGCTGCTCTCCGTGTCTCCAATCTCCCTTTTGTTTTGATGC  
 30 ATTTCTGTTTTAATTTATTTTCCAGGCACCACTGTAGTTTAGTGATCCCCAGTGTCCC  
 CCTTCCCTATGGGAATAATAAAAGTCTCTCTCTTAATGACACGGGCATCCAGCTCCA  
 GCCCCAGAGCCTGGGGTGGTAGATTCCGGCTCTGAGGGCCAGTGGGGGCTGGTAGA  
 35 GCAAACGCGTTCAGGGCCTGGGAGCCTGGGGTGGGGTACTGGTGGAGGGGGTCAAG  
 GGTAATTCATTAACCTCTCTTTTGTGTTGGGGGACCCTGGTCTCTACCTCCAGCTCCA  
 CAGCAGGAGAAACAGGCTAGACATAGGGAAGGGCCATCCTGTATCTTGAGGGAGGA  
 40 CAGGCCCAGGTCTTTCTTAACGTATTGAGAGGTGGGAATCAGGCCCAGGTAGTTCAA  
 TGGGAGAGGGAGAGTGCTTCCCTCTGCCTAGAGACTCTGGTGGCTTCTCCAGTTGAG  
 45 GAGAAACCAGAGGAAAGGGGAGGATTGGGGTCTGGGGGAGGGAACACCATTCACA  
 AAGGCTGACGGTTCCAGTCCGAAGTCGTGGGCCCACCAGGATGCTCACCTGTCCTTG  
 GAGAACCGCTGGGCAGGTTGAGACTGCAGAGACAGGGCTTAAGGCTGAGCCTGCAA  
 50 CCAGTCCCCAGTGACTCAGGGCCTCCTCAGCCCAAGAAAGAGCAACGTGCCAGGGC  
 CCGCTGAGCTCTTGTGTTACCTG

[0169] NLS-StCsn1-NLS:

MKRPAATKKAGQAKKKKSDLVLGLDIGIGSVGVGILNKVTGEIIHKNSRIFPAAQAENN  
 LVRRTNRQGRRLARRKKHRRVRLNRLFEESSLITDFTKISINLNPYQLRVKGLTDELSNE  
 5 ELFIALKNMVKHGRGISYDDASDDGNSSVGDYAQIVKENSQKLETKTPGQIQLERYQTY  
 GQLRGDFTVEKDGGKHRLINVFPTSAYRSEALRILQTQQEFNPQITDEFINRYLEILTGRK  
 KYYHGPNEKSRTDYGRYRTSGETLDNIFGILIGKCTFYPDEFRAAKASYTAQEFNLLND  
 10 LNNLTVPTETKKLSKEQKNQIINYVKNEKAMGPAKLFKYIAKLLSCDVADIKGYRIDKS  
 GKAEIHTFEAYRKMKTLETLDIEQMDRETLDKLAYVLTNTEREGIQEALEHEFADGSFS  
 QKQVDELVQFRKANSSIFGKGWHNFSVKLMMELIPELYETSEEQMTILTRLGKQKTTSS  
 15 SNKTKYIDEKLLTEEIYNPVVAKSVRQAIKIVNAAIKEYGDFDNIVIEMARETNEDDEKK  
 AIQKIQKANKDEKDAAMLKAANQYNGKAELPHSVFHGHKQLATKIRLWHQQGERCLY  
 TGKTISIHDLINNSNQFEVDHILPLSITFDDSLANKVLVYATANQEKQRTPYQALDSMD  
 20 DAWSFRELKAFVRESKTLNKKKEYLLTEEDISKFDVRKKFIERNLVDTRYASRVVNA  
 LQEHFRAHKIDTKVSVVRGQFTSQLRRHWGIEKTRDTYHHHAVDALIAASSQLNLWKK  
 QKNTLVSYSEDQLLDIETGELISDDEYKESVFKAPYQHFVDTLKSKEFEDSILFSYQVDSK  
 25 FNRKISDATIYATRQAKVGKDKADETYVLGKIKDIYTQDGYDAFMKIYKKDKSKFLMY  
 RHDPQTFEKVIEPILENYPNKQINEKGKEVPCNPFLKYKEEHGYIRKYSKKGNGPEIKSLK  
 YYDSKLGNHIDITPKDSNNKVVLQSVSPWRADVFNKTTGKYEILGLKYADLQFEKGT  
 30 GTYKISQEKYNDIKKKEGVDSSEFKFTLYKNDLLLVKDTETKEQQLFRFLSRTMPKQK  
 HYVELKPYDKQKFEGGEALIKVLGNVANSGQCKKGLGKSNISYKVRTDVLGNQHIIKN  
 35 EGDKPKLDFKRPAATKKAGQAKKKK

**[0170]** U6-St\_tracrRNA(7-97):

40 GAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAGA  
 GAGATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTG  
 ACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTTAAAATTATGTTTTTAAAT  
 45 GGACTATCATATGCTTACCGTAACTTGAAAGTATTTTCGATTTCTTGGCTTTATATATC  
 TTGTGGAAAGGACGAAACACCGTTACTTAAATCTTGCAGAAGCTACAAAGATAAGG  
 CTTTCATGCCGAAATCAACACCCTGTCATTTTATGGCAGGGTGTTTTTCGTTATTTAA

**[0171]** U6-DR-spacer-DR (*S. pyogenes* SF370)

gagggcctatttcccatgattccttcatttgcataacgatacaaggctgttagagagataattggaattaatttgactgtaaacacaaagatat  
 55 tagtacaaaatacgtgacgtagaaagtaataatttcttgggtagtttgcagtttttaaattatgttttaaaatggactatcatatgcttaccgtaactt  
 gaaagtatttcgatttcttgctttatatacttggtaaaggacgaaacaccgggttttagagctatgctgttttgaatggccccaaacNNN

[illegible]

(lowercase underline = direct repeat; N = guide sequence; bold = terminator)

**[0172]** Chimeric RNA containing +48 tracr RNA (*S. pyogenes* SF370)

gagggcctatttcccatgattccttcataattgcatatacgatacaaggctgtagagagataattggaattaattgactgtaaacacaaagatat

tagtacaaaatacgtgacgtagaaagtaataatttcttgggtagtttgacagttttaaaattatgttttaaaatggactatcatatgcttaccgtaactt

[illegible]

gctagaaatagcaagttaaaataaggctagtcgTTTTTT (N = guide sequence; first underline = tracr mate

sequence; second underline = tracr sequence; bold = terminator)

**[0173]** Chimeric RNA containing +54 tracr RNA (*S. pyogenes* SF370)

gagggcctatttcccatgattccttcataatttgcataacgatacaaggctgtagagagataattggaattaatttgactgtaaacacaaagatat

tagtacaaaatacgtgacgtagaaagtaataatttcttgggtagtttgcagttttaaaattatgttttaaagtggactatcatatgcttaccgtaactt

gaaagtatttcgatttcttggccttatataccttgtggaaaaggacgaaacaccNNNNNNNNNNNNNNNNNNNNNNgttttaga

gctagaaatagcaagttaaaataaggctagtccggtatcaTTTTTTT (N = guide sequence; first underline =

| tracr | mate | sequence; second underline = tracr sequence; bold = terminator) |

**[0174]** Chimeric RNA containing +67 tracr RNA (*S. pyogenes* SF370)

gagggcctatttcccatgattccttcattttgcatatacgatacaaggctgttagagagataattggaattaatttgactgtaaacacaaagatat

tagtacaaaatacgtgacgtagaaagtaataatttcttgggtagtttgcagttttaaaattatgttttaaattggactatcatatgcttaccgtaactt

[illegible]

gctagaaatagcaagttaaaataaggctagtcggttatcaacttgaaaaagtg**TTTTTTT** (N = guide sequence; first

underline = tracr mate sequence; second underline = tracr sequence; bold = terminator)

**[0175]** Chimeric RNA containing +85 tracr RNA (*S. pyogenes* SF370)

gagggcctatttcccatgattccttcataatttgcataacgatacaaggcctgttagagagataatttgaattaatttgactgtaaacacaaagatat

tagtacaaaatacgtgacgtagaaagtaataatttcttgggtagtttgcagttttaaattatgttttaaaatggactatcatatgcttaccgtaactt

[illegible]gctagaaatagcaagttaaaaataaaggctagtccgttatcaacttgaaaaagtggcaccgaagtcggtgc**TTTTTTT** (N = guide

sequence: first underline = tracr mate sequence: second underline = tracr sequence: bold =

terminator)

**[0176]** CBh-NLS-SpCas9-NLS

**EP 2 940 140 A1**

CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCC  
ATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCATTG  
5 ACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTA

10

15

20

25

30

35

40

45

50

55

TCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCCGCCTGGCA  
 TTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTA  
 5 GTCATCGCTATTACCATGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCCCATCT  
 CCCCCCCCCTCCCCACCCCCAATTTTGTATTTATTTATTTTTTAATTATTTTGTGCAGCG  
 ATGGGGGGCGGGGGGGGGGGGGGGGGGGCGCGCGCCAGGCGGGGGCGGGGGCGGGGGCGAG  
 10 GGGCGGGGGCGGGGGCGAGGCGGAGAGGTGCGGGCGGCAGCCAATCAGAGCGGGCGCGC  
 TCCGAAAGTTTCCTTTTATGGCGAGGCGGCGGGCGGGCGGGCCCTATAAAAAGCGA  
 AGCGCGCGGGCGGGCGGGAGTCGCTGCGACGCTGCCTTCGCCCCGTGCCCCGCTCCG  
 15 CCGCCGCCTCGCGCCCGCCCGCCCCGGCTCTGACTGACCGCGTTACTCCCACAGGTGA  
 GCGGGCGGGACGGCCCTTCTCCTCCGGGCTGTAATTAGCTGAGCAAGAGGTAAGGG  
 TTTAAGGGATGGTTGGTTGGTGGGGTATTAATGTTTAATTACCTGGAGCACCTGCCT  
 20 GAAATCACTTTTTTTCAGGTTGGaccggtgccaccATGGACTATAAGGACCACGACGGAGA  
CTACAAGGATCATGATATTGATTACAAAGACGATGACGATAAGATGGCCCCAAAGA  
AGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCGACAAGAAGTACAGCATC  
 25 GGCCTGGACATCGGCACCAACTCTGTGGGCTGGGGCCGTGATCACCGACGAGTACAA  
GGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGACCGGCACAGCATCAAGA  
AGAACCTGATCGGAGCCCTGCTGTTTCGACAGCGGCGAAACAGCCGAGGCCACCCGG  
 30 CTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAGAACCGGATCTGCTATCT  
GCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGACAGCTTCTTCCACAGAC  
 35 TGGAAGAGTCCTTCCTGGTGGAAAGAGGATAAGAAGCACGAGCGGCACCCCATCTTC  
GGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTACCCACCATCTACCACCT  
GAGAAAGAACTGGTGGACAGCACCGACAAGGCCGACCTGCGGCTGATCTATCTGG  
 40 CCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGATCGAGGGCGACCTGAACC  
CCGACAACAGCGACGTGGACAAGCTGTTTCATCCAGCTGGTGCAGACCTACAACCAG  
 45 CTGTTTCGAGGAAAACCCCATCAACGCCAGCGGCGTGGACGCCAAGGCCATCCTGTC  
TGCCAGACTGAGCAAGAGCAGACGGCTGGAAAATCTGATCGCCCAGCTGCCCGGCG  
AGAAGAAGAATGGCCTGTTCGGCAACCTGATTGCCCTGAGCCTGGGCCTGACCCCC  
 50 AACTTCAAGAGCAACTTCGACCTGGCCGAGGATGCCAACTGCAGCTGAGCAAGGA  
CACCTACGACGACGACCTGGACAACCTGCTGGCCCAGATCGGCGACCAGTACGCCG  
 55 ACCTGTTTCTGGCCGCCAAGAACCTGTCCGACGCCATCCTGCTGAGCGACATCCTGA  
GAGTGAACACCGAGATCACCAAGGCCCCCCCTGAGCGCCTCTATGATCAAGAGATAC

GACGAGCACCACCAGGACCTGACCCTGCTGAAAGCTCTCGTGCGGCAGCAGCTGCC  
TGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAACGGCTACGCCGGCTACA  
5 TTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCATCAAGCCCATCCTGGAA  
AAGATGGACGGCACCGAGGAAGTCTGCTCGTGAAGCTGAACAGAGAGGACCTGCTGCG  
GAAGCAGCGGACCTTCGACAACGGCAGCATCCCCACCAGATCCACCTGGGAGAGC  
10 TGCACGCCATTCTGCGGCGGCAGGAAGATTTTTACCCATTCTGAAGGACAACCGGG  
AAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGGCCCTCTGGCCA  
GGGGAAACAGCAGATTTCGCCTGGATGACCAGAAAGAGCGAGGAAACCATCACCCC  
15 CTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCTTCATCGAGC  
GGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGC  
CTGCTGTACGAGTACTTCACCGTGTATAACGAGCTGACCAAAGTGAAATACGTGACC  
20 GAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAGAAAAAGGCCATCGTGG  
ACCTGCTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTAC  
TTCAAGAAAATCGAGTGCTTCGACTCCGTGGAAATCTCCGGCGTGGAAGATCGGTTC  
25 AACGCCTCCCTGGGCACATACCACGATCTGCTGAAAATTATCAAGGACAAGGACTT  
CCTGGACAATGAGGAAAACGAGGACATTCTGGAAGATATCGTGCTGACCCTGACAC  
TGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAACCTATGCCACCTGTTC  
30 GACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACACCGGCTGGGGCAGGC  
TGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCCGGCAAGACAATCCTG  
35 GATTTCTGAAGTCCGACGGCTTCGCCAACAGAACTTCATGCAGCTGATCCACGAC  
GACAGCCTGACCTTTAAAGAGGACATCCAGAAAGCCCAGGTGTCCGGCCAGGGCGA  
TAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCGCCATTAAGAAGGGCA  
40 TCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCCGGCACAAG  
CCCGAGAACATCGTGATCGAAATGGCCAGAGAGAACCAGACCACCCAGAAGGGAC  
AGAAGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGCATCAAAGAGCTGGG  
45 CAGCCAGATCCTGAAAGAACACCCCGTGGAAAACACCCAGCTGCAGAACGAGAAG  
CTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTGGACCAGGAACTGGA  
CATCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCCTCAGAGCTTTCTGAA  
50 GGACGACTCCATCGACAACAAGGTGCTGACCAGAAGCGACAAGAACCGGGGCAAG  
AGCGACAACGTGCCCTCCGAAGAGGTCTGTAAGAAGATGAAGAACTACTGGCGGCA  
GCTGCTGAACGCCAAGCTGATTACCCAGAGAAAGTTCGACAATCTGACCAAGGCCG  
55

AGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATCAAGAGACAGCTGGTG  
GAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCTGGACTCCCGGATGAACAC  
5 TAAGTACGACGAGAATGACAAGCTGATCCGGGAAGTGAAAGTGATCACCTGAAGT  
CCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTACAAAGTGCGCGAGATCA  
ACAACACCACCACGCCCACGACGCCTACCTGAACGCCGTCGTGGGAACCGCCCTG  
10 ATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCGACTACAAGGTGTA  
CGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTACCGCC  
AAGTACTTCTTCTACAGCAACATCATGAACTTTTTCAAGACCGAGATTACCCTGGCC  
15 AACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAACCGGGGAGA  
TCGTGTGGGATAAAGGGCCGGGATTTTGCCACCGTGCGGAAAGTGCTGAGCATGCCC  
CAAGTGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAGTC  
20 TATCCTGCCCAAGAGGAACAGCGATAAGCTGATCGCCAGAAAGAAGGACTGGGACC  
CTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGTGGTGG  
CCAAAGTGGA AAAAGGGCAAGTCCAAGAACTGAAGAGTGTGAAAGAGCTGCTGGG  
25 GATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAATCCCATCGACTTTCTGGAAG  
CCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCCTAAGTACTCC  
CTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTGCCGGCGAACTGCA  
30 GAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGTGAACTTCCTGTACCTGGCCA  
GCCACTATGAGAAGCTGAAGGGCTCCCCCGAGGATAATGAGCAGAAACAGCTGTTT  
GTGGAACAGCACAAGCACTACCTGGACGAGATCATCGAGCAGATCAGCGAGTTCTC  
35 CAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGTCCGCCTACAACA  
AGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCACCTGTTTACC  
40 CTGACCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGACACCACCATCGACCGG  
AAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGATCCACCAGAGCAT  
CACCGGCCTGTACGAGACACGGATCGACCTGTCTCAGCTGGGAGGCGACTTTCTTTT  
45 TCTTAGCTTGACCAGCTTTCTTAGTAGCAGCAGGACGCTTTAA (underline = NLS-  
hSpCas9-NLS)

**[0177]** Example chimeric RNA for *S. thermophilus* LMD-9 CRISPR1 Cas9 (with PAM of NNAGAAW)

NNNNNNNNNNNNNNNNNNNNNNNNgttttgtactctcaagatttaGAAAtaaatcttgcaagactacaagataagcctt  
catgccgaaatcaacaccctgtcattttatggcaggggtgttttcgttatttaa**TTTTTT** (N = guide sequence; first  
underline = tracr mate sequence; second underline = tracr sequence; bold = terminator)

**[0178]** Example chimeric RNA for *S. thermophilus* LMD-9 CRISPR1 Cas9 (with PAM of NNAGAAW)



NNNNNNNNNNNNNNNNNNNNNNNNgttttgtactctcaGAAAtgcagaagctacaagataaggcttcacccgaatca  
acaccctgtcattttatggcagggtgttttcgtatttaa**TTTTTT** (N = guide sequence; first underline = tracr  
mate sequence; second underline = tracr sequence; bold = terminator)

**[0179]** Example chimeric RNA for *S. thermophilus* LMD-9 CRISPR1 Cas9 (with PAM of NNAGAAW)

NNNNNNNNNNNNNNNNNNNNNNNNNgttttgtactctcaGAAAtgcagaagctacaaagataaggcttcatgccgaaatca  
acaccctgtcattttatggcaggggt**TTTTTT** (N = guide sequence; first underline = tracr mate sequence;  
second underline = tracr sequence; bold = terminator)

**[0180]** Example chimeric RNA for *S. thermophilus* LMD-9 CRISPR1 Cas9 (with PAM of NNAGAAW)

NNNNNNNNNNNNNNNNNNNNNNgttattgtactctcaagatttaGAAAtaaattctgcagaagctacaaagataaggctt  
catgccgaaatcaaccctgtcattttatggcaggggtgtttcgttatttaa**TTTTTT** (N = guide sequence; first  
underline = tracr mate sequence; second underline = tracr sequence; bold = terminator)

**[0181]** Example chimeric RNA for *S. thermophilus* LMD-9 CRISPR1 Cas9 (with PAM of NNAGAAW)

NNNNNNNNNNNNNNNNNNNNNNNNgttattgtactctcaGAAAtgcagaagctacaagataaggc**ttcatgcc**gaatc  
aacaccctgtcattttatggcagggtgttttcgttat**taTTTTT** (N = guide sequence; first underline = tracr  
mate sequence; second underline = tracr sequence; bold = terminator)

**[0182]** Example chimeric RNA for *S. thermophilus* LMD-9 CRISPR1 Cas9 (with PAM of NNAGAAW)

NNNNNNNNNNNNNNNNNNNNNNNNNgttattgtactctcaGAAAtgcagaagctacaaagataaggcttcatgccgaaatc  
TTTTTT (N = guide sequence; first underline = tracr mate  
sequence; second underline = tracr sequence; bold = terminator)

**[0183]** Example chimeric RNA for *S. thermophilus* LMD-9 CRISPR1 Cas9 (with PAM of NNAGAAW)

NNNNNNNNNNNNNNNNNNNNNNNNNNgttattgtactctcaagatttaGAAAtaatcttgcagaagctacaatgataaggctt  
catgccgaatatcaacaccctgtcattttatggcaggggtgttttcgttatttaa**TTTTTT** (N = guide sequence; first  
underline = tracr mate sequence; second underline = tracr sequence; bold = terminator)

**[0184]** Example chimeric RNA for *S. thermophilus* LMD-9 CRISPR1 Cas9 (with PAM of NNAGAAW)

NNNNNNNNNNNNNNNNNNNNNNNNgttattgtactctcaGAAAtgcagaagctacaatgataaggcttcattgccgaatca  
acaccctgtcattttatggcagggtgttttcgtatttaa**TTTTTT** (N = guide sequence; first underline = tracr  
 mate sequence; second underline = tracr sequence; bold = terminator)

**[0185]** Example chimeric RNA for *S. thermophilus* LMD-9 CRISPR1 Cas9 (with PAM of NNAGAAW)

NNNNNNNNNNNNNNNNNNNNNNNNNgttattgtactctcaGAAAtgcagaagctacaatgataaggcttcatgccgaatatc  
acaccctgtcattttatggcaggggt**TTTTT** (N = guide sequence; first underline = tracr mate sequence;  
second underline = tracr sequence; bold = terminator)

**[0186]** Example chimeric RNA for *S. thermophilus* LMD-9 CRISPR3 Cas9 (with PAM of NGGNG)

NNNNNNNNNNNNNNNNNNNNNNgttttagagctgtgGAAAcacagcgagtttaaataaggcttagtccgtactcaacttgaaaagg<sup>tggcaccgattcggtgt</sup>**TTTTTT** (N = guide sequence; first underline = tracr mate sequence; second underline = tracr sequence; bold = terminator)

**[0187]** Codon-optimized version of Cas9 from *S. thermophilus* LMD-9 CRISPR3 locus (with an NLS at both 5' and 3' ends)

ATGAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCCAAAAAAGAAAAAGACCA  
AGCCCTACAGCATCGGCCTGGACATCGGCACCAATAGCGTGGGCTGGGCCGTGACC  
ACCGACAACCTACAAGGTGCCAGCAAGAAAATGAAGGTGCTGGGCAACACCTCCAA  
GAAGTACATCAAGAAAAACCTGCTGGGCGTGCTGCTGTTCGACAGCGGCATTACAG  
CCGAGGGCAGACGGCTGAAGAGAACCGCCAGACGGCGGTACACCCGGCGGAGAAA  
CAGAATCCTGTATCTGCAAGAGATCTTCAGCACCGAGATGGCTACCCTGGACGACG  
CCTTCTTCCAGCGGCTGGACGACAGCTTCCTGGTGCCCGACGACAAGCGGGACAGC  
AAGTACCCCATCTTCGGCAACCTGGTGGAAGAGAAGGCCTACCACGACGAGTTCCC  
CACCATCTACCACCTGAGAAAGTACCTGGCCGACAGCACCAAGAAGGCCGACCTGA  
GACTGGTGTATCTGGCCCTGGCCCACATGATCAAGTACCGGGGGCCACTTCCTGATCG  
AGGGCGAGTTCAACAGCAAGAACAACGACATCCAGAAGAAGTTCCAGGACTTCCTG

GACACCTACAACGCCATCTTCGAGAGCGACCTGTCCCTGGAAAACAGCAAGCAGCT  
 GGAAGAGATCGTGAAGGACAAGATCAGCAAGCTGGAAAAGAAGGACCGCATCCTG  
 5 AAGCTGTTCCCCGGCGAGAAGAACAGCGGAATCTTCAGCGAGTTTCTGAAGCTGAT  
 CGTGGGCAACCAGGCCGACTTCAGAAAGTGCTTCAACCTGGACGAGAAAGCCAGCC  
 TGCACTTCAGCAAAGAGAGCTACGACGAGGACCTGGAAACCCTGCTGGGATATATC  
 10 GGCGACGACTACAGCGACGTGTTCTCTGAAGGCCAAGAAGCTGTACGACGCTATCCT  
 GCTGAGCGGCTTCCTGACCGTGACCGACAACGAGACAGAGGCCCCACTGAGCAGCG  
 CCATGATTAAGCGGTACAACGAGCACAAAGAGGATCTGGCTCTGCTGAAAGAGTAC  
 15 ATCCGGAACATCAGCCTGAAAACCTACAATGAGGTGTTCAAGGACGACACCAAGAA  
 CGGCTACGCCGGCTACATCGACGGCAAGACCAACCAGGAAGATTTCTATGTGTACC  
 TGAAGAAGCTGCTGGCCGAGTTCGAGGGGGCCGACTACTTTCTGGAAAAAATCGAC  
 20 CGCGAGGATTTCTCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCTACCA  
 GATCCATCTGCAGGAAATGCGGGCCATCCTGGACAAGCAGGCCAAGTTCTACCCAT  
 25 TCCTGGCCAAGAACAAGAGCGGATCGAGAAGATCCTGACCTTCCGCATCCCCTTACT  
 ACGTGGGCCCCCTGGCCAGAGGCAACAGCGATTTTGCCTGGTCCATCCGGAAGCGC  
 AATGAGAAGATCACCCCCTGGAACCTTCGAGGACGTGATCGACAAAGAGTCCAGCGC  
 30 CGAGGCCTTCATCAACCGGATGACCAGCTTCGACCTGTACCTGCCCCGAGGAAAAGG  
 TGCTGCCCCAAGCACAGCCTGCTGTACGAGACATTCAATGTGTATAACGAGCTGACCA  
 AAGTGCGGTTTTATCGCCGAGTCTATGCGGGACTACCAGTTCCTGGACTCCAAGCAGA  
 35 AAAAGGACATCGTGCGGCTGTACTTCAAGGACAAGCGGAAAGTGACCGATAAGGAC  
 ATCATCGAGTACCTGCACGCCATCTACGGCTACGATGGCATCGAGCTGAAGGGCAT  
 CGAGAAGCAGTTCAACTCCAGCCTGAGCACATAACCACGACCTGCTGAACATTATCA  
 40 ACGACAAAGAATTTCTGGACGACTCCAGCAACGAGGCCATCATCGAAGAGATCATC  
 CACACCCTGACCATCTTTGAGGACCGCGAGATGATCAAGCAGCGGCTGAGCAAGTT  
 CGAGAACATCTTCGACAAGAGCGTGCTGAAAAAGCTGAGCAGACGGCACTACACCG  
 45 GCTGGGGCAAGCTGAGCGCCAAGCTGATCAACGGCATCCGGGACGAGAAGTCCGGC  
 AACACAATCCTGGACTACCTGATCGACGACGGCATCAGCAACCGGAACCTTCATGCA  
 GCTGATCCACGACGACGCCCTGAGCTTCAAGAAGAAGATCCAGAAGGCCCCAGATCA  
 50 TCGGGGACGAGGACAAGGGCAACATCAAAGAAGTCGTGAAGTCCCTGCCCCGGCAGC  
 CCCGCCATCAAGAAGGGAATCCTGCAGAGCATCAAGATCGTGGACGAGCTCGTGAA  
 AGTGATGGGCGGCAGAAAGCCCCGAGAGCATCGTGGTGGAAATGGCTAGAGAGAAC  
 55

CAGTACACCAATCAGGGCAAGAGCAACAGCCAGCAGAGACTGAAGAGACTGGAAA  
 AGTCCCTGAAAGAGCTGGGCAGCAAGATTCTGAAAGAGAATATCCCTGCCAAGCTG  
 5 TCCAAGATCGACAACAACGCCCTGCAGAACGACCGGCTGTACCTGTACTACCTGCA  
 GAATGGCAAGGACATGTATACAGGCGACGACCTGGATATCGACCGCCTGAGCAACT  
 ACGACATCGACCATATTATCCCCAGGCCTTCCTGAAAGACAACAGCATTGACAAC  
 10 AAAGTGCTGGTGTCTCTCCGCCAGCAACCGCGGCAAGTCCGATGATGTGCCCAGCCT  
 GGAAGTCGTGAAAAAGAGAAAGACCTTCTGGTATCAGCTGCTGAAAAGCAAGCTGA  
 TTAGCCAGAGGAAGTTCGACAACCTGACCAAGGCCGAGAGAGGCGGCCTGAGCCCT  
 15 GAAGATAAGGCCGGCTTCATCCAGAGACAGCTGGTGGAAACCCGGCAGATCACCAA  
 GCACGTGGCCAGACTGCTGGATGAGAAGTTTAACAACAAGAAGGACGAGAACAACC  
 GGGCCGTGCGGACCGTGAAGATCATCACCTGAAGTCCACCCTGGTGTCCCAGTTCC  
 20 GGAAGGACTTCGAGCTGTATAAAGTGCGCGAGATCAATGACTTTCACCACGCCAC  
 GACGCCTACCTGAATGCCGTGGTGGCTTCCGCCCTGCTGAAGAAGTACCCTAAGCTG  
 GAACCCGAGTTCGTGTACGGCGACTACCCCAAGTACAACCTCCTTCAGAGAGCGGAA  
 25 GTCCGCCACCGAGAAGGTGTACTTCTACTCCAACATCATGAATATCTTTAAGAAGTC  
 CATCTCCCTGGCCGATGGCAGAGTGATCGAGCGGCCCTGATCGAAGTGAACGAAG  
 AGACAGGCGAGAGCGTGTGGAACAAAGAAAGCGACCTGGCCACCGTGCGGCGGGT  
 30 GCTGAGTTATCCTCAAGTGAATGTCGTGAAGAAGGTGGAAGAACAGAACCACGGCC  
 TGGATCGGGGCAAGCCCAAGGGCCTGTTCAACGCCAACCTGTCCAGCAAGCCTAAG  
 35 CCCAACTCCAACGAGAATCTCGTGGGGGCCAAAGAGTACCTGGACCCTAAGAAGTA  
 CGGCGGATACGCCGGCATCTCCAATAGCTTCACCGTGCTCGTGAAGGGCACAATCG  
 AGAAGGGCGCTAAGAAAAAGATCACAAACGTGCTGGAATTTTCAGGGGATCTCTATC  
 40 CTGGACCGGATCAACTACCGGAAGGATAAGCTGAACTTTCTGCTGGAAAAAGGCTA  
 CAAGGACATTGAGCTGATTATCGAGCTGCCTAAGTACTCCCTGTTTCAACTGAGCGA  
 CGGCTCCAGACGGATGCTGGCCTCCATCCTGTCCACCAACAACAAGCGGGGCGAGA  
 45 TCCACAAGGGAAACCAGATCTTCCTGAGCCAGAAATTTGTGAAACTGCTGTACCACG  
 CCAAGCGGATCTCCAACACCATCAATGAGAACCACCGGAAATACGTGGAAAACCA  
 AAGAAAGAGTTTGAGGAACTGTTCTACTACATCCTGGAGTTCAACGAGAACTATGTG  
 50 GGAGCCAAGAAGAACGGCAAACCTGCTGAACTCCGCCTTCCAGAGCTGGCAGAACCA  
 CAGCATCGACGAGCTGTGCAGCTCCTTCATCGGCCCTACCGGCAGCGAGCGGAAGG  
 GACTGTTTGAGCTGACCTCCAGAGGCTCTGCCGCCGACTTTGAGTTCCTGGGAGTGA  
 55

AGATCCCCCGGTACAGAGACTACACCCCCTCTAGTCTGCTGAAGGACGCCACCCTGA  
 TCCACCAGAGCGTGACCGGCCTGTACGAAACCCGGATCGACCTGGCTAAGCTGGGC  
 5 GAGGGAAAGCGTCCTGCTGCTACTAAGAAAGCTGGTCAAGCTAAGAAAAAGAAATA  
 A

Example 5: Optimization of the guide RNA for *Streptococcus pyogenes* Cas9 (referred to as SpCas9).

[0188] Applicants mutated the tracrRNA and direct repeat sequences, or mutated the chimeric guide RNA to enhance the RNAs in cells.

[0189] The optimization is based on the observation that there were stretches of thymines (Ts) in the tracrRNA and guide RNA, which might lead to early transcription termination by the pol 3 promoter. Therefore Applicants generated the following optimized sequences. Optimized tracrRNA and corresponding optimized direct repeat are presented in pairs.

[0190] Optimized tracrRNA 1 (mutation underlined):

GGAACCATTCatAACAGCATAGCAAGTTAtAATAAGGCTAGTCCGTTATCAACTTGAA  
 20 AAAGTGGCACCGAGTCGGTGCTTTTT

[0191] Optimized direct repeat 1 (mutation underlined):

25 GTTaTAGAGCTATGCTGTTaTGAATGGTCCCCAAAC

[0192] Optimized tracrRNA 2 (mutation underlined):

30 GGAACCATTCAAtACAGCATAGCAAGTTAAtATAAGGCTAGTCCGTTATCAACTTGAA  
 AAAGTGGCACCGAGTCGGTGCTTTTT

[0193] Optimized direct repeat 2 (mutation underlined):

35 GTaTTAGAGCTATGCTGTaTTGAATGGTCCCCAAAC

[0194] Applicants also optimized the chimeric guideRNA for optimal activity in eukaryotic cells.

[0195] Original guide RNA:

40 NNNNNNNNNNNNNNNNNNNNNNGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGC  
 TAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTTT

[0196] Optimized chimeric guide RNA sequence 1:

50 NNNNNNNNNNNNNNNNNNNNNNGTATTAGAGCTAGAAATAGCAAGTTAATATAAGGC  
 TAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTTT

[0197] Optimized chimeric guide RNA sequence 2:

NNNNNNNNNNNNNNNNNNNNNNNGTTTTAGAGCTATGCTGTTTTGGAAACAAAACAGCA  
TAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCG  
5 GTGCTTTTTTTT

**[0198]** Optimized chimeric guide RNA sequence 3:

NNNNNNNNNNNNNNNNNNNNNNNGTATTAGAGCTATGCTGTATTGGAAACAATACAGC  
10 ATAGCAAGTTAAATATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTC  
GGTGCTTTTTTTT

**[0199]** Applicants showed that optimized chimeric guide RNA works better as indicated in Figure 9. The experiment was conducted by co-transfecting 293FT cells with Cas9 and a U6-guide RNA DNA cassette to express one of the four RNA forms shown above. The target of the guide RNA is the same target site in the human Emx1 locus: "GTCACCTC-CAATGACTAGGG"

**Example 6: Optimization of *Streptococcus thermophilus* LMD-9 CRISPR1 Cas9 (referred to as St1Cas9).**

**[0200]** Applicants designed guide chimeric RNAs as shown in Figure 12.

**[0201]** The St1Cas9 guide RNAs can under go the same type of optimization as for SpCas9 guide RNAs, by breaking the stretches of poly thymines (Ts).

**Example 7: Improvement of the Cas9 system for *in vivo* application**

**[0202]** Applicants conducted a Metagenomic search for a Cas9 with small molecular weight. Most Cas9 homologs are fairly large. For example the SpCas9 is around 1368aa long, which is too large to be easily packaged into viral vectors for delivery. Some of the sequences may have been mis-annotated and therefore the exact frequency for each length may not necessarily be accurate. Nevertheless it provides a glimpse at distribution of Cas9 proteins and suggest that there are shorter Cas9 homologs.

**[0203]** Through computational analysis, Applicants found that in the bacterial strain *Campylobacter*, there are two Cas9 proteins with less than 1000 amino acids. The sequence for one Cas9 from *Campylobacter jejuni* is presented below. At this length, CjCas9 can be easily packaged into AAV, lentiviruses, Adenoviruses, and other viral vectors for robust delivery into primary cells and *in vivo* in animal models.

**[0204]** >Campylobacter jejuni Cas9 (CjCas9)

MARILAFDIGISSIGWAFSENDELKDCGVRIFTKVENPKTGESLALPRRLARSARKRLARR  
40 KARLNHLKHLIANEFKLNIEDYQSFDESLAKAYKGSLSIPYELRFRALNELLSKQDFAR  
VILHIAKRRGYDDIKNSDDKEKGAILKAIKQNEEKLANYQSVGEYLYKEYFQKFKENSK  
EFTNVRNKKESYERCIAQSFLKDELKLIFKKQREFGFSFSKKFEEVLSVAFYKRALKDFS  
HLVGNCSSFTDEKRAPKNSPLAFMFVALTRIINLLNNLNKNTGILYTKDDLNALLNEVLK  
45 NGTLTYKQTKLLGLSDDYEFKGEKGTYFIEFKKYKEFIKALGEHNLSQDDLNEIAKDIT  
LIKDEIKLKKALAKYDLNQNQIDSLSKLEFKDHLNISFKALKLVTPLMLEGKKYDEACNE  
LNLKVAINEDKKDFLPAFNETYYKDEVTPVVLRAIKEYRKVLNALLKKYGVHKNIE  
LAREVGKNHSQRAKIEKEQNENYKAKKDAELECEKLGLKINSKNILKLRLFKEQKEFCA  
50 YSGEKIKISDLQDEKMLEIDHIYPYSRFSDDSYMKNKVLVFTKQNQEKLNQTPFEAFGND  
AKWQKIEVLAKNLPKKQKRILDKNYKDKEQKNFKDRNLNDTRYIARLVNLYTKDYL  
DFLPLSDDENTKLNLTQKGSKVHVEAKSGMLTSALRHTWGFSKDRNNHLHHAIDAVI  
IAYANNSIVKAFSDFKKEQESNSAELYAKKISELDYKNKRKFFEPFSGFRQKVLDKIDEIF  
55 VSKPERKKPSGALHEETFRKEEEFYQSYGGKEGVLKALELGKIRKVNGKIVKNGDMFR  
VDIFKHKKTNKFYAVPIYTMDFAKVLPNKAVARSKKGEIKDWILMDENYEFCSLYK  
DSLILIQTKDMQEPEFVYYNAFTSSTVSLIVSKHDNKFETLSKNQKILFKNANEKEVIAKS  
IGIQNLKVFEKYIVSALGEVTKAEFRQREDFKK.

[0205] The putative tracrRNA element for this CjCas9 is:

TATAATCTCATAAGAAATTTAAAAAGGGACTAAAATAAAGAGTTTGCGGGACTCTG  
CGGGGTTACAATCCCCTAAAACCGCTTTTAAAATT

[0206] The Direct Repeat sequence is:

ATTTTACCATAAAGAAATTTAAAAAGGGACTAAAAC

[0207] The co-fold structure of the tracrRNA and direct repeat is provided in Figure 6.

[0208] An example of a chimeric guideRNA for CjCas9 is:

NNNNNNNNNNNNNNNNNNNNNGUUUUAGUCCCGAAAGGGACUAAAAUAAAGAGUU  
UGCGGGACUCUGCGGGGUUACAAUCCCCUAAAACCGCUUUU

[0209] Applicants have also optimized Cas9 guide RNA using *in vitro* methods. Figure 18 shows data from the St1Cas9 chimeric guide RNA optimization *in vitro*.

[0210] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

#### Example 8: Sa sgRNA Optimization

[0211] Applicants designed five sgRNA variants for SaCas9 for an optimal truncated architecture with highest cleavage efficiency. In addition, the native direct repeat:tracr duplex system was tested alongside sgRNAs. Guides with indicated lengths were co-transfected with SaCas9 and tested in HEK 293FT cells for activity. A total of 100ng sgRNA U6-PCR amplicon (or 50ng of direct repeat and 50ng of tracrRNA) and 400ng of SaCas9 plasmid were co-transfected into 200,000 Hepa1-6 mouse hepatocytes, and DNA was harvested 72-hours post-transfection for SURVEYOR analysis. The results are shown in Fig. 23.

[0212] References:

1. Urnov, F.D., Rebar, E.J., Holmes, M.C., Zhang, H.S. & Gregory, P.D. Genome editing with engineered zinc finger nucleases. *Nat. Rev. Genet.* 11, 636-646 (2010).
2. Bogdanove, A.J. & Voytas, D.F. TAL effectors: customizable proteins for DNA targeting. *Science* 333, 1843-1846 (2011).
3. Stoddard, B.L. Homing endonuclease structure and function. *Q. Rev. Biophys.* 38, 49-95 (2005).
4. Bae, T. & Schneewind, O. Allelic replacement in *Staphylococcus aureus* with inducible counter-selection. *Plasmid* 55, 58-63 (2006).
5. Sung, C.K., Li, H., Claverys, J.P. & Morrison, D.A. An rpsL cassette, janus, for gene replacement through negative selection in *Streptococcus pneumoniae*. *Appl. Environ. Microbiol.* 67, 5190-5196 (2001).
6. Sharan, S.K., Thomason, L.C., Kuznetsov, S.G. & Court, D.L. Recombineering: a homologous recombination-based method of genetic engineering. *Nat. Protoc.* 4, 206-223 (2009).
7. Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science* 337, 816-821 (2012).
8. Deveau, H., Garneau, J.E. & Moineau, S. CRISPR-Cas system and its role in phage-bacteria interactions. *Annu. Rev. Microbiol.* 64, 475-493 (2010).
9. Horvath, P. & Barrangou, R. CRISPR-Cas, the immune system of bacteria and archaea. *Science* 327, 167-170 (2010).
10. Terns, M.P. & Terns, R.M. CRISPR-based adaptive immune systems. *Curr. Opin. Microbiol.* 14, 321-327 (2011).
11. van der Oost, J., Jore, M.M., Westra, E.R., Lundgren, M. & Brouns, S.J. CRISPR-based adaptive and heritable immunity in prokaryotes. *Trends. Biochem. Sci.* 34, 401-407 (2009).
12. Brouns, S.J. et al. Small CRISPR RNAs guide antiviral defense in prokaryotes. *Science* 321, 960-964 (2008).
13. Carte, J., Wang, R., Li, H., Terns, R.M. & Terns, M.P. Cas6 is an endoribonuclease that generates guide RNAs

for invader defense in prokaryotes. *Genes Dev.* 22, 3489-3496 (2008).

14. Deltcheva, E. et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. *Nature* 471, 602-607 (2011).

15. Hatoum-Aslan, A., Maniv, I. & Marraffini, L.A. Mature clustered, regularly interspaced, short palindromic repeats RNA (crRNA) length is measured by a ruler mechanism anchored at the precursor processing site. *Proc. Natl. Acad. Sci. U.S.A.* 108, 21218-21222 (2011).

16. Haurwitz, R.E., Jinek, M., Wiedenheft, B., Zhou, K. & Doudna, J.A. Sequence- and structure-specific RNA processing by a CRISPR endonuclease. *Science* 329, 1355-1358 (2010).

17. Deveau, H. et al. Phage response to CRISPR-encoded resistance in *Streptococcus thermophilus*. *J. Bacteriol.* 190, 1390-1400 (2008).

18. Gasiunas, G., Barrangou, R., Horvath, P. & Siksnys, V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. *Proc. Natl. Acad. Sci. U.S.A.* (2012).

19. Makarova, K.S., Aravind, L., Wolf, Y.I. & Koonin, E.V. Unification of Cas protein families and a simple scenario for the origin and evolution of CRISPR-Cas systems. *Biol. Direct.* 6, 38 (2011).

20. Barrangou, R. RNA-mediated programmable DNA cleavage. *Nat. Biotechnol.* 30, 836-838 (2012).

21. Brouns, S.J. Molecular biology. A Swiss army knife of immunity. *Science* 337, 808-809 (2012).

22. Carroll, D. A CRISPR Approach to Gene Targeting. *Mol. Ther.* 20, 1658-1660 (2012).

23. Bikard, D., Hatoum-Aslan, A., Mucida, D. & Marraffini, L.A. CRISPR interference can prevent natural transformation and virulence acquisition during in vivo bacterial infection. *Cell Host Microbe* 12, 177-186 (2012).

24. Sapranas, R. et al. The *Streptococcus thermophilus* CRISPR-Cas system provides immunity in *Escherichia coli*. *Nucleic Acids Res.* (2011).

25. Semenova, E. et al. Interference by clustered regularly interspaced short palindromic repeat (CRISPR) RNA is governed by a seed sequence. *Proc. Natl. Acad. Sci. U.S.A.* (2011).

26. Wiedenheft, B. et al. RNA-guided complex from a bacterial immune system enhances target recognition through seed sequence interactions. *Proc. Natl. Acad. Sci. U.S.A.* (2011).

27. Zahner, D. & Hakenbeck, R. The *Streptococcus pneumoniae* beta-galactosidase is a surface protein. *J. Bacteriol.* 182, 5919-5921 (2000).

28. Marraffini, L.A., Dedent, A.C. & Schneewind, O. Sortases and the art of anchoring proteins to the envelopes of gram-positive bacteria. *Microbiol. Mol. Biol. Rev.* 70, 192-221 (2006).

29. Motamedi, M.R., Szigety, S.K. & Rosenberg, S.M. Double-strand-break repair recombination in *Escherichia coli*: physical evidence for a DNA replication mechanism in vivo. *Genes Dev.* 13, 2889-2903 (1999).

30. Hosaka, T. et al. The novel mutation K87E in ribosomal protein S12 enhances protein synthesis activity during the late growth phase in *Escherichia coli*. *Mol. Genet. Genomics* 271, 317-324 (2004).

31. Costantino, N. & Court, D.L. Enhanced levels of lambda Red-mediated recombinants in mismatch repair mutants. *Proc. Natl. Acad. Sci. U.S.A.* 100, 15748-15753 (2003).

32. Edgar, R. & Qimron, U. The *Escherichia coli* CRISPR system protects from lambda lysogenization, lysogens, and prophage induction. *J. Bacteriol.* 192, 6291-6294 (2010).

33. Marraffini, L.A. & Sontheimer, E.J. Self versus non-self discrimination during CRISPR RNA-directed immunity. *Nature* 463, 568-571 (2010).

34. Fischer, S. et al. An archaeal immune system can detect multiple Protospacer Adjacent Motifs (PAMs) to target invader DNA. *J. Biol. Chem.* 287, 33351-33363 (2012).

35. Gudbergsson, S. et al. Dynamic properties of the *Sulfolobus* CRISPR-Cas and CRISPR/Cmr systems when challenged with vector-borne viral and plasmid genes and protospacers. *Mol. Microbiol.* 79, 35-49 (2011).

36. Wang, H.H. et al. Genome-scale promoter engineering by coselection MAGE. *Nat Methods* 9, 591-593 (2012).

37. Cong, L. et al. Multiplex Genome Engineering Using CRISPR-Cas Systems. *Science* In press (2013).

38. Mali, P. et al. RNA-Guided Human Genome Engineering via Cas9. *Science* In press (2013).

39. Hoskins, J. et al. Genome of the bacterium *Streptococcus pneumoniae* strain R6. *J. Bacteriol.* 183, 5709-5717 (2001).

40. Havarstein, L.S., Coomaraswamy, G. & Morrison, D.A. An unmodified heptadecapeptide pheromone induces competence for genetic transformation in *Streptococcus pneumoniae*. *Proc. Natl. Acad. Sci. U.S.A.* 92, 11140-11144 (1995).

41. Horinouchi, S. & Weisblum, B. Nucleotide sequence and functional map of pC194, a plasmid that specifies inducible chloramphenicol resistance. *J. Bacteriol.* 150, 815-825 (1982).

42. Horton, R.M. In Vitro Recombination and Mutagenesis of DNA : SOEing Together Tailor-Made Genes. *Methods Mol. Biol.* 15, 251-261 (1993).

43. Podbielski, A., Spellerberg, B., Woischnik, M., Pohl, B. & Lutticken, R. Novel series of plasmid vectors for gene inactivation and expression analysis in group A streptococci (GAS). *Gene* 177, 137-147 (1996).

44. Husmann, L.K., Scott, J.R., Lindahl, G. & Stenberg, L. Expression of the Arp protein, a member of the M protein



family, is not sufficient to inhibit phagocytosis of *Streptococcus pyogenes*. *Infection and immunity* 63, 345-348 (1995).  
 45. Gibson, D.G. et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. *Nat Methods* 6, 343-345 (2009).  
 46. Tangri S, et al. ("Rationally engineered therapeutic proteins with reduced immunogenicity" *J Immunol.* 2005 Mar 15;174(6):3187-96.

**[0213]** While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. Further aspects of the invention are defined in the following numbered clauses.

1. A non-naturally occurring or engineered composition comprising:

A) a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises

(a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell,

(b) a tracr mate sequence, and

(c) a tracr sequence

wherein (a), (b) and (c) are arranged in a 5' to 3' orientation,

wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence

directs sequence-specific binding of a CRISPR complex to the target sequence,

wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, or

B) a CRISPR enzyme system, wherein the system is encoded by a vector system comprising one or more vectors comprising

I. a first regulatory element operably linked to a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises

(a) one or more guide sequences capable of hybridizing to one or more target sequences in a eukaryotic cell,

(b) a tracr mate sequence, and

(c) one or more tracr sequences, and

II. a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences,

wherein (a), (b) and (c) are arranged in a 5' to 3' orientation,

wherein components I and II are located on the same or different vectors of the system,

wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence,

wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, or

C) a multiplexed CRISPR enzyme system, wherein the system is encoded by a vector system comprising one or more vectors comprising

I. a first regulatory element operably linked to a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises

(a) one or more guide sequences capable of hybridizing to one or more target sequences in a eukaryotic cell,

- (b) a tracr mate sequence, and
- (c) one or more tracr sequences, and

II. a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences, wherein (a), (b) and (c) are arranged in a 5' to 3' orientation, wherein components I and II are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, wherein in the multiplexed system multiple chiRNA polynucleotide sequences are used or

D) a multiplexed CRISPR enzyme system, wherein the system is encoded by a vector system comprising one or more vectors comprising

I. a first regulatory element operably linked to

- (a) one or more guide sequences capable of hybridizing to a target sequence in a cell, and
- (b) at least one or more tracr mate sequences,

II. a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme, and

III. a third regulatory element operably linked to a tracr sequence, wherein components I, II and III are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, and wherein in the multiplexed system multiple guide sequences and a single tracr sequence is used; and wherein, in the polynucleotide sequence of A), or in the system of B), C) or D), one or more of the guide, tracr and tracr mate sequences are modified to improve stability.

2. The CRISPR-Cas system chiRNA or CRISPR enzyme system of clause 1 wherein the modification comprises an engineered secondary structure.

3. The CRISPR-Cas system chiRNA or CRISPR enzyme system of clause 1 or clause 2 wherein the modification comprises a reduction in a region of hybridization between the tracr mate sequence and the tracr sequence.

4. The CRISPR-Cas system chiRNA or CRISPR enzyme system of any preceding clause wherein the modification comprises fusing the tracr mate sequence and the tracr sequence through an artificial loop.

5. The CRISPR-Cas system chiRNA or CRISPR enzyme system of any preceding clause wherein the modification comprises the tracr sequence having a length between 40 and 120bp.

6. The CRISPR-Cas system chiRNA or CRISPR enzyme system of any preceding clause wherein the tracr sequence is between 40 bp and full length of the tracr.

7. The CRISPR-Cas system chiRNA or CRISPR enzyme system of any preceding clause wherein the tracr sequence includes at least nucleotides 1-67 of the corresponding wild type tracrRNA.

8. The CRISPR-Cas system chiRNA or CRISPR enzyme system of any preceding clause wherein the tracr sequence includes at least nucleotides 1-85 of the corresponding wild type tracrRNA.

9. The CRISPR-Cas system chiRNA or CRISPR enzyme system of any preceding clause wherein the tracr sequence comprises nucleotides corresponding to nucleotides 1-67 of wild type *S. pyogenes* Cas9 tracrRNA.

10. The CRISPR-Cas system chiRNA or CRISPR enzyme system of any preceding clause wherein the tracr sequence comprises nucleotides corresponding to nucleotides 1-85 of wild type *S. pyogenes* Cas9 tracrRNA.

11. The CRISPR-Cas system chiRNA or CRISPR enzyme system of clause 9 wherein the tracr sequence consists essentially of nucleotides corresponding to nucleotides 1-67 of wild type *S. pyogenes* Cas9 tracrRNA.

12. The CRISPR-Cas system chiRNA or CRISPR enzyme system of clause 10 wherein the tracr sequence consists essentially of nucleotides corresponding to nucleotides 1-85 of wild type *S. pyogenes* Cas9 tracrRNA.

13. The CRISPR-Cas system chiRNA or CRISPR enzyme system of any preceding clause wherein the modification comprises sequence optimization.

14. The CRISPR-Cas system chiRNA or CRISPR enzyme system of clause 13 wherein the modification comprises reduction in polyT sequences in the tracr and/or tracr mate sequence.

15. The CRISPR-Cas system chiRNA or CRISPR enzyme system of clause 14 wherein one or more Ts present in a poly-T sequence of the relevant wild type sequence have been substituted with a non-T nucleotide.

16. The CRISPR-Cas system chiRNA or CRISPR enzyme system of clause 13, 14, or 15 wherein the modified sequence does not comprise any polyT sequence having more than 4 contiguous Ts.

17. The CRISPR-Cas system chiRNA or CRISPR enzyme system of any preceding clause wherein the modification comprises adding a polyT terminator sequence.

18. The CRISPR-Cas system chiRNA or CRISPR enzyme system of clause 17 wherein the modification comprises adding a polyT terminator sequence in tracr and/or tracr mate sequences.

19. The CRISPR-Cas system chiRNA or CRISPR enzyme system of clause 17 or 18 wherein the modification comprises adding a polyT terminator sequence in the guide sequence.

20. The CRISPR-Cas system chiRNA or CRISPR enzyme system of any preceding clause wherein the modification comprises altering loops and/or hairpins.

21. The CRISPR-Cas system chiRNA or CRISPR enzyme system of clause 20 wherein the modification comprises providing a minimum of two hairpins in the guide sequence.

22. The CRISPR-Cas system chiRNA or CRISPR enzyme system of clause 20 or 21 wherein the modification comprises providing a hairpin formed by complementation between the tracr and tracr mate sequence.

23. The CRISPR-Cas system chiRNA or CRISPR enzyme system of clause 20 to 22 wherein the modification comprises providing one or more further hairpin(s) at the 3' end of the tracrRNA sequence.

24. The CRISPR-Cas system chiRNA or CRISPR enzyme system of clause 20 to 23 wherein the modification comprises providing one or more additional hairpin(s) added to the 3' of the guide sequence.

25. The CRISPR-Cas system chiRNA or CRISPR enzyme system of any preceding clause wherein the modification comprises extending the 5' end of the guide sequence.

26. The CRISPR-Cas system chiRNA or CRISPR enzyme system of clause 25 wherein the modification comprises providing one or more hairpins in the 5' end of the guide sequence.

27. The CRISPR-Cas system chiRNA or CRISPR enzyme system of clause 25 or 26 wherein the modification comprises appending the sequence (5'-AGGACGAAGTCCTAA) to the 5' end of the guide sequence

28. The CRISPR-Cas system chiRNA or CRISPR enzyme system of any preceding clause wherein the modification comprises providing cross linking or providing one or more modified nucleotides in the polynucleotide sequence.

29. The CRISPR-Cas system chiRNA or CRISPR enzyme system of clause 28, wherein modified nucleotides are provided in any or all of the tracr, tracr mate, and/or guide sequences, and/or in the enzyme coding sequence, and/or in vector sequences.

30. The CRISPR-Cas system chiRNA or CRISPR enzyme system of clause 28 or 29 wherein providing modified nucleotides comprises inclusion of at least one non naturally occurring nucleotide, or a modified nucleotide, or analogs thereof.

31. The CRISPR-Cas system chiRNA or CRISPR enzyme system of clause 30 wherein the modified nucleotides are modified at the ribose, phosphate, and/or base moiety.

32. The CRISPR-Cas system chiRNA or CRISPR enzyme system of clause 30 wherein the modified nucleotide is selected from the group consisting of 2'-O-methyl analogs, 2'-deoxy analogs, or 2'-fluoro analogs.

33. The CRISPR-Cas system chiRNA or CRISPR enzyme system of clause 30 wherein the modified nucleotide is selected from the group consisting of 2-aminopurine, 5-bromo-uridine, pseudouridine, inosine, 7-methylguanosine.

34. The CRISPR-Cas system chiRNA or CRISPR enzyme system of any preceding clause wherein the modification comprises two hairpins.

35. The CRISPR-Cas system chiRNA or CRISPR enzyme system of any preceding clause wherein the modification comprises three hairpins.

36. The CRISPR-Cas system chiRNA or CRISPR enzyme system of any preceding clause wherein the modification comprises at most five hairpins.

37. The CRISPR-Cas system chiRNA or CRISPR enzyme system of any preceding clause wherein the CRISPR enzyme is a type II CRISPR system enzyme.

38. The CRISPR-Cas system chiRNA or CRISPR enzyme system of any preceding clause wherein the CRISPR enzyme is a Cas9 enzyme.

39. The CRISPR-Cas system chiRNA or CRISPR enzyme system of any preceding clause wherein the CRISPR enzyme is comprised of less than one thousand amino acids.

40. The CRISPR-Cas system chiRNA or CRISPR enzyme system of any of clauses 1 to 38 wherein the CRISPR enzyme is comprised of less than four thousand amino acids.

41. The CRISPR-Cas system chiRNA or CRISPR enzyme system of any preceding clause wherein the Cas9 enzyme is StCas9 or StlCas9.

42. The CRISPR-Cas system chiRNA or CRISPR enzyme system of any preceding clause wherein the Cas9 enzyme is a Cas9 enzyme from an organism selected from the group comprising of genus *Streptococcus*, *Campylobacter*, *Nitratifractor*, *Staphylococcus*, *Parvibaculum*, *Rosehuria*, *Neisseria*, *Gluconacetobacter*, *Azospirillum*, *Sphaerochaeta*, *Lactobacillus*, *Eubacterium* or *Corynebacter*.

43. The CRISPR-Cas system chiRNA or CRISPR enzyme system of any preceding clause wherein the CRISPR enzyme is a nuclease directing cleavage of both strands at the location of the target sequence.

44. The CRISPR-Cas system chiRNA or CRISPR enzyme system of any preceding clause, wherein the first regulatory element is a polymerase III promoter.

45. The CRISPR-Cas system chiRNA or CRISPR enzyme system of any preceding clause wherein the second regulatory element is a polymerase II promoter.

46. The CRISPR-Cas system chiRNA or CRISPR enzyme system of any preceding clause wherein the guide sequence comprises at least fifteen nucleotides.

47. The CRISPR-Cas system chiRNA or CRISPR enzyme system of any preceding clause wherein the modification comprises optimized tracr sequence and/or optimized guide sequence RNA and/or, co-fold structure of tracr sequence and/or tracr mate sequence(s) and/or stabilizing secondary structures of tracr sequence and/or tracr sequence with a reduced region of base-pairing and/or tracr sequence fused RNA elements; and/or, in the multiplexed system there are two RNAs comprising a tracer and comprising a plurality of guides or one RNA comprising a plurality of chimerics.

48. The CRISPR-Cas system chiRNA or CRISPR enzyme system of any one of clauses 1-47 wherein the CRISPR enzyme is codon-optimized for expression in a eukaryotic cell.

49. The composition of any preceding clause wherein the composition comprises a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence.

50. The composition of clause 49, wherein the composition further comprises a polynucleotide sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences.

51. The CRISPR enzyme system of any preceding clause.

52. The multiplexed CRISPR enzyme system of any preceding clause.

53. The transcription or translation product of the composition of clause 49 or 50, the CRISPR enzyme system of clause 51, or the multiplexed CRISPR enzyme system of clause 52.

## EP 2 940 140 A1

### SEQUENCE LISTING

5  
5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

<110> THE BROAD INSTITUTE, INC.  
MASSACHUSETTS INSTITUTE OF TECHNOLOGY

<120> ENGINEERING OF SYSTEMS, METHODS AND OPTIMIZED GUIDE COMPOSITIONS  
FOR SEQUENCE MANIPULATION

<130> PC927381EPB

<140> PCT/US2013/074819  
<141> 2013-12-12

<150> 61/836,127  
<151> 2013-06-17

<150> 61/835,931  
<151> 2013-06-17

<150> 61/828,130  
<151> 2013-05-28

<150> 61/819,803  
<151> 2013-05-06

<150> 61/814,263  
<151> 2013-04-20

<150> 61/806,375  
<151> 2013-03-28

<150> 61/802,174  
<151> 2013-03-15

<150> 61/791,409  
<151> 2013-03-15

<150> 61/769,046  
<151> 2013-02-25

<150> 61/758,468  
<151> 2013-01-30

<150> 61/748,427  
<151> 2013-01-02

<150> 61/736,527  
<151> 2012-12-12

<160> 264

<170> PatentIn version 3.5

<210> 1  
<211> 15  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> source  
<223> /note="Description of Artificial Sequence: Synthetic  
oligonucleotide"

<400> 1  
aggacgaagt cctaa

15

5 <210> 2  
<211> 7  
<212> PRT  
<213> Simian virus 40

10 <400> 2  
Pro Lys Lys Lys Arg Lys Val  
1 5

15 <210> 3  
<211> 16  
<212> PRT  
<213> Unknown

20 <220>  
<221> source  
<223> /note="Description of Unknown:  
Nucleoplasmin bipartite NLS sequence"

25 <400> 3  
Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys Lys  
1 5 10 15

30 <210> 4  
<211> 9  
<212> PRT  
<213> Unknown

35 <220>  
<221> source  
<223> /note="Description of Unknown:  
C-myc NLS sequence"

<400> 4  
Pro Ala Ala Lys Arg Val Lys Leu Asp  
1 5

40 <210> 5  
<211> 11  
<212> PRT  
<213> Unknown

45 <220>  
<221> source  
<223> /note="Description of Unknown:  
C-myc NLS sequence"

50 <400> 5  
Arg Gln Arg Arg Asn Glu Leu Lys Arg Ser Pro  
1 5 10

55 <210> 6  
<211> 38  
<212> PRT  
<213> Homo sapiens

# EP 2 940 140 A1

<400> 6

Asn Gln Ser Ser Asn Phe Gly Pro Met Lys Gly Gly Asn Phe Gly Gly  
1 5 10 15

5

Arg Ser Ser Gly Pro Tyr Gly Gly Gly Gly Gln Tyr Phe Ala Lys Pro  
20 25 30

10

Arg Asn Gln Gly Gly Tyr  
35

<210> 7

<211> 42

<212> PRT

<213> Unknown

15

<220>

<221> source

<223> /note="Description of Unknown:  
IBB domain from importin-alpha sequence"

20

<400> 7

Arg Met Arg Ile Glx Phe Lys Asn Lys Gly Lys Asp Thr Ala Glu Leu  
1 5 10 15

25

Arg Arg Arg Arg Val Glu Val Ser Val Glu Leu Arg Lys Ala Lys Lys  
20 25 30

30

Asp Glu Gln Ile Leu Lys Arg Arg Asn Val  
35 40

<210> 8

<211> 8

<212> PRT

<213> Unknown

35

<220>

<221> source

<223> /note="Description of Unknown:  
Myoma T protein sequence"

40

<400> 8

Val Ser Arg Lys Arg Pro Arg Pro  
1 5

45

<210> 9

<211> 8

<212> PRT

<213> Unknown

50

<220>

<221> source

<223> /note="Description of Unknown:  
Myoma T protein sequence"

55

<400> 9

# EP 2 940 140 A1

Pro Pro Lys Lys Ala Arg Glu Asp  
1 5

5  
<210> 10  
<211> 8  
<212> PRT  
<213> Homo sapiens

10  
<400> 10  
Pro Gln Pro Lys Lys Lys Pro Leu  
1 5

15  
<210> 11  
<211> 12  
<212> PRT  
<213> Mus musculus

20  
<400> 11  
Ser Ala Leu Ile Lys Lys Lys Lys Lys Met Ala Pro  
1 5 10

25  
<210> 12  
<211> 5  
<212> PRT  
<213> Influenza virus

30  
<400> 12  
Asp Arg Leu Arg Arg  
1 5

35  
<210> 13  
<211> 7  
<212> PRT  
<213> Influenza virus

40  
<400> 13  
Pro Lys Gln Lys Lys Arg Lys  
1 5

45  
<210> 14  
<211> 10  
<212> PRT  
<213> Hepatitis delta virus

50  
<400> 14  
Arg Lys Leu Lys Lys Lys Ile Lys Lys Leu  
1 5 10

55  
<210> 15  
<211> 10  
<212> PRT  
<213> Mus musculus

55  
<400> 15  
Arg Glu Lys Lys Lys Phe Leu Lys Arg Arg  
1 5 10



<210> 16  
 <211> 20  
 <212> PRT  
 <213> Homo sapiens

5

<400> 16  
 Lys Arg Lys Gly Asp Glu Val Asp Gly Val Asp Glu Val Ala Lys Lys  
 1 5 10 15

10

Lys Ser Lys Lys  
 20

15

<210> 17  
 <211> 17  
 <212> PRT  
 <213> Homo sapiens

20

<400> 17  
 Arg Lys Cys Leu Gln Ala Gly Met Asn Leu Glu Ala Arg Lys Thr Lys  
 1 5 10 15

Lys

25

<210> 18  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

30

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"

35

<220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, t or g

<220>  
 <221> modified\_base  
 <222> (21)..(22)  
 <223> a, c, t, g, unknown or other

40

45

<400> 18  
 nnnnnnnnnn nnnnnnnnnn nnagaaw

27

50

<210> 19  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence

55

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"

<220>  
 <221> modified\_base  
 <222> (1)..(12)  
 <223> a, c, t or g  
 5  
 <220>  
 <221> modified\_base  
 <222> (13)..(14)  
 <223> a, c, t, g, unknown or other  
 10  
 <400> 19  
 nnnnnnnnnn nnnnagaaw 19  
 <210> 20  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 20  
 <220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, t or g  
 25  
 <220>  
 <221> modified\_base  
 <222> (21)..(22)  
 <223> a, c, t, g, unknown or other  
 30  
 <400> 20  
 nnnnnnnnnn nnnnnnnnnn nnagaaw 27  
 35  
 <210> 21  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence  
 40  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 45  
 <220>  
 <221> modified\_base  
 <222> (1)..(11)  
 <223> a, c, t or g  
 50  
 <220>  
 <221> modified\_base  
 <222> (12)..(13)  
 <223> a, c, t, g, unknown or other  
 55  
 <400> 21

nnnnnnnnnn nnnagaaw

18

5 <210> 22  
 <211> 137  
 <212> DNA  
 <213> Artificial Sequence

10 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 polynucleotide"

15 <220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, t, g, unknown or other

20 <400> 22  
 nnnnnnnnnn nnnnnnnnnn gtttttgtac tctcaagatt tagaaataaa tcttgcagaa 60  
 gctacaaaga taaggcttca tgccgaaatc aacacctgt cattttatgg cagggtgttt 120  
 tcgttattta atttttt 137

25 <210> 23  
 <211> 123  
 <212> DNA  
 <213> Artificial Sequence

30 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 polynucleotide"

35 <220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, t, g, unknown or other

40 <400> 23  
 nnnnnnnnnn nnnnnnnnnn gtttttgtac tctcagaaat gcagaagcta caaagataag 60  
 gcttcattgcc gaaatcaaca ccctgtcatt ttatggcagg gtgttttcgt tatttaattt 120  
 ttt 123

45 <210> 24  
 <211> 110  
 <212> DNA  
 <213> Artificial Sequence

50 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 polynucleotide"

55 <220>

# EP 2 940 140 A1

<221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, t, g, unknown or other

5 <400> 24  
 nnnnnnnnnn nnnnnnnnnn gttttgtac tctcagaaat gcagaagcta caaagataag 60  
 gcttcatgcc gaaatcaaca ccctgtcatt ttatggcagg gtgttttttt 110

10 <210> 25  
 <211> 102  
 <212> DNA  
 <213> Artificial Sequence

15 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic polynucleotide"

20 <220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, t, g, unknown or other

25 <400> 25  
 nnnnnnnnnn nnnnnnnnnn gttttagagc tagaaatagc aagttaaaat aaggctagtc 60  
 cgttatcaac ttgaaaaagt ggcaccgagt cggtgctttt tt 102

30 <210> 26  
 <211> 88  
 <212> DNA  
 <213> Artificial Sequence

35 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"

40 <220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, t, g, unknown or other

45 <400> 26  
 nnnnnnnnnn nnnnnnnnnn gttttagagc tagaaatagc aagttaaaat aaggctagtc 60  
 cgttatcaac ttgaaaaagt gttttttt 88

50 <210> 27  
 <211> 76  
 <212> DNA  
 <213> Artificial Sequence

55 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"

<220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, t, g, unknown or other  
 5

<400> 27  
 nnnnnnnnnn nnnnnnnnnn gtttttagagc tagaaatagc aagttaaaat aaggctagtc 60  
 cgttatcatt tttttt 76  
 10

<210> 28  
 <211> 12  
 <212> RNA  
 <213> Artificial Sequence  
 15

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 20

<400> 28  
 guuuuagagc ua 12

<210> 29  
 <211> 33  
 <212> DNA  
 <213> Homo sapiens  
 25

<400> 29  
 ggacatcgat gtcacctcca atgactaggg tgg 33  
 30

<210> 30  
 <211> 33  
 <212> DNA  
 <213> Homo sapiens  
 35

<400> 30  
 cattggaggt gacatcgatg tcctcccat tgg 33  
 40

<210> 31  
 <211> 33  
 <212> DNA  
 <213> Homo sapiens  
 45

<400> 31  
 ggaagggcct gagtccgagc agaagaagaa ggg 33

<210> 32  
 <211> 33  
 <212> DNA  
 <213> Homo sapiens  
 50

<400> 32  
 ggtggcgaga ggggccgaga ttgggtgttc agg 33  
 55

<210> 33  
 <211> 33  
 <212> DNA  
 <213> Homo sapiens  
 5  
 <400> 33  
 atgcaggagg gtggcgagag gggccgagat tgg 33  
  
 <210> 34  
 10 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 15 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 primer"  
  
 <400> 34  
 20 aaaaccaccc ttctctctgg c 21  
  
 <210> 35  
 <211> 21  
 <212> DNA  
 25 <213> Artificial Sequence  
  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 primer"  
 30  
 <400> 35  
 ggagattgga gacacggaga g 21  
  
 <210> 36  
 35 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 40 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 primer"  
  
 <400> 36  
 45 ctggaaagcc aatgcctgac 20  
  
 <210> 37  
 <211> 20  
 <212> DNA  
 50 <213> Artificial Sequence  
  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 primer"  
 55  
 <400> 37  
 ggcagcaaac tccttgcct 20

<210> 38  
 <211> 12  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"

<400> 38  
 gtttttagagc ta

12

<210> 39  
 <211> 335  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 polynucleotide"

<400> 39  
 gagggcctat ttcccatgat tccttcatat ttgcatatac gatacaaggc tgtagagag 60  
 ataattggaa ttaatttgac tgtaaacaca aagatattag tacaaaatac gtgacgtaga 120  
 aagtaataat ttcttgggta gtttgcagtt ttaaaattat gttttaaaat ggactatcat 180  
 atgcttaccg taacttgaaa gtatttcgat ttcttggcctt tatatatcctt gtggaaagga 240  
 cgaaacaccg gaaccattca aaacagcata gcaagttaaa ataaggctag tccgttatca 300  
 acttgaaaaa gtggcaccga gtcggtgctt ttttt 335

<210> 40  
 <211> 423  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 polynucleotide"

<400> 40  
 gagggcctat ttcccatgat tccttcatat ttgcatatac gatacaaggc tgtagagag 60  
 ataattggaa ttaatttgac tgtaaacaca aagatattag tacaaaatac gtgacgtaga 120  
 aagtaataat ttcttgggta gtttgcagtt ttaaaattat gttttaaaat ggactatcat 180  
 atgcttaccg taacttgaaa gtatttcgat ttcttggcctt tatatatcctt gtggaaagga 240  
 cgaaacaccg gtagtattaa gtattgtttt atggctgata aatttctttg aatttctcct 300  
 tgattatttg ttataaaagt tataaaataa tcttggttga accattcaaa acagcatagc 360

# EP 2 940 140 A1

aagttaaaat aaggctagtc cgttatcaac ttgaaaaagt ggcaccgagt cggtgctttt 420  
 ttt 423

5  
 <210> 41  
 <211> 339  
 <212> DNA  
 <213> Artificial Sequence

10  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 polynucleotide"

15  
 <400> 41  
 gagggcctat ttcccatgat tccttcatat ttgcatatac gatacaaggc tgtagagag 60  
 ataattggaa ttaatttgac tgtaaacaca aagatattag tacaaaatac gtgacgtaga 120  
 aagtaataat ttcttgggta gtttgcagtt ttaaaattat gttttaaaat ggactatcat 180  
 20 atgcttaccg taacttgaaa gtatttcgat ttcttggctt tatatatctt gtggaaagga 240  
 cgaaacaccg ggttttagag ctatgctgtt ttgaatggtc ccaaaacggg tcttcgagaa 300  
 25 gacgttttag agctatgctg ttttgaatgg tcccaaac 339

<210> 42  
 <211> 309  
 <212> DNA  
 30 <213> Artificial Sequence

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 35 polynucleotide"

<400> 42  
 gagggcctat ttcccatgat tccttcatat ttgcatatac gatacaaggc tgtagagag 60  
 ataattggaa ttaatttgac tgtaaacaca aagatattag tacaaaatac gtgacgtaga 120  
 40 aagtaataat ttcttgggta gtttgcagtt ttaaaattat gttttaaaat ggactatcat 180  
 atgcttaccg taacttgaaa gtatttcgat ttcttggctt tatatatctt gtggaaagga 240  
 45 cgaaacaccg ggtcttcgag aagacctgtt ttagagctag aaatagcaag ttaaaataag 300  
 gctagtccg 309

<210> 43  
 50 <211> 1648  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <221> source  
 55 <223> /note="Description of Artificial Sequence: Synthetic  
 polypeptide"



# EP 2 940 140 A1

<400> 43

Met	Asp	Tyr	Lys	Asp	His	Asp	Gly	Asp	Tyr	Lys	Asp	His	Asp	Ile	Asp
1				5					10					15	
5															
Tyr	Lys	Asp	Asp	Asp	Asp	Lys	Met	Ala	Pro	Lys	Lys	Lys	Arg	Lys	Val
			20					25					30		
10															
Gly	Ile	His	Gly	Val	Pro	Ala	Ala	Asp	Lys	Lys	Tyr	Ser	Ile	Gly	Leu
		35					40					45			
15															
Asp	Ile	Gly	Thr	Asn	Ser	Val	Gly	Trp	Ala	Val	Ile	Thr	Asp	Glu	Tyr
	50					55					60				
20															
Lys	Val	Pro	Ser	Lys	Lys	Phe	Lys	Val	Leu	Gly	Asn	Thr	Asp	Arg	His
65					70					75					80
25															
Ser	Ile	Lys	Lys	Asn	Leu	Ile	Gly	Ala	Leu	Leu	Phe	Asp	Ser	Gly	Glu
				85					90					95	
30															
Thr	Ala	Glu	Ala	Thr	Arg	Leu	Lys	Arg	Thr	Ala	Arg	Arg	Arg	Tyr	Thr
			100					105						110	
35															
Arg	Arg	Lys	Asn	Arg	Ile	Cys	Tyr	Leu	Gln	Glu	Ile	Phe	Ser	Asn	Glu
		115					120					125			
40															
Met	Ala	Lys	Val	Asp	Asp	Ser	Phe	Phe	His	Arg	Leu	Glu	Glu	Ser	Phe
	130					135					140				
45															
Leu	Val	Glu	Glu	Asp	Lys	Lys	His	Glu	Arg	His	Pro	Ile	Phe	Gly	Asn
145					150					155					160
50															
Ile	Val	Asp	Glu	Val	Ala	Tyr	His	Glu	Lys	Tyr	Pro	Thr	Ile	Tyr	His
				165					170					175	
55															
Leu	Arg	Lys	Lys	Leu	Val	Asp	Ser	Thr	Asp	Lys	Ala	Asp	Leu	Arg	Leu
			180					185					190		
60															
Ile	Tyr	Leu	Ala	Leu	Ala	His	Met	Ile	Lys	Phe	Arg	Gly	His	Phe	Leu
		195					200					205			
65															
Ile	Glu	Gly	Asp	Leu	Asn	Pro	Asp	Asn	Ser	Asp	Val	Asp	Lys	Leu	Phe
	210					215					220				
70															
Ile	Gln	Leu	Val	Gln	Thr	Tyr	Asn	Gln	Leu	Phe	Glu	Glu	Asn	Pro	Ile
225					230					235					240
75															
Asn	Ala	Ser	Gly	Val	Asp	Ala	Lys	Ala	Ile	Leu	Ser	Ala	Arg	Leu	Ser
				245					250					255	

EP 2 940 140 A1

	Lys	Ser	Arg	Arg	Leu	Glu	Asn	Leu	Ile	Ala	Gln	Leu	Pro	Gly	Glu	Lys	
				260					265					270			
5	Lys	Asn	Gly	Leu	Phe	Gly	Asn	Leu	Ile	Ala	Leu	Ser	Leu	Gly	Leu	Thr	
			275					280					285				
10	Pro	Asn	Phe	Lys	Ser	Asn	Phe	Asp	Leu	Ala	Glu	Asp	Ala	Lys	Leu	Gln	
		290					295					300					
15	Leu	Ser	Lys	Asp	Thr	Tyr	Asp	Asp	Asp	Leu	Asp	Asn	Leu	Leu	Ala	Gln	
	305					310					315					320	
20	Ile	Gly	Asp	Gln	Tyr	Ala	Asp	Leu	Phe	Leu	Ala	Ala	Lys	Asn	Leu	Ser	
					325					330					335		
25	Asp	Ala	Ile	Leu	Leu	Ser	Asp	Ile	Leu	Arg	Val	Asn	Thr	Glu	Ile	Thr	
				340					345					350			
30	Lys	Ala	Pro	Leu	Ser	Ala	Ser	Met	Ile	Lys	Arg	Tyr	Asp	Glu	His	His	
			355					360					365				
35	Gln	Asp	Leu	Thr	Leu	Leu	Lys	Ala	Leu	Val	Arg	Gln	Gln	Leu	Pro	Glu	
		370					375					380					
40	Lys	Tyr	Lys	Glu	Ile	Phe	Phe	Asp	Gln	Ser	Lys	Asn	Gly	Tyr	Ala	Gly	
	385					390					395					400	
45	Tyr	Ile	Asp	Gly	Gly	Ala	Ser	Gln	Glu	Glu	Phe	Tyr	Lys	Phe	Ile	Lys	
					405					410					415		
50	Pro	Ile	Leu	Glu	Lys	Met	Asp	Gly	Thr	Glu	Glu	Leu	Leu	Val	Lys	Leu	
				420					425					430			
55	Asn	Arg	Glu	Asp	Leu	Leu	Arg	Lys	Gln	Arg	Thr	Phe	Asp	Asn	Gly	Ser	
			435					440					445				
60	Ile	Pro	His	Gln	Ile	His	Leu	Gly	Glu	Leu	His	Ala	Ile	Leu	Arg	Arg	
		450					455					460					
65	Gln	Glu	Asp	Phe	Tyr	Pro	Phe	Leu	Lys	Asp	Asn	Arg	Glu	Lys	Ile	Glu	
	465					470					475					480	
70	Lys	Ile	Leu	Thr	Phe	Arg	Ile	Pro	Tyr	Tyr	Val	Gly	Pro	Leu	Ala	Arg	
					485					490					495		
75	Gly	Asn	Ser	Arg	Phe	Ala	Trp	Met	Thr	Arg	Lys	Ser	Glu	Glu	Thr	Ile	

EP 2 940 140 A1

	500						505						510					
5	Thr	Pro	Trp	Asn	Phe	Glu	Glu	Val	Val	Asp	Lys	Gly	Ala	Ser	Ala	Gln		
			515					520					525					
	Ser	Phe	Ile	Glu	Arg	Met	Thr	Asn	Phe	Asp	Lys	Asn	Leu	Pro	Asn	Glu		
10		530					535					540						
	Lys	Val	Leu	Pro	Lys	His	Ser	Leu	Leu	Tyr	Glu	Tyr	Phe	Thr	Val	Tyr		
	545					550					555					560		
15	Asn	Glu	Leu	Thr	Lys	Val	Lys	Tyr	Val	Thr	Glu	Gly	Met	Arg	Lys	Pro		
					565					570					575			
	Ala	Phe	Leu	Ser	Gly	Glu	Gln	Lys	Lys	Ala	Ile	Val	Asp	Leu	Leu	Phe		
20				580					585					590				
	Lys	Thr	Asn	Arg	Lys	Val	Thr	Val	Lys	Gln	Leu	Lys	Glu	Asp	Tyr	Phe		
			595					600					605					
25																		
	Lys	Lys	Ile	Glu	Cys	Phe	Asp	Ser	Val	Glu	Ile	Ser	Gly	Val	Glu	Asp		
		610					615					620						
30	Arg	Phe	Asn	Ala	Ser	Leu	Gly	Thr	Tyr	His	Asp	Leu	Leu	Lys	Ile	Ile		
	625					630					635					640		
	Lys	Asp	Lys	Asp	Phe	Leu	Asp	Asn	Glu	Glu	Asn	Glu	Asp	Ile	Leu	Glu		
35					645					650					655			
	Asp	Ile	Val	Leu	Thr	Leu	Thr	Leu	Phe	Glu	Asp	Arg	Glu	Met	Ile	Glu		
				660					665					670				
40																		
	Glu	Arg	Leu	Lys	Thr	Tyr	Ala	His	Leu	Phe	Asp	Asp	Lys	Val	Met	Lys		
			675					680					685					
45	Gln	Leu	Lys	Arg	Arg	Arg	Tyr	Thr	Gly	Trp	Gly	Arg	Leu	Ser	Arg	Lys		
		690					695					700						
	Leu	Ile	Asn	Gly	Ile	Arg	Asp	Lys	Gln	Ser	Gly	Lys	Thr	Ile	Leu	Asp		
50		705				710					715					720		
	Phe	Leu	Lys	Ser	Asp	Gly	Phe	Ala	Asn	Arg	Asn	Phe	Met	Gln	Leu	Ile		
					725					730					735			
55	His	Asp	Asp	Ser	Leu	Thr	Phe	Lys	Glu	Asp	Ile	Gln	Lys	Ala	Gln	Val		
				740					745					750				

EP 2 940 140 A1

	Ser	Gly	Gln	Gly	Asp	Ser	Leu	His	Glu	His	Ile	Ala	Asn	Leu	Ala	Gly	
			755					760					765				
5	Ser	Pro	Ala	Ile	Lys	Lys	Gly	Ile	Leu	Gln	Thr	Val	Lys	Val	Val	Asp	
		770					775					780					
	Glu	Leu	Val	Lys	Val	Met	Gly	Arg	His	Lys	Pro	Glu	Asn	Ile	Val	Ile	
10		785				790					795					800	
	Glu	Met	Ala	Arg	Glu	Asn	Gln	Thr	Thr	Gln	Lys	Gly	Gln	Lys	Asn	Ser	
					805					810					815		
15	Arg	Glu	Arg	Met	Lys	Arg	Ile	Glu	Glu	Gly	Ile	Lys	Glu	Leu	Gly	Ser	
				820					825					830			
	Gln	Ile	Leu	Lys	Glu	His	Pro	Val	Glu	Asn	Thr	Gln	Leu	Gln	Asn	Glu	
20			835					840					845				
	Lys	Leu	Tyr	Leu	Tyr	Tyr	Leu	Gln	Asn	Gly	Arg	Asp	Met	Tyr	Val	Asp	
		850					855					860					
25																	
	Gln	Glu	Leu	Asp	Ile	Asn	Arg	Leu	Ser	Asp	Tyr	Asp	Val	Asp	His	Ile	
		865				870					875					880	
	Val	Pro	Gln	Ser	Phe	Leu	Lys	Asp	Asp	Ser	Ile	Asp	Asn	Lys	Val	Leu	
30					885					890					895		
	Thr	Arg	Ser	Asp	Lys	Asn	Arg	Gly	Lys	Ser	Asp	Asn	Val	Pro	Ser	Glu	
35				900					905					910			
	Glu	Val	Val	Lys	Lys	Met	Lys	Asn	Tyr	Trp	Arg	Gln	Leu	Leu	Asn	Ala	
			915					920					925				
40																	
	Lys	Leu	Ile	Thr	Gln	Arg	Lys	Phe	Asp	Asn	Leu	Thr	Lys	Ala	Glu	Arg	
		930					935					940					
45	Gly	Gly	Leu	Ser	Glu	Leu	Asp	Lys	Ala	Gly	Phe	Ile	Lys	Arg	Gln	Leu	
		945				950					955					960	
	Val	Glu	Thr	Arg	Gln	Ile	Thr	Lys	His	Val	Ala	Gln	Ile	Leu	Asp	Ser	
					965					970					975		
50																	
	Arg	Met	Asn	Thr	Lys	Tyr	Asp	Glu	Asn	Asp	Lys	Leu	Ile	Arg	Glu	Val	
				980					985					990			
55	Lys	Val	Ile	Thr	Leu	Lys	Ser	Lys	Leu	Val	Ser	Asp	Phe	Arg	Lys	Asp	
			995					1000					1005				

EP 2 940 140 A1

	Phe	Gln	Phe	Tyr	Lys	Val	Arg	Glu	Ile	Asn	Asn	Tyr	His	His	Ala
	1010						1015					1020			
5	His	Asp	Ala	Tyr	Leu	Asn	Ala	Val	Val	Gly	Thr	Ala	Leu	Ile	Lys
	1025						1030					1035			
10	Lys	Tyr	Pro	Lys	Leu	Glu	Ser	Glu	Phe	Val	Tyr	Gly	Asp	Tyr	Lys
	1040						1045					1050			
15	Val	Tyr	Asp	Val	Arg	Lys	Met	Ile	Ala	Lys	Ser	Glu	Gln	Glu	Ile
	1055						1060					1065			
20	Gly	Lys	Ala	Thr	Ala	Lys	Tyr	Phe	Phe	Tyr	Ser	Asn	Ile	Met	Asn
	1070						1075					1080			
25	Phe	Phe	Lys	Thr	Glu	Ile	Thr	Leu	Ala	Asn	Gly	Glu	Ile	Arg	Lys
	1085						1090					1095			
30	Arg	Pro	Leu	Ile	Glu	Thr	Asn	Gly	Glu	Thr	Gly	Glu	Ile	Val	Trp
	1100						1105					1110			
35	Asp	Lys	Gly	Arg	Asp	Phe	Ala	Thr	Val	Arg	Lys	Val	Leu	Ser	Met
	1115						1120					1125			
40	Pro	Gln	Val	Asn	Ile	Val	Lys	Lys	Thr	Glu	Val	Gln	Thr	Gly	Gly
	1130						1135					1140			
45	Phe	Ser	Lys	Glu	Ser	Ile	Leu	Pro	Lys	Arg	Asn	Ser	Asp	Lys	Leu
	1145						1150					1155			
50	Ile	Ala	Arg	Lys	Lys	Asp	Trp	Asp	Pro	Lys	Lys	Tyr	Gly	Gly	Phe
	1160						1165					1170			
55	Asp	Ser	Pro	Thr	Val	Ala	Tyr	Ser	Val	Leu	Val	Val	Ala	Lys	Val
	1175						1180					1185			
60	Glu	Lys	Gly	Lys	Ser	Lys	Lys	Leu	Lys	Ser	Val	Lys	Glu	Leu	Leu
	1190						1195					1200			
65	Gly	Ile	Thr	Ile	Met	Glu	Arg	Ser	Ser	Phe	Glu	Lys	Asn	Pro	Ile
	1205						1210					1215			
70	Asp	Phe	Leu	Glu	Ala	Lys	Gly	Tyr	Lys	Glu	Val	Lys	Lys	Asp	Leu
	1220						1225					1230			
75	Ile	Ile	Lys	Leu	Pro	Lys	Tyr	Ser	Leu	Phe	Glu	Leu	Glu	Asn	Gly
	1235						1240					1245			

EP 2 940 140 A1

	Arg Lys	Arg Met	Leu Ala	Ser	Ala Gly	Glu Leu	Gln	Lys Gly	Asn			
	1250			1255			1260					
5	Glu Leu	Ala Leu	Pro Ser	Lys	Tyr Val	Asn Phe	Leu	Tyr Leu	Ala			
	1265			1270			1275					
10	Ser His	Tyr Glu	Lys Leu	Lys	Gly Ser	Pro Glu	Asp	Asn Glu	Gln			
	1280			1285			1290					
15	Lys Gln	Leu Phe	Val Glu	Gln	His Lys	His Tyr	Leu	Asp Glu	Ile			
	1295			1300			1305					
20	Ile Glu	Gln Ile	Ser Glu	Phe	Ser Lys	Arg Val	Ile	Leu Ala	Asp			
	1310			1315			1320					
25	Ala Asn	Leu Asp	Lys Val	Leu	Ser Ala	Tyr Asn	Lys	His Arg	Asp			
	1325			1330			1335					
30	Lys Pro	Ile Arg	Glu Gln	Ala	Glu Asn	Ile Ile	His	Leu Phe	Thr			
	1340			1345			1350					
35	Leu Thr	Asn Leu	Gly Ala	Pro	Ala Ala	Phe Lys	Tyr	Phe Asp	Thr			
	1355			1360			1365					
40	Thr Ile	Asp Arg	Lys Arg	Tyr	Thr Ser	Thr Lys	Glu	Val Leu	Asp			
	1370			1375			1380					
45	Ala Thr	Leu Ile	His Gln	Ser	Ile Thr	Gly Leu	Tyr	Glu Thr	Arg			
	1385			1390			1395					
50	Ile Asp	Leu Ser	Gln Leu	Gly	Gly Asp	Ala Ala	Ala	Val Ser	Lys			
	1400			1405			1410					
55	Gly Glu	Glu Leu	Phe Thr	Gly	Val Val	Pro Ile	Leu	Val Glu	Leu			
	1415			1420			1425					
60	Asp Gly	Asp Val	Asn Gly	His	Lys Phe	Ser Val	Ser	Gly Glu	Gly			
	1430			1435			1440					
65	Glu Gly	Asp Ala	Thr Tyr	Gly	Lys Leu	Thr Leu	Lys	Phe Ile	Cys			
	1445			1450			1455					
70	Thr Thr	Gly Lys	Leu Pro	Val	Pro Trp	Pro Thr	Leu	Val Thr	Thr			
	1460			1465			1470					
75	Leu Thr	Tyr Gly	Val Gln	Cys	Phe Ser	Arg Tyr	Pro	Asp His	Met			

# EP 2 940 140 A1

	1475		1480		1485
5	Lys Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val				
	1490		1495		1500
10	Gln Glu Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr				
	1505		1510		1515
15	Arg Ala Glu Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile				
	1520		1525		1530
20	Glu Leu Lys Gly Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly				
	1535		1540		1545
25	His Lys Leu Glu Tyr Asn Tyr Asn Ser His Asn Val Tyr Ile Met				
	1550		1555		1560
30	Ala Asp Lys Gln Lys Asn Gly Ile Lys Val Asn Phe Lys Ile Arg				
	1565		1570		1575
35	His Asn Ile Glu Asp Gly Ser Val Gln Leu Ala Asp His Tyr Gln				
	1580		1585		1590
40	Gln Asn Thr Pro Ile Gly Asp Gly Pro Val Leu Leu Pro Asp Asn				
	1595		1600		1605
45	His Tyr Leu Ser Thr Gln Ser Ala Leu Ser Lys Asp Pro Asn Glu				
	1610		1615		1620
50	Lys Arg Asp His Met Val Leu Leu Glu Phe Val Thr Ala Ala Gly				
	1625		1630		1635
55	Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys				
	1640		1645		
	<210> 44				
	<211> 1625				
	<212> PRT				
	<213> Artificial Sequence				
	<220>				
	<221> source				
	<223> /note="Description of Artificial Sequence: Synthetic polypeptide"				
	<400> 44				
	Met Asp Lys Lys Tyr Ser Ile Gly Leu Asp Ile Gly Thr Asn Ser Val				
	1 5 10 15				
	Gly Trp Ala Val Ile Thr Asp Glu Tyr Lys Val Pro Ser Lys Lys Phe				

EP 2 940 140 A1

	20					25					30					
5	Lys	Val	Leu	Gly	Asn	Thr	Asp	Arg	His	Ser	Ile	Lys	Lys	Asn	Leu	Ile
			35					40					45			
10	Gly	Ala	Leu	Leu	Phe	Asp	Ser	Gly	Glu	Thr	Ala	Glu	Ala	Thr	Arg	Leu
		50					55					60				
15	Lys	Arg	Thr	Ala	Arg	Arg	Arg	Tyr	Thr	Arg	Arg	Lys	Asn	Arg	Ile	Cys
	65					70					75					80
20	Tyr	Leu	Gln	Glu	Ile	Phe	Ser	Asn	Glu	Met	Ala	Lys	Val	Asp	Asp	Ser
					85					90					95	
25	Phe	Phe	His	Arg	Leu	Glu	Glu	Ser	Phe	Leu	Val	Glu	Glu	Asp	Lys	Lys
				100					105					110		
30	His	Glu	Arg	His	Pro	Ile	Phe	Gly	Asn	Ile	Val	Asp	Glu	Val	Ala	Tyr
			115					120					125			
35	His	Glu	Lys	Tyr	Pro	Thr	Ile	Tyr	His	Leu	Arg	Lys	Lys	Leu	Val	Asp
		130					135					140				
40	Ser	Thr	Asp	Lys	Ala	Asp	Leu	Arg	Leu	Ile	Tyr	Leu	Ala	Leu	Ala	His
	145					150					155					160
45	Met	Ile	Lys	Phe	Arg	Gly	His	Phe	Leu	Ile	Glu	Gly	Asp	Leu	Asn	Pro
				165						170					175	
50	Asp	Asn	Ser	Asp	Val	Asp	Lys	Leu	Phe	Ile	Gln	Leu	Val	Gln	Thr	Tyr
				180					185					190		
55	Asn	Gln	Leu	Phe	Glu	Glu	Asn	Pro	Ile	Asn	Ala	Ser	Gly	Val	Asp	Ala
			195					200					205			
60	Lys	Ala	Ile	Leu	Ser	Ala	Arg	Leu	Ser	Lys	Ser	Arg	Arg	Leu	Glu	Asn
		210					215					220				
65	Leu	Ile	Ala	Gln	Leu	Pro	Gly	Glu	Lys	Lys	Asn	Gly	Leu	Phe	Gly	Asn
						230					235					240
70	Leu	Ile	Ala	Leu	Ser	Leu	Gly	Leu	Thr	Pro	Asn	Phe	Lys	Ser	Asn	Phe
				245						250					255	
75	Asp	Leu	Ala	Glu	Asp	Ala	Lys	Leu	Gln	Leu	Ser	Lys	Asp	Thr	Tyr	Asp
				260					265					270		



EP 2 940 140 A1

	Asp	Asp	Leu	Asp	Asn	Leu	Leu	Ala	Gln	Ile	Gly	Asp	Gln	Tyr	Ala	Asp	
			275					280					285				
5	Leu	Phe	Leu	Ala	Ala	Lys	Asn	Leu	Ser	Asp	Ala	Ile	Leu	Leu	Ser	Asp	
			290				295					300					
	Ile	Leu	Arg	Val	Asn	Thr	Glu	Ile	Thr	Lys	Ala	Pro	Leu	Ser	Ala	Ser	
10						310					315					320	
	Met	Ile	Lys	Arg	Tyr	Asp	Glu	His	His	Gln	Asp	Leu	Thr	Leu	Leu	Lys	
					325					330					335		
15	Ala	Leu	Val	Arg	Gln	Gln	Leu	Pro	Glu	Lys	Tyr	Lys	Glu	Ile	Phe	Phe	
				340					345					350			
	Asp	Gln	Ser	Lys	Asn	Gly	Tyr	Ala	Gly	Tyr	Ile	Asp	Gly	Gly	Ala	Ser	
20				355				360					365				
	Gln	Glu	Glu	Phe	Tyr	Lys	Phe	Ile	Lys	Pro	Ile	Leu	Glu	Lys	Met	Asp	
25			370				375					380					
	Gly	Thr	Glu	Glu	Leu	Leu	Val	Lys	Leu	Asn	Arg	Glu	Asp	Leu	Leu	Arg	
						390					395					400	
30	Lys	Gln	Arg	Thr	Phe	Asp	Asn	Gly	Ser	Ile	Pro	His	Gln	Ile	His	Leu	
					405					410					415		
	Gly	Glu	Leu	His	Ala	Ile	Leu	Arg	Arg	Gln	Glu	Asp	Phe	Tyr	Pro	Phe	
35				420					425					430			
	Leu	Lys	Asp	Asn	Arg	Glu	Lys	Ile	Glu	Lys	Ile	Leu	Thr	Phe	Arg	Ile	
			435					440					445				
40	Pro	Tyr	Tyr	Val	Gly	Pro	Leu	Ala	Arg	Gly	Asn	Ser	Arg	Phe	Ala	Trp	
		450					455					460					
	Met	Thr	Arg	Lys	Ser	Glu	Glu	Thr	Ile	Thr	Pro	Trp	Asn	Phe	Glu	Glu	
45						470					475					480	
	Val	Val	Asp	Lys	Gly	Ala	Ser	Ala	Gln	Ser	Phe	Ile	Glu	Arg	Met	Thr	
50					485					490					495		
	Asn	Phe	Asp	Lys	Asn	Leu	Pro	Asn	Glu	Lys	Val	Leu	Pro	Lys	His	Ser	
				500					505					510			
55	Leu	Leu	Tyr	Glu	Tyr	Phe	Thr	Val	Tyr	Asn	Glu	Leu	Thr	Lys	Val	Lys	
			515					520					525				

EP 2 940 140 A1

	Tyr	Val	Thr	Glu	Gly	Met	Arg	Lys	Pro	Ala	Phe	Leu	Ser	Gly	Glu	Gln
	530						535					540				
5	Lys	Lys	Ala	Ile	Val	Asp	Leu	Leu	Phe	Lys	Thr	Asn	Arg	Lys	Val	Thr
	545					550					555					560
	Val	Lys	Gln	Leu	Lys	Glu	Asp	Tyr	Phe	Lys	Lys	Ile	Glu	Cys	Phe	Asp
10					565					570					575	
	Ser	Val	Glu	Ile	Ser	Gly	Val	Glu	Asp	Arg	Phe	Asn	Ala	Ser	Leu	Gly
				580					585					590		
15	Thr	Tyr	His	Asp	Leu	Leu	Lys	Ile	Ile	Lys	Asp	Lys	Asp	Phe	Leu	Asp
			595					600					605			
	Asn	Glu	Glu	Asn	Glu	Asp	Ile	Leu	Glu	Asp	Ile	Val	Leu	Thr	Leu	Thr
20		610					615					620				
	Leu	Phe	Glu	Asp	Arg	Glu	Met	Ile	Glu	Glu	Arg	Leu	Lys	Thr	Tyr	Ala
25	625					630					635					640
	His	Leu	Phe	Asp	Asp	Lys	Val	Met	Lys	Gln	Leu	Lys	Arg	Arg	Arg	Tyr
				645						650					655	
30	Thr	Gly	Trp	Gly	Arg	Leu	Ser	Arg	Lys	Leu	Ile	Asn	Gly	Ile	Arg	Asp
				660					665					670		
	Lys	Gln	Ser	Gly	Lys	Thr	Ile	Leu	Asp	Phe	Leu	Lys	Ser	Asp	Gly	Phe
35			675					680					685			
	Ala	Asn	Arg	Asn	Phe	Met	Gln	Leu	Ile	His	Asp	Asp	Ser	Leu	Thr	Phe
		690					695					700				
40	Lys	Glu	Asp	Ile	Gln	Lys	Ala	Gln	Val	Ser	Gly	Gln	Gly	Asp	Ser	Leu
	705					710					715					720
	His	Glu	His	Ile	Ala	Asn	Leu	Ala	Gly	Ser	Pro	Ala	Ile	Lys	Lys	Gly
45					725					730					735	
	Ile	Leu	Gln	Thr	Val	Lys	Val	Val	Asp	Glu	Leu	Val	Lys	Val	Met	Gly
50				740					745					750		
	Arg	His	Lys	Pro	Glu	Asn	Ile	Val	Ile	Glu	Met	Ala	Arg	Glu	Asn	Gln
			755					760					765			
55	Thr	Thr	Gln	Lys	Gly	Gln	Lys	Asn	Ser	Arg	Glu	Arg	Met	Lys	Arg	Ile
	770						775					780				

EP 2 940 140 A1

	Glu	Glu	Gly	Ile	Lys	Glu	Leu	Gly	Ser	Gln	Ile	Leu	Lys	Glu	His	Pro	785	790	795	800
5	Val	Glu	Asn	Thr	Gln	Leu	Gln	Asn	Glu	Lys	Leu	Tyr	Leu	Tyr	Tyr	Leu		805	810	815
10	Gln	Asn	Gly	Arg	Asp	Met	Tyr	Val	Asp	Gln	Glu	Leu	Asp	Ile	Asn	Arg		820	825	830
15	Leu	Ser	Asp	Tyr	Asp	Val	Asp	His	Ile	Val	Pro	Gln	Ser	Phe	Leu	Lys		835	840	845
20	Asp	Asp	Ser	Ile	Asp	Asn	Lys	Val	Leu	Thr	Arg	Ser	Asp	Lys	Asn	Arg		850	855	860
25	Gly	Lys	Ser	Asp	Asn	Val	Pro	Ser	Glu	Glu	Val	Val	Lys	Lys	Met	Lys		865	870	875
30	Asn	Tyr	Trp	Arg	Gln	Leu	Leu	Asn	Ala	Lys	Leu	Ile	Thr	Gln	Arg	Lys		885	890	895
35	Phe	Asp	Asn	Leu	Thr	Lys	Ala	Glu	Arg	Gly	Gly	Leu	Ser	Glu	Leu	Asp		900	905	910
40	Lys	Ala	Gly	Phe	Ile	Lys	Arg	Gln	Leu	Val	Glu	Thr	Arg	Gln	Ile	Thr		915	920	925
45	Lys	His	Val	Ala	Gln	Ile	Leu	Asp	Ser	Arg	Met	Asn	Thr	Lys	Tyr	Asp		930	935	940
50	Glu	Asn	Asp	Lys	Leu	Ile	Arg	Glu	Val	Lys	Val	Ile	Thr	Leu	Lys	Ser		945	950	955
55	Lys	Leu	Val	Ser	Asp	Phe	Arg	Lys	Asp	Phe	Gln	Phe	Tyr	Lys	Val	Arg		965	970	975
	Glu	Ile	Asn	Asn	Tyr	His	His	Ala	His	Asp	Ala	Tyr	Leu	Asn	Ala	Val		980	985	990
	Val	Gly	Thr	Ala	Leu	Ile	Lys	Lys	Tyr	Pro	Lys	Leu	Glu	Ser	Glu	Phe		995	1000	1005
	Val	Tyr	Gly	Asp	Tyr	Lys	Val	Tyr	Asp	Val	Arg	Lys	Met	Ile	Ala		1010	1015	1020	
	Lys	Ser	Glu	Gln	Glu	Ile	Gly	Lys	Ala	Thr	Ala	Lys	Tyr	Phe	Phe					

**EP 2 940 140 A1**

[illegible]

EP 2 940 140 A1

	His	Tyr	Leu	Asp	Glu	Ile	Ile	Glu	Gln	Ile	Ser	Glu	Phe	Ser	Lys
	1265						1270					1275			
5	Arg	Val	Ile	Leu	Ala	Asp	Ala	Asn	Leu	Asp	Lys	Val	Leu	Ser	Ala
	1280						1285					1290			
10	Tyr	Asn	Lys	His	Arg	Asp	Lys	Pro	Ile	Arg	Glu	Gln	Ala	Glu	Asn
	1295						1300					1305			
	Ile	Ile	His	Leu	Phe	Thr	Leu	Thr	Asn	Leu	Gly	Ala	Pro	Ala	Ala
	1310						1315					1320			
15	Phe	Lys	Tyr	Phe	Asp	Thr	Thr	Ile	Asp	Arg	Lys	Arg	Tyr	Thr	Ser
	1325						1330					1335			
20	Thr	Lys	Glu	Val	Leu	Asp	Ala	Thr	Leu	Ile	His	Gln	Ser	Ile	Thr
	1340						1345					1350			
25	Gly	Leu	Tyr	Glu	Thr	Arg	Ile	Asp	Leu	Ser	Gln	Leu	Gly	Gly	Asp
	1355						1360					1365			
	Ala	Ala	Ala	Val	Ser	Lys	Gly	Glu	Glu	Leu	Phe	Thr	Gly	Val	Val
	1370						1375					1380			
30	Pro	Ile	Leu	Val	Glu	Leu	Asp	Gly	Asp	Val	Asn	Gly	His	Lys	Phe
	1385						1390					1395			
35	Ser	Val	Ser	Gly	Glu	Gly	Glu	Gly	Asp	Ala	Thr	Tyr	Gly	Lys	Leu
	1400						1405					1410			
	Thr	Leu	Lys	Phe	Ile	Cys	Thr	Thr	Gly	Lys	Leu	Pro	Val	Pro	Trp
	1415						1420					1425			
40	Pro	Thr	Leu	Val	Thr	Thr	Leu	Thr	Tyr	Gly	Val	Gln	Cys	Phe	Ser
	1430						1435					1440			
45	Arg	Tyr	Pro	Asp	His	Met	Lys	Gln	His	Asp	Phe	Phe	Lys	Ser	Ala
	1445						1450					1455			
50	Met	Pro	Glu	Gly	Tyr	Val	Gln	Glu	Arg	Thr	Ile	Phe	Phe	Lys	Asp
	1460						1465					1470			
	Asp	Gly	Asn	Tyr	Lys	Thr	Arg	Ala	Glu	Val	Lys	Phe	Glu	Gly	Asp
	1475						1480					1485			
55	Thr	Leu	Val	Asn	Arg	Ile	Glu	Leu	Lys	Gly	Ile	Asp	Phe	Lys	Glu
	1490						1495					1500			

# EP 2 940 140 A1

Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn Tyr Asn Ser  
 1505 1510 1515  
 5 His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly Ile Lys  
 1520 1525 1530  
 10 Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val Gln  
 1535 1540 1545  
 15 Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro  
 1550 1555 1560  
 20 Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu  
 1565 1570 1575  
 25 Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu  
 1580 1585 1590  
 Phe Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr  
 1595 1600 1605  
 30 Lys Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys  
 1610 1615 1620  
 Lys Lys  
 1625  
 <210> 45  
 <211> 1664  
 <212> PRT  
 <213> Artificial Sequence  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 polypeptide"  
 <400> 45  
 45 Met Asp Tyr Lys Asp His Asp Gly Asp Tyr Lys Asp His Asp Ile Asp  
 1 5 10 15  
 Tyr Lys Asp Asp Asp Asp Lys Met Ala Pro Lys Lys Lys Arg Lys Val  
 20 25 30  
 50 Gly Ile His Gly Val Pro Ala Ala Asp Lys Lys Tyr Ser Ile Gly Leu  
 35 40 45  
 55 Asp Ile Gly Thr Asn Ser Val Gly Trp Ala Val Ile Thr Asp Glu Tyr  
 50 55 60

EP 2 940 140 A1

	Lys	Val	Pro	Ser	Lys	Lys	Phe	Lys	Val	Leu	Gly	Asn	Thr	Asp	Arg	His	65	70	75	80
5	Ser	Ile	Lys	Lys	Asn	Leu	Ile	Gly	Ala	Leu	Leu	Phe	Asp	Ser	Gly	Glu	85	90	95	
10	Thr	Ala	Glu	Ala	Thr	Arg	Leu	Lys	Arg	Thr	Ala	Arg	Arg	Arg	Tyr	Thr	100	105	110	
	Arg	Arg	Lys	Asn	Arg	Ile	Cys	Tyr	Leu	Gln	Glu	Ile	Phe	Ser	Asn	Glu	115	120	125	
15	Met	Ala	Lys	Val	Asp	Asp	Ser	Phe	Phe	His	Arg	Leu	Glu	Glu	Ser	Phe	130	135	140	
20	Leu	Val	Glu	Glu	Asp	Lys	Lys	His	Glu	Arg	His	Pro	Ile	Phe	Gly	Asn	145	150	155	160
	Ile	Val	Asp	Glu	Val	Ala	Tyr	His	Glu	Lys	Tyr	Pro	Thr	Ile	Tyr	His	165	170	175	
25	Leu	Arg	Lys	Lys	Leu	Val	Asp	Ser	Thr	Asp	Lys	Ala	Asp	Leu	Arg	Leu	180	185	190	
30	Ile	Tyr	Leu	Ala	Leu	Ala	His	Met	Ile	Lys	Phe	Arg	Gly	His	Phe	Leu	195	200	205	
35	Ile	Glu	Gly	Asp	Leu	Asn	Pro	Asp	Asn	Ser	Asp	Val	Asp	Lys	Leu	Phe	210	215	220	
	Ile	Gln	Leu	Val	Gln	Thr	Tyr	Asn	Gln	Leu	Phe	Glu	Glu	Asn	Pro	Ile	225	230	235	240
40	Asn	Ala	Ser	Gly	Val	Asp	Ala	Lys	Ala	Ile	Leu	Ser	Ala	Arg	Leu	Ser	245	250	255	
45	Lys	Ser	Arg	Arg	Leu	Glu	Asn	Leu	Ile	Ala	Gln	Leu	Pro	Gly	Glu	Lys	260	265	270	
	Lys	Asn	Gly	Leu	Phe	Gly	Asn	Leu	Ile	Ala	Leu	Ser	Leu	Gly	Leu	Thr	275	280	285	
50	Pro	Asn	Phe	Lys	Ser	Asn	Phe	Asp	Leu	Ala	Glu	Asp	Ala	Lys	Leu	Gln	290	295	300	
55	Leu	Ser	Lys	Asp	Thr	Tyr	Asp	Asp	Asp	Leu	Asp	Asn	Leu	Leu	Ala	Gln	305	310	315	320

EP 2 940 140 A1

	Ile	Gly	Asp	Gln	Tyr	Ala	Asp	Leu	Phe	Leu	Ala	Ala	Lys	Asn	Leu	Ser	
					325					330					335		
5	Asp	Ala	Ile	Leu	Leu	Ser	Asp	Ile	Leu	Arg	Val	Asn	Thr	Glu	Ile	Thr	
				340					345					350			
10	Lys	Ala	Pro	Leu	Ser	Ala	Ser	Met	Ile	Lys	Arg	Tyr	Asp	Glu	His	His	
			355					360					365				
15	Gln	Asp	Leu	Thr	Leu	Leu	Lys	Ala	Leu	Val	Arg	Gln	Gln	Leu	Pro	Glu	
		370					375					380					
20	Lys	Tyr	Lys	Glu	Ile	Phe	Phe	Asp	Gln	Ser	Lys	Asn	Gly	Tyr	Ala	Gly	
	385					390					395					400	
25	Tyr	Ile	Asp	Gly	Gly	Ala	Ser	Gln	Glu	Glu	Phe	Tyr	Lys	Phe	Ile	Lys	
					405					410					415		
30	Pro	Ile	Leu	Glu	Lys	Met	Asp	Gly	Thr	Glu	Glu	Leu	Leu	Val	Lys	Leu	
				420					425					430			
35	Asn	Arg	Glu	Asp	Leu	Leu	Arg	Lys	Gln	Arg	Thr	Phe	Asp	Asn	Gly	Ser	
			435					440					445				
40	Ile	Pro	His	Gln	Ile	His	Leu	Gly	Glu	Leu	His	Ala	Ile	Leu	Arg	Arg	
		450					455					460					
45	Gln	Glu	Asp	Phe	Tyr	Pro	Phe	Leu	Lys	Asp	Asn	Arg	Glu	Lys	Ile	Glu	
	465					470					475					480	
50	Lys	Ile	Leu	Thr	Phe	Arg	Ile	Pro	Tyr	Tyr	Val	Gly	Pro	Leu	Ala	Arg	
					485					490					495		
55	Gly	Asn	Ser	Arg	Phe	Ala	Trp	Met	Thr	Arg	Lys	Ser	Glu	Glu	Thr	Ile	
				500					505					510			
60	Thr	Pro	Trp	Asn	Phe	Glu	Glu	Val	Val	Asp	Lys	Gly	Ala	Ser	Ala	Gln	
			515					520					525				
65	Ser	Phe	Ile	Glu	Arg	Met	Thr	Asn	Phe	Asp	Lys	Asn	Leu	Pro	Asn	Glu	
		530					535					540					
70	Lys	Val	Leu	Pro	Lys	His	Ser	Leu	Leu	Tyr	Glu	Tyr	Phe	Thr	Val	Tyr	
	545					550					555					560	
75	Asn	Glu	Leu	Thr	Lys	Val	Lys	Tyr	Val	Thr	Glu	Gly	Met	Arg	Lys	Pro	



## EP 2 940 140 A1

565

570

575

5	Ala	Phe	Leu	Ser	Gly	Glu	Gln	Lys	Lys	Ala	Ile	Val	Asp	Leu	Leu	Phe
				580					585					590		
10	Lys	Thr	Asn	Arg	Lys	Val	Thr	Val	Lys	Gln	Leu	Lys	Glu	Asp	Tyr	Phe
			595					600					605			
15	Lys	Lys	Ile	Glu	Cys	Phe	Asp	Ser	Val	Glu	Ile	Ser	Gly	Val	Glu	Asp
		610					615					620				
20	Arg	Phe	Asn	Ala	Ser	Leu	Gly	Thr	Tyr	His	Asp	Leu	Leu	Lys	Ile	Ile
	625					630					635					640
25	Lys	Asp	Lys	Asp	Phe	Leu	Asp	Asn	Glu	Glu	Asn	Glu	Asp	Ile	Leu	Glu
					645					650					655	
30	Asp	Ile	Val	Leu	Thr	Leu	Thr	Leu	Phe	Glu	Asp	Arg	Glu	Met	Ile	Glu
				660					665					670		
35	Glu	Arg	Leu	Lys	Thr	Tyr	Ala	His	Leu	Phe	Asp	Asp	Lys	Val	Met	Lys
			675					680					685			
40	Gln	Leu	Lys	Arg	Arg	Arg	Tyr	Thr	Gly	Trp	Gly	Arg	Leu	Ser	Arg	Lys
		690					695					700				
45	Leu	Ile	Asn	Gly	Ile	Arg	Asp	Lys	Gln	Ser	Gly	Lys	Thr	Ile	Leu	Asp
	705					710					715					720
50	Phe	Leu	Lys	Ser	Asp	Gly	Phe	Ala	Asn	Arg	Asn	Phe	Met	Gln	Leu	Ile
					725					730					735	
55	His	Asp	Asp	Ser	Leu	Thr	Phe	Lys	Glu	Asp	Ile	Gln	Lys	Ala	Gln	Val
				740					745					750		
60	Ser	Gly	Gln	Gly	Asp	Ser	Leu	His	Glu	His	Ile	Ala	Asn	Leu	Ala	Gly
			755					760					765			
65	Ser	Pro	Ala	Ile	Lys	Lys	Gly	Ile	Leu	Gln	Thr	Val	Lys	Val	Val	Asp
		770					775					780				
70	Glu	Leu	Val	Lys	Val	Met	Gly	Arg	His	Lys	Pro	Glu	Asn	Ile	Val	Ile
	785					790					795					800
75	Glu	Met	Ala	Arg	Glu	Asn	Gln	Thr	Thr	Gln	Lys	Gly	Gln	Lys	Asn	Ser
					805					810					815	

EP 2 940 140 A1

	Arg	Glu	Arg	Met	Lys	Arg	Ile	Glu	Glu	Gly	Ile	Lys	Glu	Leu	Gly	Ser	
				820					825					830			
5	Gln	Ile	Leu	Lys	Glu	His	Pro	Val	Glu	Asn	Thr	Gln	Leu	Gln	Asn	Glu	
			835					840					845				
	Lys	Leu	Tyr	Leu	Tyr	Tyr	Leu	Gln	Asn	Gly	Arg	Asp	Met	Tyr	Val	Asp	
10		850					855					860					
	Gln	Glu	Leu	Asp	Ile	Asn	Arg	Leu	Ser	Asp	Tyr	Asp	Val	Asp	His	Ile	
	865					870					875					880	
15	Val	Pro	Gln	Ser	Phe	Leu	Lys	Asp	Asp	Ser	Ile	Asp	Asn	Lys	Val	Leu	
					885					890					895		
	Thr	Arg	Ser	Asp	Lys	Asn	Arg	Gly	Lys	Ser	Asp	Asn	Val	Pro	Ser	Glu	
20				900					905					910			
	Glu	Val	Val	Lys	Lys	Met	Lys	Asn	Tyr	Trp	Arg	Gln	Leu	Leu	Asn	Ala	
25			915					920					925				
	Lys	Leu	Ile	Thr	Gln	Arg	Lys	Phe	Asp	Asn	Leu	Thr	Lys	Ala	Glu	Arg	
		930					935					940					
30	Gly	Gly	Leu	Ser	Glu	Leu	Asp	Lys	Ala	Gly	Phe	Ile	Lys	Arg	Gln	Leu	
	945					950					955					960	
	Val	Glu	Thr	Arg	Gln	Ile	Thr	Lys	His	Val	Ala	Gln	Ile	Leu	Asp	Ser	
35					965					970					975		
	Arg	Met	Asn	Thr	Lys	Tyr	Asp	Glu	Asn	Asp	Lys	Leu	Ile	Arg	Glu	Val	
				980					985					990			
40	Lys	Val	Ile	Thr	Leu	Lys	Ser	Lys	Leu	Val	Ser	Asp	Phe	Arg	Lys	Asp	
			995					1000					1005				
	Phe	Gln	Phe	Tyr	Lys	Val	Arg	Glu	Ile	Asn	Asn	Tyr	His	His	Ala		
45		1010					1015					1020					
	His	Asp	Ala	Tyr	Leu	Asn	Ala	Val	Val	Gly	Thr	Ala	Leu	Ile	Lys		
50		1025					1030					1035					
	Lys	Tyr	Pro	Lys	Leu	Glu	Ser	Glu	Phe	Val	Tyr	Gly	Asp	Tyr	Lys		
		1040					1045					1050					
55	Val	Tyr	Asp	Val	Arg	Lys	Met	Ile	Ala	Lys	Ser	Glu	Gln	Glu	Ile		
		1055					1060					1065					

EP 2 940 140 A1

	Gly	Lys	Ala	Thr	Ala	Lys	Tyr	Phe	Phe	Tyr	Ser	Asn	Ile	Met	Asn
	1070						1075					1080			
5	Phe	Phe	Lys	Thr	Glu	Ile	Thr	Leu	Ala	Asn	Gly	Glu	Ile	Arg	Lys
	1085						1090					1095			
10	Arg	Pro	Leu	Ile	Glu	Thr	Asn	Gly	Glu	Thr	Gly	Glu	Ile	Val	Trp
	1100						1105					1110			
15	Asp	Lys	Gly	Arg	Asp	Phe	Ala	Thr	Val	Arg	Lys	Val	Leu	Ser	Met
	1115						1120					1125			
20	Pro	Gln	Val	Asn	Ile	Val	Lys	Lys	Thr	Glu	Val	Gln	Thr	Gly	Gly
	1130						1135					1140			
25	Phe	Ser	Lys	Glu	Ser	Ile	Leu	Pro	Lys	Arg	Asn	Ser	Asp	Lys	Leu
	1145						1150					1155			
30	Ile	Ala	Arg	Lys	Lys	Asp	Trp	Asp	Pro	Lys	Lys	Tyr	Gly	Gly	Phe
	1160						1165					1170			
35	Asp	Ser	Pro	Thr	Val	Ala	Tyr	Ser	Val	Leu	Val	Val	Ala	Lys	Val
	1175						1180					1185			
40	Glu	Lys	Gly	Lys	Ser	Lys	Lys	Leu	Lys	Ser	Val	Lys	Glu	Leu	Leu
	1190						1195					1200			
45	Gly	Ile	Thr	Ile	Met	Glu	Arg	Ser	Ser	Phe	Glu	Lys	Asn	Pro	Ile
	1205						1210					1215			
50	Asp	Phe	Leu	Glu	Ala	Lys	Gly	Tyr	Lys	Glu	Val	Lys	Lys	Asp	Leu
	1220						1225					1230			
55	Ile	Ile	Lys	Leu	Pro	Lys	Tyr	Ser	Leu	Phe	Glu	Leu	Glu	Asn	Gly
	1235						1240					1245			
60	Arg	Lys	Arg	Met	Leu	Ala	Ser	Ala	Gly	Glu	Leu	Gln	Lys	Gly	Asn
	1250						1255					1260			
65	Glu	Leu	Ala	Leu	Pro	Ser	Lys	Tyr	Val	Asn	Phe	Leu	Tyr	Leu	Ala
	1265						1270					1275			
70	Ser	His	Tyr	Glu	Lys	Leu	Lys	Gly	Ser	Pro	Glu	Asp	Asn	Glu	Gln
	1280						1285					1290			
75	Lys	Gln	Leu	Phe	Val	Glu	Gln	His	Lys	His	Tyr	Leu	Asp	Glu	Ile
	1295						1300					1305			

EP 2 940 140 A1

	Ile	Glu	Gln	Ile	Ser	Glu	Phe	Ser	Lys	Arg	Val	Ile	Leu	Ala	Asp
	1310						1315					1320			
5	Ala	Asn	Leu	Asp	Lys	Val	Leu	Ser	Ala	Tyr	Asn	Lys	His	Arg	Asp
	1325						1330					1335			
10	Lys	Pro	Ile	Arg	Glu	Gln	Ala	Glu	Asn	Ile	Ile	His	Leu	Phe	Thr
	1340						1345					1350			
15	Leu	Thr	Asn	Leu	Gly	Ala	Pro	Ala	Ala	Phe	Lys	Tyr	Phe	Asp	Thr
	1355						1360					1365			
20	Thr	Ile	Asp	Arg	Lys	Arg	Tyr	Thr	Ser	Thr	Lys	Glu	Val	Leu	Asp
	1370						1375					1380			
25	Ala	Thr	Leu	Ile	His	Gln	Ser	Ile	Thr	Gly	Leu	Tyr	Glu	Thr	Arg
	1385						1390					1395			
30	Ile	Asp	Leu	Ser	Gln	Leu	Gly	Gly	Asp	Ala	Ala	Ala	Val	Ser	Lys
	1400						1405					1410			
35	Gly	Glu	Glu	Leu	Phe	Thr	Gly	Val	Val	Pro	Ile	Leu	Val	Glu	Leu
	1415						1420					1425			
40	Asp	Gly	Asp	Val	Asn	Gly	His	Lys	Phe	Ser	Val	Ser	Gly	Glu	Gly
	1430						1435					1440			
45	Glu	Gly	Asp	Ala	Thr	Tyr	Gly	Lys	Leu	Thr	Leu	Lys	Phe	Ile	Cys
	1445						1450					1455			
50	Thr	Thr	Gly	Lys	Leu	Pro	Val	Pro	Trp	Pro	Thr	Leu	Val	Thr	Thr
	1460						1465					1470			
55	Leu	Thr	Tyr	Gly	Val	Gln	Cys	Phe	Ser	Arg	Tyr	Pro	Asp	His	Met
	1475						1480					1485			
60	Lys	Gln	His	Asp	Phe	Phe	Lys	Ser	Ala	Met	Pro	Glu	Gly	Tyr	Val
	1490						1495					1500			
65	Gln	Glu	Arg	Thr	Ile	Phe	Phe	Lys	Asp	Asp	Gly	Asn	Tyr	Lys	Thr
	1505						1510					1515			
70	Arg	Ala	Glu	Val	Lys	Phe	Glu	Gly	Asp	Thr	Leu	Val	Asn	Arg	Ile
	1520						1525					1530			
75	Glu	Leu	Lys	Gly	Ile	Asp	Phe	Lys	Glu	Asp	Gly	Asn	Ile	Leu	Gly

# EP 2 940 140 A1

	1535		1540		1545											
5	His	Lys	Leu	Glu	Tyr	Asn	Tyr	Asn	Ser	His	Asn	Val	Tyr	Ile	Met	
	1550						1555					1560				
10	Ala	Asp	Lys	Gln	Lys	Asn	Gly	Ile	Lys	Val	Asn	Phe	Lys	Ile	Arg	
	1565						1570					1575				
15	His	Asn	Ile	Glu	Asp	Gly	Ser	Val	Gln	Leu	Ala	Asp	His	Tyr	Gln	
	1580						1585					1590				
20	Gln	Asn	Thr	Pro	Ile	Gly	Asp	Gly	Pro	Val	Leu	Leu	Pro	Asp	Asn	
	1595						1600					1605				
25	His	Tyr	Leu	Ser	Thr	Gln	Ser	Ala	Leu	Ser	Lys	Asp	Pro	Asn	Glu	
	1610						1615					1620				
30	Lys	Arg	Asp	His	Met	Val	Leu	Leu	Glu	Phe	Val	Thr	Ala	Ala	Gly	
	1625						1630					1635				
35	Ile	Thr	Leu	Gly	Met	Asp	Glu	Leu	Tyr	Lys	Lys	Arg	Pro	Ala	Ala	
	1640						1645					1650				
40	Thr	Lys	Lys	Ala	Gly	Gln	Ala	Lys	Lys	Lys	Lys					
	1655						1660									
45	<210>	46														
	<211>	1423														
50	<212>	PRT														
	<213>	Artificial Sequence														
55	<220>															
	<221>	source														
60	<223>	/note="Description of Artificial Sequence: Synthetic polypeptide"														
65	<400>	46														
	Met	Asp	Tyr	Lys	Asp	His	Asp	Gly	Asp	Tyr	Lys	Asp	His	Asp	Ile	Asp
	1				5					10				15		
70	Tyr	Lys	Asp	Asp	Asp	Asp	Lys	Met	Ala	Pro	Lys	Lys	Lys	Arg	Lys	Val
				20					25					30		
75	Gly	Ile	His	Gly	Val	Pro	Ala	Ala	Asp	Lys	Lys	Tyr	Ser	Ile	Gly	Leu
		35					40						45			
80	Asp	Ile	Gly	Thr	Asn	Ser	Val	Gly	Trp	Ala	Val	Ile	Thr	Asp	Glu	Tyr
	50						55					60				
85	Lys	Val	Pro	Ser	Lys	Lys	Phe	Lys	Val	Leu	Gly	Asn	Thr	Asp	Arg	His

EP 2 940 140 A1

	65				70				75				80			
5	Ser	Ile	Lys	Lys	Asn	Leu	Ile	Gly	Ala	Leu	Leu	Phe	Asp	Ser	Gly	Glu
					85					90					95	
10	Thr	Ala	Glu	Ala	Thr	Arg	Leu	Lys	Arg	Thr	Ala	Arg	Arg	Arg	Tyr	Thr
				100					105					110		
15	Arg	Arg	Lys	Asn	Arg	Ile	Cys	Tyr	Leu	Gln	Glu	Ile	Phe	Ser	Asn	Glu
			115					120					125			
20	Met	Ala	Lys	Val	Asp	Asp	Ser	Phe	Phe	His	Arg	Leu	Glu	Glu	Ser	Phe
		130					135					140				
25	Leu	Val	Glu	Glu	Asp	Lys	Lys	His	Glu	Arg	His	Pro	Ile	Phe	Gly	Asn
	145					150					155					160
30	Ile	Val	Asp	Glu	Val	Ala	Tyr	His	Glu	Lys	Tyr	Pro	Thr	Ile	Tyr	His
					165					170					175	
35	Leu	Arg	Lys	Lys	Leu	Val	Asp	Ser	Thr	Asp	Lys	Ala	Asp	Leu	Arg	Leu
				180					185					190		
40	Ile	Tyr	Leu	Ala	Leu	Ala	His	Met	Ile	Lys	Phe	Arg	Gly	His	Phe	Leu
			195					200					205			
45	Ile	Glu	Gly	Asp	Leu	Asn	Pro	Asp	Asn	Ser	Asp	Val	Asp	Lys	Leu	Phe
	210						215					220				
50	Ile	Gln	Leu	Val	Gln	Thr	Tyr	Asn	Gln	Leu	Phe	Glu	Glu	Asn	Pro	Ile
	225					230					235					240
55	Asn	Ala	Ser	Gly	Val	Asp	Ala	Lys	Ala	Ile	Leu	Ser	Ala	Arg	Leu	Ser
					245					250					255	
60	Lys	Ser	Arg	Arg	Leu	Glu	Asn	Leu	Ile	Ala	Gln	Leu	Pro	Gly	Glu	Lys
				260					265					270		
65	Lys	Asn	Gly	Leu	Phe	Gly	Asn	Leu	Ile	Ala	Leu	Ser	Leu	Gly	Leu	Thr
			275					280					285			
70	Pro	Asn	Phe	Lys	Ser	Asn	Phe	Asp	Leu	Ala	Glu	Asp	Ala	Lys	Leu	Gln
		290					295					300				
75	Leu	Ser	Lys	Asp	Thr	Tyr	Asp	Asp	Asp	Leu	Asp	Asn	Leu	Leu	Ala	Gln
	305					310					315					320

EP 2 940 140 A1

	Ile Gly Asp Gln Tyr Ala Asp Leu Phe Leu Ala Ala Lys Asn Leu Ser	325	330	335
5	Asp Ala Ile Leu Leu Ser Asp Ile Leu Arg Val Asn Thr Glu Ile Thr	340	345	350
10	Lys Ala Pro Leu Ser Ala Ser Met Ile Lys Arg Tyr Asp Glu His His	355	360	365
	Gln Asp Leu Thr Leu Leu Lys Ala Leu Val Arg Gln Gln Leu Pro Glu	370	375	380
15	Lys Tyr Lys Glu Ile Phe Phe Asp Gln Ser Lys Asn Gly Tyr Ala Gly	385	390	395
20	Tyr Ile Asp Gly Gly Ala Ser Gln Glu Glu Phe Tyr Lys Phe Ile Lys	405	410	415
	Pro Ile Leu Glu Lys Met Asp Gly Thr Glu Glu Leu Leu Val Lys Leu	420	425	430
25	Asn Arg Glu Asp Leu Leu Arg Lys Gln Arg Thr Phe Asp Asn Gly Ser	435	440	445
30	Ile Pro His Gln Ile His Leu Gly Glu Leu His Ala Ile Leu Arg Arg	450	455	460
35	Gln Glu Asp Phe Tyr Pro Phe Leu Lys Asp Asn Arg Glu Lys Ile Glu	465	470	475
	Lys Ile Leu Thr Phe Arg Ile Pro Tyr Tyr Val Gly Pro Leu Ala Arg	485	490	495
40	Gly Asn Ser Arg Phe Ala Trp Met Thr Arg Lys Ser Glu Glu Thr Ile	500	505	510
45	Thr Pro Trp Asn Phe Glu Glu Val Val Asp Lys Gly Ala Ser Ala Gln	515	520	525
	Ser Phe Ile Glu Arg Met Thr Asn Phe Asp Lys Asn Leu Pro Asn Glu	530	535	540
50	Lys Val Leu Pro Lys His Ser Leu Leu Tyr Glu Tyr Phe Thr Val Tyr	545	550	555
55	Asn Glu Leu Thr Lys Val Lys Tyr Val Thr Glu Gly Met Arg Lys Pro	565	570	575

EP 2 940 140 A1

	Ala	Phe	Leu	Ser	Gly	Glu	Gln	Lys	Lys	Ala	Ile	Val	Asp	Leu	Leu	Phe	
				580					585					590			
5	Lys	Thr	Asn	Arg	Lys	Val	Thr	Val	Lys	Gln	Leu	Lys	Glu	Asp	Tyr	Phe	
			595					600					605				
10	Lys	Lys	Ile	Glu	Cys	Phe	Asp	Ser	Val	Glu	Ile	Ser	Gly	Val	Glu	Asp	
		610					615					620					
15	Arg	Phe	Asn	Ala	Ser	Leu	Gly	Thr	Tyr	His	Asp	Leu	Leu	Lys	Ile	Ile	
	625					630					635					640	
20	Lys	Asp	Lys	Asp	Phe	Leu	Asp	Asn	Glu	Glu	Asn	Glu	Asp	Ile	Leu	Glu	
					645				650						655		
25	Asp	Ile	Val	Leu	Thr	Leu	Thr	Leu	Phe	Glu	Asp	Arg	Glu	Met	Ile	Glu	
				660					665					670			
30	Glu	Arg	Leu	Lys	Thr	Tyr	Ala	His	Leu	Phe	Asp	Asp	Lys	Val	Met	Lys	
			675					680					685				
35	Gln	Leu	Lys	Arg	Arg	Arg	Tyr	Thr	Gly	Trp	Gly	Arg	Leu	Ser	Arg	Lys	
		690					695					700					
40	Leu	Ile	Asn	Gly	Ile	Arg	Asp	Lys	Gln	Ser	Gly	Lys	Thr	Ile	Leu	Asp	
	705					710					715					720	
45	Phe	Leu	Lys	Ser	Asp	Gly	Phe	Ala	Asn	Arg	Asn	Phe	Met	Gln	Leu	Ile	
				725						730					735		
50	His	Asp	Asp	Ser	Leu	Thr	Phe	Lys	Glu	Asp	Ile	Gln	Lys	Ala	Gln	Val	
				740					745					750			
55	Ser	Gly	Gln	Gly	Asp	Ser	Leu	His	Glu	His	Ile	Ala	Asn	Leu	Ala	Gly	
			755					760					765				
60	Ser	Pro	Ala	Ile	Lys	Lys	Gly	Ile	Leu	Gln	Thr	Val	Lys	Val	Val	Asp	
		770					775					780					
65	Glu	Leu	Val	Lys	Val	Met	Gly	Arg	His	Lys	Pro	Glu	Asn	Ile	Val	Ile	
	785					790					795					800	
70	Glu	Met	Ala	Arg	Glu	Asn	Gln	Thr	Thr	Gln	Lys	Gly	Gln	Lys	Asn	Ser	
				805						810					815		
75	Arg	Glu	Arg	Met	Lys	Arg	Ile	Glu	Glu	Gly	Ile	Lys	Glu	Leu	Gly	Ser	
			820						825					830			



# EP 2 940 140 A1

	Gln	Ile	Leu	Lys	Glu	His	Pro	Val	Glu	Asn	Thr	Gln	Leu	Gln	Asn	Glu	
			835					840					845				
5	Lys	Leu	Tyr	Leu	Tyr	Tyr	Leu	Gln	Asn	Gly	Arg	Asp	Met	Tyr	Val	Asp	
		850					855					860					
10	Gln	Glu	Leu	Asp	Ile	Asn	Arg	Leu	Ser	Asp	Tyr	Asp	Val	Asp	His	Ile	
	865					870					875					880	
15	Val	Pro	Gln	Ser	Phe	Leu	Lys	Asp	Asp	Ser	Ile	Asp	Asn	Lys	Val	Leu	
					885					890					895		
20	Thr	Arg	Ser	Asp	Lys	Asn	Arg	Gly	Lys	Ser	Asp	Asn	Val	Pro	Ser	Glu	
				900					905					910			
25	Glu	Val	Val	Lys	Lys	Met	Lys	Asn	Tyr	Trp	Arg	Gln	Leu	Leu	Asn	Ala	
			915					920					925				
30	Lys	Leu	Ile	Thr	Gln	Arg	Lys	Phe	Asp	Asn	Leu	Thr	Lys	Ala	Glu	Arg	
		930					935					940					
35	Gly	Gly	Leu	Ser	Glu	Leu	Asp	Lys	Ala	Gly	Phe	Ile	Lys	Arg	Gln	Leu	
	945					950					955					960	
40	Val	Glu	Thr	Arg	Gln	Ile	Thr	Lys	His	Val	Ala	Gln	Ile	Leu	Asp	Ser	
					965					970					975		
45	Arg	Met	Asn	Thr	Lys	Tyr	Asp	Glu	Asn	Asp	Lys	Leu	Ile	Arg	Glu	Val	
				980					985					990			
50	Lys	Val	Ile	Thr	Leu	Lys	Ser	Lys	Leu	Val	Ser	Asp	Phe	Arg	Lys	Asp	
			995					1000					1005				
55	Phe	Gln	Phe	Tyr	Lys	Val	Arg	Glu	Ile	Asn	Asn	Tyr	His	His	Ala		
		1010					1015					1020					
60	His	Asp	Ala	Tyr	Leu	Asn	Ala	Val	Val	Gly	Thr	Ala	Leu	Ile	Lys		
		1025					1030					1035					
65	Lys	Tyr	Pro	Lys	Leu	Glu	Ser	Glu	Phe	Val	Tyr	Gly	Asp	Tyr	Lys		
		1040					1045					1050					
70	Val	Tyr	Asp	Val	Arg	Lys	Met	Ile	Ala	Lys	Ser	Glu	Gln	Glu	Ile		
		1055					1060					1065					
75	Gly	Lys	Ala	Thr	Ala	Lys	Tyr	Phe	Phe	Tyr	Ser	Asn	Ile	Met	Asn		

EP 2 940 140 A1

	1070					1075						1080			
5	Phe	Phe	Lys	Thr	Glu	Ile	Thr	Leu	Ala	Asn	Gly	Glu	Ile	Arg	Lys
	1085						1090					1095			
	Arg	Pro	Leu	Ile	Glu	Thr	Asn	Gly	Glu	Thr	Gly	Glu	Ile	Val	Trp
10	1100						1105					1110			
	Asp	Lys	Gly	Arg	Asp	Phe	Ala	Thr	Val	Arg	Lys	Val	Leu	Ser	Met
	1115						1120					1125			
15	Pro	Gln	Val	Asn	Ile	Val	Lys	Lys	Thr	Glu	Val	Gln	Thr	Gly	Gly
	1130						1135					1140			
	Phe	Ser	Lys	Glu	Ser	Ile	Leu	Pro	Lys	Arg	Asn	Ser	Asp	Lys	Leu
20	1145						1150					1155			
	Ile	Ala	Arg	Lys	Lys	Asp	Trp	Asp	Pro	Lys	Lys	Tyr	Gly	Gly	Phe
25	1160						1165					1170			
	Asp	Ser	Pro	Thr	Val	Ala	Tyr	Ser	Val	Leu	Val	Val	Ala	Lys	Val
	1175						1180					1185			
30	Glu	Lys	Gly	Lys	Ser	Lys	Lys	Leu	Lys	Ser	Val	Lys	Glu	Leu	Leu
	1190						1195					1200			
	Gly	Ile	Thr	Ile	Met	Glu	Arg	Ser	Ser	Phe	Glu	Lys	Asn	Pro	Ile
35	1205						1210					1215			
	Asp	Phe	Leu	Glu	Ala	Lys	Gly	Tyr	Lys	Glu	Val	Lys	Lys	Asp	Leu
	1220						1225					1230			
40	Ile	Ile	Lys	Leu	Pro	Lys	Tyr	Ser	Leu	Phe	Glu	Leu	Glu	Asn	Gly
	1235						1240					1245			
	Arg	Lys	Arg	Met	Leu	Ala	Ser	Ala	Gly	Glu	Leu	Gln	Lys	Gly	Asn
45	1250						1255					1260			
	Glu	Leu	Ala	Leu	Pro	Ser	Lys	Tyr	Val	Asn	Phe	Leu	Tyr	Leu	Ala
50	1265						1270					1275			
	Ser	His	Tyr	Glu	Lys	Leu	Lys	Gly	Ser	Pro	Glu	Asp	Asn	Glu	Gln
	1280						1285					1290			
55	Lys	Gln	Leu	Phe	Val	Glu	Gln	His	Lys	His	Tyr	Leu	Asp	Glu	Ile
	1295						1300					1305			

# EP 2 940 140 A1

Ile Glu Gln Ile Ser Glu Phe Ser Lys Arg Val Ile Leu Ala Asp  
1310 1315 1320

5 Ala Asn Leu Asp Lys Val Leu Ser Ala Tyr Asn Lys His Arg Asp  
1325 1330 1335

10 Lys Pro Ile Arg Glu Gln Ala Glu Asn Ile Ile His Leu Phe Thr  
1340 1345 1350

15 Leu Thr Asn Leu Gly Ala Pro Ala Ala Phe Lys Tyr Phe Asp Thr  
1355 1360 1365

20 Thr Ile Asp Arg Lys Arg Tyr Thr Ser Thr Lys Glu Val Leu Asp  
1370 1375 1380

Ala Thr Leu Ile His Gln Ser Ile Thr Gly Leu Tyr Glu Thr Arg  
1385 1390 1395

25 Ile Asp Leu Ser Gln Leu Gly Gly Asp Lys Arg Pro Ala Ala Thr  
1400 1405 1410

Lys Lys Ala Gly Gln Ala Lys Lys Lys Lys  
1415 1420

30 <210> 47  
<211> 483  
<212> PRT  
<213> Artificial Sequence

35 <220>  
<221> source  
<223> /note="Description of Artificial Sequence: Synthetic  
polypeptide"

40 <400> 47  
Met Phe Leu Phe Leu Ser Leu Thr Ser Phe Leu Ser Ser Ser Arg Thr  
1 5 10 15

45 Leu Val Ser Lys Gly Glu Glu Asp Asn Met Ala Ile Ile Lys Glu Phe  
20 25 30

Met Arg Phe Lys Val His Met Glu Gly Ser Val Asn Gly His Glu Phe  
35 40 45

50 Glu Ile Glu Gly Glu Gly Glu Gly Arg Pro Tyr Glu Gly Thr Gln Thr  
50 55 60

55 Ala Lys Leu Lys Val Thr Lys Gly Gly Pro Leu Pro Phe Ala Trp Asp  
65 70 75 80

EP 2 940 140 A1

	Ile	Leu	Ser	Pro	Gln	Phe	Met	Tyr	Gly	Ser	Lys	Ala	Tyr	Val	Lys	His	
					85					90					95		
5	Pro	Ala	Asp	Ile	Pro	Asp	Tyr	Leu	Lys	Leu	Ser	Phe	Pro	Glu	Gly	Phe	
				100					105					110			
10	Lys	Trp	Glu	Arg	Val	Met	Asn	Phe	Glu	Asp	Gly	Gly	Val	Val	Thr	Val	
			115					120					125				
15	Thr	Gln	Asp	Ser	Ser	Leu	Gln	Asp	Gly	Glu	Phe	Ile	Tyr	Lys	Val	Lys	
		130					135					140					
20	Leu	Arg	Gly	Thr	Asn	Phe	Pro	Ser	Asp	Gly	Pro	Val	Met	Gln	Lys	Lys	
	145					150					155					160	
25	Thr	Met	Gly	Trp	Glu	Ala	Ser	Ser	Glu	Arg	Met	Tyr	Pro	Glu	Asp	Gly	
					165					170					175		
30	Ala	Leu	Lys	Gly	Glu	Ile	Lys	Gln	Arg	Leu	Lys	Leu	Lys	Asp	Gly	Gly	
				180					185					190			
35	His	Tyr	Asp	Ala	Glu	Val	Lys	Thr	Thr	Tyr	Lys	Ala	Lys	Lys	Pro	Val	
			195					200					205				
40	Gln	Leu	Pro	Gly	Ala	Tyr	Asn	Val	Asn	Ile	Lys	Leu	Asp	Ile	Thr	Ser	
		210					215					220					
45	His	Asn	Glu	Asp	Tyr	Thr	Ile	Val	Glu	Gln	Tyr	Glu	Arg	Ala	Glu	Gly	
	225					230					235					240	
50	Arg	His	Ser	Thr	Gly	Gly	Met	Asp	Glu	Leu	Tyr	Lys	Gly	Ser	Lys	Gln	
					245					250					255		
55	Leu	Glu	Glu	Leu	Leu	Ser	Thr	Ser	Phe	Asp	Ile	Gln	Phe	Asn	Asp	Leu	
				260					265					270			
60	Thr	Leu	Leu	Glu	Thr	Ala	Phe	Thr	His	Thr	Ser	Tyr	Ala	Asn	Glu	His	
			275					280					285				
65	Arg	Leu	Leu	Asn	Val	Ser	His	Asn	Glu	Arg	Leu	Glu	Phe	Leu	Gly	Asp	
		290					295					300					
70	Ala	Val	Leu	Gln	Leu	Ile	Ile	Ser	Glu	Tyr	Leu	Phe	Ala	Lys	Tyr	Pro	
	305					310					315					320	
75	Lys	Lys	Thr	Glu	Gly	Asp	Met	Ser	Lys	Leu	Arg	Ser	Met	Ile	Val	Arg	
					325					330					335		

# EP 2 940 140 A1

Glu Glu Ser Leu Ala Gly Phe Ser Arg Phe Cys Ser Phe Asp Ala Tyr  
 340 345 350  
 5 Ile Lys Leu Gly Lys Gly Glu Glu Lys Ser Gly Gly Arg Arg Arg Asp  
 355 360 365  
 10 Thr Ile Leu Gly Asp Leu Phe Glu Ala Phe Leu Gly Ala Leu Leu Leu  
 370 375 380  
 Asp Lys Gly Ile Asp Ala Val Arg Arg Phe Leu Lys Gln Val Met Ile  
 385 390 395 400  
 15 Pro Gln Val Glu Lys Gly Asn Phe Glu Arg Val Lys Asp Tyr Lys Thr  
 405 410 415  
 20 Cys Leu Gln Glu Phe Leu Gln Thr Lys Gly Asp Val Ala Ile Asp Tyr  
 420 425 430  
 Gln Val Ile Ser Glu Lys Gly Pro Ala His Ala Lys Gln Phe Glu Val  
 435 440 445  
 25 Ser Ile Val Val Asn Gly Ala Val Leu Ser Lys Gly Leu Gly Lys Ser  
 450 455 460  
 30 Lys Lys Leu Ala Glu Gln Asp Ala Ala Lys Asn Ala Leu Ala Gln Leu  
 465 470 475 480  
 35 Ser Glu Val  
 <210> 48  
 <211> 483  
 40 <212> PRT  
 <213> Artificial Sequence  
 <220>  
 <221> source  
 45 <223> /note="Description of Artificial Sequence: Synthetic  
 polypeptide"  
 <400> 48  
 Met Lys Gln Leu Glu Glu Leu Leu Ser Thr Ser Phe Asp Ile Gln Phe  
 1 5 10 15  
 50 Asn Asp Leu Thr Leu Leu Glu Thr Ala Phe Thr His Thr Ser Tyr Ala  
 20 25 30  
 55 Asn Glu His Arg Leu Leu Asn Val Ser His Asn Glu Arg Leu Glu Phe  
 35 40 45

EP 2 940 140 A1

	Leu	Gly	Asp	Ala	Val	Leu	Gln	Leu	Ile	Ile	Ser	Glu	Tyr	Leu	Phe	Ala	
	50						55					60					
5	Lys	Tyr	Pro	Lys	Lys	Thr	Glu	Gly	Asp	Met	Ser	Lys	Leu	Arg	Ser	Met	
	65					70					75					80	
	Ile	Val	Arg	Glu	Glu	Ser	Leu	Ala	Gly	Phe	Ser	Arg	Phe	Cys	Ser	Phe	
10					85					90					95		
	Asp	Ala	Tyr	Ile	Lys	Leu	Gly	Lys	Gly	Glu	Glu	Lys	Ser	Gly	Gly	Arg	
				100					105					110			
15	Arg	Arg	Asp	Thr	Ile	Leu	Gly	Asp	Leu	Phe	Glu	Ala	Phe	Leu	Gly	Ala	
			115					120					125				
	Leu	Leu	Leu	Asp	Lys	Gly	Ile	Asp	Ala	Val	Arg	Arg	Phe	Leu	Lys	Gln	
20		130					135					140					
	Val	Met	Ile	Pro	Gln	Val	Glu	Lys	Gly	Asn	Phe	Glu	Arg	Val	Lys	Asp	
25		145				150				155						160	
	Tyr	Lys	Thr	Cys	Leu	Gln	Glu	Phe	Leu	Gln	Thr	Lys	Gly	Asp	Val	Ala	
					165					170					175		
30	Ile	Asp	Tyr	Gln	Val	Ile	Ser	Glu	Lys	Gly	Pro	Ala	His	Ala	Lys	Gln	
				180					185					190			
	Phe	Glu	Val	Ser	Ile	Val	Val	Asn	Gly	Ala	Val	Leu	Ser	Lys	Gly	Leu	
35			195					200					205				
	Gly	Lys	Ser	Lys	Lys	Leu	Ala	Glu	Gln	Asp	Ala	Ala	Lys	Asn	Ala	Leu	
		210					215					220					
40	Ala	Gln	Leu	Ser	Glu	Val	Gly	Ser	Val	Ser	Lys	Gly	Glu	Glu	Asp	Asn	
	225					230					235					240	
	Met	Ala	Ile	Ile	Lys	Glu	Phe	Met	Arg	Phe	Lys	Val	His	Met	Glu	Gly	
45					245					250					255		
	Ser	Val	Asn	Gly	His	Glu	Phe	Glu	Ile	Glu	Gly	Glu	Gly	Glu	Gly	Arg	
50				260					265					270			
	Pro	Tyr	Glu	Gly	Thr	Gln	Thr	Ala	Lys	Leu	Lys	Val	Thr	Lys	Gly	Gly	
			275					280					285				
55	Pro	Leu	Pro	Phe	Ala	Trp	Asp	Ile	Leu	Ser	Pro	Gln	Phe	Met	Tyr	Gly	
		290					295					300					

# EP 2 940 140 A1

Ser Lys Ala Tyr Val Lys His Pro Ala Asp Ile Pro Asp Tyr Leu Lys  
305 310 315 320

Leu Ser Phe Pro Glu Gly Phe Lys Trp Glu Arg Val Met Asn Phe Glu  
325 330 335

Asp Gly Gly Val Val Thr Val Thr Gln Asp Ser Ser Leu Gln Asp Gly  
340 345 350

Glu Phe Ile Tyr Lys Val Lys Leu Arg Gly Thr Asn Phe Pro Ser Asp  
355 360 365

Gly Pro Val Met Gln Lys Lys Thr Met Gly Trp Glu Ala Ser Ser Glu  
370 375 380

Arg Met Tyr Pro Glu Asp Gly Ala Leu Lys Gly Glu Ile Lys Gln Arg  
385 390 395 400

Leu Lys Leu Lys Asp Gly Gly His Tyr Asp Ala Glu Val Lys Thr Thr  
405 410 415

Tyr Lys Ala Lys Lys Pro Val Gln Leu Pro Gly Ala Tyr Asn Val Asn  
420 425 430

Ile Lys Leu Asp Ile Thr Ser His Asn Glu Asp Tyr Thr Ile Val Glu  
435 440 445

Gln Tyr Glu Arg Ala Glu Gly Arg His Ser Thr Gly Gly Met Asp Glu  
450 455 460

Leu Tyr Lys Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys  
465 470 475 480

Lys Lys Lys

<210> 49  
<211> 1423  
<212> PRT  
<213> Artificial Sequence

<220>  
<221> source  
<223> /note="Description of Artificial Sequence: Synthetic  
polypeptide"

<400> 49  
Met Asp Tyr Lys Asp His Asp Gly Asp Tyr Lys Asp His Asp Ile Asp  
1 5 10 15

EP 2 940 140 A1

	Tyr	Lys	Asp	Asp	Asp	Asp	Lys	Met	Ala	Pro	Lys	Lys	Lys	Arg	Lys	Val	
				20					25					30			
5	Gly	Ile	His	Gly	Val	Pro	Ala	Ala	Asp	Lys	Lys	Tyr	Ser	Ile	Gly	Leu	
			35					40					45				
	Ala	Ile	Gly	Thr	Asn	Ser	Val	Gly	Trp	Ala	Val	Ile	Thr	Asp	Glu	Tyr	
10		50					55					60					
	Lys	Val	Pro	Ser	Lys	Lys	Phe	Lys	Val	Leu	Gly	Asn	Thr	Asp	Arg	His	
	65					70					75					80	
15																	
	Ser	Ile	Lys	Lys	Asn	Leu	Ile	Gly	Ala	Leu	Leu	Phe	Asp	Ser	Gly	Glu	
					85					90					95		
	Thr	Ala	Glu	Ala	Thr	Arg	Leu	Lys	Arg	Thr	Ala	Arg	Arg	Arg	Tyr	Thr	
20				100					105						110		
	Arg	Arg	Lys	Asn	Arg	Ile	Cys	Tyr	Leu	Gln	Glu	Ile	Phe	Ser	Asn	Glu	
			115					120					125				
25																	
	Met	Ala	Lys	Val	Asp	Asp	Ser	Phe	Phe	His	Arg	Leu	Glu	Glu	Ser	Phe	
		130					135					140					
30																	
	Leu	Val	Glu	Glu	Asp	Lys	Lys	His	Glu	Arg	His	Pro	Ile	Phe	Gly	Asn	
	145					150					155					160	
35	Ile	Val	Asp	Glu	Val	Ala	Tyr	His	Glu	Lys	Tyr	Pro	Thr	Ile	Tyr	His	
					165					170					175		
	Leu	Arg	Lys	Lys	Leu	Val	Asp	Ser	Thr	Asp	Lys	Ala	Asp	Leu	Arg	Leu	
				180					185					190			
40																	
	Ile	Tyr	Leu	Ala	Leu	Ala	His	Met	Ile	Lys	Phe	Arg	Gly	His	Phe	Leu	
			195					200					205				
45	Ile	Glu	Gly	Asp	Leu	Asn	Pro	Asp	Asn	Ser	Asp	Val	Asp	Lys	Leu	Phe	
		210					215					220					
	Ile	Gln	Leu	Val	Gln	Thr	Tyr	Asn	Gln	Leu	Phe	Glu	Glu	Asn	Pro	Ile	
50		225				230					235					240	
	Asn	Ala	Ser	Gly	Val	Asp	Ala	Lys	Ala	Ile	Leu	Ser	Ala	Arg	Leu	Ser	
					245					250					255		
55																	
	Lys	Ser	Arg	Arg	Leu	Glu	Asn	Leu	Ile	Ala	Gln	Leu	Pro	Gly	Glu	Lys	



## EP 2 940 140 A1

	260	265	270
5	Lys Asn Gly Leu Phe Gly Asn Leu Ile Ala Leu Ser Leu Gly Leu Thr 275 280 285		
10	Pro Asn Phe Lys Ser Asn Phe Asp Leu Ala Glu Asp Ala Lys Leu Gln 290 295 300		
15	Leu Ser Lys Asp Thr Tyr Asp Asp Asp Leu Asp Asn Leu Leu Ala Gln 305 310 315 320		
20	Ile Gly Asp Gln Tyr Ala Asp Leu Phe Leu Ala Ala Lys Asn Leu Ser 325 330 335		
25	Asp Ala Ile Leu Leu Ser Asp Ile Leu Arg Val Asn Thr Glu Ile Thr 340 345 350		
30	Lys Ala Pro Leu Ser Ala Ser Met Ile Lys Arg Tyr Asp Glu His His 355 360 365		
35	Gln Asp Leu Thr Leu Leu Lys Ala Leu Val Arg Gln Gln Leu Pro Glu 370 375 380		
40	Lys Tyr Lys Glu Ile Phe Phe Asp Gln Ser Lys Asn Gly Tyr Ala Gly 385 390 395 400		
45	Tyr Ile Asp Gly Gly Ala Ser Gln Glu Glu Phe Tyr Lys Phe Ile Lys 405 410 415		
50	Pro Ile Leu Glu Lys Met Asp Gly Thr Glu Glu Leu Leu Val Lys Leu 420 425 430		
55	Asn Arg Glu Asp Leu Leu Arg Lys Gln Arg Thr Phe Asp Asn Gly Ser 435 440 445		
60	Ile Pro His Gln Ile His Leu Gly Glu Leu His Ala Ile Leu Arg Arg 450 455 460		
65	Gln Glu Asp Phe Tyr Pro Phe Leu Lys Asp Asn Arg Glu Lys Ile Glu 465 470 475 480		
70	Lys Ile Leu Thr Phe Arg Ile Pro Tyr Tyr Val Gly Pro Leu Ala Arg 485 490 495		
75	Gly Asn Ser Arg Phe Ala Trp Met Thr Arg Lys Ser Glu Glu Thr Ile 500 505 510		

EP 2 940 140 A1

	Thr	Pro	Trp	Asn	Phe	Glu	Glu	Val	Val	Asp	Lys	Gly	Ala	Ser	Ala	Gln	
			515					520					525				
5	Ser	Phe	Ile	Glu	Arg	Met	Thr	Asn	Phe	Asp	Lys	Asn	Leu	Pro	Asn	Glu	
		530					535					540					
10	Lys	Val	Leu	Pro	Lys	His	Ser	Leu	Leu	Tyr	Glu	Tyr	Phe	Thr	Val	Tyr	
	545					550					555					560	
	Asn	Glu	Leu	Thr	Lys	Val	Lys	Tyr	Val	Thr	Glu	Gly	Met	Arg	Lys	Pro	
					565					570					575		
15	Ala	Phe	Leu	Ser	Gly	Glu	Gln	Lys	Lys	Ala	Ile	Val	Asp	Leu	Leu	Phe	
				580					585					590			
20	Lys	Thr	Asn	Arg	Lys	Val	Thr	Val	Lys	Gln	Leu	Lys	Glu	Asp	Tyr	Phe	
			595					600					605				
25	Lys	Lys	Ile	Glu	Cys	Phe	Asp	Ser	Val	Glu	Ile	Ser	Gly	Val	Glu	Asp	
		610					615					620					
	Arg	Phe	Asn	Ala	Ser	Leu	Gly	Thr	Tyr	His	Asp	Leu	Leu	Lys	Ile	Ile	
	625					630					635					640	
30	Lys	Asp	Lys	Asp	Phe	Leu	Asp	Asn	Glu	Glu	Asn	Glu	Asp	Ile	Leu	Glu	
					645					650					655		
35	Asp	Ile	Val	Leu	Thr	Leu	Thr	Leu	Phe	Glu	Asp	Arg	Glu	Met	Ile	Glu	
				660					665					670			
40	Glu	Arg	Leu	Lys	Thr	Tyr	Ala	His	Leu	Phe	Asp	Asp	Lys	Val	Met	Lys	
			675					680					685				
	Gln	Leu	Lys	Arg	Arg	Arg	Tyr	Thr	Gly	Trp	Gly	Arg	Leu	Ser	Arg	Lys	
		690					695					700					
45	Leu	Ile	Asn	Gly	Ile	Arg	Asp	Lys	Gln	Ser	Gly	Lys	Thr	Ile	Leu	Asp	
	705					710					715					720	
50	Phe	Leu	Lys	Ser	Asp	Gly	Phe	Ala	Asn	Arg	Asn	Phe	Met	Gln	Leu	Ile	
				725						730					735		
	His	Asp	Asp	Ser	Leu	Thr	Phe	Lys	Glu	Asp	Ile	Gln	Lys	Ala	Gln	Val	
				740					745					750			
55	Ser	Gly	Gln	Gly	Asp	Ser	Leu	His	Glu	His	Ile	Ala	Asn	Leu	Ala	Gly	
		755						760					765				

EP 2 940 140 A1

	Ser	Pro	Ala	Ile	Lys	Lys	Gly	Ile	Leu	Gln	Thr	Val	Lys	Val	Val	Asp	
	770						775					780					
5	Glu	Leu	Val	Lys	Val	Met	Gly	Arg	His	Lys	Pro	Glu	Asn	Ile	Val	Ile	
	785					790					795					800	
10	Glu	Met	Ala	Arg	Glu	Asn	Gln	Thr	Thr	Gln	Lys	Gly	Gln	Lys	Asn	Ser	
					805					810					815		
15	Arg	Glu	Arg	Met	Lys	Arg	Ile	Glu	Glu	Gly	Ile	Lys	Glu	Leu	Gly	Ser	
				820					825					830			
20	Gln	Ile	Leu	Lys	Glu	His	Pro	Val	Glu	Asn	Thr	Gln	Leu	Gln	Asn	Glu	
			835					840					845				
25	Lys	Leu	Tyr	Leu	Tyr	Tyr	Leu	Gln	Asn	Gly	Arg	Asp	Met	Tyr	Val	Asp	
	850						855					860					
30	Gln	Glu	Leu	Asp	Ile	Asn	Arg	Leu	Ser	Asp	Tyr	Asp	Val	Asp	His	Ile	
	865				870					875						880	
35	Val	Pro	Gln	Ser	Phe	Leu	Lys	Asp	Asp	Ser	Ile	Asp	Asn	Lys	Val	Leu	
					885					890					895		
40	Thr	Arg	Ser	Asp	Lys	Asn	Arg	Gly	Lys	Ser	Asp	Asn	Val	Pro	Ser	Glu	
				900					905					910			
45	Glu	Val	Val	Lys	Lys	Met	Lys	Asn	Tyr	Trp	Arg	Gln	Leu	Leu	Asn	Ala	
			915					920					925				
50	Lys	Leu	Ile	Thr	Gln	Arg	Lys	Phe	Asp	Asn	Leu	Thr	Lys	Ala	Glu	Arg	
	930						935					940					
55	Gly	Gly	Leu	Ser	Glu	Leu	Asp	Lys	Ala	Gly	Phe	Ile	Lys	Arg	Gln	Leu	
	945					950					955					960	
60	Val	Glu	Thr	Arg	Gln	Ile	Thr	Lys	His	Val	Ala	Gln	Ile	Leu	Asp	Ser	
					965					970					975		
65	Arg	Met	Asn	Thr	Lys	Tyr	Asp	Glu	Asn	Asp	Lys	Leu	Ile	Arg	Glu	Val	
				980					985					990			
70	Lys	Val	Ile	Thr	Leu	Lys	Ser	Lys	Leu	Val	Ser	Asp	Phe	Arg	Lys	Asp	
			995					1000					1005				
75	Phe	Gln	Phe	Tyr	Lys	Val	Arg	Glu	Ile	Asn	Asn	Tyr	His	His	Ala		
	1010						1015					1020					

EP 2 940 140 A1

	His	Asp	Ala	Tyr	Leu	Asn	Ala	Val	Val	Gly	Thr	Ala	Leu	Ile	Lys
	1025						1030					1035			
5	Lys	Tyr	Pro	Lys	Leu	Glu	Ser	Glu	Phe	Val	Tyr	Gly	Asp	Tyr	Lys
	1040						1045					1050			
10	Val	Tyr	Asp	Val	Arg	Lys	Met	Ile	Ala	Lys	Ser	Glu	Gln	Glu	Ile
	1055						1060					1065			
15	Gly	Lys	Ala	Thr	Ala	Lys	Tyr	Phe	Phe	Tyr	Ser	Asn	Ile	Met	Asn
	1070						1075					1080			
20	Phe	Phe	Lys	Thr	Glu	Ile	Thr	Leu	Ala	Asn	Gly	Glu	Ile	Arg	Lys
	1085						1090					1095			
25	Arg	Pro	Leu	Ile	Glu	Thr	Asn	Gly	Glu	Thr	Gly	Glu	Ile	Val	Trp
	1100						1105					1110			
30	Asp	Lys	Gly	Arg	Asp	Phe	Ala	Thr	Val	Arg	Lys	Val	Leu	Ser	Met
	1115						1120					1125			
35	Pro	Gln	Val	Asn	Ile	Val	Lys	Lys	Thr	Glu	Val	Gln	Thr	Gly	Gly
	1130						1135					1140			
40	Phe	Ser	Lys	Glu	Ser	Ile	Leu	Pro	Lys	Arg	Asn	Ser	Asp	Lys	Leu
	1145						1150					1155			
45	Ile	Ala	Arg	Lys	Lys	Asp	Trp	Asp	Pro	Lys	Lys	Tyr	Gly	Gly	Phe
	1160						1165					1170			
50	Asp	Ser	Pro	Thr	Val	Ala	Tyr	Ser	Val	Leu	Val	Val	Ala	Lys	Val
	1175						1180					1185			
55	Glu	Lys	Gly	Lys	Ser	Lys	Lys	Leu	Lys	Ser	Val	Lys	Glu	Leu	Leu
	1190						1195					1200			
60	Gly	Ile	Thr	Ile	Met	Glu	Arg	Ser	Ser	Phe	Glu	Lys	Asn	Pro	Ile
	1205						1210					1215			
65	Asp	Phe	Leu	Glu	Ala	Lys	Gly	Tyr	Lys	Glu	Val	Lys	Lys	Asp	Leu
	1220						1225					1230			
70	Ile	Ile	Lys	Leu	Pro	Lys	Tyr	Ser	Leu	Phe	Glu	Leu	Glu	Asn	Gly
	1235						1240					1245			
75	Arg	Lys	Arg	Met	Leu	Ala	Ser	Ala	Gly	Glu	Leu	Gln	Lys	Gly	Asn

# EP 2 940 140 A1

	1250		1255		1260	
5	Glu Leu Ala Leu Pro Ser Lys Tyr Val Asn Phe Leu Tyr Leu Ala	1265	1270	1275		
	Ser His Tyr Glu Lys Leu Lys Gly Ser Pro Glu Asp Asn Glu Gln	1280	1285	1290		
10	Lys Gln Leu Phe Val Glu Gln His Lys His Tyr Leu Asp Glu Ile	1295	1300	1305		
15	Ile Glu Gln Ile Ser Glu Phe Ser Lys Arg Val Ile Leu Ala Asp	1310	1315	1320		
	Ala Asn Leu Asp Lys Val Leu Ser Ala Tyr Asn Lys His Arg Asp	1325	1330	1335		
20	Lys Pro Ile Arg Glu Gln Ala Glu Asn Ile Ile His Leu Phe Thr	1340	1345	1350		
25	Leu Thr Asn Leu Gly Ala Pro Ala Ala Phe Lys Tyr Phe Asp Thr	1355	1360	1365		
30	Thr Ile Asp Arg Lys Arg Tyr Thr Ser Thr Lys Glu Val Leu Asp	1370	1375	1380		
	Ala Thr Leu Ile His Gln Ser Ile Thr Gly Leu Tyr Glu Thr Arg	1385	1390	1395		
35	Ile Asp Leu Ser Gln Leu Gly Gly Asp Lys Arg Pro Ala Ala Thr	1400	1405	1410		
40	Lys Lys Ala Gly Gln Ala Lys Lys Lys Lys	1415	1420			
45	<210> 50 <211> 2012 <212> DNA <213> Artificial Sequence					
50	<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic polynucleotide"					
	<400> 50 gaatgctgcc ctcagacccg cttcctccct gtccttgtct gtccaaggag aatgaggtct					60
55	cactgggtgga tttcggacta ccctgaggag ctggcacctg agggacaagg cccccacct					120
	gccacgtcc agcctctgat gaggggtggg agagagctac atgaggttgc taagaaagcc					180

EP 2 940 140 A1

	tcccctgaag gagaccacac agtgtgtgag gttggagtct ctagcagcgg gttctgtgcc	240
	cccagggata gtctggctgt ccaggcactg ctcttgatat aaacaccacc tcctagttat	300
5	gaaaccatgc ccattctgcc tctctgtatg gaaaagagca tggggctggc ccgtggggtg	360
	gtgtccactt taggccctgt gggagatcat gggaaaccac gcagtgggtc ataggctctc	420
	tcatttacta ctcacatcca ctctgtgaag aagcgattat gatctctcct ctagaaactc	480
10	gtagagtccc atgtctgccg gcttccagag cctgcactcc tccaccttgg cttggccttg	540
	ctggggctag aggagctagg atgcacagca gctctgtgac cctttgtttg agaggaacag	600
	gaaaaccacc cttctctctg gcccaactgtg tcctcttctc gccctgccat ccccttctgt	660
15	gaatgttaga cccatgggag cagctggtca gaggggaccc cggcctgggg cccctaacc	720
	tatgtagcct cagtcttccc atcaggctct cagctcagcc tgagtgttga ggccccagtg	780
20	gctgctctgg gggcctcctg agtttctcat ctgtgcccct ccctccctgg ccaggtgaa	840
	ggtgtggttc cagaaccgga ggacaaagta caaacggcag aagctggagg aggaagggcc	900
	tgagtccgag cagaagaaga agggctccca tcacatcaac cgggtggcgca ttgccacgaa	960
25	gcaggccaat ggggaggaca tcgatgtcac ctccaatgac aagcttgcta gcggtgggca	1020
	accacaaaacc cacgagggca gagtgtgtgt tgctgtgtggc caggccctg cgtgggcccc	1080
	agctggactc tggccactcc ctggccaggc tttggggagg cctggagtca tggccccaca	1140
30	gggcttgaag cccggggccg ccattgacag agggacaagc aatgggctgg ctgaggcctg	1200
	ggaccacttg gccttctcct cggagagcct gcctgcctgg gggggcccg cggccaccgc	1260
35	agcctcccag ctgctctccg tgtctccaat ctcccttttg ttttgatgca tttctgtttt	1320
	aatttatattt ccaggcacca ctgtagttta gtgatcccca gtgtccccct tcctatggg	1380
	aataataaaa gtctctctct taatgacacg ggcattccagc tcagcccca gagcctgggg	1440
40	tggtagattc cggctctgag ggccagtggg ggctggtaga gcaaacgcgt tcagggcctg	1500
	ggagcctggg gtgggggtact ggtggagggg gtcaagggtg attcattaac tcctctcttt	1560
	tgttggggga ccctggtctc tacctccagc tccacagcag gagaaacagg ctagacatag	1620
45	ggaagggcca tcctgtatct tgagggagga caggcccagg tctttcttaa cgtattgaga	1680
	ggtgggaatc agggccagggt agttcaatgg gagagggaga gtgcttccct ctgcctagag	1740
	actctgggtg cttctccagt tgaggagaaa ccagaggaaa ggggaggatt ggggtctggg	1800
50	ggagggaaca ccattcacia aggctgacgg ttccagtccg aagtcgtggg cccaccagga	1860
	tgctcacctg tccttggaga accgctgggc aggttgagac tgcagagaca gggcttaagg	1920
55	ctgagcctgc aaccagtccc cagtgactca gggcctcctc agcccaagaa agagcaacgt	1980
	gccagggccc gctgagctct tgtgttcacc tg	2012

# EP 2 940 140 A1

<210> 51  
 <211> 1153  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic polypeptide"

<400> 51  
 Met Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys  
 1 5 10 15

Lys Ser Asp Leu Val Leu Gly Leu Asp Ile Gly Ile Gly Ser Val Gly  
 20 25 30

Val Gly Ile Leu Asn Lys Val Thr Gly Glu Ile Ile His Lys Asn Ser  
 35 40 45

Arg Ile Phe Pro Ala Ala Gln Ala Glu Asn Asn Leu Val Arg Arg Thr  
 50 55 60

Asn Arg Gln Gly Arg Arg Leu Ala Arg Arg Lys Lys His Arg Arg Val  
 65 70 75 80

Arg Leu Asn Arg Leu Phe Glu Glu Ser Gly Leu Ile Thr Asp Phe Thr  
 85 90 95

Lys Ile Ser Ile Asn Leu Asn Pro Tyr Gln Leu Arg Val Lys Gly Leu  
 100 105 110

Thr Asp Glu Leu Ser Asn Glu Glu Leu Phe Ile Ala Leu Lys Asn Met  
 115 120 125

Val Lys His Arg Gly Ile Ser Tyr Leu Asp Asp Ala Ser Asp Asp Gly  
 130 135 140

Asn Ser Ser Val Gly Asp Tyr Ala Gln Ile Val Lys Glu Asn Ser Lys  
 145 150 155 160

Gln Leu Glu Thr Lys Thr Pro Gly Gln Ile Gln Leu Glu Arg Tyr Gln  
 165 170 175

Thr Tyr Gly Gln Leu Arg Gly Asp Phe Thr Val Glu Lys Asp Gly Lys  
 180 185 190

Lys His Arg Leu Ile Asn Val Phe Pro Thr Ser Ala Tyr Arg Ser Glu  
 195 200 205

EP 2 940 140 A1

	Ala	Leu	Arg	Ile	Leu	Gln	Thr	Gln	Gln	Glu	Phe	Asn	Pro	Gln	Ile	Thr	
	210						215					220					
5	Asp	Glu	Phe	Ile	Asn	Arg	Tyr	Leu	Glu	Ile	Leu	Thr	Gly	Lys	Arg	Lys	
	225				230						235					240	
	Tyr	Tyr	His	Gly	Pro	Gly	Asn	Glu	Lys	Ser	Arg	Thr	Asp	Tyr	Gly	Arg	
10					245					250					255		
	Tyr	Arg	Thr	Ser	Gly	Glu	Thr	Leu	Asp	Asn	Ile	Phe	Gly	Ile	Leu	Ile	
				260					265					270			
15	Gly	Lys	Cys	Thr	Phe	Tyr	Pro	Asp	Glu	Phe	Arg	Ala	Ala	Lys	Ala	Ser	
			275					280					285				
	Tyr	Thr	Ala	Gln	Glu	Phe	Asn	Leu	Leu	Asn	Asp	Leu	Asn	Asn	Leu	Thr	
20							295					300					
	Val	Pro	Thr	Glu	Thr	Lys	Lys	Leu	Ser	Lys	Glu	Gln	Lys	Asn	Gln	Ile	
25	305					310					315					320	
	Ile	Asn	Tyr	Val	Lys	Asn	Glu	Lys	Ala	Met	Gly	Pro	Ala	Lys	Leu	Phe	
					325					330					335		
30	Lys	Tyr	Ile	Ala	Lys	Leu	Leu	Ser	Cys	Asp	Val	Ala	Asp	Ile	Lys	Gly	
				340					345					350			
	Tyr	Arg	Ile	Asp	Lys	Ser	Gly	Lys	Ala	Glu	Ile	His	Thr	Phe	Glu	Ala	
35				355				360					365				
	Tyr	Arg	Lys	Met	Lys	Thr	Leu	Glu	Thr	Leu	Asp	Ile	Glu	Gln	Met	Asp	
				370			375					380					
40	Arg	Glu	Thr	Leu	Asp	Lys	Leu	Ala	Tyr	Val	Leu	Thr	Leu	Asn	Thr	Glu	
	385					390					395					400	
	Arg	Glu	Gly	Ile	Gln	Glu	Ala	Leu	Glu	His	Glu	Phe	Ala	Asp	Gly	Ser	
45					405					410					415		
	Phe	Ser	Gln	Lys	Gln	Val	Asp	Glu	Leu	Val	Gln	Phe	Arg	Lys	Ala	Asn	
50				420					425					430			
	Ser	Ser	Ile	Phe	Gly	Lys	Gly	Trp	His	Asn	Phe	Ser	Val	Lys	Leu	Met	
				435				440					445				
55	Met	Glu	Leu	Ile	Pro	Glu	Leu	Tyr	Glu	Thr	Ser	Glu	Glu	Gln	Met	Thr	
	450						455					460					



EP 2 940 140 A1

	Ile	Leu	Thr	Arg	Leu	Gly	Lys	Gln	Lys	Thr	Thr	Ser	Ser	Ser	Asn	Lys	465	470	475	480
5	Thr	Lys	Tyr	Ile	Asp	Glu	Lys	Leu	Leu	Thr	Glu	Glu	Ile	Tyr	Asn	Pro		485	490	495
10	Val	Val	Ala	Lys	Ser	Val	Arg	Gln	Ala	Ile	Lys	Ile	Val	Asn	Ala	Ala		500	505	510
	Ile	Lys	Glu	Tyr	Gly	Asp	Phe	Asp	Asn	Ile	Val	Ile	Glu	Met	Ala	Arg		515	520	525
15	Glu	Thr	Asn	Glu	Asp	Asp	Glu	Lys	Lys	Ala	Ile	Gln	Lys	Ile	Gln	Lys		530	535	540
20	Ala	Asn	Lys	Asp	Glu	Lys	Asp	Ala	Ala	Met	Leu	Lys	Ala	Ala	Asn	Gln		545	550	555
	Tyr	Asn	Gly	Lys	Ala	Glu	Leu	Pro	His	Ser	Val	Phe	His	Gly	His	Lys		565	570	575
25	Gln	Leu	Ala	Thr	Lys	Ile	Arg	Leu	Trp	His	Gln	Gln	Gly	Glu	Arg	Cys		580	585	590
30	Leu	Tyr	Thr	Gly	Lys	Thr	Ile	Ser	Ile	His	Asp	Leu	Ile	Asn	Asn	Ser		595	600	605
	Asn	Gln	Phe	Glu	Val	Asp	His	Ile	Leu	Pro	Leu	Ser	Ile	Thr	Phe	Asp		610	615	620
35	Asp	Ser	Leu	Ala	Asn	Lys	Val	Leu	Val	Tyr	Ala	Thr	Ala	Asn	Gln	Glu		625	630	635
40	Lys	Gly	Gln	Arg	Thr	Pro	Tyr	Gln	Ala	Leu	Asp	Ser	Met	Asp	Asp	Ala		645	650	655
45	Trp	Ser	Phe	Arg	Glu	Leu	Lys	Ala	Phe	Val	Arg	Glu	Ser	Lys	Thr	Leu		660	665	670
	Ser	Asn	Lys	Lys	Lys	Glu	Tyr	Leu	Leu	Thr	Glu	Glu	Asp	Ile	Ser	Lys		675	680	685
50	Phe	Asp	Val	Arg	Lys	Lys	Phe	Ile	Glu	Arg	Asn	Leu	Val	Asp	Thr	Arg		690	695	700
55	Tyr	Ala	Ser	Arg	Val	Val	Leu	Asn	Ala	Leu	Gln	Glu	His	Phe	Arg	Ala				

EP 2 940 140 A1

	705				710					715					720
5	His	Lys	Ile	Asp	Thr	Lys	Val	Ser	Val	Val	Arg	Gly	Gln	Phe	Thr Ser
					725					730					735
	Gln	Leu	Arg	Arg	His	Trp	Gly	Ile	Glu	Lys	Thr	Arg	Asp	Thr	Tyr His
10				740					745					750	
	His	His	Ala	Val	Asp	Ala	Leu	Ile	Ile	Ala	Ala	Ser	Ser	Gln	Leu Asn
			755					760					765		
15	Leu	Trp	Lys	Lys	Gln	Lys	Asn	Thr	Leu	Val	Ser	Tyr	Ser	Glu	Asp Gln
		770					775					780			
	Leu	Leu	Asp	Ile	Glu	Thr	Gly	Glu	Leu	Ile	Ser	Asp	Asp	Glu	Tyr Lys
20						790					795				800
	Glu	Ser	Val	Phe	Lys	Ala	Pro	Tyr	Gln	His	Phe	Val	Asp	Thr	Leu Lys
					805					810					815
25	Ser	Lys	Glu	Phe	Glu	Asp	Ser	Ile	Leu	Phe	Ser	Tyr	Gln	Val	Asp Ser
				820					825					830	
30	Lys	Phe	Asn	Arg	Lys	Ile	Ser	Asp	Ala	Thr	Ile	Tyr	Ala	Thr	Arg Gln
			835					840					845		
	Ala	Lys	Val	Gly	Lys	Asp	Lys	Ala	Asp	Glu	Thr	Tyr	Val	Leu	Gly Lys
35			850				855					860			
	Ile	Lys	Asp	Ile	Tyr	Thr	Gln	Asp	Gly	Tyr	Asp	Ala	Phe	Met	Lys Ile
						870					875				880
40	Tyr	Lys	Lys	Asp	Lys	Ser	Lys	Phe	Leu	Met	Tyr	Arg	His	Asp	Pro Gln
					885					890					895
	Thr	Phe	Glu	Lys	Val	Ile	Glu	Pro	Ile	Leu	Glu	Asn	Tyr	Pro	Asn Lys
45				900					905					910	
	Gln	Ile	Asn	Glu	Lys	Gly	Lys	Glu	Val	Pro	Cys	Asn	Pro	Phe	Leu Lys
			915					920					925		
50	Tyr	Lys	Glu	Glu	His	Gly	Tyr	Ile	Arg	Lys	Tyr	Ser	Lys	Lys	Gly Asn
			930				935					940			
55	Gly	Pro	Glu	Ile	Lys	Ser	Leu	Lys	Tyr	Tyr	Asp	Ser	Lys	Leu	Gly Asn
						950					955				960

# EP 2 940 140 A1

His Ile Asp Ile Thr Pro Lys Asp Ser Asn Asn Lys Val Val Leu Gln  
965 970 975

5 Ser Val Ser Pro Trp Arg Ala Asp Val Tyr Phe Asn Lys Thr Thr Gly  
980 985 990

10 Lys Tyr Glu Ile Leu Gly Leu Lys Tyr Ala Asp Leu Gln Phe Glu Lys  
995 1000 1005

Gly Thr Gly Thr Tyr Lys Ile Ser Gln Glu Lys Tyr Asn Asp Ile  
1010 1015 1020

15 Lys Lys Lys Glu Gly Val Asp Ser Asp Ser Glu Phe Lys Phe Thr  
1025 1030 1035

20 Leu Tyr Lys Asn Asp Leu Leu Leu Val Lys Asp Thr Glu Thr Lys  
1040 1045 1050

Glu Gln Gln Leu Phe Arg Phe Leu Ser Arg Thr Met Pro Lys Gln  
1055 1060 1065

25 Lys His Tyr Val Glu Leu Lys Pro Tyr Asp Lys Gln Lys Phe Glu  
1070 1075 1080

30 Gly Gly Glu Ala Leu Ile Lys Val Leu Gly Asn Val Ala Asn Ser  
1085 1090 1095

35 Gly Gln Cys Lys Lys Gly Leu Gly Lys Ser Asn Ile Ser Ile Tyr  
1100 1105 1110

Lys Val Arg Thr Asp Val Leu Gly Asn Gln His Ile Ile Lys Asn  
1115 1120 1125

40 Glu Gly Asp Lys Pro Lys Leu Asp Phe Lys Arg Pro Ala Ala Thr  
1130 1135 1140

45 Lys Lys Ala Gly Gln Ala Lys Lys Lys Lys  
1145 1150

<210> 52  
<211> 340  
<212> DNA  
50 <213> Artificial Sequence

<220>  
<221> source  
<223> /note="Description of Artificial Sequence: Synthetic  
55 polynucleotide"

<400> 52

# EP 2 940 140 A1

gagggcctat ttcccatgat tccttcatat ttgcatatac gatacaaggc tgtagagag 60  
 ataattggaa ttaatttgac tgtaaacaca aagatattag tacaaaatac gtgacgtaga 120  
 5 aagtaataat ttcttgggta gtttgcagtt ttaaaattat gttttaaaat ggactatcat 180  
 atgcttaccg taacttgaaa gtatttcgat ttcttggctt tatatatctt gtggaaagga 240  
 cgaaacaccg ttactttaa cttgcagaag ctacaaagat aaggcttcat gccgaaatca 300  
 10 acaccctgtc attttatggc aggggtgttt cgttatttaa 340

<210> 53  
 <211> 360  
 <212> DNA  
 15 <213> Artificial Sequence

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 20 polynucleotide"

<220>  
 <221> modified\_base  
 <222> (288)..(317)  
 25 <223> a, c, t, g, unknown or other

<400> 53  
 gagggcctat ttcccatgat tccttcatat ttgcatatac gatacaaggc tgtagagag 60  
 30 ataattggaa ttaatttgac tgtaaacaca aagatattag tacaaaatac gtgacgtaga 120  
 aagtaataat ttcttgggta gtttgcagtt ttaaaattat gttttaaaat ggactatcat 180  
 atgcttaccg taacttgaaa gtatttcgat ttcttggctt tatatatctt gtggaaagga 240  
 35 cgaaacaccg ggttttagag ctatgctgtt ttgaatggtc ccaaaacnnn nnnnnnnnnn 300  
 nnnnnnnnnn nnnnnnngtt ttagagctat gctgttttga atggtcccaa aacttttttt 360

<210> 54  
 <211> 318  
 <212> DNA  
 40 <213> Artificial Sequence

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 45 polynucleotide"

<220>  
 <221> modified\_base  
 <222> (250)..(269)  
 50 <223> a, c, t, g, unknown or other

<400> 54  
 gagggcctat ttcccatgat tccttcatat ttgcatatac gatacaaggc tgtagagag 60  
 55 ataattggaa ttaatttgac tgtaaacaca aagatattag tacaaaatac gtgacgtaga 120

# EP 2 940 140 A1

aagtaataat ttcttgggta gtttgcagtt ttaaaattat gttttaaaat ggactatcat 180

atgcttaccg taacttgaaa gtatttcgat ttcttgggctt tatatatctt gtggaaagga 240

5 cgaaacaccn nnnnnnnnnn nnnnnnnnng ttttagagct agaaatagca agttaaata 300

aggctagtcc gttttttt 318

<210> 55  
 <211> 325  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 15 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic polynucleotide"

<220>  
 20 <221> modified\_base  
 <222> (250)..(269)  
 <223> a, c, t, g, unknown or other

<400> 55  
 25 gagggcctat ttcccatgat tccttcatat ttgcatatac gatacaaggc tgtagagag 60

ataattggaa ttaatttgac tgtaaacaca aagatattag tacaaaatac gtgacgtaga 120

aagtaataat ttcttgggta gtttgcagtt ttaaaattat gttttaaaat ggactatcat 180

30 atgcttaccg taacttgaaa gtatttcgat ttcttgggctt tatatatctt gtggaaagga 240

cgaaacaccn nnnnnnnnnn nnnnnnnnng ttttagagct agaaatagca agttaaata 300

aggctagtcc gttatcattt ttttt 325

35 <210> 56  
 <211> 337  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic polynucleotide"

45 <220>  
 <221> modified\_base  
 <222> (250)..(269)  
 <223> a, c, t, g, unknown or other

<400> 56  
 gagggcctat ttcccatgat tccttcatat ttgcatatac gatacaaggc tgtagagag 60

ataattggaa ttaatttgac tgtaaacaca aagatattag tacaaaatac gtgacgtaga 120

55 aagtaataat ttcttgggta gtttgcagtt ttaaaattat gttttaaaat ggactatcat 180

# EP 2 940 140 A1

atgcttaccg taacttgaaa gtatttcgat ttcttggctt tatatatctt gtggaaagga 240

cgaacacccn nnnnnnnnnn nnnnnnnnng ttttagagct agaaatagca agttaaata 300

5 aggctagtcc gttatcaact tgaaaaagtg ttttttt 337

<210> 57  
 <211> 352  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 polynucleotide"

<220>  
 <221> modified\_base  
 <222> (250)..(269)  
 <223> a, c, t, g, unknown or other

<400> 57  
 gagggcctat ttcccatgat tccttcatat ttgcatatac gatacaaggc tgtagagag 60

ataattggaa ttaatttgac tgtaaacaca aagatattag tacaaaatac gtgacgtaga 120

aagtaataat ttcttgggta gtttgcagtt ttaaattat gttttaaaat ggactatcat 180

atgcttaccg taacttgaaa gtatttcgat ttcttggctt tatatatctt gtggaaagga 240

cgaacacccn nnnnnnnnnn nnnnnnnnng ttttagagct agaaatagca agttaaata 300

aggctagtcc gttatcaact tgaaaaagtg gcaccgagtc ggtgcttttt tt 352

<210> 58  
 <211> 5101  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 polynucleotide"

<400> 58  
 cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc cccgcccatt 60

gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc attgacgtca 120

atgggtggag tatttacggt aaactgccca cttggcagta catcaagtgt atcatatgcc 180

aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta 240

catgacctta tgggactttc ctacttggca gtacatctac gtattagtca tcgctattac 300

catggtcgag gtgagcccca cgttctgctt cactctcccc atctcccccc cctccccacc 360

cccaattttg tatttattta ttttttaatt attttgtgca gcgatggggg cggggggggg 420

ggggggggcg gcgccaggcg gggcggggcg gggcgagggg cggggcgggg cgaggcggag 480

# EP 2 940 140 A1

	aggtgcggcg gcagccaatc agagcggcgc gctccgaaag tttcctttta tggcgaggcg	540
	gcggcgggcg cgccctata aaaagcgaag cgcgcggcgg gcgggagtcg ctgcgacgct	600
5	gccttcgccc cgtgccccgc tccgcgcgcg cctcgcgcgc cccgccccgg ctctgactga	660
	ccgcgttact cccacaggtg agcgggcggg acggcccttc tcctccgggc tgtaattagc	720
	tgagcaagag gtaagggttt aagggatggt tggttggtgg ggtattaatg ttttaattacc	780
10	tggagcacct gcctgaaatc actttttttc aggttggacc ggtgccacca tggactataa	840
	ggaccacgac ggagactaca aggatcatga tattgattac aaagacgatg acgataagat	900
15	ggccccaaag aagaagcggg aggtcggtat ccacggagtc ccagcagcgc acaagaagta	960
	cagcatcggc ctggacatcg gcaccaactc tgtgggctgg gccgtgatca ccgacgagta	1020
	caaggtgccc agcaagaaat tcaaggtgct gggcaacacc gaccggcaca gcatcaagaa	1080
20	gaacctgatc ggagccctgc tgttcgacag cggcgaaaca gccgaggcca cccggctgaa	1140
	gagaaccgcc agaagaagat acaccagacg gaagaaccgg atctgctatc tgcaagagat	1200
	cttcagcaac gagatggcca aggtggacga cagcttcttc cacagactgg aagagtcctt	1260
25	cctggtggaa gaggataaga agcacgagcg gcaccccatc ttcggcaaca tcgtggacga	1320
	ggtggcctac cacgagaagt accccaccat ctaccacctg agaaagaaac tggaggacag	1380
	caccgacaag gccgacctgc ggctgatcta tctggccctg gccacatga tcaagttccg	1440
30	ggggccacttc ctgatcgagg gcgacctgaa ccccgacaac agcgacgtgg acaagctggt	1500
	catccagctg gtgcagacct acaaccagct gttcgaggaa aaccccatca acgccagcgg	1560
35	cgtggacgcc aaggccatcc tgtctgccag actgagcaag agcagacggc tggaaaatct	1620
	gatcgcccag ctgcccgcg agaagaagaa tggcctgttc ggcaacctga ttgccctgag	1680
	cctgggcctg acccccaact tcaagagcaa cttcgacctg gccgaggatg ccaaactgca	1740
40	gctgagcaag gacacctacg acgacgacct ggacaacctg ctggcccaga tcggcgacca	1800
	gtacgccgac ctgtttctgg ccgccaagaa cctgtccgac gccatcctgc tgagcgacat	1860
	cctgagagtg aacaccgaga tcaccaaggc cccctgagc gcctctatga tcaagagata	1920
45	cgacgagcac caccaggacc tgacctgct gaaagctctc gtgcggcagc agctgcctga	1980
	gaagtacaaa gagattttct tcgaccagag caagaacggc tacgccggct acattgacgg	2040
50	cggagccagc caggaagagt tctacaagtt catcaagccc atcctggaaa agatggacgg	2100
	caccgaggaa ctgctcgtga agctgaacag agaggacctg ctgcggaagc agcggacctt	2160
	cgacaacggc agcatcccc accagatcca cctgggagag ctgcacgcca ttctgcggcg	2220
55	gcaggaagat ttttacctat tcctgaagga caaccgggaa aagatcgaga agatcctgac	2280
	cttcgcgcatc ccctactacg tgggcctctt ggccagggga aacagcagat tcgcctggat	2340

# EP 2 940 140 A1

	gaccagaaag agcgaggaaa ccatcacccc ctggaacttc gaggaagtgg tggacaaggg	2400
	cgcttccgcc cagagcttca tcgagcggat gaccaacttc gataagaacc tgcccaacga	2460
5	gaaggtgctg cccaagcaca gcctgctgta cgagtacttc accgtgtata acgagctgac	2520
	caaagtgaaa tacgtgaccg agggaatgag aaagcccgcc ttcctgagcg gcgagcagaa	2580
	aaaggccatc gtggacctgc tgttcaagac caaccggaaa gtgaccgtga agcagctgaa	2640
10	agaggactac ttcaagaaaa tcgagtgcct cgactccgtg gaaatctccg gcgtggaaga	2700
	tcggttcaac gcctccctgg gcacatacca cgatctgctg aaaattatca aggacaagga	2760
	cttcctggac aatgaggaaa acgaggacat tctggaagat atcgtgctga ccctgacact	2820
15	gtttgaggac agagagatga tcgaggaacg gctgaaaacc tatgcccacc tgttcgacga	2880
	caaagtgatg aagcagctga agcggcggag atacaccggc tggggcaggc tgagccggaa	2940
	gctgatcaac ggcatccggg acaagcagtc cggcaagaca atcctggatt tcctgaagtc	3000
20	cgacggcttc gccaacagaa acttcatgca gctgatccac gacgacagcc tgacctttaa	3060
	agaggacatc cagaaagccc aggtgtccgg ccagggcgat agcctgcacg agcacattgc	3120
	caatctggcc ggcagccccg ccattaagaa gggcatcctg cagacagtga aggtggtgga	3180
25	cgagctcgtg aaagtgatgg gccggcacia gcccgagaac atcgtgatcg aaatggccag	3240
	agagaaccag accacccaga agggacagaa gaacagccgc gagagaatga agcggatcga	3300
	agagggcatc aaagagctgg gcagccagat cctgaaagaa caccctgtgg aaaacaccca	3360
	gctgcagaac gagaagctgt acctgtacta cctgcagaat gggcgggata tgtacgtgga	3420
	ccaggaactg gacatcaacc ggctgtccga ctacgatgtg gaccatatcg tgcctcagag	3480
35	ctttctgaag gacgactcca tcgacaacia ggtgctgacc agaagcgaca agaaccgggg	3540
	caagagcgac aacgtgccct ccgaagaggt cgtgaagaag atgaagaact actggcggca	3600
	gctgctgaac gccaaagctga ttaccagag aaagttcgac aatctgacca aggccgagag	3660
40	aggcggcctg agcgaactgg ataaggccgg cttcacaaag agacagctgg tggaaacccg	3720
	gcagatcaca aagcacgtgg cacagatcct ggactccgg atgaacacta agtacgacga	3780
	gaatgacaag ctgatccggg aagtgaaggt gatcacccctg aagtccaagc tgggtgtccga	3840
45	tttccggaag gatttccagt ttacaaaagt gcgcgagatc aacaactacc accacgcca	3900
	cgacgcctac ctgaacgccg tcgtgggaac cgccctgatc aaaaagtacc ctaagctgga	3960
	aagcgagttc gtgtacggcg actacaaggt gtacgacgtg cggaagatga tcgccaagag	4020
50	cgagcaggaa atcggcaagg ctaccgcaa gtacttcttc tacagcaaca tcatgaactt	4080
	tttcaagacc gagattacc tggccaacgg cgagatccgg aagcggcctc tgatcgagac	4140
55	aaacggcgaa accggggaga tcgtgtggga taagggccgg gattttgcca ccgtgcggaa	4200
	agtgtgagc atgccccaa tgaatatcgt gaaaaagacc gaggtgcaga caggcggctt	4260



# EP 2 940 140 A1

cagcaaagag tctatcctgc ccaagaggaa cagcgataag ctgatcgcca gaaagaagga 4320

ctgggaccct aagaagtacg gcggcttcga cagccccacc gtggcctatt ctgtgctggt 4380

5 ggtggccaaa gtggaaaagg gcaagtccaa gaaactgaag agtgtgaaag agctgctggg 4440

gatcaccatc atggaaaagaa gcagcttcga gaagaatccc atcgactttc tggaagccaa 4500

gggctacaaa gaagtgaaaa aggacctgat catcaagctg cctaagtact ccctgttcga 4560

10 gctggaaaac ggccggaaga gaatgctggc ctctgccggc gaactgcaga agggaaacga 4620

actggccctg ccctccaaat atgtgaactt cctgtacctg gccagccact atgagaagct 4680

gaagggctcc cccgaggata atgagcagaa acagctgttt gtggaacagc acaagcacta 4740

15 cctggacgag atcatcgagc agatcagcga gttctccaag agagtgatcc tggccgacgc 4800

taatctggac aaagtgctgt ccgcctacaa caagcaccgg gataagccca tcagagagca 4860

ggccgagaat atcatccacc tgtttaccct gaccaatctg ggagcccctg ccgccttcaa 4920

20 gtactttgac accaccatcg accggaagag gtacaccagc accaaagagg tgctggacgc 4980

caccctgatc caccagagca tcaccggcct gtacgagaca cggatcgacc tgtctcagct 5040

25 gggaggcgac tttctttttc ttagcttgac cagctttctt agtagcagca ggacgcttta 5100

a 5101

<210> 59

<211> 137

<212> DNA

<213> Artificial Sequence

<220>

35 <221> source

<223> /note="Description of Artificial Sequence: Synthetic polynucleotide"

<220>

40 <221> modified\_base

<222> (1)..(20)

<223> a, c, t, g, unknown or other

<400> 59

45 nnnnnnnnnn nnnnnnnnnn gtttttgtac tctcaagatt tagaaataaa tcttgcagaa 60

gctacaaaaga taaggcttca tgccgaaatc aacaccctgt cattttatgg caggggtgttt 120

tcgttattta atttttt 137

50 <210> 60

<211> 123

<212> DNA

<213> Artificial Sequence

55 <220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic polynucleotide"

5 <220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, t, g, unknown or other

10 <400> 60  
 nnnnnnnnnn nnnnnnnnnn gtttttgtac tctcagaaat gcagaagcta caaagataag 60  
 gcttcatgcc gaaatcaaca ccctgtcatt ttatggcagg gtgttttcgt tatttaattt 120  
 ttt 123

15 <210> 61  
 <211> 110  
 <212> DNA  
 <213> Artificial Sequence

20 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic polynucleotide"

25 <220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, t, g, unknown or other

30 <400> 61  
 nnnnnnnnnn nnnnnnnnnn gtttttgtac tctcagaaat gcagaagcta caaagataag 60  
 gcttcatgcc gaaatcaaca ccctgtcatt ttatggcagg gtgttttttt 110

35 <210> 62  
 <211> 137  
 <212> DNA  
 <213> Artificial Sequence

40 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic polynucleotide"

45 <220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, t, g, unknown or other

50 <400> 62  
 nnnnnnnnnn nnnnnnnnnn gttattgtac tctcaagatt tagaaataaa tcttgcagaa 60  
 gctacaaaga taaggcttca tgccgaaatc aacaccctgt cattttatgg cagggtgttt 120  
 tcgttattta atttttt 137

55

<210> 63  
 <211> 123  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 polynucleotide"

<220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, t, g, unknown or other

<400> 63  
 nnnnnnnnnn nnnnnnnnnn gttattgtac tctcagaaat gcagaagcta caaagataag 60  
 gcttcatgcc gaaatcaaca ccctgtcatt ttatggcagg gtgttttcgt tatttaattt 120  
 ttt 123

<210> 64  
 <211> 110  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 polynucleotide"

<220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, t, g, unknown or other

<400> 64  
 nnnnnnnnnn nnnnnnnnnn gttattgtac tctcagaaat gcagaagcta caaagataag 60  
 gcttcatgcc gaaatcaaca ccctgtcatt ttatggcagg gtgttttttt 110

<210> 65  
 <211> 137  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 polynucleotide"

<220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, t, g, unknown or other

<400> 65

# EP 2 940 140 A1

nnnnnnnnnn nnnnnnnnnn gttattgtac tctcaagatt tagaaataaa tcttgcagaa 60  
 gctacaatga taaggcttca tgccgaaatc aacaccctgt cattttatgg caggggtgttt 120  
 5 tcgttattta atttttt 137

<210> 66  
 <211> 123  
 <212> DNA  
 10 <213> Artificial Sequence

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 15 polynucleotide"

<220>  
 <221> modified\_base  
 <222> (1)..(20)  
 20 <223> a, c, t, g, unknown or other

<400> 66  
 nnnnnnnnnn nnnnnnnnnn gttattgtac tctcagaaat gcagaagcta caatgataag 60  
 25 gcttcatgcc gaaatcaaca ccctgtcatt ttatggcagg gtgttttcgt tatttaattt 120  
 ttt 123

<210> 67  
 30 <211> 110  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> source  
 35 <223> /note="Description of Artificial Sequence: Synthetic  
 polynucleotide"

<220>  
 <221> modified\_base  
 40 <222> (1)..(20)  
 <223> a, c, t, g, unknown or other

<400> 67  
 45 nnnnnnnnnn nnnnnnnnnn gttattgtac tctcagaaat gcagaagcta caatgataag 60  
 gcttcatgcc gaaatcaaca ccctgtcatt ttatggcagg gtgttttttt 110

<210> 68  
 50 <211> 107  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> source  
 55 <223> /note="Description of Artificial Sequence: Synthetic  
 polynucleotide"

<220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, t, g, unknown or other

<400> 68  
 nnnnnnnnnn nnnnnnnnnn gtttttagagc tgtgggaaaca cagcgagtta aaataaggct 60  
 tagtccgtac tcaacttgaa aaggtggcac cgattcgggtg tttttttt 107

<210> 69  
 <211> 4263  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 polynucleotide"

<400> 69  
 atgaaaaggc cggcggccac gaaaaaggcc ggccaggcaa aaaagaaaaa gaccaagccc 60  
 tacagcatcg gcctggacat cggcaccaat agcgtgggct gggccgtgac caccgacaac 120  
 tacaagggtgc ccagcaagaa aatgaagggtg ctgggcaaca cctccaagaa gtacatcaag 180  
 aaaaacctgc tgggcgtgct gctgttcgac agcggcatta cagccgaggg cagacggctg 240  
 aagagaaccg ccagacggcg gtacaccccg cggagaaaca gaatcctgta tctgcaagag 300  
 atcttcagca ccgagatggc taccctggac gacgccttct tccagcggct ggacgacagc 360  
 ttcctggtgc ccgacgacaa gcgggacagc aagtacccca tcttcggcaa cctggtggaa 420  
 gagaaggcct accacgacga gttccccacc atctaccacc tgagaaagta cctggccgac 480  
 agcaccaaga aggccgacct gagactggtg tatctggccc tggccacat gatcaagtac 540  
 cggggccact tctgatcga gggcgagttc aacagcaaga acaacgacat ccagaagaac 600  
 ttccaggact tcttgacac ctacaacgcc atcttcgaga ggcacctgtc cctggaaaac 660  
 agcaagcagc tggaagagat cgtgaaggac aagatcagca agctggaaaa gaaggaccgc 720  
 atcctgaagc tgttcccccg cgagaagaac agcggaatct tcagcgagtt tctgaagctg 780  
 atcgtgggca accaggccga cttcagaaag tgcttcaacc tggacgagaa agccagcctg 840  
 cacttcagca aagagagcta cgacgaggac ctggaaaccc tgctgggata tatcggcgac 900  
 gactacagcg acgtgttcct gaaggccaag aagctgtacg acgctatcct gctgagcggc 960  
 ttcctgaccg tgaccgacaa cgagacagag gccccactga gcagcgccat gattaagcgg 1020  
 tacaacgagc acaaagagga tctggctctg ctgaaagagt acatccggaa catcagcctg 1080  
 aaaacctaca atgaggtggt caaggacgac accaagaacg gctacgccgg ctacatcgac 1140  
 ggcaagacca accaggaaga tttctatgtg tacctgaaga agctgctggc cgagttcgag 1200

EP 2 940 140 A1

	ggggccgact	actttctgga	aaaaatcgac	cgcgaggatt	tcctgcggaa	gcagcggacc	1260
	ttcgacaacg	gcagcatccc	ctaccagatc	catctgcagg	aatgcgggc	catcctggac	1320
5	aagcaggcca	agttctaccc	attcctggcc	aagaacaaag	agcggatcga	gaagatcctg	1380
	accttccgca	tcccttacta	cgtgggcccc	ctggccagag	gcaacagcga	ttttgcctgg	1440
	tccatccgga	agcgcaatga	gaagatcacc	ccctggaact	tcgaggacgt	gatcgacaaa	1500
10	gagtccagcg	ccgaggcctt	catcaaccgg	atgaccagct	tcgacctgta	cctgcccag	1560
	gaaaaggtgc	tgcccaagca	cagcctgctg	tacgagacat	tcaatgtgta	taacgagctg	1620
	accaaagtgc	ggtttatcgc	cgagtctatg	cgggactacc	agttcctgga	ctccaagcag	1680
15	aaaaaggaca	tcgtgctggc	gtacttcaag	gacaagcgga	aagtgaccga	taaggacatc	1740
	atcgagtacc	tgcacgccat	ctacggctac	gatggcatcg	agctgaaggg	catcgagaag	1800
	cagttcaact	ccagcctgag	cacataccac	gacctgctga	acattatcaa	cgacaaagaa	1860
20	tttctggacg	actccagcaa	cgaggccatc	atcgaagaga	tcattccacac	cctgaccatc	1920
	tttgaggacc	gcgagatgat	caagcagcgg	ctgagcaagt	tcgagaacat	cttcgacaag	1980
	agcgtgctga	aaaagctgag	cagacggcac	tacaccggct	ggggcaagct	gagcgccaag	2040
25	ctgatcaacg	gcatccggga	cgagaagtcc	ggcaacacaa	tcctggacta	cctgatcgac	2100
	gacggcatca	gcaaccggaa	cttcatgcag	ctgatccacg	acgacgccct	gagcttcaag	2160
	aagaagatcc	agaaggccca	gatcatcggg	gacgaggaca	agggcaacat	caaagaagtc	2220
30	gtgaagtccc	tgcccggcag	ccccgccatc	aagaagggaa	tcctgcagag	catcaagatc	2280
	gtggacgagc	tcgtgaaagt	gatgggcggc	agaaagcccg	agagcatcgt	ggtggaaatg	2340
35	gctagagaga	accagtacac	caatcagggc	aagagcaaca	gccagcagag	actgaagaga	2400
	ctggaaaagt	ccctgaaaga	gctgggcagc	aagattctga	aagagaatat	ccctgccaaag	2460
	ctgtccaaga	tcgacaacaa	cgccctgcag	aacgaccggc	tgtacctgta	ctacctgcag	2520
40	aatggcaagg	acatgtatac	aggcgacgac	ctggatatcg	accgcctgag	caactacgac	2580
	atcgaccata	ttatccccc	ggccttcctg	aaagacaaca	gcattgacaa	caaagtgtg	2640
	gtgtcctccg	ccagcaaccg	cggcaagtcc	gatgatgtgc	ccagcctgga	agtcgtgaaa	2700
45	aagagaaaga	ccttctggta	tcagctgctg	aaaagcaagc	tgattagcca	gaggaagttc	2760
	gacaacctga	ccaaggccga	gagaggcggc	ctgagccctg	aagataaggc	cggcttcac	2820
	cagagacagc	tggtggaaac	ccggcagatc	accaagcacg	tggccagact	gctggatgag	2880
50	aagtttaaca	acaagaagga	cgagaacaac	cgggcccgtgc	ggaccgtgaa	gatcatcacc	2940
	ctgaagtcca	ccctggtgtc	ccagttccgg	aaggacttcg	agctgtataa	agtgcgcgag	3000
55	atcaatgact	ttcaccacgc	ccacgacgcc	tacctgaatg	ccgtggtggc	ttccgccctg	3060
	ctgaagaagt	accctaagct	ggaacccgag	ttcgtgtacg	gcgactaccc	caagtacaac	3120

# EP 2 940 140 A1

	tccttcagag agcgggaagtc cgccaccgag aaggtgtact tctactccaa catcatgaat	3180
	atctttaaga agtccatctc cctggccgat ggcagagtga tcgagcggcc cctgatcgaa	3240
5	gtgaacgaag agacaggcga gagcgtgtgg aacaaagaaa gcgacctggc caccgtgcgg	3300
	cgggtgctga gttatcctca agtgaatgtc gtgaagaagg tggaagaaca gaaccacggc	3360
	ctggatcggg gcaagcccaa gggcctgttc aacgccaaacc tgtccagcaa gcctaagccc	3420
10	aactccaacg agaatctcgt gggggccaaa gagtacctgg accctaagaa gtacggcgga	3480
	tacgccggca tctccaatag cttcacctgt ctcgtgaagg gcacaatcga gaagggcgct	3540
	aagaaaaaga tcacaaacgt gctggaattt caggggatct ctatcctgga ccggatcaac	3600
15	taccggaagg ataagctgaa ctttctgctg gaaaaaggct acaaggacat tgagctgatt	3660
	atcgagctgc ctaagtactc cctgttcgaa ctgagcgacg gctccagacg gatgctggcc	3720
	tccatcctgt ccaccaacaa caagcggggc gagatccaca agggaaacca gatcttcctg	3780
20	agccagaaat ttgtgaaact gctgtaccac gccaaagcga tctccaacac catcaatgag	3840
	aaccaccgga aatacgtgga aaaccacaag aaagagtttg aggaactggt ctactacatc	3900
25	ctggagttca acgagaacta tgtgggagcc aagaagaacg gcaaactgct gaactccgcc	3960
	ttccagagct ggcagaacca cagcatcgac gagctgtgca gtccttcat cggccctacc	4020
	ggcagcgagc ggaagggact gtttgagctg acctccagag gctctgccgc cgactttgag	4080
30	ttcctgggag tgaagatccc ccggtacaga gactacaccc cctctagtct gctgaaggac	4140
	gccaccctga tccaccagag cgtgaccggc ctgtacgaaa cccggatcga cctggctaag	4200
	ctgggcgagg gaaagcgtcc tgctgtact aagaaagctg gtcaagctaa gaaaaagaaa	4260
35	taa	4263

40	<210> 70
	<211> 84
	<212> DNA
	<213> Artificial Sequence

45	<220>
	<221> source
	<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"

50	<400> 70	
	ggaaccattc ataacagcat agcaagttat aataaggcta gtccgttatc aacttgaaaa	60
	agtggcaccg agtcggtgct tttt	84

55	<210> 71
	<211> 36
	<212> DNA
	<213> Artificial Sequence

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 5  
 <400> 71  
 gttatagagc tatgctgtta tgaatggtcc caaaac 36  
  
 <210> 72  
 10 <211> 84  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 15 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
  
 <400> 72  
 20 ggaaccattc aatacagcat agcaagttaa tataaggcta gtccgttatc aacttgaaaa 60  
 agtggcaccg agtcggtgct tttt 84  
  
 <210> 73  
 25 <211> 36  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 30 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
  
 <400> 73  
 gtattagagc tatgctgtat tgaatggtcc caaaac 36  
 35  
 <210> 74  
 <211> 103  
 <212> DNA  
 <213> Artificial Sequence  
 40  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 polynucleotide"  
 45  
 <220>  
 <221> modified\_base  
 <222> (1) .. (20)  
 <223> a, c, t, g, unknown or other  
 50  
 <400> 74  
 nnnnnnnnnn nnnnnnnnnn gttttagagc tagaaatagc aagttaaaat aaggctagtc 60  
 cgttatcaac ttgaaaaagt ggcaccgagt cggtgctttt ttt 103  
 55  
 <210> 75  
 <211> 103



<212> DNA  
 <213> Artificial Sequence

5 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic polynucleotide"

10 <220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, t, g, unknown or other

15 <400> 75  
 nnnnnnnnnn nnnnnnnnnn gtattagagc tagaaatagc aagttaatat aaggctagtc 60  
 cgttatcaac ttgaaaaagt ggcaccgagt cggtgctttt ttt 103

20 <210> 76  
 <211> 123  
 <212> DNA  
 <213> Artificial Sequence

25 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic polynucleotide"

30 <220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, t, g, unknown or other

35 <400> 76  
 nnnnnnnnnn nnnnnnnnnn gttttagagc tatgctgttt tggaacaaa acagcatagc 60  
 aagttaaaat aaggctagtc cgttatcaac ttgaaaaagt ggcaccgagt cggtgctttt 120  
 ttt 123

40 <210> 77  
 <211> 123  
 <212> DNA  
 <213> Artificial Sequence

45 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic polynucleotide"

50 <220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, t, g, unknown or other

55 <400> 77  
 nnnnnnnnnn nnnnnnnnnn gtattagagc tatgctgtat tggaacaat acagcatagc 60

EP 2 940 140 A1

aagttaatat aaggctagtc cgttatcaac ttgaaaaagt ggcaccgagt cggtgctttt 120  
 ttt 123

5  
 <210> 78  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens

10  
 <400> 78  
 gtcacctcca atgactaggg 20

15  
 <210> 79  
 <211> 984  
 <212> PRT  
 <213> Campylobacter jejuni

20  
 <400> 79  
 Met Ala Arg Ile Leu Ala Phe Asp Ile Gly Ile Ser Ser Ile Gly Trp  
 1 5 10 15

Ala Phe Ser Glu Asn Asp Glu Leu Lys Asp Cys Gly Val Arg Ile Phe  
 20 25 30

25  
 Thr Lys Val Glu Asn Pro Lys Thr Gly Glu Ser Leu Ala Leu Pro Arg  
 35 40 45

30  
 Arg Leu Ala Arg Ser Ala Arg Lys Arg Leu Ala Arg Arg Lys Ala Arg  
 50 55 60

35  
 Leu Asn His Leu Lys His Leu Ile Ala Asn Glu Phe Lys Leu Asn Tyr  
 65 70 75 80

Glu Asp Tyr Gln Ser Phe Asp Glu Ser Leu Ala Lys Ala Tyr Lys Gly  
 85 90 95

40  
 Ser Leu Ile Ser Pro Tyr Glu Leu Arg Phe Arg Ala Leu Asn Glu Leu  
 100 105 110

45  
 Leu Ser Lys Gln Asp Phe Ala Arg Val Ile Leu His Ile Ala Lys Arg  
 115 120 125

Arg Gly Tyr Asp Asp Ile Lys Asn Ser Asp Asp Lys Glu Lys Gly Ala  
 130 135 140

50  
 Ile Leu Lys Ala Ile Lys Gln Asn Glu Glu Lys Leu Ala Asn Tyr Gln  
 145 150 155 160

55  
 Ser Val Gly Glu Tyr Leu Tyr Lys Glu Tyr Phe Gln Lys Phe Lys Glu  
 165 170 175

EP 2 940 140 A1

	Asn	Ser	Lys	Glu	Phe	Thr	Asn	Val	Arg	Asn	Lys	Lys	Glu	Ser	Tyr	Glu	180	185	190	
5	Arg	Cys	Ile	Ala	Gln	Ser	Phe	Leu	Lys	Asp	Glu	Leu	Lys	Leu	Ile	Phe	195	200	205	
10	Lys	Lys	Gln	Arg	Glu	Phe	Gly	Phe	Ser	Phe	Ser	Lys	Lys	Phe	Glu	Glu	210	215	220	
	Glu	Val	Leu	Ser	Val	Ala	Phe	Tyr	Lys	Arg	Ala	Leu	Lys	Asp	Phe	Ser	225	230	235	240
15	His	Leu	Val	Gly	Asn	Cys	Ser	Phe	Phe	Thr	Asp	Glu	Lys	Arg	Ala	Pro	245	250	255	
20	Lys	Asn	Ser	Pro	Leu	Ala	Phe	Met	Phe	Val	Ala	Leu	Thr	Arg	Ile	Ile	260	265	270	
25	Asn	Leu	Leu	Asn	Asn	Leu	Lys	Asn	Thr	Glu	Gly	Ile	Leu	Tyr	Thr	Lys	275	280	285	
	Asp	Asp	Leu	Asn	Ala	Leu	Leu	Asn	Glu	Val	Leu	Lys	Asn	Gly	Thr	Leu	290	295	300	
30	Thr	Tyr	Lys	Gln	Thr	Lys	Lys	Leu	Leu	Gly	Leu	Ser	Asp	Asp	Tyr	Glu	305	310	315	320
35	Phe	Lys	Gly	Glu	Lys	Gly	Thr	Tyr	Phe	Ile	Glu	Phe	Lys	Lys	Tyr	Lys	325	330	335	
40	Glu	Phe	Ile	Lys	Ala	Leu	Gly	Glu	His	Asn	Leu	Ser	Gln	Asp	Asp	Leu	340	345	350	
	Asn	Glu	Ile	Ala	Lys	Asp	Ile	Thr	Leu	Ile	Lys	Asp	Glu	Ile	Lys	Leu	355	360	365	
45	Lys	Lys	Ala	Leu	Ala	Lys	Tyr	Asp	Leu	Asn	Gln	Asn	Gln	Ile	Asp	Ser	370	375	380	
50	Leu	Ser	Lys	Leu	Glu	Phe	Lys	Asp	His	Leu	Asn	Ile	Ser	Phe	Lys	Ala	385	390	395	400
	Leu	Lys	Leu	Val	Thr	Pro	Leu	Met	Leu	Glu	Gly	Lys	Lys	Tyr	Asp	Glu	405	410	415	
55	Ala	Cys	Asn	Glu	Leu	Asn	Leu	Lys	Val	Ala	Ile	Asn	Glu	Asp	Lys	Lys	420	425	430	

EP 2 940 140 A1

	Asp	Phe	Leu	Pro	Ala	Phe	Asn	Glu	Thr	Tyr	Tyr	Lys	Asp	Glu	Val	Thr	
			435					440					445				
5	Asn	Pro	Val	Val	Leu	Arg	Ala	Ile	Lys	Glu	Tyr	Arg	Lys	Val	Leu	Asn	
			450				455					460					
10	Ala	Leu	Leu	Lys	Lys	Tyr	Gly	Lys	Val	His	Lys	Ile	Asn	Ile	Glu	Leu	
	465					470					475					480	
15	Ala	Arg	Glu	Val	Gly	Lys	Asn	His	Ser	Gln	Arg	Ala	Lys	Ile	Glu	Lys	
					485					490					495		
20	Glu	Gln	Asn	Glu	Asn	Tyr	Lys	Ala	Lys	Lys	Asp	Ala	Glu	Leu	Glu	Cys	
				500					505					510			
25	Glu	Lys	Leu	Gly	Leu	Lys	Ile	Asn	Ser	Lys	Asn	Ile	Leu	Lys	Leu	Arg	
			515					520					525				
30	Leu	Phe	Lys	Glu	Gln	Lys	Glu	Phe	Cys	Ala	Tyr	Ser	Gly	Glu	Lys	Ile	
	530						535					540					
35	Lys	Ile	Ser	Asp	Leu	Gln	Asp	Glu	Lys	Met	Leu	Glu	Ile	Asp	His	Ile	
	545					550					555					560	
40	Tyr	Pro	Tyr	Ser	Arg	Ser	Phe	Asp	Asp	Ser	Tyr	Met	Asn	Lys	Val	Leu	
					565					570					575		
45	Val	Phe	Thr	Lys	Gln	Asn	Gln	Glu	Lys	Leu	Asn	Gln	Thr	Pro	Phe	Glu	
				580					585					590			
50	Ala	Phe	Gly	Asn	Asp	Ser	Ala	Lys	Trp	Gln	Lys	Ile	Glu	Val	Leu	Ala	
			595					600					605				
55	Lys	Asn	Leu	Pro	Thr	Lys	Lys	Gln	Lys	Arg	Ile	Leu	Asp	Lys	Asn	Tyr	
			610				615					620					
60	Lys	Asp	Lys	Glu	Gln	Lys	Asn	Phe	Lys	Asp	Arg	Asn	Leu	Asn	Asp	Thr	
	625					630				635						640	
65	Arg	Tyr	Ile	Ala	Arg	Leu	Val	Leu	Asn	Tyr	Thr	Lys	Asp	Tyr	Leu	Asp	
					645					650					655		
70	Phe	Leu	Pro	Leu	Ser	Asp	Asp	Glu	Asn	Thr	Lys	Leu	Asn	Asp	Thr	Gln	
				660					665					670			
75	Lys	Gly	Ser	Lys	Val	His	Val	Glu	Ala	Lys	Ser	Gly	Met	Leu	Thr	Ser	

EP 2 940 140 A1

	675					680					685				
5	Ala	Leu	Arg	His	Thr	Trp	Gly	Phe	Ser	Ala	Lys	Asp	Arg	Asn	His
	690						695					700			
	Leu	His	His	Ala	Ile	Asp	Ala	Val	Ile	Ile	Ala	Tyr	Ala	Asn	Ser
10	705					710					715				720
	Ile	Val	Lys	Ala	Phe	Ser	Asp	Phe	Lys	Lys	Glu	Gln	Glu	Ser	Asn
					725					730					735
15	Ala	Glu	Leu	Tyr	Ala	Lys	Lys	Ile	Ser	Glu	Leu	Asp	Tyr	Lys	Asn
				740					745					750	Lys
	Arg	Lys	Phe	Phe	Glu	Pro	Phe	Ser	Gly	Phe	Arg	Gln	Lys	Val	Leu
20			755					760					765		Asp
	Lys	Ile	Asp	Glu	Ile	Phe	Val	Ser	Lys	Pro	Glu	Arg	Lys	Lys	Pro
25		770					775					780			Ser
	Gly	Ala	Leu	His	Glu	Glu	Thr	Phe	Arg	Lys	Glu	Glu	Glu	Phe	Tyr
	785					790					795				Gln
30	Ser	Tyr	Gly	Gly	Lys	Glu	Gly	Val	Leu	Lys	Ala	Leu	Glu	Leu	Gly
					805					810					815
	Ile	Arg	Lys	Val	Asn	Gly	Lys	Ile	Val	Lys	Asn	Gly	Asp	Met	Phe
35				820					825					830	Arg
	Val	Asp	Ile	Phe	Lys	His	Lys	Lys	Thr	Asn	Lys	Phe	Tyr	Ala	Val
			835					840					845		Pro
40	Ile	Tyr	Thr	Met	Asp	Phe	Ala	Leu	Lys	Val	Leu	Pro	Asn	Lys	Ala
		850					855					860			Val
45	Ala	Arg	Ser	Lys	Lys	Gly	Glu	Ile	Lys	Asp	Trp	Ile	Leu	Met	Asp
	865					870					875				Glu
	Asn	Tyr	Glu	Phe	Cys	Phe	Ser	Leu	Tyr	Lys	Asp	Ser	Leu	Ile	Leu
50					885					890					895
	Gln	Thr	Lys	Asp	Met	Gln	Glu	Pro	Glu	Phe	Val	Tyr	Tyr	Asn	Ala
				900					905					910	Phe
55	Thr	Ser	Ser	Thr	Val	Ser	Leu	Ile	Val	Ser	Lys	His	Asp	Asn	Lys
			915					920					925		Phe

# EP 2 940 140 A1

Glu Thr Leu Ser Lys Asn Gln Lys Ile Leu Phe Lys Asn Ala Asn Glu  
930 935 940

5 Lys Glu Val Ile Ala Lys Ser Ile Gly Ile Gln Asn Leu Lys Val Phe  
945 950 955 960

10 Glu Lys Tyr Ile Val Ser Ala Leu Gly Glu Val Thr Lys Ala Glu Phe  
965 970 975

Arg Gln Arg Glu Asp Phe Lys Lys  
980

15 <210> 80  
<211> 91  
<212> DNA  
<213> Artificial Sequence

20 <220>  
<221> source  
<223> /note="Description of Artificial Sequence: Synthetic  
oligonucleotide"

25 <400> 80  
tataatctca taagaaattt aaaaaggac taaaataaag agtttgctggg actctgctggg 60  
gttacaatcc cctaaaaccg cttttaaaat t 91

30 <210> 81  
<211> 36  
<212> DNA  
<213> Artificial Sequence

35 <220>  
<221> source  
<223> /note="Description of Artificial Sequence: Synthetic  
oligonucleotide"

40 <400> 81  
attttaccat aaagaaattt aaaaaggac taaaac 36

45 <210> 82  
<211> 95  
<212> RNA  
<213> Artificial Sequence

50 <220>  
<221> source  
<223> /note="Description of Artificial Sequence: Synthetic  
oligonucleotide"

55 <220>  
<221> modified\_base  
<222> (1)..(20)  
<223> a, c, u, g, unknown or other  
<400> 82

nnnnnnnnnnn nnnnnnnnnnnn guuuuagucc cgaaagggac uaaaauaaag aguuugcggg 60

acucugcggg guuacaaucc ccuaaaaccg cuuuu 95

5  
 <210> 83  
 <211> 69  
 <212> RNA  
 <213> Artificial Sequence

10  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"

15  
 <400> 83  
 gucaccucca augacuaggg guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60  
 cguuuuuuuu 69

20  
 <210> 84  
 <211> 69  
 <212> RNA  
 <213> Artificial Sequence

25  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"

30  
 <400> 84  
 gacaucgaug uccuccccau guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60  
 cguuuuuuuu 69

35  
 <210> 85  
 <211> 69  
 <212> RNA  
 <213> Artificial Sequence

40  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"

45  
 <400> 85  
 gaguccgagc agaagaagaa guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60  
 cguuuuuuuu 69

50  
 <210> 86  
 <211> 69  
 <212> RNA  
 <213> Artificial Sequence

55  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"

<400> 86  
 ggggccgaga ugggguguuc guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60  
 cguuuuuuuu 69  
 5  
 <210> 87  
 <211> 69  
 <212> RNA  
 <213> Artificial Sequence  
 10  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 15  
 <400> 87  
 gggccgagag guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60  
 cguuuuuuuu 69  
 20  
 <210> 88  
 <211> 76  
 <212> RNA  
 <213> Artificial Sequence  
 25  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 30  
 <400> 88  
 gucaccucca augacuaggg guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60  
 cguuaucauu uuuuuu 76  
 35  
 <210> 89  
 <211> 76  
 <212> RNA  
 <213> Artificial Sequence  
 40  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 45  
 <400> 89  
 gacaucgaug uccuccccau guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60  
 cguuaucauu uuuuuu 76  
 50  
 <210> 90  
 <211> 76  
 <212> RNA  
 <213> Artificial Sequence  
 55  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"



<400> 90  
 gaguccgagc agaagaagaa guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60  
 cguaaucauu uuuuuu 76

5

<210> 91  
 <211> 76  
 <212> RNA  
 <213> Artificial Sequence

10

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"

15

<400> 91  
 ggggccgaga uuggguguuc guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60  
 cguaaucauu uuuuuu 76

20

<210> 92  
 <211> 76  
 <212> RNA  
 <213> Artificial Sequence

25

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"

30

<400> 92  
 guggcgagag gggccgagau guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60  
 cguaaucauu uuuuuu 76

35

<210> 93  
 <211> 88  
 <212> RNA  
 <213> Artificial Sequence

40

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"

45

<400> 93  
 gucaccucca augacuaggg guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60  
 cguaaucaac uugaaaaagu guuuuuuu 88

50

<210> 94  
 <211> 88  
 <212> RNA  
 <213> Artificial Sequence

55

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic

oligonucleotide"

<400> 94

gacaucgaug uccuccccau guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu guuuuuuu 88

<210> 95

<211> 88

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic  
oligonucleotide"

<400> 95

gaguccgagc agaagaagaa guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu guuuuuuu 88

<210> 96

<211> 88

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic  
oligonucleotide"

<400> 96

ggggccgaga ugggguguuc guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu guuuuuuu 88

<210> 97

<211> 88

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic  
oligonucleotide"

<400> 97

guggcgagag gggccgagau guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu guuuuuuu 88

<210> 98

<211> 103

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic  
oligonucleotide"

<400> 98

gucaccucca augacuaggg guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu ggcaccgagu cgugucuuuu uuu 103

<210> 99

<211> 103

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic  
oligonucleotide"

<400> 99

gacaucgaug uccuccccau guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu ggcaccgagu cgugucuuuu uuu 103

<210> 100

<211> 103

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic  
oligonucleotide"

<400> 100

gaguccgagc agaagaagaa guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu ggcaccgagu cgugucuuuu uuu 103

<210> 101

<211> 103

<212> RNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic  
oligonucleotide"

<400> 101

ggggccgaga ugggguguuc guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu ggcaccgagu cgugucuuuu uuu 103

<210> 102

<211> 103

<212> RNA

<213> Artificial Sequence

<220>

# EP 2 940 140 A1

<221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"

5      <400> 102  
 guggcgagag gggccgagau guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc      60  
 cguaaucaac uugaaaaagu ggcaccgagu cggugcuuuu uuu      103

10  
 <210> 103  
 <211> 102  
 <212> DNA  
 <213> Artificial Sequence

15  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 polynucleotide"

20      <400> 103  
 gtttttagagc tatgctgttt tgaatggtcc caaaacggaa ggcctgagt ccgagcagaa      60  
 gaagaagttt tagagctatg ctgttttgaa tggccccaaa ac      102

25  
 <210> 104  
 <211> 100  
 <212> DNA  
 <213> Homo sapiens

30      <400> 104  
 cggaggacaa agtacaaacg gcagaagctg gaggaggaag ggcctgagtc cgagcagaag      60  
 aagaagggct cccatcacat caaccggtgg cgcattgccca      100

35  
 <210> 105  
 <211> 50  
 <212> DNA  
 <213> Homo sapiens

40      <400> 105  
 agctggagga ggaagggcct gagtccgagc agaagaagaa gggctccac      50

45  
 <210> 106  
 <211> 30  
 <212> RNA  
 <213> Artificial Sequence

50  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"

55      <400> 106  
 gaguccgagc agaagaagaa guuuuagagc      30

<210> 107  
 <211> 49

# EP 2 940 140 A1

<212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 5 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
  
 <400> 107  
 10 agctggagga ggaagggcct ggtccgagc agaagagaag ggctcccat 49  
  
 <210> 108  
 <211> 53  
 <212> DNA  
 15 <213> Homo sapiens  
  
 <400> 108  
 ctggaggagg aagggcctga gtccgagcag aagaagaagg gctcccatca cat 53  
  
 <210> 109  
 <211> 52  
 <212> DNA  
 20 <213> Homo sapiens  
  
 <400> 109  
 25 ctggaggagg aagggcctga gtccgagcag aagaagaagg ctcccatcac at 52  
  
 <210> 110  
 <211> 54  
 <212> DNA  
 30 <213> Homo sapiens  
  
 <400> 110  
 ctggaggagg aagggcctga gtccgagcag aagaagaagg ggctcccatc acat 54  
  
 <210> 111  
 <211> 50  
 <212> DNA  
 35 <213> Homo sapiens  
  
 <400> 111  
 40 ctggaggagg aagggcctga gtccgagcag aagaagggt cccatcacat 50  
  
 <210> 112  
 <211> 47  
 <212> DNA  
 45 <213> Homo sapiens  
  
 <400> 112  
 50 ctggaggagg aagggcctga gcccgagcag aagggtccc atcacat 47  
  
 <210> 113  
 <211> 66  
 <212> DNA  
 55 <213> Artificial Sequence  
  
 <220>

<221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"

5

<220>  
 <221> source  
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic  
 oligonucleotide"

10

<220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, t, g, unknown or other

15

<400> 113  
 nnnnnnnnnn nnnnnnnnnn guuuuagagc uagaaauagc aaguuaaaau aaggctagtc 60  
 cguuuu 66

20

<210> 114  
 <211> 20  
 <212> RNA  
 <213> Artificial Sequence

25

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"

30

<400> 114  
 gaguccgagc agaagaagaa 20

35

<210> 115  
 <211> 20  
 <212> RNA  
 <213> Artificial Sequence

40

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"

45

<400> 115  
 gacaucgaug uccuccccau 20

50

<210> 116  
 <211> 20  
 <212> RNA  
 <213> Artificial Sequence

55

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"

<400> 116  
 gucaccucca augacuaggg 20

<210> 117  
 <211> 20  
 <212> RNA  
 <213> Artificial Sequence  
 5  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 10  
 <400> 117  
 auuggguguu cagggcagag 20  
 <210> 118  
 <211> 20  
 <212> RNA  
 <213> Artificial Sequence  
 15  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 20  
 <400> 118  
 guggcgagag gggccgagau 20  
 25  
 <210> 119  
 <211> 20  
 <212> RNA  
 <213> Artificial Sequence  
 30  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 35  
 <400> 119  
 ggggccgaga uuggguguuc 20  
 <210> 120  
 <211> 20  
 <212> RNA  
 <213> Artificial Sequence  
 40  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 45  
 <400> 120  
 gugccauuag cuaaaugcau 20  
 50  
 <210> 121  
 <211> 20  
 <212> RNA  
 <213> Artificial Sequence  
 55  
 <220>  
 <221> source

**EP 2 940 140 A1**

<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"

<400> 121

guaccacca caggugccag

20

**<210> 122**

<211> 20

**<212> RNA**

<213> Artificial Sequence

<220>

<221> source

```
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"
```

<400> 122

gaaagccucu gggccaggaa

20

$\langle 210 \rangle$  123

<211> 48

<212> DNA

<213> Homo sapiens

<400> 123

ctggaggagg aagggcctga gtccgagcag aagaagaagg gctcccat

48

<210> 124

$\langle 211 \rangle$  20

<212> RNA

### <213> Artificial Sequence

**<220>**

<221> source

```
<223> /note="Description of Artificial Sequence: Synthetic
oligonucleotide"
```

**<400> 124**

gaguccgagc agaagaagau

20

<210> 125

<211> 20

**<212> RNA**

<213> Artificial Sequence

**<220>**

<221> source

<223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"

<400> 125

gaguccgagc agaagaagua

20

<210> 126

<211> 20

**<212> RNA**

<213> Artificial Sequence



<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 5  
 <400> 126  
 gaguccgagc agaagaacaa 20  
  
 <210> 127  
 10 <211> 20  
 <212> RNA  
 <213> Artificial Sequence  
  
 <220>  
 15 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
  
 <400> 127  
 20 gaguccgagc agaaugaa 20  
  
 <210> 128  
 <211> 20  
 <212> RNA  
 25 <213> Artificial Sequence  
  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 30  
 <400> 128  
 gaguccgagc agaaguagaa 20  
  
 <210> 129  
 35 <211> 20  
 <212> RNA  
 <213> Artificial Sequence  
  
 <220>  
 40 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
  
 <400> 129  
 45 gaguccgagc agaugaagaa 20  
  
 <210> 130  
 <211> 20  
 <212> RNA  
 50 <213> Artificial Sequence  
  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 55  
 <400> 130  
 gaguccgagc acaagaagaa 20

5 <210> 131  
 <211> 20  
 <212> RNA  
 <213> Artificial Sequence  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 10 <400> 131  
 gaguccgagg agaagaagaa 20

15 <210> 132  
 <211> 20  
 <212> RNA  
 <213> Artificial Sequence  
 <220>  
 20 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 25 <400> 132  
 gaguccgugc agaagaagaa 20

30 <210> 133  
 <211> 20  
 <212> RNA  
 <213> Artificial Sequence  
 <220>  
 <221> source  
 35 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 <400> 133  
 gagucggagc agaagaagaa 20

40 <210> 134  
 <211> 20  
 <212> RNA  
 <213> Artificial Sequence  
 45 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 50 <400> 134  
 gagaccgagc agaagaagaa 20

55 <210> 135  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 5  
 <400> 135  
 aatgacaagc ttgctagcgg tggg 24

<210> 136  
 <211> 39  
 <212> DNA  
 <213> Artificial Sequence  
 10  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 15  
 <400> 136  
 aaaacggaag ggcctgagtc cgagcagaag aagaagttt 39

<210> 137  
 <211> 39  
 <212> DNA  
 <213> Artificial Sequence  
 20  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 25  
 <400> 137  
 aaacaggggc cgagattggg tggtcagggc agaggtttt 39

<210> 138  
 <211> 38  
 <212> DNA  
 <213> Artificial Sequence  
 30  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 35  
 <400> 138  
 aaaacggaag ggcctgagtc cgagcagaag aagaagtt 38

<210> 139  
 <211> 40  
 <212> DNA  
 <213> Artificial Sequence  
 40  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 45  
 <400> 139  
 aacggaggga ggggcacaga tgagaaactc agggtttttag 40

<210> 140  
 <211> 38  
 <212> DNA  
 <213> Homo sapiens  
 5  
 <400> 140  
 agcccttctt cttctgctcg gactcaggcc cttcctcc 38

<210> 141  
 <211> 40  
 <212> DNA  
 <213> Homo sapiens  
 10  
 <400> 141  
 15 cagggagggga ggggcacaga tgagaaactc aggaggcccc 40

<210> 142  
 <211> 80  
 <212> DNA  
 <213> Artificial Sequence  
 20  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 25 oligonucleotide"  
 <400> 142  
 ggcaatgctc caccggttga tgtgatggga gcccttctag gagggcccca gaggcagccac 60  
 30 tggggcctca acactcaggc 80

<210> 143  
 <211> 98  
 <212> DNA  
 <213> Artificial Sequence  
 35  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 40 oligonucleotide"  
 <400> 143  
 ggacgaaaca ccggaaccat tcaaaacagc atagcaagtt aaaataaggc tagtccgtta 60  
 45 tcaacttgaa aaagtggcac cgagtcggtg cttttttt 98

<210> 144  
 <211> 186  
 <212> DNA  
 <213> Artificial Sequence  
 50  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 55 polynucleotide"  
 <400> 144

# EP 2 940 140 A1

ggacgaaaca ccggtagtat taagtattgt tttatggctg ataaatttct ttgaatttct 60  
 ccttgattat ttgttataaa agttataaaa taatcttggt ggaaccattc aaaacagcat 120  
 5 agcaagttaa aataaggcta gtccgttatc aacttgaaaa agtggcaccg agtcggtgct 180  
 tttttt 186  
  
 <210> 145  
 10 <211> 46  
 <212> RNA  
 <213> Artificial Sequence  
  
 <220>  
 15 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
  
 <220>  
 20 <221> modified\_base  
 <222> (1)..(19)  
 <223> a, c, u, g, unknown or other  
  
 <400> 145  
 25 nnnnnnnnnn nnnnnnnnng uuauuguacu cucaagauuu auuuuu 46  
  
 <210> 146  
 <211> 91  
 <212> RNA  
 30 <213> Artificial Sequence  
  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 35  
 <400> 146  
 guuacuuaaa ucuugcagaa gcuacaaaga uaaggcuuca ugccgaauc aacacccugu 60  
 cauuuuauagg caggguguuu ucguuuuuu a 91  
 40  
 <210> 147  
 <211> 70  
 <212> DNA  
 <213> Homo sapiens  
 45  
 <400> 147  
 ttttctagtg ctgagtttct gtgactcctc tacattctac ttctctgtgt ttctgtatac 60  
 tacctcctcc 70  
 50  
 <210> 148  
 <211> 122  
 <212> DNA  
 <213> Homo sapiens  
 55  
 <400> 148  
 ggaggaaggc cctgagtccg agcagaagaa gaagggtcc catcacatca accggtggcg 60

cattgccacg aagcaggcca atggggagga catcgatgtc acctccaatg actaggggtgg 120

gc 122

5

<210> 149  
 <211> 48  
 <212> RNA  
 <213> Artificial Sequence

10

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"

15

<220>  
 <221> modified\_base  
 <222> (3)..(32)  
 <223> a, c, u, g, unknown or other

20

<400> 149  
 acnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnguuiuaga gcuaugcu 48

25

<210> 150  
 <211> 67  
 <212> DNA  
 <213> Artificial Sequence

30

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"

35

<220>  
 <221> source  
 <223> /note="Description of Combined DNA/RNA Molecule: Synthetic  
 oligonucleotide"

40

<400> 150  
 agcauagcaa guuaaaauaa ggctaguccg uuaucaacuu gaaaaagugg caccgagucg 60

gugcuuu 67

45

<210> 151  
 <211> 62  
 <212> RNA  
 <213> Artificial Sequence

50

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"

55

<220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, u, g, unknown or other

# EP 2 940 140 A1

<400> 151  
 nnnnnnnnnn nnnnnnnnnn guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60  
 cg 62  
 5  
 <210> 152  
 <211> 73  
 <212> DNA  
 <213> Artificial Sequence  
 10  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 15  
 <400> 152  
 tgaatggtcc caaaacggaa gggcctgagt ccgagcagaa gaagaagttt tagagctatg 60  
 ctgttttgaa tgg 73  
 20  
 <210> 153  
 <211> 99  
 <212> RNA  
 <213> Artificial Sequence  
 25  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 30  
 <220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, u, g, unknown or other  
 35  
 <400> 153  
 nnnnnnnnnn nnnnnnnnnn guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60  
 cguaaucaac uugaaaaagu ggcaccgagu cggugcuuu 99  
 40  
 <210> 154  
 <211> 127  
 <212> RNA  
 <213> Artificial Sequence  
 45  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 polynucleotide"  
 50  
 <400> 154  
 guuuuuguac ucucaagauu uaaguaacug uacaacguua cuuaaaucuu gcagaagcua 60  
 caaagauaag gcuucaugcc gaaaucaaca ccugucauu uuauggcagg guguuuucgu 120  
 uauuuuaa 127  
 55  
 <210> 155

<211> 56  
 <212> DNA  
 <213> Artificial Sequence

5 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"

10 <220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, t, g, unknown or other

15 <400> 155  
 nnnnnnnnnn nnnnnnnnnn gtttttgtac tctcaagatt taagtaactg tacaac 56

20 <210> 156  
 <211> 91  
 <212> DNA  
 <213> Artificial Sequence

25 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"

30 <400> 156  
 gttacttaaa tcttgcagaa gctacaaaga taaggcttca tgccgaaatc aacaccctgt 60  
 cattttatgg cagggtgttt tcgttattta a 91

35 <210> 157  
 <211> 134  
 <212> DNA  
 <213> Artificial Sequence

40 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 polynucleotide"

45 <220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, t, g, unknown or other

50 <400> 157  
 nnnnnnnnnn nnnnnnnnnn gtttttgtac tctcaagatt taaggaaact aaatcttgca 60  
 gaagctacaa agataaggct tcatgccgaa atcaacaccc tgtcatttta tggcagggtg 120  
 ttttcgttat ttaa 134

55 <210> 158  
 <211> 131  
 <212> DNA  
 <213> Artificial Sequence



<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 polynucleotide"

5

<220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, t, g, unknown or other

10

<400> 158  
 nnnnnnnnnn nnnnnnnnnn gtttttgtac tctcaagatt tagaaataaa tcttgacagaa 60  
 gctacaaaga taaggcttca tgccgaaatc aacaccctgt cattttatgg caggggtgttt 120  
 tcggttattta a 131

15

<210> 159  
 <211> 125  
 <212> DNA  
 <213> Artificial Sequence

20

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 polynucleotide"

25

<220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, t, g, unknown or other

30

<400> 159  
 nnnnnnnnnn nnnnnnnnnn gtttttgtac tctcaagatg aaaatcttgc agaagctaca 60  
 aagataaggc ttcatgccga aatcaacacc ctgtcatttt atggcagggt gttttcgtaa 120  
 ttttaa 125

35

<210> 160  
 <211> 112  
 <212> DNA  
 <213> Artificial Sequence

40

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 polynucleotide"

45

<220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, t, g, unknown or other

50

<400> 160  
 nnnnnnnnnn nnnnnnnnnn gtttttgtac tctgaaaaga agctacaaag ataaggcttc 60

55

atgccgaaat caacaccctg tcattttatg gcagggtgtt ttcgttattt aa 112

5 <210> 161  
 <211> 107  
 <212> DNA  
 <213> Artificial Sequence

10 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic polynucleotide"

15 <220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, t, g, unknown or other

20 <400> 161  
 nnnnnnnnnn nnnnnnnnnn gtttttgtac tgaaaagcta caaagataag gttcatgcc 60  
 gaaatcaaca ccctgtcatt ttatggcagg gtgttttcgt tatttaa 107

25 <210> 162  
 <211> 108  
 <212> DNA  
 <213> Artificial Sequence

30 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic polynucleotide"

35 <220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, t, g, unknown or other

40 <400> 162  
 nnnnnnnnnn nnnnnnnnnn gtttttgtac tctcaagatt tagaaataaa tcttcagaa 60  
 gctacaaaga taaggcttca tgccgaaatc aacaccctgt cattttat 108

45 <210> 163  
 <211> 86  
 <212> DNA  
 <213> Artificial Sequence

50 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"

55 <220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, t, g, unknown or other

# EP 2 940 140 A1

<400> 163  
 nnnnnnnnnn nnnnnnnnnn gtttttgtac tctcaagatt tagaaataaa tcttgcagaa 60  
 gctacaaaga taaggcttca tgccga 86  
 5

<210> 164  
 <211> 79  
 <212> DNA  
 <213> Artificial Sequence  
 10

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 15

<220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, t, g, unknown or other  
 20

<400> 164  
 nnnnnnnnnn nnnnnnnnnn gtttttgtac tctcaagatt tagaaataaa tcttgcagaa 60  
 gctacaaaga taaggcttc 79  
 25

<210> 165  
 <211> 73  
 <212> DNA  
 <213> Artificial Sequence  
 30

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 35

<220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, t, g, unknown or other  
 40

<400> 165  
 nnnnnnnnnn nnnnnnnnnn gtttttgtac tctcaagatt tagaaataaa tcttgcagaa 60  
 gctacaaaga taa 73  
 45

<210> 166  
 <211> 125  
 <212> RNA  
 <213> Artificial Sequence  
 50

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 polynucleotide"  
 55

<400> 166  
 guuuuagucc cuuuuuuuuu uucuuuauagg uaaaauuaua aucucauaag aaauuuuuuu 60

# EP 2 940 140 A1

	agggacuaaa auaaagaguu ugcgggacuc ugcggggguua caaucccccua aaaccgcuuu	120
	uaaaa	125
5	<210> 167 <211> 91 <212> RNA <213> Artificial Sequence	
10	<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
15	<400> 167 guuacuuaaa ucuugcagaa gcuacaaaga uaaggcuuca ugccgaaauc aacaccugug cauuuuaugg caggguuuu ucguuuuuu a	60 91
20	<210> 168 <211> 56 <212> RNA <213> Artificial Sequence	
25	<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	
30	<400> 168 gggacucaac caagucuuuc guuuuuguac ucucaagauu uaaguaacug uacaac	56
35	<210> 169 <211> 147 <212> RNA <213> Artificial Sequence	
40	<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic polynucleotide"	
45	<400> 169 gggacucaac caagucuuuc guuuuuguac ucucaagauu uaaguaacug uacaacguua cuuuuauuu gcagaagcua caaagauaag gcuucaugcc gaaaucaaca ccugucuu uuauggcagg guguuuucgu uuuuuu	60 120 147
50	<210> 170 <211> 70 <212> RNA <213> Artificial Sequence	
55	<220> <221> source <223> /note="Description of Artificial Sequence: Synthetic oligonucleotide"	

# EP 2 940 140 A1

<400> 170  
 cuugcagaag cuacaaagau aaggcuucau gccgaaaauca acaccuguc auuuuauaggc 60  
 aggguguuuu 70  
 5  
 <210> 171  
 <211> 42  
 <212> RNA  
 <213> Artificial Sequence  
 10  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 15  
 <400> 171  
 gggacucaac caagucuuuc guuuuuguac ucucaagauu ua 42  
 <210> 172  
 <211> 112  
 <212> RNA  
 <213> Artificial Sequence  
 20  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 polynucleotide"  
 25  
 <400> 172  
 gggacucaac caagucuuuc guuuuuguac ucucaagauu uacuugcaga agcuacaaag 60  
 30  
 auaaggcuuc augccgaaau caacacccug ucauuuuuauug gcaggguguu uu 112  
 <210> 173  
 <211> 116  
 <212> RNA  
 <213> Artificial Sequence  
 35  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 polynucleotide"  
 40  
 <400> 173  
 gggacucaac caagucuuuc guuuuuguac ucucaagauu uagaaacuug cagaagcuac 60  
 45  
 aaagauaagg cuucaugccg aaaucaacac ccugucuuuu uauaggcaggg uguuuu 116  
 <210> 174  
 <211> 116  
 <212> RNA  
 <213> Artificial Sequence  
 50  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 polynucleotide"  
 55  
 <400> 174

# EP 2 940 140 A1

gggacucaac caagucauuc guuuuuguac ucucaagauu uagaaacuug cagaagcuac 60  
 aaagauaagg cuucaugccg aaaucaacac ccugucauuu uauggcaggg uguuuu 116  
 5  
 <210> 175  
 <211> 102  
 <212> RNA  
 <213> Artificial Sequence  
 10  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 polynucleotide"  
 15  
 <400> 175  
 gggacucaac caagucauuc guuuuuguag aaauacaaag auaaggcuuc augccgaaau 60  
 caacacccug ucauuuuuug gcaggguguu uucguuauuu aa 102  
 20  
 <210> 176  
 <211> 102  
 <212> RNA  
 <213> Artificial Sequence  
 25  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 polynucleotide"  
 30  
 <400> 176  
 gggacucaac caagucauuc guuuuuguag aaauacaaag auaaggcuuc augccgaaau 60  
 caacacccug ucauuuuuug gcaggguguu uucguuauuu aa 102  
 35  
 <210> 177  
 <211> 57  
 <212> RNA  
 <213> Artificial Sequence  
 40  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 45  
 <400> 177  
 gggacucaac caagucauuc guuuuuguag aaauacaaag auaaggcuuc augccga 57  
 50  
 <210> 178  
 <211> 57  
 <212> RNA  
 <213> Artificial Sequence  
 55  
 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"  
 <400> 178  
 gggacucaac caagucauuc guuuuuguag aaauacaaag auaaggcuuc augccga 57

5 <210> 179  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence

10 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"

<400> 179  
 gtggtgtcac gctcgtcggt tgg 23

15 <210> 180  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence

20 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"

25 <400> 180  
 tccagtctat taattgttgc cgg 23

30 <210> 181  
 <211> 64  
 <212> DNA  
 <213> Homo sapiens

<400> 181  
 caagaggctt gagtaggaga ggagtgccgc cgaggcgggg cggggcgggg cgtggagctg 60

35 ggct 64

40 <210> 182  
 <211> 99  
 <212> RNA  
 <213> Artificial Sequence

45 <220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 oligonucleotide"

50 <220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, u, g, unknown or other

55 <400> 182  
 nnnnnnnnnn nnnnnnnnnn guauuagagc uagaaaauagc aaguuaauau aaggcuaguc 60

cguaaucaac uugaaaaagu ggcaccgagu cggugcuuu 99

<210> 183  
 <211> 119  
 <212> RNA  
 <213> Artificial Sequence

5

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 polynucleotide"

10

<220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, u, g, unknown or other

15

<400> 183  
 nnnnnnnnnn nnnnnnnnnn guuuuagagc uaugcuguuu uggaacaaa acagcauagc 60  
 aaguuaaaau aaggcuaguc cguuaucaac uugaaaaagu ggcaccgagu cggugcuuu 119

20

<210> 184  
 <211> 119  
 <212> RNA  
 <213> Artificial Sequence

25

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic  
 polynucleotide"

30

<220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, u, g, unknown or other

35

<400> 184  
 nnnnnnnnnn nnnnnnnnnn guauuagagc uaugcuguau uggaacaaau acagcauagc 60  
 aaguuaauau aaggcuaguc cguuaucaac uugaaaaagu ggcaccgagu cggugcuuu 119

40

<210> 185  
 <211> 12  
 <212> DNA  
 <213> Homo sapiens

45

<400> 185  
 tagcgggtaa gc 12

50

<210> 186  
 <211> 12  
 <212> DNA  
 <213> Homo sapiens

<400> 186  
 tcggtgacat gt 12

55

<210> 187



	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
5	<400> 187 actccccgta gg	12
	<210> 188	
10	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
	<400> 188 actgcgtggt aa	12
15		
	<210> 189	
	<211> 12	
	<212> DNA	
20	<213> Homo sapiens	
	<400> 189 acgtcgctg at	12
25		
	<210> 190	
	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
30	<400> 190 taggtcgacc ag	12
35		
	<210> 191	
	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
	<400> 191 ggcgtaaatg at	12
40		
	<210> 192	
	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 192 tgtcgcatgt ta	12
50		
	<210> 193	
	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
55	<400> 193 atggaaacgc at	12
	<210> 194	

	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
5	<400> 194	
	gccgaattcc tc	12
	<210> 195	
10	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
	<400> 195	
15	gcatggtacg ga	12
	<210> 196	
	<211> 12	
	<212> DNA	
20	<213> Homo sapiens	
	<400> 196	
	cggtactctt ac	12
	<210> 197	
25	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
	<400> 197	
30	gcctgtgccg ta	12
	<210> 198	
	<211> 12	
	<212> DNA	
35	<213> Homo sapiens	
	<400> 198	
	tacggtaagt cg	12
40	<210> 199	
	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 199	
	cacgaaatta cc	12
	<210> 200	
50	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
	<400> 200	
55	aaccaagata cg	12
	<210> 201	

	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
5	<400> 201	
	gagtcgatac gc	12
	<210> 202	
10	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
	<400> 202	
15	gtctcacgat cg	12
	<210> 203	
	<211> 12	
	<212> DNA	
20	<213> Homo sapiens	
	<400> 203	
	tcgtcgggtg ca	12
	<210> 204	
25	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
	<400> 204	
30	actccgtagt ga	12
	<210> 205	
	<211> 12	
	<212> DNA	
35	<213> Homo sapiens	
	<400> 205	
	caggacgtcc gt	12
40	<210> 206	
	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 206	
	tcgtatccct ac	12
	<210> 207	
50	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
	<400> 207	
55	tttcaaggcc gg	12
	<210> 208	

	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
5	<400> 208	
	cgccggtgga at	12
	<210> 209	
10	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
	<400> 209	
15	gaacccgtcc ta	12
	<210> 210	
	<211> 12	
	<212> DNA	
20	<213> Homo sapiens	
	<400> 210	
	gattcatcag cg	12
	<210> 211	
25	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
	<400> 211	
30	acaccgtct tc	12
	<210> 212	
	<211> 12	
	<212> DNA	
35	<213> Homo sapiens	
	<400> 212	
	atcgtgccct aa	12
40	<210> 213	
	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 213	
	gcgtcaatgt tc	12
	<210> 214	
50	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
	<400> 214	
55	ctccgtatct cg	12
	<210> 215	

	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
5	<400> 215	
	ccgattcctt cg	12
	<210> 216	
10	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
	<400> 216	
15	tgcgctcca gt	12
	<210> 217	
	<211> 12	
	<212> DNA	
20	<213> Homo sapiens	
	<400> 217	
	taacgtcgga gc	12
	<210> 218	
25	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
	<400> 218	
30	aaggtcgccc at	12
	<210> 219	
	<211> 12	
	<212> DNA	
35	<213> Homo sapiens	
	<400> 219	
	gtcggggact at	12
40	<210> 220	
	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 220	
	ttcgagcgat tt	12
	<210> 221	
50	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
	<400> 221	
55	tgagtcgtcg ag	12
	<210> 222	

	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
5	<400> 222	
	tttacgcaga gg	12
	<210> 223	
10	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
	<400> 223	
15	aggaagtatc gc	12
	<210> 224	
	<211> 12	
	<212> DNA	
20	<213> Homo sapiens	
	<400> 224	
	actcgatacc at	12
	<210> 225	
25	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
	<400> 225	
30	cgctacatag ca	12
	<210> 226	
	<211> 12	
	<212> DNA	
35	<213> Homo sapiens	
	<400> 226	
	ttcataaccg gc	12
40	<210> 227	
	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 227	
	ccaaacgggt aa	12
	<210> 228	
50	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
	<400> 228	
55	cgattccttc gt	12
	<210> 229	

	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
5	<400> 229 cgtcacgaat aa	12
	<210> 230	
10	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
	<400> 230 agtggcgatg ac	12
15		
	<210> 231	
	<211> 12	
	<212> DNA	
20	<213> Homo sapiens	
	<400> 231 cccctacggc ac	12
	<210> 232	
25	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
	<400> 232 gcccaaccgc ac	12
30		
	<210> 233	
	<211> 12	
	<212> DNA	
35	<213> Homo sapiens	
	<400> 233 tgggacaccg gt	12
40		
	<210> 234	
	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 234 ttgactgcgg cg	12
	<210> 235	
50	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
	<400> 235 actatgcgta gg	12
55		
	<210> 236	

	<211> 12		
	<212> DNA		
	<213> Homo sapiens		
5	<400> 236		
	tcacccaaag cg		12
	<210> 237		
10	<211> 12		
	<212> DNA		
	<213> Homo sapiens		
	<400> 237		
15	gcaggacgtc cg		12
	<210> 238		
	<211> 12		
	<212> DNA		
20	<213> Homo sapiens		
	<400> 238		
	acaccgaaaa cg		12
	<210> 239		
25	<211> 12		
	<212> DNA		
	<213> Homo sapiens		
	<400> 239		
30	cgggtgtattg ag		12
	<210> 240		
	<211> 12		
	<212> DNA		
35	<213> Homo sapiens		
	<400> 240		
	cacgaggtat gc		12
40	<210> 241		
	<211> 12		
	<212> DNA		
	<213> Homo sapiens		
45	<400> 241		
	taaagcgacc cg		12
	<210> 242		
50	<211> 12		
	<212> DNA		
	<213> Homo sapiens		
	<400> 242		
55	cttagtcggc ca		12
	<210> 243		



	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
5	<400> 243	
	cgaaaacgtg gc	12
	<210> 244	
10	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
	<400> 244	
15	cgtgccctga ac	12
	<210> 245	
	<211> 12	
	<212> DNA	
20	<213> Homo sapiens	
	<400> 245	
	tttaccatcg aa	12
	<210> 246	
25	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
	<400> 246	
30	cgtagccatg tt	12
	<210> 247	
	<211> 12	
	<212> DNA	
35	<213> Homo sapiens	
	<400> 247	
	cccaaacggt ta	12
40	<210> 248	
	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 248	
	gcgttatcag aa	12
	<210> 249	
50	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
	<400> 249	
55	tcgatggtaa ac	12
	<210> 250	

	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
5	<400> 250	
	cgactttttg ca	12
	<210> 251	
10	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
	<400> 251	
15	tcgacgactc ac	12
	<210> 252	
	<211> 12	
	<212> DNA	
20	<213> Homo sapiens	
	<400> 252	
	acgcgtcaga ta	12
	<210> 253	
25	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
	<400> 253	
30	cgtacggcac ag	12
	<210> 254	
	<211> 12	
	<212> DNA	
35	<213> Homo sapiens	
	<400> 254	
	ctatgccgtg ca	12
40	<210> 255	
	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 255	
	cgcgtcagat at	12
	<210> 256	
50	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
	<400> 256	
55	aagatcggta gc	12
	<210> 257	

	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
5	<400> 257 cttcgcaagg ag	12
	<210> 258	
10	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
	<400> 258 gtcgtggact ac	12
15		
	<210> 259	
	<211> 12	
	<212> DNA	
20	<213> Homo sapiens	
	<400> 259 ggtcgtcatc aa	12
	<210> 260	
25	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
	<400> 260 gttaacagcg tg	12
30		
	<210> 261	
	<211> 12	
	<212> DNA	
35	<213> Homo sapiens	
	<400> 261 tagctaaccg tt	12
40		
	<210> 262	
	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 262 agtaaaggcg ct	12
	<210> 263	
50	<211> 12	
	<212> DNA	
	<213> Homo sapiens	
	<400> 263 ggtaatttcg tg	12
55		
	<210> 264	

<211> 147  
 <212> RNA  
 <213> Artificial Sequence

<220>  
 <221> source  
 <223> /note="Description of Artificial Sequence: Synthetic polynucleotide"

<220>  
 <221> modified\_base  
 <222> (1)..(20)  
 <223> a, c, u, g, unknown or other

<400> 264  
 nnnnnnnnnn nnnnnnnnnn guuuuaguac ucuguaauuu uagguaugag guagacgaaa 60  
 auuguacuua uaccuaaaau uacagaauuc acuaaaacaa ggcaaaaugc cguguuuauuc 120  
 ucgucaacuu guuggcgaga uuuuuuuu 147

## Claims

### 1. A non-naturally occurring or engineered composition comprising:

a Clustered Regularly Interspersed Short Palindromic Repeats (CRISPR)-CRISPR associated (Cas) (CRISPR-Cas) system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises

- (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, wherein the target sequence is associated with a Protospacer Adjacent Motif (PAM),
- (b) a tracr mate sequence, and
- (c) a tracrRNA sequence

wherein (a), (b) and (c) are arranged in a 5' to 3' orientation,  
 wherein when transcribed, the tracr mate sequence hybridizes to the tracrRNA sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the PAM is recognised by the CRISPR complex,  
 wherein the CRISPR complex comprises a Type II Cas9 protein complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracrRNA sequence,  
 wherein the tracrRNA sequence is 30 or more nucleotides in length, and  
 wherein the tracrRNA sequence exhibits at least 50% of sequence complementarity along the length of the tracr mate sequence when optimally aligned.

### 2. A Clustered Regularly Interspersed Short Palindromic Repeats (CRISPR)-CRISPR associated (Cas) (CRISPR-Cas) vector system comprising one or more vectors comprising

I. a first regulatory element operably linked to a nucleotide sequence encoding a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence as defined in claim 1, and

II. a second regulatory element operably linked to a nucleotide sequence encoding a Type II Cas9 protein comprising one or more nuclear localization sequences, of sufficient strength to drive accumulation of said Cas9 protein in a detectable amount in the nucleus of a eukaryotic cell;  
 wherein components I and II are located on the same or different vectors of the system.

### 3. The composition of claim 1, wherein the Cas9 enzyme comprises one or more nuclear localization sequences of sufficient strength to drive accumulation of said Cas9 enzyme in a detectable amount in the nucleus of a eukaryotic cell.

4. The composition of claim 1, or the vector system of claim 2, wherein the Cas9 protein is a nuclease directing cleavage of both strands of the polynucleotide locus.
- 5 5. The composition of claim 1, or the vector system of claim 2, wherein the Cas9 protein comprises one or more mutations in a catalytic domain, and is a nickase that cleaves only one strand of the polynucleotide locus.
6. The vector system of claim 2, or any claim dependent thereon, wherein the nucleotide sequence encoding the Cas9 protein is codon-optimized for expression in a eukaryotic cell.
- 10 7. The vector system of claim 2, or any claim dependent thereon, wherein the vectors are viral vectors.
8. The vector system of claim 7, wherein the viral vectors are retroviral, lentiviral, adenoviral, adeno-associated or herpes simplex viral vectors.
- 15 9. The vector system of claim 2, or any claim dependent thereon, wherein the vector system comprises nucleotide sequence(s) coding for two or more nuclear localisation signals (NLSs) expressed with the nucleotide sequence encoding the Cas9 protein.
- 20 10. The vector system of claim 9, wherein when expressed at least one NLS is at or near amino-terminus of the Cas9 protein and/or at least one NLS is at or near carboxy terminus of the Cas9 protein.
11. The vector system of claim 9, wherein at least one NLS is at or near amino-terminus of the Cas9 protein and at least one NLS is at or near carboxy terminus of the Cas9 protein.
- 25 12. The vector system of claim 2, or of any claim dependent thereon, wherein components I and II are located on the same vector.
13. The vector system of claim 2, or of any one of claims 4 to 12 when dependent thereon, wherein components I and II are located on different vectors.
- 30 14. The composition or vector system according to any one of the preceding claims, wherein the guide sequence is between 10-30 nucleotides in length.
15. The composition or vector system according to any one of the preceding claims, wherein the guide sequence is between 10-30 nucleotides in length, and the tracr sequence is 50 or more nucleotides in length.
- 35 16. Use of the composition of claim 1, or the vector system of claim 2 or any claim dependent thereon for genome engineering, provided that said use is not a method for treatment of the human or animal body by surgery or therapy, and provided that said use is not a process for modifying the germ line genetic identity of human beings.
- 40 17. The use of claim 16 wherein the genome engineering comprises modifying a target polynucleotide in a eukaryotic cell, modifying expression of a polynucleotide in a eukaryotic cell, generating a model eukaryotic cell comprising a mutated disease gene, or knocking out a gene.
- 45 18. The use of claim 16 wherein the use further comprises repairing said cleaved target polynucleotide by inserting an exogenous template polynucleotide, wherein said repair results in a mutation comprising an insertion, deletion, or substitution of one or more nucleotides of said target polynucleotide.
- 50 19. The use of claim 16 wherein the use further comprises editing said cleaved target polynucleotide by inserting an exogenous template polynucleotide, wherein said edit results in a mutation comprising an insertion, deletion, or substitution of one or more nucleotides of said target polynucleotide.
20. The use of any one of claims 18 or 19 wherein the inserting is by homologous recombination.
- 55 21. Use of the composition of claim 1, or the vector system of claim 2 or any claim dependent thereon, in the production of a non-human transgenic animal or transgenic plant.




FIG. 1




FIG. 2A




FIG. 2B







FIG. 2C

**D**

2xNLS-SpCas9	+	+	+	+	+
SpRNase III	-	+	+	-	+
short tracrRNA	-	+	-	+	+
DR-EMX1-DR	+	-	+	+	+



indel (%): 4.7 5.0

FIG. 2D





FIG. 2E-F




FIG. 3A-C




FIG. 4A-C




FIG. 4D




FIG. 5A-B




FIG. 5C-E






FIG. 5F





FIG. 5G

**A****B**

SpCas9	+	+	+	+
long tracrRNA	+	+	-	-
short tracrRNA	-	-	+	+
SpRNase III	+	+	+	+
DR- <i>EMX1</i> (1)-DR	+	+	+	+




FIG. 6A-B

**C**




FIG. 6C




**A** *Streptococcus thermophilus* LMD-9 CRISPR1**B****C**

FIG. 7A-C

D




FIG. 7D





FIG. 8A-C

**A**



**B**




FIG. 9A-B




**a**

FIG. 10A

**b**




FIG. 10B

**C**




FIG. 10C




FIG. 11A-B




FIG. 12

FIG. 13A

211

212



FIG. 13D




FIG. 14A






FIG. 14C




FIG. 14D






FIG. 14E




FIG. 14F





FIG. 15



## S. thermophilus CRISPR1 RNA cofold of tracrRNA with direct repeat



## chimeric guide RNA design



FIG. 16





FIG. 17


St1Cas9 Test

Ladder 1 2 3 4 5



Lane 1: full tracrRNA + full spacer\_DR

full tracrRNA: GUUACUUAAAUCUUGCAGAAAGCUACAAAGAUAAAGGCUUCAUGCCGAAAUCAACACCCUGUCAUUUUUUGGCAGGGUGUUUUCGUUAL  
full spacer\_DR: GGGACUCAACCAAGUCAUUCGUUUUUGUACUCUCAAGAUUUAGUAACUGUACAAC



Lane 2: mature tracrRNA + mature spacer\_DR

mature tracrRNA: CUUGCAGAAAGCUACAAAGAUAAAGGCUUCAUGCCGAAAUCAACACCCUGUCAUUUUUUGGCAGGGUGUUUU  
mature spacer\_DR: GGGACUCAACCAAGUCAUUCGUUUUUGUACUCUCAAGAUUUU





FIG. 18A


Lane 3: chimeric guideRNA design 1 (1-22 DR, 12-81 tracrRNA)

sequence: GGACUCACCAAGCUCAUUCUUUUUGUACUCUCACAGAUUAGAAACUUCGACAGACUACAAACAAAGAGGCUUCAGUCCGAAGUCAAACACCCUGUCAUUUUAUGGACGGGUGUUU



Lane 4: chimeric guide RNA design 2 (1-9 DR, 20-91 tracrRNA)

sequence: GGGGUCACCAAGCUCAUUCUUUUUGUACUCUCACAGAUUAGAAACUUCGACAGACUACAAACAAAGAGGCUUCAGUCCGAAGUCAAACACCCUGUCAUUUUAUGGACGGGUGUUU



Lane 5: chimeric guide RNA design 3 (1-9 DR, 20-46 tracrRNA)

sequence: GGACUCACCAAGCUCAUUCUUUUUGUACUCUCACAGAUUAGAAACUUCGACAGACUACAAACAAAGAGGCUUCAGUCCGAAGUCAAACACCCUGUCAUUUUAUGGACGGGUGUUU





FIG. 18B

**a**



**b**





FIG. 19A-B






move <<< << < > >> >>> zoom in 1.5x 3x 10x base zoom out 1.5x 3x 10x


chr12:2,614,008-2,675,748 61,741 bp.

chr12 (p13.33)





A



B

target 1




FIG. 23A-B



## EUROPEAN SEARCH REPORT

Application Number  
EP 15 15 4565

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	M. JINEK ET AL: "A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity", SCIENCE, vol. 337, no. 6096, 17 August 2012 (2012-08-17), pages 816-821, XP055067740, ISSN: 0036-8075, DOI: 10.1126/science.1225829 * the whole document *	1-21	INV. C12N15/63
A	G. GASIUNAS ET AL: "PNAS Plus: Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 109, no. 39, 25 September 2012 (2012-09-25), pages E2579-E2586, XP055068588, ISSN: 0027-8424, DOI: 10.1073/pnas.1208507109 * abstract; figures 4, S9 * * page E2579 * * page E2583 *	1-21	C12N
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (IPC)
Place of search Munich		Date of completion of the search 15 July 2015	Examiner Seroz, Thierry
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			



## EUROPEAN SEARCH REPORT

Application Number  
EP 15 15 4565

5

10

15

20

25

30

35

40

45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT				
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)	
A,P	JIANG WENYAN ET AL: "RNA-guided editing of bacterial genomes using CRISPR-Cas systems", NATURE BIOTECHNOLOGY,, vol. 31, no. 3, 29 January 2013 (2013-01-29), pages 233-239, XP002699849, * abstract; figures 1-5 *	1-21		
A	BLAKE WIEDENHEFT ET AL: "RNA-guided genetic silencing systems in bacteria and archaea", NATURE, vol. 482, no. 7385, 15 February 2012 (2012-02-15), pages 331-338, XP055116249, ISSN: 0028-0836, DOI: 10.1038/nature10886 * the whole document *	1-21		
A	ELITZA DELTCHEVA ET AL: "CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III", NATURE, vol. 471, no. 7340, 31 March 2011 (2011-03-31), pages 602-607, XP055068535, ISSN: 0028-0836, DOI: 10.1038/nature09886 * abstract; figures 1-6 *	1-21		TECHNICAL FIELDS SEARCHED (IPC)
A	MICHAEL P TERNS ET AL: "CRISPR-based adaptive immune systems", CURRENT OPINION IN MICROBIOLOGY, vol. 14, no. 3, 1 June 2011 (2011-06-01), pages 321-327, XP055097823, ISSN: 1369-5274, DOI: 10.1016/j.mib.2011.03.005 * the whole document *	1-21		
The present search report has been drawn up for all claims				
Place of search Munich		Date of completion of the search 15 July 2015	Examiner Seroz, Thierry	
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document		

EPO FORM 1503 03.82 (P04C01)



## EUROPEAN SEARCH REPORT

Application Number  
EP 15 15 4565

5

10

15

20

25

30

35

40

45

DOCUMENTS CONSIDERED TO BE RELEVANT				
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)	
X,P	GAJ THOMAS ET AL: "ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering", TRENDS IN BIOTECHNOLOGY, vol. 31, no. 7, 1 July 2013 (2013-07-01), pages 397-405, XP028571313, ISSN: 0167-7799, DOI: 10.1016/J.TIBTECH.2013.04.004 * the whole document *	1-21		
X,P	WANG HAOYI ET AL: "One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering", CELL, vol. 153, no. 4, 9 May 2013 (2013-05-09), pages 910-918, XP028538358, ISSN: 0092-8674, DOI: 10.1016/J.CELL.2013.04.025 * abstract *	1-21		
X,P	LUKE A. GILBERT ET AL: "CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes", CELL, vol. 154, no. 2, 1 July 2013 (2013-07-01), pages 442-451, XP055115843, ISSN: 0092-8674, DOI: 10.1016/j.cell.2013.06.044 * abstract *	1-21		TECHNICAL FIELDS SEARCHED (IPC)
X,P	KRZYSZTOF CHYLINSKI ET AL: "The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems", RNA BIOLOGY, vol. 10, no. 5, 1 May 2013 (2013-05-01), pages 726-737, XP055116068, ISSN: 1547-6286, DOI: 10.4161/rna.24321 * the whole document *	1-21		
The present search report has been drawn up for all claims				
Place of search <b>Munich</b>		Date of completion of the search <b>15 July 2015</b>	Examiner <b>Seroz, Thierry</b>	
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document				

1

50

55

EPO FORM 1503 03.82 (P04C01)

## REFERENCES CITED IN THE DESCRIPTION

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

## Patent documents cited in the description

- US 61836127 B [0001]
- US 61758468 B [0001]
- US 61769046 B [0001]
- US 61802174 B [0001]
- US 61806375 B [0001]
- US 61814263 B [0001]
- US 61819803 B [0001]
- US 61828130 B [0001]
- US 61736527 B [0001] [0096] [0100]
- US 61748427 B [0001] [0096] [0100]
- US 61791409 B [0001]
- US 61835931 B [0001]
- US 61835936 B [0002]
- US 61836101 B [0002]
- US 61836080 B [0002]
- US 61836123 B [0002]
- US 61835973 B [0002]
- US 4873316 A [0062]
- EP 264166 A [0062]
- US 20110059502 A [0077]
- US 5049386 A [0079]
- US 4946787 A [0079] [0080]
- US 4897355 A [0079]
- WO 9117424 A [0079]
- WO 9116024 A [0079]
- US 4186183 A [0080]
- US 4217344 A [0080]
- US 4235871 A [0080]
- US 4261975 A [0080]
- US 4485054 A [0080]
- US 4501728 A [0080]
- US 4774085 A [0080]
- US 4837028 A [0080]
- US 9405700 W [0082]
- US 4797368 A [0083]
- WO 9324641 A [0083]
- US 5173414 A [0083]
- US 20030087817 A [0084]
- US 6603061 B [0090]
- US 7868149 B [0090]
- US 20090100536 A [0090]

## Non-patent literature cited in the description

- **GOEDDEL.** GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY. Academic Press, 1990, vol. 185 [0010] [0056]
- **BOSHART et al.** *Cell*, 1985, vol. 41, 521-530 [0010]
- *Mol. Cell. Biol.*, 1988, vol. 8 (1), 466-472 [0010]
- *Proc. Natl. Acad. Sci. USA.*, 1981, vol. 78 (3), 1527-31 [0010]
- **SAMBROOK ; FRITSCH ; MANIATIS.** MOLECULAR CLONING: A LABORATORY MANUAL. 1989 [0055]
- CURRENT PROTOCOLS IN MOLECULAR BIOLOGY. 1987 [0055]
- METHODS IN ENZYMOLOGY. Academic Press, Inc, [0055]
- PCR 2: A PRACTICAL APPROACH. 1995 [0055]
- ANTIBODIES, A LABORATORY MANUAL, and ANIMAL CELL CULTURE. 1988 [0055]
- **SMITH ; JOHNSON.** *Gene*, 1988, vol. 67, 31-40 [0057]
- **AMRANN et al.** *Gene*, 1988, vol. 69, 301-315 [0058]
- **STUDIER et al.** GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY. Academic Press, 1990, vol. 185, 60-89 [0058]
- **BALDARI et al.** *EMBO J.*, 1987, vol. 6, 229-234 [0059]
- **KUIJAN ; HERSKOWITZ.** *Cell*, 1982, vol. 30, 933-943 [0059]
- **SCHULTZ et al.** *Gene*, 1987, vol. 54, 113-123 [0059]
- **SMITH et al.** *Mol. Cell. Biol.*, 1983, vol. 3, 2156-2165 [0060]
- **LUCKLOW ; SUMMERS.** *Virology*, 1989, vol. 170, 31-39 [0060]
- **SEED.** *Nature*, 1987, vol. 329, 840 [0061]
- **KAUFMAN et al.** *EMBO J.*, 1987, vol. 6, 187-195 [0061]
- **SAMBROOK et al.** MOLECULAR CLONING: A LABORATORY MANUAL. Cold Spring Harbor Laboratory Press, 1989 [0061]
- **PINKERT et al.** *Genes Dev.*, 1987, vol. 1, 268-277 [0062]
- **CALAME ; EATON.** *Adv. Immunol.*, 1988, vol. 43, 235-275 [0062]
- **WINOTO ; BALTIMORE.** *EMBO J.*, 1989, vol. 8, 729-733 [0062]
- **BANEIJI et al.** *Cell*, 1983, vol. 33, 729-740 [0062]
- **QUEEN ; BALTIMORE.** *Cell*, 1983, vol. 33, 741-748 [0062]

- **BYRNE ; RUDDLE.** *Proc. Natl. Acad. Sci. USA*, 1989, vol. 86, 5473-5477 [0062]
- **EDLUND et al.** *Science*, 1985, vol. 230, 912-916 [0062]
- **KESSEL ; GRUSS.** *Science*, 1990, vol. 249, 374-379 [0062]
- **CAMPES ; TILGHMAN.** *Genes Dev.*, 1989, vol. 3, 537-546 [0062]
- **ISHINO et al.** *J. Bacteriol.*, 1987, vol. 169, 5429-5433 [0063]
- **NAKATA et al.** *J. Bacteriol.*, 1989, vol. 171, 3553-3556 [0063]
- **GROENEN et al.** *Mol. Microbiol.*, 1993, vol. 10, 1057-1065 [0063]
- **HOE et al.** *Emerg. Infect. Dis.*, 1999, vol. 5, 254-263 [0063]
- **MASEPOHL et al.** *Biochim. Biophys. Acta*, 1996, vol. 1307, 26-30 [0063]
- **MOJICA et al.** *Mol. Microbiol.*, 1995, vol. 17, 85-93 [0063]
- **JANSSEN et al.** *OMICS J. Integ. Biol*, 2002, vol. 6, 23-33 [0063]
- **MOJICA et al.** *Mol. Microbiol.*, 2002, vol. 36, 244-246 [0063]
- **VAN EMBDEN et al.** *J. Bacteriol.*, 2000, vol. 182, 2393-2401 [0063]
- **JANSEN et al.** *Mol. Microbiol.*, 2002, vol. 43, 1565-1575 [0063]
- **NAKAMURA, Y. et al.** Codon usage tabulated from the international DNA sequence databases: status for the year 2000. *Nucl. Acids Res.*, 2000, vol. 28, 292 [0069]
- **ZUKER ; STIEGLER.** *Nucleic Acids Res.*, 1981, vol. 9, 133-148 [0074]
- **A.R. GRUBER et al.** *Cell*, 2008, vol. 106 (1), 23-24 [0074]
- **PA CARR ; GM CHURCH.** *Nature Biotechnology*, 2009, vol. 27 (12), 1151-62 [0074]
- **ANDERSON.** *Science*, 1992, vol. 256, 808-813 [0078]
- **NABEL ; FELGNER.** *TIBTECH*, 1993, vol. 11, 211-217 [0078]
- **MITANI ; CASKEY.** *TIBTECH*, 1993, vol. 11, 162-166 [0078]
- **DILLON.** *TIBTECH*, 1993, vol. 11, 167-175 [0078]
- **MILLER.** *Nature*, 1992, vol. 357, 455-460 [0078]
- **VAN BRUNT.** *Biotechnology*, 1988, vol. 6 (10), 1149-1154 [0078]
- **VIGNE.** *Restorative Neurology and Neuroscience*, 1995, vol. 8, 35-36 [0078]
- **KREMER ; PERRICAUDET.** *British Medical Bulletin*, 1995, vol. 51 (1), 31-44 [0078]
- **HADDADA et al.** *Current Topics in Microbiology and Immunology*. 1995 [0078]
- **YU et al.** *Gene Therapy*, 1994, vol. 1, 13-26 [0078]
- **CRYSTAL.** *Science*, 1995, vol. 270, 404-410 [0080]
- **BLAESE et al.** *Cancer Gene Ther.*, 1995, vol. 2, 291-297 [0080]
- **BEHR et al.** *Bioconjugate Chem.*, 1994, vol. 5, 382-389 [0080]
- **REMY et al.** *Bioconjugate Chem.*, 1994, vol. 5, 647-654 [0080]
- **GAO et al.** *Gene Therapy*, 1995, vol. 2, 710-722 [0080]
- **AHMAD et al.** *Cancer Res.*, 1992, vol. 52, 4817-4820 [0080]
- **BUCHSCHER et al.** *J. Virol.*, 1992, vol. 66, 2731-2739 [0082]
- **JOHANN et al.** *J. Virol.*, 1992, vol. 66, 1635-1640 [0082]
- **SOMMNERFELT et al.** *Virol.*, 1990, vol. 176, 58-59 [0082]
- **WILSON et al.** *J. Virol.*, 1989, vol. 63, 2374-2378 [0082]
- **MILLER et al.** *J. Virol.*, vol. 65, 2220-2224 [0082]
- **WEST et al.** *Virology*, 1987, vol. 160, 38-47 [0083]
- **KOTIN.** *Human Gene Therapy*, 1994, vol. 5, 793-801 [0083]
- **MUZYCZKA.** *J. Clin. Invest.*, 1994, vol. 94, 1351 [0083]
- **TRATSCHIN et al.** *Mol. Cell. Biol.*, 1985, vol. 5, 3251-3260 [0083]
- **TRATSCHIN et al.** *Mol. Cell. Biol.*, 1984, vol. 4, 2072-2081 [0083]
- **HERMONAT ; MUZYCZKA.** *PNAS*, 1984, vol. 81, 6466-6470 [0083]
- **SAMULSKI et al.** *J. Virol.*, 1989, vol. 63, 03822-3828 [0083]
- **MORRELL et al.** *Crop genomics: advances and applications.* *Nat Rev Genet.*, 29 December 2011, vol. 13 (2), 85-96 [0090]
- **ROBERT D. WELLS ; TETSUO ASHIZAWA.** *Genetic Instabilities and Neurological Diseases.* Academic Press, 13 October 2011 [0101]
- **MCIVOR EI ; POLAK U ; NAPIERALA M.** *New insights into repeat instability: role of RNA-DNA hybrids.* *RNA Biol.*, September 2010, vol. 7 (5), 551-8 [0101]
- *Genetics of Epilepsy and Genetic Epilepsies.* Mariani Foundation Paediatric Neurology, 2009, 20 [0102]
- *Genetic Diseases of the Eye.* Oxford University Press, 2010 [0103]
- **TANGRI S et al.** *Rationally engineered therapeutic proteins with reduced immunogenicity.* *J Immunol.*, 15 March 2005, vol. 174 (6), 3187-96 [0124] [0212]
- **GUSCHIN et al.** *Methods Mol Biol*, 2010, vol. 649, 247 [0132]
- **SAPRANAUSAKS et al.** *Nucleic Acids Research*, 2011, vol. 39, 9275 [0143]
- **GASIUNAS et al.** *Proc. Natl. Acad. Sci. USA*, 2012, vol. 109, 2579 [0143]
- **JINEK et al.** *Science*, 2012, vol. 337, 816 [0145]
- **MAKAROVA et al.** *Nat Rev Microbiol*, 2011, vol. 9, 467 [0145]

- **URNOV, F.D. ; REBAR, E.J. ; HOLMES, M.C. ; ZHANG, H.S. ; GREGORY, P.D.** Genome editing with engineered zinc finger nucleases. *Nat. Rev. Genet.*, 2010, vol. 11, 636-646 [0212]
- **BOGDANOVE, A.J. ; VOYTAS, D.F.** TAL effectors: customizable proteins for DNA targeting. *Science*, 2011, vol. 333, 1843-1846 [0212]
- **STODDARD, B.L.** Homing endonuclease structure and function. *Q. Rev. Biophys.*, 2005, vol. 38, 49-95 [0212]
- **BAE, T. ; SCHNEEWIND, O.** Allelic replacement in *Staphylococcus aureus* with inducible counter-selection. *Plasmid*, 2006, 55, , 58-63 [0212]
- **SUNG, C.K. ; LI, H. ; CLAVERYS, J.P. ; MORRISON, D.A.** An rpsL cassette, janus, for gene replacement through negative selection in *Streptococcus pneumoniae*. *Appl. Environ. Microbiol.*, 2001, vol. 67, 5190-5196 [0212]
- **SHARAN, S.K. ; THOMASON, L.C. ; KUZNETSOV, S.G. ; COURT, D.L.** Recombineering: a homologous recombination-based method of genetic engineering. *Nat. Protoc.*, 2009, vol. 4, 206-223 [0212]
- **JINEK, M. et al.** A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science*, 2012, vol. 337, 816-821 [0212]
- **DEVEAU, H. ; GARNEAU, J.E. ; MOINEAU, S.** CRISPR-Cas system and its role in phage-bacteria interactions. *Annu. Rev. Microbiol.*, 2010, vol. 64, 475-493 [0212]
- **HORVATH, P. ; BARRANGOU, R.** CRISPR-Cas, the immune system of bacteria and archaea. *Science*, 2010, vol. 327, 167-170 [0212]
- **TERNS, M.P. ; TERNS, R.M.** CRISPR-based adaptive immune systems. *Curr. Opin. Microbiol.*, 2011, vol. 14, 321-327 [0212]
- **VAN DER OOST, J. ; JORE, M.M. ; WESTRA, E.R. ; LUNDGREN, M. ; BROUNS, S.J.** CRISPR-based adaptive and heritable immunity in prokaryotes. *Trends. Biochem. Sci.*, 2009, vol. 34, 401-407 [0212]
- **BROUNS, S.J. et al.** Small CRISPR RNAs guide antiviral defense in prokaryotes. *Science*, 2008, vol. 321, 960-964 [0212]
- **CARTE, J. ; WANG, R. ; LI, H. ; TERNS, R.M. ; TERNS, M.P.** Cas6 is an endoribonuclease that generates guide RNAs for invader defense in prokaryotes. *Genes Dev.*, 2008, vol. 22, 3489-3496 [0212]
- **DELTCHEVA, E. et al.** CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. *Nature*, 2011, vol. 471, 602-607 [0212]
- **HATOUM-ASLAN, A. ; MANIV, I. ; MARRAFFINI, L.A.** Mature clustered, regularly interspaced, short palindromic repeats RNA (crRNA) length is measured by a ruler mechanism anchored at the precursor processing site. *Proc. Natl. Acad. Sci. U.S.A.*, 2011, vol. 108, 21218-21222 [0212]
- **HAURWITZ, R.E. ; JINEK, M. ; WIEDENHEFT, B. ; ZHOU, K. ; DOUDNA, J.A.** Sequence- and structure-specific RNA processing by a CRISPR endonuclease. *Science*, 2010, vol. 329, 1355-1358 [0212]
- **DEVEAU, H. et al.** Phage response to CRISPR-encoded resistance in *Streptococcus thermophilus*. *J. Bacteriol.*, 2008, vol. 190, 1390-1400 [0212]
- **GASIUNAS, G. ; BARRANGOU, R. ; HORVATH, P. ; SIKSNYS, V.** Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. *Proc. Natl. Acad. Sci. U.S.A.*, 2012 [0212]
- **MAKAROVA, K.S. ; ARAVIND, L. ; WOLF, Y.I. ; KOONIN, E.V.** Unification of Cas protein families and a simple scenario for the origin and evolution of CRISPR-Cas systems. *Biol. Direct.*, 2011, vol. 6, 38 [0212]
- **BARRANGOU, R.** RNA-mediated programmable DNA cleavage. *Nat. Biotechnol.*, 2012, vol. 30, 836-838 [0212]
- **BROUNS, S.J.** Molecular biology. A Swiss army knife of immunity. *Science*, 2012, vol. 337, 808-809 [0212]
- **CARROLL, D.** A CRISPR Approach to Gene Targeting. *Mol. Ther.*, 2012, vol. 20, 1658-1660 [0212]
- **BIKARD, D. ; HATOUM-ASLAN, A. ; MUCIDA, D. ; MARRAFFINI, L.A.** CRISPR interference can prevent natural transformation and virulence acquisition during in vivo bacterial infection. *Cell Host Microbe*, 2012, vol. 12, 177-186 [0212]
- **SAPRANAUSKAS, R. et al.** The *Streptococcus thermophilus* CRISPR-Cas system provides immunity in *Escherichia coli*. *Nucleic Acids Res.*, 2011 [0212]
- **SEMEANOVA, E. et al.** Interference by clustered regularly interspaced short palindromic repeat (CRISPR) RNA is governed by a seed sequence. *Proc. Natl. Acad. Sci. U.S.A.*, 2011 [0212]
- **WIEDENHEFT, B. et al.** RNA-guided complex from a bacterial immune system enhances target recognition through seed sequence interactions. *Proc. Natl. Acad. Sci. U.S.A.*, 2011 [0212]
- **ZAHNER, D. ; HAKENBECK, R.** The *Streptococcus pneumoniae* beta-galactosidase is a surface protein. *J. Bacteriol.*, 2000, vol. 182, 5919-5921 [0212]
- **MARRAFFINI, L.A. ; DEDENT, A.C. ; SCHNEEWIND, O.** Sortases and the art of anchoring proteins to the envelopes of gram-positive bacteria. *Microbiol. Mol. Biol. Rev.*, 2006, vol. 70, 192-221 [0212]
- **MOTAMED, M.R. ; SZIGETY, S.K. ; ROSENBERG, S.M.** Double-strand-break repair recombination in *Escherichia coli*: physical evidence for a DNA replication mechanism in vivo. *Genes Dev.*, 1999, vol. 13, 2889-2903 [0212]
- **HOSAKA, T. et al.** The novel mutation K87E in ribosomal protein S12 enhances protein synthesis activity during the late growth phase in *Escherichia coli*. *Mol. Genet. Genomics*, 2004, vol. 271, 317-324 [0212]

- **COSTANTINO, N. ; COURT, D.L.** Enhanced levels of lambda Red-mediated recombinants in mismatch repair mutants. *Proc. Natl. Acad. Sci. U.S.A.*, 2003, vol. 100, 15748-15753 [0212]
- **EDGAR, R. ; QIMRON, U.** The Escherichia coli CRISPR system protects from lambda lysogenization, lysogens, and prophage induction. *J. Bacteriol.*, 2010, vol. 192, 6291-6294 [0212]
- **MARRAFFINI, L.A. ; SONTHEIMER, E.J.** Self versus non-self discrimination during CRISPR RNA-directed immunity. *Nature*, 2010, vol. 463, 568-571 [0212]
- **FISCHER, S. et al.** An archaeal immune system can detect multiple Protospacer Adjacent Motifs (PAMs) to target invader DNA. *J. Biol. Chem.*, 2012, vol. 287, 33351-33363 [0212]
- **GUDBERGSDOTTIR, S et al.** Dynamic properties of the Sulfolobus CRISPR-Cas and CRISPR/Cmr systems when challenged with vector-borne viral and plasmid genes and protospacers. *Mol. Microbiol.*, 2011, vol. 79, 35-49 [0212]
- **WANG, H.H. et al.** Genome-scale promoter engineering by coselection MAGE. *Nat Methods*, 2012, vol. 9, 591-593 [0212]
- **CONG, L. et al.** Multiplex Genome Engineering Using CRISPR-Cas Systems. *Science*, 2013 [0212]
- **MALI, P. et al.** RNA-Guided Human Genome Engineering via Cas9. *Science*, 2013 [0212]
- **HOSKINS, J. et al.** Genome of the bacterium Streptococcus pneumoniae strain R6. *J. Bac*, 2001, vol. 183, 5709-5717 [0212]
- **HAVARSTEIN, L.S. ; COOMARASWAMY, G. ; MORRISON, D.A.** An unmodified heptadecapeptide pheromone induces competence for genetic transformation in Streptococcus pneumoniae. *Proc. Natl. Acad. Sci. U.S.A.*, 1995, vol. 92, 11140-11144 [0212]
- **HORINOUCHI, S. ; WEISBLUM, B.** Nucleotide sequence and functional map of pC194, a plasmid that specifies inducible chloramphenicol resistance. *J. Bacteriol.*, 1982, vol. 150, 815-825 [0212]
- **HORTON, R.M.** In Vitro Recombination and Mutagenesis of DNA : SOEing Together Tailor-Made Genes. *Methods Mol. Biol.*, 1993, vol. 15, 251-261 [0212]
- **PODBIELSKI, A. ; SPELLERBERG, B. ; WOISCHNIK, M. ; POHL, B. ; LUTTICKEN, R.** Novel series of plasmid vectors for gene inactivation and expression analysis in group A streptococci (GAS). *Gene*, 1996, vol. 177, 137-147 [0212]
- **HUSMANN, L.K. ; SCOTT, J.R. ; LINDAHL, G. ; STENBERG, L.** Expression of the Arp protein, a member of the M protein family, is not sufficient to inhibit phagocytosis of Streptococcus pyogenes. *Infection and immunity*, 1995, vol. 63, 345-348 [0212]
- **GIBSON, D.G. et al.** Enzymatic assembly of DNA molecules up to several hundred kilobases. *Nat Methods*, 2009, vol. 6, 343-345 [0212]



## 摘要

：本發明促成了用於操控序列及/或標的序列活性的系統、方法及組成物。所提供的是一些載體及載體系統，其中某些編碼出一個或多個 **CRISPR** 複合體的一個或多個成份，亦提供出用於設計並使用此等載體的方法。此外，所提供的亦包括用於引導 **CRISPR** 複合體於真核細胞中形成的方法，以及用上該 **CRISPR-Cas** 系統且用於透過引入精確突變而選取特定細胞的方法。